US20210009555A1 - Therapeutic compounds - Google Patents

Therapeutic compounds Download PDF

Info

Publication number
US20210009555A1
US20210009555A1 US16/882,804 US202016882804A US2021009555A1 US 20210009555 A1 US20210009555 A1 US 20210009555A1 US 202016882804 A US202016882804 A US 202016882804A US 2021009555 A1 US2021009555 A1 US 2021009555A1
Authority
US
United States
Prior art keywords
membered
heteroaryl
groups
heterocycle
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US16/882,804
Inventor
Gediminas Brizgys
Eda Canales
Chien-Hung Chou
Michael Graupe
Randall L. Halcomb
Yunfeng Eric Hu
Scott E. Lazerwith
John O. Link
Qi Liu
Yafan Lu
Roland D. SAITO
Scott D. Schroeder
John R. SOMOZA
Winston C. Tse
Jennifer R. Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50382584&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20210009555(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Priority to US16/882,804 priority Critical patent/US20210009555A1/en
Assigned to GILEAD SCIENCES, INC. reassignment GILEAD SCIENCES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HALCOMB, RANDALL L., LAZERWITH, SCOTT E., BRIZGYS, Gediminas, CANALES, EDA, CHOU, CHIEN-HUNG, GRAUPE, MICHAEL, HU, Yunfeng Eric, LINK, JOHN O., LIU, QI, LU, YAFAN, SAITO, ROLAND D., SCHROEDER, SCOTT D., SOMOZA, JOHN R., TSE, WINSTON C., ZHANG, JENNIFER R.
Publication of US20210009555A1 publication Critical patent/US20210009555A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Definitions

  • heterocycles include, but are not limited to aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydrofuranyl, dihydrooxazolyl, tetrahydropyranyl, tetrahydrothiopyranyl, 1,2,3,4-tetrahydroquinolyl, benzoxazinyl, dihydrooxazolyl, chromanyl, 1,2-dihydropyridinyl, 2,3-dihydrobenzofuranyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl, spiro[cyclopropane-1,1′-isoindolinyl]-3′-one, isoindolinyl-1-one, 2-oxa-6-azaspiro[3.3]heptanyl, imid
  • the dashed bonds are selected from single bonds and double bonds, wherein the dashed bonds, V, W, X and Y are selected so that the 5 or 6 membered monocyclic-heteroaryl B is aromatic;
  • W is CZ 4c or N
  • a specific value for each Z 4 is independently selected from fluoro, trifluoromethyl and difluoromethyl.
  • A is pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl;
  • R 1 is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl, wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R 1 is optionally substituted with 1, 2, 3, 4, or 5 Z 4 groups; and each Z 4 is independently fluoro, trifluoromethyl, or difluoromethyl.
  • each R p4 is independently (C 1 -C 8 )alkyl, (C 1 -C 4 )haloalkyl, or (C 1 -C 4 )heteroalkyl;
  • each Z 3 is independently a (C 1 -C 4 )heteroalkyl or halogen
  • R 1 has the following formula IIc:
  • the dashed bonds are selected from single bonds and double bonds, wherein the dashed bonds, V, W, X and Y are selected so that the 5 or 6 membered monocyclic-heteroaryl B is aromatic;
  • each Z 4c is independently selected from H or Z 4 , wherein the Z 4 groups are the same or different.
  • Z 1 is phenyl, 5-14 membered heteroaryl, or 3-14 membered heterocycle, wherein any phenyl, 5-14 membered heteroaryl, or 3-14 membered heterocycle of Z 1 is optionally substituted with 1, 2, 3, 4 or 5 Z 1a or Z 1b groups.
  • the invention provides pharmaceutical compositions comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with at least one additional therapeutic agent, and a pharmaceutically acceptable carrier.
  • the therapeutic agent used in combination with the compound disclosed herein can be any anti-HIV agent.
  • a compound disclosed herein, or a pharmaceutically acceptable salt thereof is combined with an HIV nucleotide inhibitor of reverse transcriptase, an HIV non-nucleoside inhibitor of reverse transcriptase, and a pharmacokinetic enhancer.

Abstract

Compounds of formula (I) or salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.
Figure US20210009555A1-20210114-C00001

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application claims the benefit of and priority to U.S. Provisional Patent Application Serial Nos. 61/771,655, filed Mar. 1, 2013 and 61/857,636, filed Jul. 23, 2013, the disclosures of each of which are hereby incorporated herein by reference in their entirety.
    • BACKGROUND
  • Positive-single stranded RNA viruses comprising the Retroviridae family include those of the subfamily Orthoretrovirinae and genera Alpharetrovirus, Betaretrovirus, Gamaretrovirus, Deltaretrovirus, Epsilonretrovirus, Lentivirus, and Spumavirus which cause many human and animal diseases. Among the Lenlivirus, HIV-1 infection in humans leads to depletion of T helper cells and immune dysfunction, producing immunodeficiency and vulnerability to opportunistic infections. Treating HIV-1 infections with highly active antiretroviral therapies (HAART) has proven to be effective at reducing viral load and significantly delaying disease progression (Hammer, S. M., et al.; JAMA 2008, 300: 555-570). However, these treatments could lead to the emergence of HIV strains that are resistant to current therapies (Taiwo, B., International Journal of Infectious Diseases 2009, 13:552-559; Smith, R. J., et al., Science 2010, 327:697-701). Therefore, there is a pressing need to discover new antiretroviral agents that are active against emerging drug-resistant HIV variants.
    • SUMMARY
  • Provided herein are compounds and methods for the treatment of HIV (i.e., human immunodeficiency virus) infection.
  • One embodiment provides a compound of formula IIId:
  • Figure US20210009555A1-20210114-C00002
  • wherein
  • A1 is CH, C—Z3, or nitrogen;
  • A2 is CH or nitrogen;
  • R1 is 6-12 membered aryl, 5-12 membered heteroaryl, or 3-12 membered heterocycle, wherein any 6-12 membered aryl, 5-12 membered heteroaryl, or 3-12 membered heterocycle of R1 is optionally substituted with 1, 2, 3, 4 or 5 Z4 groups, wherein the Z4 groups are the same or different;
  • each R3a and R3b is independently H or (C1-C3)alkyl;
  • Z1 is 6-12 membered aryl, 5-14 membered heteroaryl, or 3-14 membered heterocycle, wherein any 6-12 membered aryl, 5-14 membered heteroaryl, or 3-14 membered heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a or Z1b, wherein the Z1a and Z1b groups are the same or different;
  • each Z1a is independently (C3-C7)carbocycle, 5-12 membered heteroaryl, 3-12 membered heterocycle, halogen, —CN, —ORn1, Rp1, —OC(O)NRq1Rr1, —SRn1, —S(O)Rp1, —S(O)2OH—, —S(O)2Rp1, —S(O)2NRq1Rr1, —NRq1Rr1, —NRn1CORp1, —NRn1CO2Rp1, —NRn1CONRq1Rr1, —NRn1S(O)2Rp1, —NRn1S(O)2ORp1, —NRn1S(O)2NRq1Rr1, —C(O)Rn1, —C(O)ORn1, —C(O)NRq1Rr1 and —S(O)2NRn1CORp1, wherein any (C3-C7)carbocycle, 5-12 membered heteroaryl and 3-12 membered heterocycle of Z1a is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different;
  • each Z1b is independently (C1-C8)alkyl optionally substituted with 1, 2, 3, 4 or 5 halogen, which are the same or different;
  • each Z1c is independently halogen, —CN, —OH, —NH2, —C(O)NRq2Rr2, or (C1-C8)heteroalkyl;
  • each Z1d is independently (C1-C8)alkyl or (C1-C8)haloalkyl;
  • each Rn1 is independently H, (C1-C8)alkyl, (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl of Rn1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different, and wherein any (C1-C8)alkyl of Rn1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c groups, wherein the Z1c groups are the same or different;
  • each Rp1 is independently (C1-C8)alkyl, (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl of Rp1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different, and wherein any (C1-C8)alkyl of Rp1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c groups, wherein the Z1c groups are the same or different;
  • each Rq1 and Rr1 is independently H, (C1-C8)alkyl, (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl of Rq1 or Rr1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different, and wherein any (C1-C8)alkyl of Rq1 or Rr1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c groups, wherein the Z1c groups are the same or different, or Rq1 and Rr1 together with the nitrogen to which they are attached form a 5, 6 or 7-membered heterocycle, wherein the 5, 6 or 7-membered heterocycle is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different;
  • each Rq2 and Rr2 is independently H, (C1-C8)alkyl, (C3-C7)carbocycle, or Rq2 and Rr2 together with the nitrogen to which they are attached form a 5, 6, or 7-membered heterocycle;
  • Z2 is (C2-C8)alkenyl, (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, —C(O)Rn3, or —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, or 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, wherein the Z2b and Z2c groups are the same or different, and wherein any (C2-C8)alkenyl or (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4, or 5 Z2c groups, wherein the Z2c groups are the same or different;
  • each Rn3 is independently H or (C1-C4)alkyl;
  • each R3q and Rr3 is independently H or (C1-C4)alkyl;
  • each Z2b is independently oxo, (C1-C4)alkyl, (C1-C4)heteroalkyl or (C1-C4)haloalkyl;
  • each Z2c is independently oxo, halogen, —CN, —ORn4, —OC(O)Rp4, —OC(O)NRq4Rr4, —SRn4, —S(O)Rp4, —S(O)2OH, —S(O)2Rp4, —S(O)2NRq4Rr4, —NRq4Rr4, —NRn4CORp4, —NRn4CO2Rp4, —NRn4CONRq4Rr4, —NRn4S(O)2Rp4, —NRn4S(O)2ORp4, —NRn4S(O)2NRq4Rr4, —NO2, —C(O)Rn4, —C(O)ORn4, or —C(O)NRq4Rr4;
  • each Rn4 is independently H, (C1-C4)alkyl, (C1-C4)haloalkyl, or (C1-C4)heteroalkyl;
  • each Rp4 is independently (C1-C8)alkyl, (C1-C4)haloalkyl, or (C1-C4)heteroalkyl;
  • each Rq4 and Rr4 is independently H, (C1-C4)alkyl, (C1-C4)haloalkyl, or (C1-C4)heteroalkyl;
  • each Z3 is independently a (C1-C4)heteroalkyl;
  • each Z4 is independently oxo, (C1-C8)alkyl, (C3-C7)carbocycle, halogen, —CN, —ORn5, —NRq5Rr5, —NRn5CORp5, —NRn5CO2Rp5, —C(O)Rn5, —C(O)ORn5, or —C(O)NRq5Rr5, wherein any (C3-C7)carbocycle or (C1-C8)alkyl of Z4 is optionally substituted with 1, 2, 3, 4 or 5 Z4a groups, wherein the Z4a groups are the same or different;
  • each Z4a is independently halogen, —CN, or —ORn6;
  • each Rn5, Rp5Rq5, Rr5, and Rn6 is independently H or (C1-C4)alkyl;
  • each Z5 is independently halogen, which may be same or different; and
  • n is 0, 1, 2,or 3;
  • or a pharmaceutically acceptable salt thereof.
  • One embodiment provides a compound of formula III:
  • Figure US20210009555A1-20210114-C00003
  • wherein
  • A is a 6-membered monocyclic-heteroaryl with one or two nitrogen atoms, wherein the 6-membered monocyclic-heteroaryl is substituted with one Z1 group at the position shown, one Z2 group, and optionally substituted with 1 or 2 Z3 groups, wherein the Z3 groups are the same or different;
  • R1 is 6-12 membered aryl, 5-12 membered heteroaryl, or 3-12 membered heterocycle, wherein any 6-12 membered aryl, 5-12 membered heteroaryl, or 3-12 membered heterocycle of R is optionally substituted with 1, 2, 3, 4 or 5 Z4 groups, wherein the Z4 groups are the same or different;
  • R2 is phenyl optionally substituted with 1, 2, 3, 4 or 5 halogen, which are the same or different;
  • each R3a and R3b is independently H or (C1-C3)alkyl;
  • Z1 is 6-12 membered aryl, 5-14 membered heteroaryl, or 3-14 membered heterocycle, wherein any 6-12 membered aryl, 5-14 membered heteroaryl, or 3-14 membered heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a or Z1b, wherein the Z1a and Z1b groups are the same or different;
  • each Z1a is independently (C3-C7)carbocycle, 5-12 membered heteroaryl, 3-12 membered heterocycle, halogen, —CN, —ORn1, —OC(O)Rp1, —OC(O)NRq1Rr1, —SRn1, —S(O)Rp1, —S(O)2OH, —S(O)2Rp1, —S(O)2NRq1Rr1, —NRq1Rr1, —NRn1CORp1, —NRn1CO2Rp1, —NRn1CONRq1Rr1, —NRn1S(O)2Rp1, —NRn1S(O)2ORp1, —NRn1S(O)2NRq1Rr1, —C(O)Rn1, —C(O)ORn1, —C(O)NRq1Rr1 and —S(O)2NRnCORP, wherein any (C3-C7)carbocycle, 5-12 membered heteroaryl and 3-12 membered heterocycle of Z1a is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different;
  • each Z1b is independently (C1—C)alkyl optionally substituted with 1, 2, 3, 4 or 5 halogen, which are the same or different;
  • each Z1c is independently halogen, —CN, —OH, —NH2, —C(O)NRq2Rr2, or (C1-C8)heteroalkyl;
  • each Z1d is independently (C1-C8)alkyl or (C1-C8)haloalkyl;
  • each Rn1 is independently H, (C1-C8)alkyl, (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl of Rn1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different, and wherein any (C1-C8)alkyl of Rn1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c groups, wherein the Z1c groups are the same or different;
  • each Rp1 is independently (C1-C8)alkyl, (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl of Rp1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different, and wherein any (C1-C8)alkyl of Rp1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c groups, wherein the Z1c groups are the same or different;
  • each Rq1 and Rr1 is independently H, (C1-C8)alkyl, (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl of Rq1 or Rr1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different, and wherein any (C1-C8)alkyl of Rq1 or Rr1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c groups, wherein the Z1c groups are the same or different, or Rq1 and Rr1 together with the nitrogen to which they are attached form a 5, 6 or 7-membered heterocycle, wherein the 5, 6 or 7-membered heterocycle is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different;
  • each Rq2 and Rr2 is independently H, (C1-C8)alkyl, (C3-C7)carbocycle, or Rq2 and Rr2 together with the nitrogen to which they are attached form a 5, 6, or 7-membered heterocycle;
  • Z2 is (C2-C8)alkenyl, (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, —C(O)Rn3, or —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, or 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, wherein the Z2b and Z2c, groups are the same or different, and wherein any (C2-C8)alkenyl or (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4, or 5 Z2c groups, wherein the Z2c groups are the same or different;
  • each Rn3 is independently H or (C1-C4)alkyl;
  • each Rq3 and Rr3 is independently H or (C1-C4)alkyl;
  • each Z2b is independently oxo, (C1-C4)alkyl, (C1-C4)heteroalkyl, or (C1-C4)haloalkyl;
  • each Z2c is independently oxo, halogen, —CN, —ORn4, —OC(O)Rp4, —OC(O)NRq4Rr4, —SRn4, —S(O)Rp4, —S(O)2OH, —S(O)2Rp4, —S(O)2NRq4Rr4, —NRq4Rr4, —NRn4CORp4, —NRn4CO2Rp4, —NRn4CONRq4Rr4, —NRn4S(O)2Rp4, —NRn4S(O)2ORp4, —NRn4S(O)2NRq4Rr4, —NO2, —C(O)Rn4, —C(O)ORn4, or —C(O)NRq4Rr4;
  • each Rn4 is independently H, (C1-C4)alkyl, (C1-C4)haloalkyl, or (C1-C4)heteroalkyl;
  • each Rp4 is independently (C1-C8)alkyl, (C1-C4)haloalkyl, or (C1-C4)heteroalkyl;
  • each Rq4 and Rr4 is independently H, (C1-C4)alkyl, (C1-C4)haloalkyl, or (C1-C4)heteroalkyl;
  • each Z3 is independently a (C1-C4)heteroalkyl or halogen;
  • each Z4 is independently oxo, (C1-C8)alkyl, (C3-C7)carbocycle, halogen, —CN, —ORn5, —NRq5Rr5, —NRn5CORp5, —NRn5CO2Rp5, —C(O)Rn5, —C(O)ORn5, or —C(O)NRq5Rr5, wherein any (C3-C7)carbocycle or (C1-C8)alkyl of Z4 is optionally substituted with 1, 2, 3, 4 or 5 Z4a groups, wherein the Z4a groups are the same or different;
  • each Z4a is independently halogen, —CN, or —ORn6; and
  • each Rn5, Rp5, Rq5, Rr5, and Rn6 is independently H or (C1-C4)alkyl;
  • or a pharmaceutically acceptable salt thereof.
  • One embodiment provides a compound of formula I
  • Figure US20210009555A1-20210114-C00004
  • wherein:
  • A is a 6-membered monocyclic-heteroaryl with one or two nitrogen atoms, wherein the 6-membered monocyclic-heteroaryl is substituted with one Z1 group at the position shown, one Z2 group, and optionally substituted with one or more (e.g., 1 or 2) Z3 groups;
  • R1 is 6-12 membered aryl, 5-12 membered heteroaryl or 3-12 membered heterocycle, wherein any 6-12 membered aryl, 5-12 membered heteroaryl or 3-12 membered heterocycle of R1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z4 groups;
  • R2 is phenyl, 5-membered monocyclic-heteroaryl, 6-membered monocyclic-heteroaryl or (C3-C7)carbocycle, wherein any phenyl, 5-membered monocyclic-heteroaryl, 6-membered monocyclic-heteroaryl or (C3-C7)carbocycle of R2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z5 groups;
  • each R3a and R3b is independently selected from H, halogen, (C1-C3)alkyl and (C1-C3)haloalkyl, or R3a is selected from H, (C1-C3)alkyl and (C1-C3)haloalkyl and R3b is selected from —OH and —CN;
  • Z1 is selected from 6-12 membered aryl, 5-14 membered heteroaryl and 3-14 membered heterocycle, wherein any 6-12 membered aryl, 5-14 membered heteroaryl and 3-14 membered heterocycle of Z is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1a or Z1b;
  • each Z1a is independently selected from (C3-C7)carbocycle, 6-12 membered aryl, 5-12 membered heteroaryl, 3-12 membered heterocycle, halogen, —CN, —ORn1, —OC(O)Rp1, —OC(O)NRq1Rr1, —SRn1, —S(O)Rp1, —S(O)2OH, —S(O)2Rp1, —S(O)2NRq1Rr1, —NRq1Rr1, —NRn1CORp1, —NRn1CO3Rp1, —NRn1CONRq1Rr1, —NRn1S(O)2Rp1, —NRn1S(O)2ORp1, —NRn1S(O)2NRq1Rr1, NO2, —C(O)Rn1, —C(O)ORn1, —C(O)NRq1Rr1 and —S(O)2NRn1CORp1, wherein any (C3-C7)carbocycle, 6-12 membered aryl, 5-12 membered heteroaryl and 3-12 membered heterocycle of Z1a is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c or Z1d groups;
  • each Z1b is independently selected from (C1-C8)alkyl, (C2-C8)alkenyl and (C2-C8)alkynyl, wherein any (C1-C8)alkyl, (C2-C8)alkenyl and (C2-C8)alkynyl of Z1b is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c groups;
  • each Z1c is independently selected from (C3-C7)carbocycle, phenyl, 5-6 membered monocyclic-heteroaryl, 3-7 membered heterocycle, halogen, —CN, —ORn2, —OC(O)Rp2, —OC(O)NRq2Rr2, —SRn2, —S(O)Rp2, —S(O)2OH, —S(O)2Rp2, —S(O)2NRq2Rr2, —NRq2Rr2, —NRn2CORp2, —NRn2CO2Rp2, —NRn2CONRq2Rr2, —NRn2S(O)2Rp2, —NRn2S(O)2ORp2, —NRn2S(O2NRq2Rr2, NO2, —C(O)Rn2, —C(O)ORn2, —C(O)NRq2Rr2, halophenyl, 5-6 membered haloheteroaryl, 3-7 membered haloheterocycle and (C1-C8)heteroalkyl;
  • each Z1d is independently selected from (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl and (C1-C8)haloalkyl;
  • each Rn1 is independently selected from H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl and phenyl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl and phenyl of Rn1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c or Z1d groups, and wherein any (C1-C8)alkyl, (C2-C8)alkenyl and (C2-C8)alkynyl of Rn1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c groups;
  • each Rp1 is independently selected from (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl and phenyl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl and phenyl of Rp1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c or Z1d groups, and wherein any (C1-C8)alkyl, (C2-C8)alkenyl and (C2-C8)alkynyl of Rp1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c groups;
  • Rq1 and Rr1 are each independently selected from H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl and phenyl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl and phenyl of Rq1 or Rr1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c or Z1d groups, and wherein any (C1-C8)alkyl, (C2-C8)alkenyl and (C2-C8)alkynyl of Rq1 or Rr1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c groups, or Rq1 and Rr1 together with the nitrogen to which they are attached form a 5, 6 or 7-membered heterocycle, wherein the 5, 6 or 7-membered heterocycle is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c or Z1d groups;
  • each Rn2 is independently selected from H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl, phenyl, halophenyl, 5-6 membered monocyclic-haloheteroaryl, 3-7 membered haloheterocycle, (C1-C8)haloalkyl and (C1-C8)heteroalkyl;
  • each Rp2 is independently selected from (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl, phenyl, halophenyl, 5-6 membered monocyclic-haloheteroaryl, 3-7 membered haloheterocycle, (C1-C8)haloalkyl and (C1-C8)heteroalkyl;
  • Rq2 and Rr2 are each independently selected from H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl, phenyl, halophenyl, 5-6 membered monocyclic-haloheteroaryl, 3-7 membered haloheterocycle, (C1-C8)haloalkyl and (C1-C8)heteroalkyl, or Rq2 and Rr2 together with the nitrogen to which they are attached form a 5, 6 or 7-membered heterocycle;
  • Z2 is selected from (C2-C8)alkenyl, (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, —C(O)Rn3 and —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl and 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2b or Z2c groups, and wherein any (C2-C8)alkenyl and (C2-C8)alkynyl of Z2 is optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) Z2c groups;
  • each Z2a is independently selected from (C3-C7)carbocycle, 6-12 membered aryl, 5-12 membered heteroaryl, 3-12 membered heterocycle, halogen, —CN, —ORn4, —OC(O)Rp4, —OC(O)NRq4Rr4, —SRn4, —S(O)Rp4, —S(O)2OH, —S(O)2Rp4, —S(O)2NRq4Rr4, —NRq4Rr4, —NRn4CORp4, —NRn4 CO2Rp4, —NRn4CONRq4Rr4, —NRn4S(O)2Rp4, —NRn4S(O)2ORp4, —NRn4S(O)2NRq4Rr4,NO2, —C(O)Rn4, —C(O)ORn4 and —C(O)NRq4Rr4, wherein any (C3-C7)carbocycle, 6-12 membered aryl, 5-12 membered heteroaryl and 3-12 membered heterocycle of Z2a is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2b or Z2c groups;
  • each Z2b is independently selected from (C1-C4)alkyl, (C1-C4)heteroalkyl and (C1-C4)haloalkyl;
  • each Z2c is independently selected from halogen, —CN, —ORn4, —OC(O)Rp4, —OC(O)NRq4Rr4, —SRn4, —S(O)Rp4, S(O)2OH, —S(O)2Rp4, —S(O)2NRq4Rr4, —NRq4Rr4, —NRn4CORp4, —NRn4CO2Rp4, —NRn4CONRq4Rr4, —NRn4S(O)2Rp4, —NRn4S(O)2ORp4, —NRn4S(O)2NRq4Rr4 NO2, —C(O)Rn4, —C(O)ORn4 and —C(O)NRq4Rr4;
  • each Rn3 is independently selected from H, (C1-C4)alkyl, (C2-C4)alkenyl, (C3-C7)carbocycle, 3-12 membered heterocycle, 5-12 membered heteroaryl and 6-12 membered aryl, wherein any (C3-C7)carbocycle, 3-12 membered heterocycle, 5-12 membered heteroaryl and 6-12 membered aryl of Rn3 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2b or Z2c groups, and wherein any (C1-C4)alkyl, (C2-C4)alkenyl and (C2-C4)alkynyl of Rn3 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2a groups;
  • Rq3 and Rr3 are each independently selected from H, (C1-C4)alkyl, (C2-C4)alkenyl, (C3-C7)carbocycle, 3-12 membered heterocycle, 5-12 membered heteroaryl and 6-12 membered aryl, wherein any (C3-C7)carbocycle, 3-12 membered heterocycle, 5-12 membered heteroaryl and 6-12 membered aryl of Rq3 or Rr3 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2b or Z2c groups, and wherein any (C1-C4)alkyl and (C2-C4)alkenyl of Rq3 or Rr3 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2a groups, or Rq3 and Rr3 together with the nitrogen to which they are attached form a heterocycle or heteroaryl, wherein the heterocycle or heteroaryl is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2b or Z2c groups;
  • each Rn4 is independently selected from H, (C1-C4)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C1-C4)haloalkyl and (C1-C4)heteroalkyl;
  • each Rp4 is independently selected from (C1-C8)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)haloalkyl and (C1-C4)heteroalkyl;
  • Rq4 and Rr4 are each independently selected from H, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)haloalkyl and (C1-C4)heteroalkyl;
  • each Z3 is independently selected from halogen, (C1-C4)alkyl, —OH, —CN, (C1-C4)heteroalkyl and (C1-C4)haloalkyl;
  • each Z4 is independently selected from (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, halogen, —CN, —ORn5, —OC(O)Rp5, —OC(O)NRq5Rr5, —SRn5, —S(O)Rp5, —S(O)2OH, —S(O)2Rp5, —S(O)2NRq5Rr5, —NRq5Rr5, —NRn5CORp5, —NRn5CO2Rp5, —NRn5CONRq5Rr5, —NRn5S(O)2Rp5, —NRn5S(O)2ORp5, —NRn5S(O)2NRq5Rr5, NO2, —C(O)Rn5, —C(O)ORn5 and —C(O)NRq5Rr5, wherein any (C3-C7)carbocycle, of Z4 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z4a or Z4b groups, and wherein any (C1-C8)alkyl, (C2-C8)alkenyl and (C2-C8)alkynyl of Z4 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z4a groups;
  • each Z4a is independently selected from halogen, —CN, —ORn6, —OC(O)Rp6, —OC(O)NRq6Rr6, —SRn6, —S(O)Rp6, —S(O)2OH, —S(O)2Rp6, —S(O)2NRq6Rr6, —NRq6Rr6, —NRn6CORp6, —NRn6CO2Rp6, —NRn6 CONRq6Rr6, —NRn6S(O)2Rp6, —NRn6S(O)2ORp6, —NRn6S(O)2NRq6Rr6, NO2, —C(O)Rn6, —C(O)ORn6 and —C(O)NRq6Rr6;
  • each Z4b is independently selected from (C1-C4)alkyl, (C2-C4)alkenyl (C2-C4)alkynyl and (C1-C4)haloalkyl;
  • each Rn5 is independently selected from H, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)heteroalkyl, (C2-C4)alkenyl and (C2-C4)alkynyl;
  • each Rp5 is independently selected from (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)heteroalkyl, (C2-C4)alkenyl and (C2-C4)alkynyl;
  • Rq5 and Rr5 are each independently selected from H, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)heteroalkyl, (C2-C4)alkenyl and (C2-C4)alkynyl;
  • each Rn6 is independently selected from H, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)heteroalkyl, (C2-C4)alkenyl and (C2-C4)alkynyl;
  • each Rp6 is independently selected from (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)heteroalkyl, (C2-C4)alkenyl and (C2-C4)alkynyl;
  • Rq6 and Rr6 are each independently selected from H, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)heteroalkyl, (C2-C4)alkenyl and (C2-C4)alkynyl;
  • each Z5 is independently selected from (C1-C6)alkyl, halogen, —CN and —ORn7, wherein any (C1-C6)alkyl of Z5 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) halogen; and
  • each Rn7 is independently selected from H, (C1-C3)alkyl, (C1-C3)haloalkyl and (C3-C7)carbocycle;
  • or a pharmaceutically acceptable salt thereof.
  • One embodiment provides a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Another embodiment provides a pharmaceutical composition comprising a compound as detailed herein, including a compound of any one of formulas I, Ia, Ib, Ic, Id, Ie, If, Ig, III, IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IIIg, IIIh, IIIi, IIIj, and IIIk, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • One embodiment provides a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof; and an additional therapeutic agent, wherein the additional therapeutic agent is an HIV protease inhibiting compound, an HIV non-nucleoside inhibitor of reverse transcriptase, an HIV nucleoside inhibitor of reverse transcriptase, an HIV nucleotide inhibitor of reverse transcriptase, an HIV integrase inhibitor, a gp41 inhibitor, a CXCR4 inhibitor, a gp120 inhibitor, a CCR5 inhibitor, a capsid polymerization inhibitor, or a non-catalytic site HIV integrase inhibitor and combinations thereof. Another embodiment provides a pharmaceutical composition comprising a compound of anty one of formulas I, Ia, Ib, Ic, Id, Ie, If, Ig, III, IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IIIg, IIIh, IIIi, IIIj, and IIIk, or a pharmaceutically acceptable salt thereof; and an additional therapeutic agent, wherein the additional therapeutic agent is an HIV protease inhibiting compound, an HIV non-nucleoside inhibitor of reverse transcriptase, an HIV nucleoside inhibitor of reverse transcriptase, an HTV nucleotide inhibitor of reverse transcriptase, an HIV integrase inhibitor, a gp41 inhibitor, a CXCR4 inhibitor, a gp120 inhibitor, a CCR5 inhibitor, a capsid polymerization inhibitor, or a non-catalytic site HIV integrase inhibitor and combinations thereof.
  • One embodiment provides a method for treating a Retroviridae viral infection (e.g., an HIV viral infection) in a mammal (e.g., a human), comprising administering a compound of formula I, or a pharmaceutically acceptable salt thereof, to the mammal. Another embodiment provides a method for treating a Retroviridae viral infection (e.g., an HIV viral infection) in a mammal (e.g., a human), comprising administering a compound as detailed herein, including a compound of any one of formulas I, Ia, Ib, Ic, Id, Ie, If, Ig, III, IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IIIg, IIIh, IIIi, IIIj, and IIIk, or a pharmaceutically acceptable salt thereof, to the mammal. Another embodiment provides a method for treating a HIV infection in a patient in need thereof comprising administering a therapeutically effective amount of a compound as detailed herein, or a pharmaceutically acceptable salt thereof, to the patient.
  • One embodiment provides a method for inhibiting the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal (e.g., a human), comprising administering a compound of formula I, or a pharmaceutically acceptable salt thereof, to the mammal. Another embodiment provides a method for inhibiting the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal (e.g., a human), comprising administering a compound as detailed herein, including a compound of any one of formulas I, Ia, Ib, Ic, Id, Ie, If, Ig, III, IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IIIg, IIIh, IIIi, IIIj, and IIIk, or a pharmaceutically acceptable salt thereof, to the mammal.
  • One embodiment provides a method for treating an HIV infection in a mammal (e.g., a human), comprising administering a compound of formula I, or a pharmaceutically acceptable salt thereof, to the mammal. Another embodiment provides a method for treating an HIV infection in a mammal (e.g., a human), comprising administering a compound as detailed herein, including a compound of any one of formulas I, Ia, Ib, Ic, Id, Ie, If, Ig, III, IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IIIg, IIIh, IIIi, IIIj, and IIIk, or a pharmaceutically acceptable salt thereof, to the mammal.
  • One embodiment provides a method for treating an HIV infection in a mammal (e.g., a human), comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, and other drugs for treating HIV, and combinations thereof. Another embodiment provides a method for treating an HIV infection in a mammal (e.g., a human), comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of any one of formulas I, Ia, Ib, Ic, Id, Ie, If, Ig, III, IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IIIg, IIIh, IIIi, IIIj, and IIIk, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, and other drugs for treating HIV, and combinations thereof. Another embodiment provides a method for treating an HIV infection in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound as described herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of an additional therapeutic agent, wherein the additional therapeutic agent is an HIV protease inhibiting compound, an HIV non-nucleoside inhibitor of reverse transcriptase, an HIV nucleoside inhibitor of reverse transcriptase, an HIV nucleotide inhibitor of reverse transcriptase, an HIV integrase inhibitor, a gp41 inhibitor, a CXCR4 inhibitor, a gp120 inhibitor, a CCR5 inhibitor, a capsid polymerization inhibitor, or a non-catalytic site HIV integrase site inhibitor and combinations thereof.
  • One embodiment provides a method for treating an HIV infection in a mammal (e.g., a human), comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, and non-catalytic site HIV integrase inhibitors, and combinations thereof. Another embodiment provides a method for treating an HIV infection in a mammal (e.g., a human), comprising administering to the mammal in need thereof a therapeutically effective amount of a compound as detailed herein, including a compound of any one of formulas I, Ia, Ib, Ic, Id, Ie, If, Ig, III, IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IIIg, IIIh, IIIi, IIIj, and IIIk, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, and non-catalytic site HIV integrase inhibitors, and combinations thereof.
  • One embodiment provides a compound of formula I, or a pharmaceutically acceptable salt thereof for use in medical therapy (e.g., for use in treating a Retroviridae viral infection (e.g., an HIV viral infection) or the proliferation of the HIV virus or AIDS or delaying the onset of AIDS or ARC symptoms in a mammal (e.g., a human)). Another embodiment provides a compound as detailed herein, including a compound of any one of formulas I, Ia, Ib, Ic, Id, Ie, If, Ig, III, IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IIIg, IIIh, IIIi, IIIj, and IIIk, or a pharmaceutically acceptable salt thereof, for use in medical therapy (e.g., for use in treating a Retroviridae viral infection (e.g., an HIV viral infection) or the proliferation of the HIV virus or AIDS or delaying the onset of AIDS or ARC symptoms in a mammal (e.g., a human)).
  • One embodiment provides a compound of formula I, or a pharmaceutically acceptable salt thereof for use in the manufacture of a medicament for treating a Retroviridae viral infection (e.g., an HIV viral infection) or the proliferation of the HIV virus or AIDS or delaying the onset of AIDS or ARC symptoms in a mammal (e.g., a human). Another embodiment provides a compound as detailed herein, including a compound of any one of formulas I, Ia, Ib, Ic, Id, Ie, If, Ig, III, IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IIIg, IIIh, IIIi, IIIj, and IIIk, or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for treating a Retroviridae viral infection (e.g., an HIV viral infection) or the proliferation of the HIV virus or AIDS or delaying the onset of AIDS or ARC symptoms in a mammal (e.g., a human).
  • One embodiment provides a compound of formula I, or a pharmaceutically acceptable salt thereof, for use in the prophylactic or therapeutic treatment of the proliferation of a Retroviridae virus, an HIV virus or AIDS or for use in the therapeutic treatment of delaying the onset of AIDS or ARC symptoms. Another embodiment provides a compound as detailed herein, including a compound of any one of formulas I, Ia, Ib, Ic, Id, Ie, If, Ig, III, IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IIIg, IIIh, IIIi, IIIj, and IIIk, or a pharmaceutically acceptable salt thereof, for use in the prophylactic or therapeutic treatment of the proliferation of a Retroviridae virus, an HIV virus or AIDS or for use in the therapeutic treatment of delaying the onset of AIDS or ARC symptoms.
  • One embodiment provides a compound of formula I, or a pharmaceutically acceptable salt thereof, for use in the prophylactic or therapeutic treatment of a Retroviridae virus infection (e.g., an HIV virus infection). Another embodiment provides a compound as detailed herein, including a compound of any one of formulas I, Ia, Ib, Ic, Id, Ie, If, Ig, III, IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IIIg, IIIh, IIIi, IIIj, and IIIk, or a pharmaceutically acceptable salt thereof, for use in the prophylactic or therapeutic treatment of a Retroviridae virus infection (e.g., an HIV virus infection).
  • One embodiment provides the use of a compound of formula I, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for a Retroviridae virus infection (e.g., an HIV virus infection) in a mammal (e.g., a human). Another embodiment provides a compound as detailed herein, including a compound of any one of formulas I, Ia, Ib, Ic, Id, Ie, If, Ig, III, IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IIIg, IIIh, IIIi, IIIj, and IIIk, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for a Retroviridae virus infection (e.g., an HIV virus infection) in a mammal (e.g., a human).
  • One embodiment provides processes and intermediates disclosed herein that are useful for preparing compounds of formula I or salts thereof. Another embodiment provides processes and intermediates disclosed herein that are useful for preparing compounds of any one of formulas I, Ia, Ib, Ic, Id, Ie, If, Ig, III, IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IIIg, IIIh, IIIi, IIIj, and IIIk, or salts thereof.
  • Other embodiments, objects, features and advantages will be set forth in the detailed description of the embodiments that follows, and in part will be apparent from the description, or may be learned by practice, of the claimed invention. These objects and advantages will be realized and attained by the processes and compositions particularly pointed out in the written description and claims hereof. The foregoing Summary has been made with the understanding that it is to be considered as a brief and general synopsis of some of the embodiments disclosed herein, is provided solely for the benefit and convenience of the reader, and is not intended to limit in any manner the scope, or range of equivalents, to which the appended claims are lawfully entitled.
    • DETAILED DESCRIPTION
  • The description below is made with the understanding that the present disclosure is to be considered as an exemplification of the claimed subject matter, and is not intended to limit the appended claims to the specific embodiments illustrated. The headings used throughout this disclosure are provided for convenience only and are not to be construed to limit the claims in any way. Embodiments illustrated under any heading may be combined with embodiments illustrated under any other heading.
    • Definitions
  • Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. A dash at the front or end of a chemical group is a matter of convenience; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning. A wavy line drawn through a line in a structure indicates a point of attachment of a group. A dashed line indicates an optional bond. A prefix such as “Cu-v” or (Cu—Cv) indicates that the following group has from u to v carbon atoms. For example, “C1-6alkyl” indicates that the alkyl group has from 1 to 6 carbon atoms.
  • Unless stated otherwise, the following terms and phrases as used herein are intended to have the following meanings:
  • When trade names are used herein, applicants intend to independently include the tradename product and the active pharmaceutical ingredient(s) of the tradename product.
  • “Alkyl” is a straight or branched saturated hydrocarbon. For example, an alkyl group can have 1 to 8 carbon atoms (i.e., (C1-C8)alkyl) or 1 to 6 carbon atoms (i.e., (C1-C6 alkyl) or 1 to 4 carbon atoms (i.e., (C1-C4)alkyl). Examples of suitable alkyl groups include, but are not limited to, methyl (Me, —CH3), ethyl (Et, —CH2CH3), 1-propyl (n-Pr, n-propyl, —CH2CH2CH3), 2-propyl (i-Pr, i-propyl, —CH(CH3)2), 1-butyl (n-Bu, n-butyl, —CH2CH2CH2CH3), 2-methyl-1-propyl (i-Bu, i-butyl, —CH2CH(CH3)2), 2-butyl (s-Bu, s-butyl, —CH(CH3)CH2CH3), 2-methyl-2-propyl (t-Bu, t-butyl, —C(CH3)3), 1-pentyl (n-pentyl, —CH2CH2CH2CH2CH3), 2-pentyl (—CH(CH3)CH2CH2CH3), 3-pentyl (—CH(CH2CH3)2), 2-methyl-2-butyl (—C(CH3)2CH2CH3), 3-methyl-2-butyl (—CH(CH3)CH(CH3)2), 3-methyl-1-butyl (—CH2CH2CH(CH3)2), 2-methyl-1-butyl (—CH2CH(CH3)CH2CH3), 1-hexyl (—CH2CH2CH2CH2CH2CH3), 2-hexyl (—CH(CH3)CH2CH2CH2CH3), 3-hexyl (—CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (—C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (—CH(CH3)CH(CH3)CH2CH3), 4-methyl-2-pentyl (—CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (—C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (—CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (—C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl (—CH(CH3)C(CH3)3, and octyl (—(CH2)7CH3).
  • “Alkenyl” is a straight or branched hydrocarbon with at least one carbon-carbon, sp double bond. For example, an alkenyl group can have 2 to 8 carbon atoms (i.e., C2-C8 alkenyl), or 2 to 6 carbon atoms (i.e., C2-C6 alkenyl). Examples of suitable alkenyl groups include, but are not limited to, ethylene or vinyl (—CH═CH2), allyl (—CH2CH═CH2) and 5-hexenyl (—CH2CH2CH2CH2CH═CH2).
  • “Alkynyl” is a straight or branched hydrocarbon with at least one carbon-carbon, sp triple bond. For example, an alkynyl group can have 2 to 8 carbon atoms (i.e., C2-C8 alkyne) or 2 to 6 carbon atoms (i.e., C2-C6 alkynyl). Examples of suitable alkynyl groups include, but are not limited to, acetylenic (—C≡CH), propargyl (—CH2C≡CH), and the like.
  • The term “halo” or “halogen” as used herein refers to fluoro, chloro, bromo and iodo.
  • The term “haloalkyl” as used herein refers to an alkyl as defined herein, wherein one or more hydrogen atoms of the alkyl are each independently replaced by a halo substituent. For example, (C1-C6)haloalkyl is a (C1-C6)alkyl wherein one or more of the hydrogen atoms of the (C1-C6)alkyl have been replaced by a halo substituent. Examples of haloalkyls include but are not limited to fluoromethyl, fluorochloromethyl, difluoromethyl, difluorochloromethyl, trifluoromethyl, 1,1,1, trifluoroethyl and pentafluoroethyl.
  • The term “heteroalkyl” as used herein refers to an alkyl as defined herein, wherein one or more of the carbon atoms of the alkyl are replaced by an O, S, or NRq, (or if the carbon atom being replaced is a terminal carbon with an OH, SH or N(Rq)2) wherein each Rq is independently H or (C1-C6)alkyl. For example, (C1-C8)heteroalkyl includes a heteroalkyl of one to eight carbons and one or more heteroatoms (e.g., O, S, NRq, OH, SH or N(Rq)2). Thus, for example, a C1 heteroalkyl encompasses, e.g., —CH2—NH2. Examples of heteroalkyls include but are not limited to methoxymethyl, ethoxymethyl, methoxy, 2-hydroxyethyl and N,N′-dimethylpropylamine.
  • The term “aryl” as used herein refers to a single all carbon aromatic ring or a multiple condensed all carbon ring system wherein at least one of the rings is aromatic. For example, in certain embodiments, an aryl group has 6 to 20 carbon atoms, 6 to 14 carbon atoms, or 6 to 12 carbon atoms. Aryl includes a phenyl radical. Aryl also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) having about 9 to 20 carbon atoms in which at least one ring is aromatic and wherein the other rings may be aromatic or not aromatic (i.e., carbocycle). Such multiple condensed ring systems are optionally substituted with one or more (e.g., 1, 2 or 3) oxo groups on any carbocycle portion of the multiple condensed ring system. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. It is to be understood that the point of attachment of a multiple condensed ring system, as defined above, can be at any position of the ring system including an aromatic or a carbocycle portion of the ring. It is also to be understood that when reference is made to a certain atom-range membered aryl (e.g., 6-12 membered aryl), the atom range is for the total ring atoms of the aryl. For example, a 6-membered aryl would include phenyl and a 10-membered aryl would include naphthyl and 1, 2, 3, 4-tetrahydronaphthyl. Non-limiting examples of aryl groups include, but are not limited to, phenyl, indenyl, naphthyl, 1, 2, 3, 4-tetrahydronaphthyl, anthracenyl, and the like.
  • The term “heteroaryl” as used herein refers to a single aromatic ring that has at least one atom other than carbon in the ring, wherein the atom is selected from the group consisting of oxygen, nitrogen and sulfur; “heteroaryl” also includes multiple condensed ring systems that have at least one such aromatic ring, which multiple condensed ring systems are further described below. Thus, “heteroaryl” includes single aromatic rings of from about 1 to 6 carbon atoms and about 1-4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur. The sulfur and nitrogen atoms may also be present in an oxidized form provided the ring is aromatic. Exemplary heteroaryl ring systems include but are not limited to pyridyl, pyrimidinyl, oxazolyl or furyl. “Heteroaryl” also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) wherein a heteroaryl group, as defined above, is condensed with one or more rings selected from heteroaryls (to form for example 1,8-naphthyridinyl), heterocycles, (to form for example 1,2,3,4-tetrahydro-1,8-naphthyridinyl), carbocycles (to form for example 5,6,7,8-tetrahydroquinolyl) and aryls (to form for example indazolyl) to form the multiple condensed ring system. Thus, a heteroaryl (a single aromatic ring or multiple condensed ring system) has about 1-20 carbon atoms and about 1-6 heteroatoms within the heteroaryl ring. Such multiple condensed ring systems may be optionally substituted with one or more (e.g., 1, 2, 3 or 4) oxo groups on the carbocycle or heterocycle portions of the condensed ring. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. It is to be understood that the individual rings of the multiple condensed ring system may be connected in any order relative to one another. It is also to be understood that the point of attachment of a multiple condensed ring system (as defined above for a heteroaryl) can be at any position of the multiple condensed ring system including a heteroaryl, heterocycle, aryl or carbocycle portion of the multiple condensed ring system. It is also to be understood that the point of attachment for a heteroaryl or heteroaryl multiple condensed ring system can be at any suitable atom of the heteroaryl or heteroaryl multiple condensed ring system including a carbon atom and a heteroatom (e.g., a nitrogen). It also to be understood that when a reference is made to a certain atom-range membered heteroaryl (e.g., a 5-14 membered heteroaryl), the atom range is for the total ring atoms of the heteroaryl and includes carbon atoms and heteroatoms. For example, a 5-membered heteroaryl would include a thiazolyl and a 10-membered heteroaryl would include a quinolinyl. Exemplary heteroaryls include but are not limited to pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, thienyl, indolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, furyl, oxadiazolyl, thiadiazolyl, quinolyl, isoquinolyl, benzothiazolyl, benzoxazolyl, indazolyl, quinoxalyl, quinazolyl, 5,6,7,8-tetrahydroisoquinolinyl benzofuranyl, benzimidazolyl, thianaphthenyl, pyrrolo[2,3-b]pyridinyl, quinazolinyl-4(3H)-one, triazolyl, 4,5,6,7-tetrahydro-1H-indazole and 3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole.
  • The term “C-linked-heteroaryl” (carbon-linked heteroaryl) as used herein refers to a heteroaryl that is linked at a carbon atom of the heteroaryl to the remainder of the compound of formula I (e.g., a C-linked-heteroaryl of Z2 bonded to the A ring of formula I through a carbon atom of the C-linked-heteroaryl).
  • The term “heterocyclyl” or “heterocycle” as used herein refers to a single saturated or partially unsaturated ring that has at least one atom other than carbon in the ring, wherein the atom is selected from the group consisting of oxygen, nitrogen and sulfur; the term also includes multiple condensed ring systems that have at least one such saturated or partially unsaturated ring, which multiple condensed ring systems are further described below. Thus, the term includes single saturated or partially unsaturated rings (e.g., 3, 4, 5, 6 or 7-membered rings) from about 1 to 6 carbon atoms and from about 1 to 3 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur in the ring. The ring may be substituted with one or more (e.g., 1, 2 or 3) oxo groups and the sulfur and nitrogen atoms may also be present in their oxidized forms. Exemplary heterocycles include but are not limited to azetidinyl, tetrahydrofuranyl and piperidinyl. The term “heterocycle” also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) wherein a single heterocycle ring (as defined above) can be condensed with one or more groups selected from heterocycles (to form for example a 1,8-decahydronapthyridinyl), carbocycles (to form for example a decahydroquinolyl) and aryls to form the multiple condensed ring system. Thus, a heterocycle (a single saturated or single partially unsaturated ring or multiple condensed ring system) has about 2-20 carbon atoms and 1-6 heteroatoms within the heterocycle ring. Such multiple condensed ring systems may be optionally substituted with one or more (e.g., 1, 2, 3 or 4) oxo groups on the carbocycle or heterocycle portions of the multiple condensed ring. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. It is to be understood that the individual rings of the multiple condensed ring system may be connected in any order relative to one another. It is also to be understood that the point of attachment of a multiple condensed ring system (as defined above for a heterocycle) can be at any position of the multiple condensed ring system including a heterocycle, aryl and carbocycle portion of the ring. It is also to be understood that the point of attachment for a heterocycle or heterocycle multiple condensed ring system can be at any suitable atom of the heterocycle or heterocycle multiple condensed ring system including a carbon atom and a heteroatom (e.g., a nitrogen). It is also to be understood that when reference is made to a certain atom-range membered heterocycle (e.g., a 3-14 membered heterocycle), the atom range is for the total ring atoms of the heterocycle and includes carbon atoms and heteroatoms. For example, a 3-membered heterocycle would include an aziridinyl and a 10-membered heterocycle would include a 1,2,3,4-tetrahydroquinolyl. Exemplary heterocycles include, but are not limited to aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydrofuranyl, dihydrooxazolyl, tetrahydropyranyl, tetrahydrothiopyranyl, 1,2,3,4-tetrahydroquinolyl, benzoxazinyl, dihydrooxazolyl, chromanyl, 1,2-dihydropyridinyl, 2,3-dihydrobenzofuranyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl, spiro[cyclopropane-1,1′-isoindolinyl]-3′-one, isoindolinyl-1-one, 2-oxa-6-azaspiro[3.3]heptanyl, imidazolidin-2-one and pyrrolidin-2-one.
  • The term “C-linked-heterocycle” (carbon-linked heterocycle) as used herein refers to a “heterocycle that is linked at a carbon atom of the heterocycle to the remainder of the compound of formula I (e.g., a C-linked-heterocycle of Z2 bonded to the A ring of formula I through a carbon atom of the C-linked-heterocycle).
  • The term “carbocycle” or “carbocyclyl” refers to a single saturated (i.e., cycloalkyl) or a single partially unsaturated (e.g., cycloalkenyl, cycloalkadienyl, etc.) all carbon ring having 3 to 7 carbon atoms (i.e., (C3-C7)carbocycle). The term “carbocycle” or “carbocyclyl” also includes multiple condensed, saturated and partially unsaturated all carbon ring systems (e.g., ring systems comprising 2, 3 or 4 carbocyclic rings). Accordingly, carbocycle includes multicyclic carbocyles such as a bicyclic carbocycles (e.g., bicyclic carbocycles having about 6 to 12 carbon atoms such as bicyclo[3.1.0]hexane and bicyclo[2.1.1]hexane), and polycyclic carbocycles (e.g tricyclic and tetracyclic carbocycles with up to about 20 carbon atoms). The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. For example, multicyclic carbocyles can be connected to each other via a single carbon atom to form a spiro connection (e.g., spiropentane, spiro[4,5]decane, etc), via two adjacent carbon atoms to form a fused connection (e.g., carbocycles such as decahydronaphthalene, norsabinane, norcarane) or via two non-adjacent carbon atoms to form a bridged connection (e.g., norbornane, bicyclo[2.2.2]octane, etc). The “carbocycle” or “carbocyclyl” can also be optionally substituted with one or more (e.g., 1, 2 or 3) oxo groups. Non-limiting examples of monocyclic carbocycles include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl and 1-cyclohex-3-enyl.
  • The term “halophenyl” as used herein refers to phenyl, wherein one or more (e.g., 1, 2, 3, 4 or 5) hydrogen atoms of the phenyl are each replaced independently by a halo substituent. Examples of halophenyl include but are not limited to fluorophenyl, 2,3-dichlorophenyl, 3-bromo-4-fluorophenyl and pentafluorophenyl.
  • The term “haloheteroaryl” as used herein refers to a heteroaryl, wherein one or more (e.g., 1, 2, 3, 4 or 5) hydrogen atoms of the heteroaryl are each replaced independently by a halo substituent. Examples of haloheteroaryl include but are not limited to 2-fluorofuryl, 2,3-dichloropyridinyl and 8-chloro-3-fluoroquinolinyl.
  • The term “haloheterocycle” as used herein refers to a heterocycle, wherein one or more (e.g., 1, 2, 3, 4 or 5) hydrogen atoms of the heterocycle are each replaced independently by a halo substituent. Examples of haloheteroaryl include but are not limited to 2-fluoropiperidinyl, 2-chloro-3-fluoropiperazinyl and 3-bromopyrrolidinyl.
  • One skilled in the art will recognize that substituents and other moieties of the compounds of formula I should be selected in order to provide a compound which is sufficiently stable to provide a pharmaceutically useful compound which can be formulated into an acceptably stable pharmaceutical composition. Compounds of formula I which have such stability are contemplated as falling within the scope of the present invention. Similarly, one skilled in the art will recognize that substituents and other moieties of the compounds detailed herein, including a compound of any one of formulas I, Ia, Ib, Ic, Id, Ie, If, Ig, III, IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IIIg, IIIh, IIIi, IIIj, and IIIk, or a pharmaceutically acceptable salt thereof, should be selected in order to provide a compound which is sufficiently stable to provide a pharmaceutically useful compound which can be formulated into an acceptably stable pharmaceutical composition. Compounds as detailed herein which have such stability are contemplated as falling within the scope of the present invention.
  • The modifier “about” used in connection with a quantity is inclusive of the stated value and has the meaning dictated by the context (e.g., includes the degree of error associated with measurement of the particular quantity). The word “about” may also be represented symbolically by “˜” in the context of a chemical measurement (e.g., ˜50 mg or pH ˜7).
  • The term “treatment” or “treating,” to the extent it relates to a disease or condition includes preventing the disease or condition from occurring, inhibiting the disease or condition, eliminating the disease or condition, and/or relieving one or more symptoms of the disease or condition.
  • In one embodiment, “treatment” or “treating” include one or more of the following: a) inhibiting the disease or condition (e.g., decreasing one or more symptoms resulting from the disease or condition, and/or diminishing the extent of the disease or condition); b) slowing or arresting the development of one or more symptoms associated with the disease or condition (e.g., stabilizing the disease or condition, delaying the worsening or progression of the disease or condition); and c) relieving the disease or condition, e.g., causing the regression of clinical symptoms, ameliorating the disease state, delaying the progression of the disease, increasing the quality of life, and/or prolonging survival.
    • Stereoisomers
  • Stereochemical definitions and conventions used herein generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., Stereochemistry of Organic Compounds (1994) John Wiley & Sons, Inc., New York.
  • The term “chiral” refers to molecules which have the property of non-superimposability of the mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner.
  • The term “stereoisomers” refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.
  • “Diastereomer” refers to a stereoisomer with two or more centers or axes of chirality and whose molecules are not mirror images of one another. Diastereomers typically have different physical properties, e.g., melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers may separate under high resolution analytical procedures such as electrophoresis and chromatography.
  • “Enantiomers” refer to two stereoisomers of a compound which are non-superimposable mirror images of one another.
  • The compounds disclosed herein may have chiral centers, e.g., chiral carbon atoms. Such compounds thus include racemic mixtures of all stereoisomers, including enantiomers, diastereomers, and atropisomers. In addition, the compounds disclosed herein include enriched or resolved optical isomers at any or all asymmetric, chiral atoms. Similarly, compositions disclosed herein also include racemic mixtures of all stereoisomers, including enantiomers, diastereomers, and atropisomers of compounds disclosed herein. In addition, the compounds and compositions disclosed herein include enriched or resolved optical isomers at any or all asymmetric, chiral atoms. In other words, the chiral centers apparent from the depictions are provided as the chiral isomers or racemic mixtures. Both racemic and diastereomeric mixtures, as well as the individual optical isomers isolated or synthesized, substantially free of their enantiomeric or diastereomeric partners, are all within the scope of the invention. The racemic mixtures can be separated into their individual, substantially optically pure isomers through well-known techniques such as, for example, the separation of diastereomeric salts formed with optically active adjuncts, e.g., acids or bases followed by conversion back to the optically active substances. The desired optical isomer can also be synthesized by means of stereospecific reactions, beginning with the appropriate stereoisomer of the desired starting material.
  • The invention includes any or all of the stereochemical forms, including any enantiomeric or diastereomeric forms and geometric isomers of the compounds described, or mixtures thereof. Unless stereochemistry is explicitly indicated in a chemical structure or name, the structure or name is intended to embrace all possible stereoisomers, including geometric isomers, of a compound depicted. Compositions comprising a compound of the invention are also intended, such as a composition of substantially pure compound, including a specific stereochemical form, including a specific geometric isomer, thereof. Compositions comprising a mixture of compounds of the invention in any ratio are also embraced by the invention, including mixtures of two or more stereochemical forms of a compound of the invention in any ratio, such that racemic, non-racemic, enantio-enriched and scalemic mixtures of a compound are embraced, or mixtures thereof.
  • It is to be understood that for compounds disclosed herein when a bond is drawn in a non-stereochemical manner (e.g., flat) the atom to which the bond is attached includes all stereochemical possibilities. It is also to be understood that when a bond is drawn in a stereochemical manner (e.g., bold, bold-wedge, dashed or dashed-wedge) the atom to which the stereochemical bond is attached has the stereochemistry as shown unless otherwise noted. Accordingly, in one embodiment, a compound disclosed herein is greater than 50% a single enantiomer. In another embodiment, a compound disclosed herein is at least 80% a single enantiomer. In another embodiment, a compound disclosed herein is at least 90% a single enantiomer. In another embodiment, a compound disclosed herein is at least 98% a single enantiomer. In another embodiment, a compound disclosed herein is at least 99% a single enantiomer. In another embodiment, a compound disclosed herein is greater than 50% a single diastereomer. In another embodiment, a compound disclosed herein is at least 80% a single diastereomer. In another embodiment, a compound disclosed herein is at least 90% a single diastereomer. In another embodiment, a compound disclosed herein is at least 98% a single diastereomer. In another embodiment, a compound disclosed herein is at least 99% a single diastereomer.
  • Accordingly, in one embodiment, a composition disclosed herein is greater than 50% a single enantiomer. In another embodiment, a composition disclosed herein is at least 80% a single enantiomer. In another embodiment, a composition disclosed herein is at least 90% a single enantiomer. In another embodiment, a composition disclosed herein is at least 98% a single enantiomer. In another embodiment, a composition disclosed herein is at least 99% a single enantiomer. In another embodiment, a composition disclosed herein is greater than 50% a single diastereomer. In another embodiment, a composition disclosed herein is at least 80% a single diastereomer. In another embodiment, a composition disclosed herein is at least 90% a single diastereomer. In another embodiment, a composition disclosed herein is at least 98% a single diastereomer. In another embodiment, a composition disclosed herein is at least 99% a single diastereomer.
  • In certain embodiments, the compounds disclosed herein display atropisomerism resulting from steric hindrance affecting the axial rotation rate around a single bond. In certain circumstances, the resultant conformational isomers are observed as distinct entities by characterization techniques such as NMR and HPLC. In certain embodiments, the compounds disclosed herein exist as a mixture of atropisomers. The synthetic examples provided herein note where such mixtures of atropisomers have been observed. However, the detection of atropisomers is dependent on factors such as temperature, solvent, conditions of purification, and timescale of spectroscopic technique. Characterization data presented herein may not represent the equilibrium state depending on the conditions of purification, isolation, handling, solvents used, and temperature.
    • Tautomers
  • The compounds disclosed herein can also exist as tautomeric isomers in certain cases. Although only one delocalized resonance structure may be depicted, all such forms are contemplated within the scope of the invention. For example, ene-amine tautomers can exist for purine, pyrimidine, imidazole, guanidine, amidine, and tetrazole systems and all their possible tautomeric forms are within the scope of the invention. Another non-limiting example includes keto-enol tautomers of heteroaryls. Such tautomers are exemplified by T1/T1′, T2/T2′ and T3/T3′. All such tautomeric forms are also within the scope of the invention.
  • Figure US20210009555A1-20210114-C00005
    • Protecting Groups
  • “Protecting group” refers to a moiety of a compound that masks or alters the properties of a functional group or the properties of the compound as a whole. Chemical protecting groups and strategies for protection/deprotection are well known in the art. See e.g., Protective Groups in Organic Chemistry, Theodora W. Greene, John Wiley & Sons, Inc., New York, 1991. Protecting groups are often utilized to mask the reactivity of certain functional groups, to assist in the efficiency of desired chemical reactions, e.g., making and breaking chemical bonds in an ordered and planned fashion. Protection of functional groups of a compound alters other physical properties besides the reactivity of the protected functional group, such as the polarity, lipophilicity (hydrophobicity), and other properties which can be measured by common analytical tools. Chemically protected intermediates may themselves be biologically active or inactive.
    • Salts and Hydrates
  • “Pharmaceutically acceptable salt” refers to a salt of a compound that is pharmaceutically acceptable and that possesses (or can be converted to a form that possesses) the desired pharmacological activity of the parent compound. Pharmaceutically acceptable salts are generally regarded as safe and suitable for use without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio. Examples of “pharmaceutically acceptable salts” of the compounds disclosed herein include salts derived from an appropriate base, such as an alkali metal (for example, sodium), an alkaline earth metal (for example, magnesium), ammonium and NX4 + (wherein X is C1-C4 alkyl). Pharmaceutically acceptable salts of a nitrogen atom or an amino group include for example salts of organic carboxylic acids such as acetic, benzoic, camphorsulfonic, citric, glucoheptonic, gluconic, lactic, fumaric, tartaric, maleic, malonic, malic, mandelic, isethionic, lactobionic, succinic, 2-napththalenesulfonic, oleic, palmitic, propionic, stearic, and trimethylacetic acids; organic sulfonic acids, such as methanesulfonic, ethanesulfonic, benzenesulfonic and p-toluenesulfonic acids; and inorganic acids, such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric and sulfamic acids. Pharmaceutically acceptable salts of a compound of a hydroxy group include the anion of said compound in combination with a suitable cation such as Na+ and NX4 + (wherein X is independently selected from H or a C1-C4 alkyl group). Pharmaceutically acceptable salts also include salts formed when an acidic proton present in the parent compound is replaced by either a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as diethanolamine, triethanolamine, N-methylglucamine and the like. Also included in this definition are ammonium and substituted or quaternized ammonium salts. Representative non-limiting lists of pharmaceutically acceptable salts can be found in S.M. Berge et al., J. Pharma Sci., 66(1), 1-19 (1977), and Remington: The Science and Practice of Pharmacy, R. Hendrickson, ed., 21st edition, Lippincott, Williams & Wilkins, Philadelphia, Pa., (2005), at p. 732, Table 38-5, both of which are hereby incorporated by reference herein.
  • For therapeutic use, salts of active ingredients of the compounds disclosed herein will typically be pharmaceutically acceptable, i.e., they will be salts derived from a physiologically acceptable acid or base. However, salts of acids or bases which are not pharmaceutically acceptable may also find use, for example, in the preparation or purification of a compound of formula I or another compound disclosed herein. All salts, whether or not derived from a physiologically acceptable acid or base, are within the scope of the present invention.
  • Metal salts typically are prepared by reacting the metal hydroxide with a compound disclosed herein. Examples of metal salts which are prepared in this way are salts containing Li+, Na+, and K+. A less soluble metal salt can be precipitated from the solution of a more soluble salt by addition of the suitable metal compound.
  • In addition, salts may be formed from acid addition of certain organic and inorganic acids, e.g., HCl, HBr, H2SO4H3PO4 or organic sulfonic acids, to basic centers, such as amines. Finally, it is to be understood that the compositions herein comprise compounds disclosed herein in their un-ionized, as well as zwitterionic form, and combinations with stoichiometric amounts of water as in hydrates.
  • Often crystallizations produce a solvate of the compound of the invention. As used herein, the term “solvate” refers to an aggregate that comprises one or more molecules of a compound of the invention with one or more molecules of solvent. The solvent may be water, in which case the solvate may be a hydrate. Alternatively, the solvent may be an organic solvent. Thus, the compounds of the present invention may exist as a hydrate, including a monohydrate, dihydrate, hemihydrate, sesquihydrate, trihydrate, tetrahydrate and the like, as well as the corresponding solvated forms. The compound of the invention may be true solvates, while in other cases, the compound of the invention may merely retain adventitious water or be a mixture of water plus some adventitious solvent.
    • Isotopes
  • It is understood by one skilled in the art that this invention also includes any compound claimed that may be enriched at any or all atoms above naturally occurring isotopic ratios with one or more isotopes such as, but not limited to, deuterium (2H or D). As a non-limiting example, in certain embodiments, a —CH3 group is replaced with—CD3.
  • Specific values listed below for radicals, substituents, and ranges in the embodiments of the invention are for illustration only; they do not exclude other defined values or other values within defined ranges for the radicals and substituents.
    • Compounds of Formula I.
  • A specific group of compounds of formula I are compounds of formula Ia.
  • Figure US20210009555A1-20210114-C00006
  • or a pharmaceutically acceptable salt thereof.
  • Another specific group of compounds of formula I are compounds of formula Ib.
  • Figure US20210009555A1-20210114-C00007
  • or a pharmaceutically acceptable thereof.
  • Another specific group of compounds of formula I are compounds of formula Ic.
  • Figure US20210009555A1-20210114-C00008
  • or a pharmaceutically acceptable thereof.
  • Another specific group of compounds of formula I are compounds of formula Id.
  • Figure US20210009555A1-20210114-C00009
  • or a pharmaceutically acceptable thereof.
  • Another specific group of compounds of formula I are compounds of formula Ie.
  • Figure US20210009555A1-20210114-C00010
  • or a pharmaceutically acceptable thereof.
  • Another specific group of compounds of formula I are compounds of formula If.
  • Figure US20210009555A1-20210114-C00011
  • or a pharmaceutically acceptable thereof.
  • Another specific group of compounds of formula I are compounds of formula Ig.
  • Figure US20210009555A1-20210114-C00012
  • or a pharmaceutically acceptable thereof.
  • Specific values listed below are values for compounds of formula I as well as all related formulas (e.g., formulas Ia, Ib, Ic, Id, Ie, If, Ig). It is to be understood that two or more values may combined. Thus, it is to be understood that any variable for compounds of formula I may be combined with any other variable for compounds of formula I the same as if each and every combination of variables were specifically and individually listed. For example, it is understood that any specific value of R1 detailed herein for compounds of formula I may be combined with any other specific value for one or more of the variables A, Z1, R2, R3a or R3b the same as if each and every combination were specifically and individually listed.
  • Specific values listed for compounds of formula I may apply equally to compounds of formula III and all related formulas (e.g., formulas IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IIIg, IIIh, IIIi, IIIj, and IIIk) as applicable. For example, specific values for ring A of formula I may apply equally to ring A of formula III provided that the ring A of formula III encompasses within its scope the specific values. It is also understood that any combination of variables for compounds of formula I may apply equally to compounds of formula III and all related formulas (e.g., formulas IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IIIg, IIIh, IIIi, IIIj, and IIIk) as applicable, the same as if each and every combination were specifically and individually listed. For example, specific values for ring A and Z1 may apply equally to the A-Z1 moeity of formula III provided that the scope of the A-Z1 moiety of formula III encompasses the specific value.
  • A specific group of compounds of formula I are compounds wherein each R3a and R3b is independently selected from H, halogen, (C1-C3)alkyl, and (C1-C3)haloalkyl.
  • A specific group of compounds of formula I are compounds wherein each R3a and R3b is independently selected from H, (C1-C3)alkyl, and (C1-C3)haloalkyl.
  • A specific group of compounds of formula I are compounds wherein each R3a and R3b is independently selected from H and (C1-C3)alkyl.
  • A specific group of compounds of formula I are compounds wherein each R3a and R3b is independently selected from H, methyl and ethyl.
  • A specific group of compounds of formula I are compounds wherein each R3a and R3b is independently selected from H and methyl.
  • A specific group of compounds of formula I are compounds wherein R3a is H and R3b is (C1-C3)alkyl.
  • A specific group of compounds of formula I are compounds wherein R3a is H and R3b is methyl or ethyl.
  • A specific group of compounds of formula I are compounds wherein R3a is H and R3b is methyl.
  • A specific value for R3a and R3b is H.
  • A specific value for R2 is phenyl or a 5-membered monocyclic-heteroaryl, wherein any phenyl or 5-membered monocyclic-heteroaryl of R2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z5 groups.
  • A specific value for R2 is phenyl or a 5-membered monocyclic-heteroaryl, wherein any phenyl or 5-membered monocyclic-heteroaryl of R2 is substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z5 groups.
  • A specific value for R2 is phenyl optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z5 groups.
  • A specific value for R2 is phenyl substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z5 groups.
  • A specific value for Z5 is halogen.
  • A specific value for Z5 is fluoro.
  • A specific value for R2 is 3,5-difluorophenyl.
  • A specific value for A is pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein any pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl of A is substituted with one Z1 group at the position shown, one Z2 group and optionally substituted with one or more (e.g., 1 or 2) Z3 groups.
  • A specific value for A is pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein any pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl of A is substituted with one Z1 group at the position shown and one Z2 group.
  • A specific value for A is pyridinyl, wherein any pyridinyl of A is substituted with one Z1 group at the position shown, one Z2 group, and optionally substituted with one or more (e.g., 1 or 2) Z3 groups.
  • A specific value for A is pyridinyl, wherein any pyridinyl of A is substituted with one Z1 group at the position shown and one Z2 group
  • A specific value for A is selected from:
  • Figure US20210009555A1-20210114-C00013
  • wherein each Z3a is independently selected from H and Z3.
  • A specific value for A is selected from:
  • Figure US20210009555A1-20210114-C00014
  • wherein each Z3a is independently selected from H and Z3.
  • A specific value for A is selected from:
  • Figure US20210009555A1-20210114-C00015
  • wherein each Z3a is independently selected from H and Z3.
  • A specific value for A is:
  • Figure US20210009555A1-20210114-C00016
  • wherein each Z3a is independently selected from H and Z3.
  • A specific value for A is:
  • Figure US20210009555A1-20210114-C00017
  • wherein each Z3a is independently selected from H and Z3.
  • A specific value for A is H.
  • Figure US20210009555A1-20210114-C00018
  • wherein each Z3a is independently selected from H and Z3.
  • A specific value for Z3a is:
  • A specific value for Z1 is selected from phenyl, 5-14 membered heteroaryl and 3-14 membered heterocycle, wherein any phenyl, 5-14 membered heteroaryl and 3-14 membered heterocycle of Z1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1a or Z1b groups.
  • A specific value for Z1 is selected from phenyl, 5-12 membered heteroaryl and 3-12 membered heterocycle, wherein any phenyl, 5-12 membered heteroaryl and 3-12 membered heterocycle of Z1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1a or Z1b groups.
  • A specific value for Z1 is selected from phenyl, 5-14 membered heteroaryl and 3-14 membered heterocycle, wherein any phenyl, 5-14 membered heteroaryl and 3-14 membered heterocycle of Z1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1a groups.
  • A specific value for Z1 is selected from phenyl, 5-12 membered heteroaryl and 3-12 membered heterocycle, wherein any phenyl, 5-12 membered heteroaryl and 3-12 membered heterocycle of Z1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1a groups.
  • A specific value for Z1 is selected from phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle and 9-12 membered tricyclic-heterocycle wherein any phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle and 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1a or Z1b groups.
  • A specific value for Z1 is selected from phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle and 9-12 membered tricyclic-heterocycle wherein any phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle and 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1a groups.
  • A specific value for Z1 is selected from phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle and 9-12 membered tricyclic-heterocycle, wherein the 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle and 9-12 membered tricyclic-heterocycle have 1-11 carbon atoms and 1-5 heteroatoms in the ring system, and wherein any phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle and 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1a or Z1b groups.
  • A specific value for Z1 is selected from phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle and 9-12 membered tricyclic-heterocycle, wherein the 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle and 9-12 membered tricyclic-heterocycle have 1-11 carbon atoms and 1-5 heteroatoms in the ring system, and wherein any phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle and 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1a groups.
  • A specific value for Z1 is selected from phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle and 9-12 membered tricyclic-heterocycle, wherein the 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle and 9-12 membered tricyclic-heterocycle have 4-11 carbon atoms and 1-3 heteroatoms in the ring system, and wherein any phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle and 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1a or Z1b groups.
  • A specific value for Z1 is selected from phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle and 9-12 membered tricyclic-heterocycle, wherein the 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle and 9-12 membered tricyclic-heterocycle have 4-11 carbon atoms and 1-3 heteroatoms in the ring system, and wherein any phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle and 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1a groups.
  • A specific value for Z1 is selected from 8-10 membered bicyclic-heteroaryl and 8-10 membered bicyclic-heterocycle, wherein any from 8-10 membered bicyclic-heteroaryl and 8-10 membered bicyclic-heterocycle of Z1 is optionally substituted with one or more Z1a or Z1b groups.
  • A specific value for Z1 is selected from 8-10 membered bicyclic-heteroaryl and 8-10 membered bicyclic-heterocycle, wherein any from 8-10 membered bicyclic-heteroaryl and 8-10 membered bicyclic-heterocycle of Z1 is optionally substituted with one or more Z1a groups.
  • A specific value for Z1 is selected from 8-10 membered bicyclic-heteroaryl and 8-10 membered bicyclic-heterocycle, wherein the 8-10 membered bicyclic-heteroaryl and 8-10 membered bicyclic-heterocycle have 3-9 carbon atoms and 1-5 heteroatoms in the ring system, and wherein any 8-10 membered bicyclic-heteroaryl and 8-10 membered bicyclic-heterocycle of Z1 is optionally substituted with one or more Z1a or Z1b groups.
  • A specific value for Z1 is selected from 8-10 membered bicyclic-heteroaryl and 8-10 membered bicyclic-heterocycle, wherein the 8-10 membered bicyclic-heteroaryl and 8-10 membered bicyclic-heterocycle have 3-9 carbon atoms and 1-5 heteroatoms in the ring system, and wherein any 8-10 membered bicyclic-heteroaryl and 8-10 membered bicyclic-heterocycle of Z1 is optionally substituted with one or more Z1a groups.
  • A specific value for Z is selected from phenyl, 1H-pyrrolo[2,3-b]pyridinyl, 1-oxoisoindolinyl, 4-oxo-3,4-dihydroquinazolinyl, 3-oxospiro[cyclopropane-1,1′-isoindolin]-yl, 1H-2-oxo-pyridinyl and 2,4-dioxo-1,2,3,4-tetrahydorquinazolinyl, wherein any phenyl, 1H-pyrrolo[2,3-b]pyridinyl, 1-oxoisoindolinyl, 4-oxo-3,4-dihydroquinazolinyl, 3-oxospiro[cyclopropane-1,1′-isoindolin]-yl, 1H-2-oxo-pyridinyl and 2,4-dioxo-1,2,3,4-tetrahydorquinazolinyl of Z is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1a or Z1b groups. A specific value for Z1 is 1H-indazol-7-yl, wherein Z1 is optionally substituted with one or more Z1a or Z1b groups.
  • A specific value for Z is selected from phenyl, 1H-pyrrolo[2,3-b]pyridinyl, 1-oxoisoindolinyl, 4-oxo-3,4-dihydroquinazolinyl, 3-oxospiro[cyclopropane-1,1′-isoindolin]-yl, 1H-2-oxo-pyridinyl and 2,4-dioxo-1,2,3,4-tetrahydorquinazolinyl as shown by the following formulas;
  • Figure US20210009555A1-20210114-C00019
  • wherein any phenyl, 1H-pyrrolo[2,3-b]pyridinyl, 1-oxoisoindolinyl, 4-oxo-3,4-dihydroquinazolinyl, 3-oxospiro[cyclopropane-1,1′-isoindolin]-yl, 1H-2-oxo-pyridinyl and 2,4-dioxo-1,2,3,4-tetrahydorquinazolinyl of Z is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1a or Z1b groups. A specific value for Z1 is
  • Figure US20210009555A1-20210114-C00020
  • A specific value for Z1 is
  • Figure US20210009555A1-20210114-C00021
  • A specific value for Z is selected from phenyl, 1H-pyrrolo[2,3-b]pyridinyl, 1-oxoisoindolinyl, 3-oxospiro[cyclopropane-1,1′-isoindolin]-yl, pyridinyl and quinazolinyl, wherein any phenyl, 1H-pyrrolo[2,3-b]pyridinyl, 1-oxoisoindolinyl, 3-oxospiro[cyclopropane-1,1′-isoindolin]-yl, pyridinyl and quinazolinyl of Z is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1a or Z1b groups.
  • A specific value for Z is selected from phenyl, 1H-pyrrolo[2,3-b]pyridinyl, 1-oxoisoindolinyl, 4-oxo-3,4-dihydroquinazolinyl, 3-oxospiro[cyclopropane-1,1′-isoindolin]-yl, 1H-2-oxo-pyridinyl and 2,4-dioxo-1,2,3,4-tetrahydorquinazolinyl, wherein any phenyl, 1H-pyrrolo[2,3-b]pyridinyl, 1-oxoisoindolinyl, 4-oxo-3,4-dihydroquinazolinyl, 3-oxospiro[cyclopropane-1,1′-isoindolin]-yl, 1H-2-oxo-pyridinyl and 2,4-dioxo-1,2,3,4-tetrahydorquinazolinyl of Z1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1a groups.
  • A specific value for Z1 is selected from phenyl, 1H-pyrrolo[2,3-b]pyridinyl, 1-oxoisoindolinyl, 3-oxospiro[cyclopropane-1,1′-isoindolin]-yl, pyridinyl and quinazolinyl, wherein any phenyl, 1H-pyrrolo[2,3-b]pyridinyl, 1-oxoisoindolinyl, 3-oxospiro[cyclopropane-1,1′-isoindolin]-yl, pyridinyl and quinazolinyl of Z1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1a groups.
  • A specific value for Z is selected from phenyl, 1H-pyrrolo[2,3-b]pyridin-5-yl, 1-oxoisoindolin-5-yl, 1-oxoisoindolin-4-yl, 4-oxo-3,4-dihydroquinazolin-8-yl, 3′-oxospiro[cyclopropane-1,1′-isoindolin]-5′-yl, 1H-2-oxo-pyridin-4-yl and 2,4-dioxo-1,2,3,4-tetrahydorquinazolin-8-yl, wherein any phenyl, 1H-pyrrolo[2,3-b]pyridin-5-yl, 1-oxoisoindolin-5-yl, 1-oxoisoindolin-4-yl, 4-oxo-3,4-dihydroquinazolin-8-yl, 3′-oxospiro[cyclopropane-1,1′-isoindolin]-5′-yl, 1H-2-oxo-pyridin-4-yl and 2,4-dioxo-1,2,3,4-tetrahydorquinazolin-8-yl of Z1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1a or Z1b groups.
  • A specific value for Z is selected from phenyl, 1H-pyrrolo[2,3-b]pyridin-5-yl, 1-oxoisoindolin-5-yl, 1-oxoisoindolin-4-yl, 3′-oxospiro[cyclopropane-1,1′-isoindolin]-5′-yl, pyridin-4-yl and quinazolin-8-yl, wherein any phenyl, 1H-pyrrolo[2,3-b]pyridin-5-yl, 1-oxoisoindolin-5-yl, 1-oxoisoindolin-4-yl, 3′-oxospiro[cyclopropane-1,1′-isoindolin]-5′-yl, pyridin-4-yl and quinazolin-8-yl of Z1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1a or Z1b groups.
  • A specific value for Z1 is selected from phenyl, 1H-pyrrolo[2,3-b]pyridin-5-yl, 1-oxoisoindolin-5-yl, 1-oxoisoindolin-4-yl, 4-oxo-3,4-dihydroquinazolin-8-yl, 3′-oxospiro[cyclopropane-1,1′-isoindolin]-5′-yl, 1H-2-oxo-pyridin-4-yl and 2,4-dioxo-1,2,3,4-tetrahydorquinazolin-8-yl as shown by the following formulas;
  • Figure US20210009555A1-20210114-C00022
  • wherein any phenyl, 1H-pyrrolo[2,3-b]pyridin-5-yl, 1-oxoisoindolin-5-yl, 1-oxoisoindolin-4-yl, 4-oxo-3,4-dihydroquinazolin-8-yl, 3′-oxospiro[cyclopropane-1,1′-isoindolin]-5′-yl, 1H-2-oxo-pyridin-4-yl and 2,4-dioxo-1,2,3,4-tetrahydorquinazolin-8-yl of Z1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1a or Z1b groups. A specific value for Z1 is
  • Figure US20210009555A1-20210114-C00023
  • A specific value for Z1 is
  • Figure US20210009555A1-20210114-C00024
  • A specific value for Z is selected from phenyl, 1H-pyrrolo[2,3-b]pyridin-5-yl, 1-oxoisoindolin-5-yl, 1-oxoisoindolin-4-yl, 4-oxo-3,4-dihydroquinazolin-8-yl, 3′-oxospiro[cyclopropane-1,1′-isoindolin]-5′-yl, 1H-2-oxo-pyridin-4-yl and 2,4-dioxo-1,2,3,4-tetrahydorquinazolin-8-yl, wherein any phenyl, 1H-pyrrolo[2,3-b]pyridin-5-yl, 1-oxoisoindolin-5-yl, 1-oxoisoindolin-4-yl, 4-oxo-3,4-dihydroquinazolin-8-yl, 3′-oxospiro[cyclopropane-1,1′-isoindolin]-5′-yl, 1H-2-oxo-pyridin-4-yl and 2,4-dioxo-1,2,3,4-tetrahydorquinazolin-8-yl of Z1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1a groups.
  • A specific value for Z1 is selected from phenyl, H-pyrrolo[2,3-b]pyridin-5-yl, 1-oxoisoindolin-5-yl, 1-oxoisoindolin-4-yl, 3′-oxospiro[cyclopropane-1,1′-isoindolin]-5′-yl, pyridin-4-yl and quinazolin-8-yl, wherein any phenyl, 1H-pyrrolo[2,3-b]pyridin-5-yl, 1-oxoisoindolin-5-yl, 1-oxoisoindolin-4-yl, 3′-oxospiro[cyclopropane-1,1′-isoindolin]-5′-yl, pyridin-4-yl and quinazolin-8-yl of Z1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1a groups.
  • A specific group of compounds of formula I are compounds wherein Z1 is not substituted with Z1.
  • A specific value for each Z1a is independently selected from halogen, —ORn1 and —C(O)NRq1Rr1.
  • A specific value for each Z1a is independently selected from halogen and —C(O)NRq1Rr1.
  • A specific value for each Rn1, Rq1 and Rr1 are each H.
  • A specific value for each Z1a is independently selected from halogen, —OH and —C(O)NH2.
  • A specific value for each Z1a is independently selected from fluoro, —OH and —C(O)NH2.
  • A specific value for Rq1 and Rr1 is H.
  • A specific value for each Z1a is independently selected from halogen and —NR1S(O)2Rp1.
  • A specific value for each Z1b is (C1-C8)alkyl, which may be same or different.
  • In certain embodiments, each Z1a is independently selected from halogen and —NRn1S(O)2Rp1 and each Z1b is (C1-C8)alkyl, which may be same or different.
  • A specific value for Z1 is selected from:
  • Figure US20210009555A1-20210114-C00025
  • A specific value for Z1 is
  • Figure US20210009555A1-20210114-C00026
  • A specific value for Z1 is
  • Figure US20210009555A1-20210114-C00027
  • A specific value for Z2 is selected from (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle and —C(O)NRq3Rr3 wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl and 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2b or Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2c groups.
  • A specific value for Z2 is selected from (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle and —C(O)NRq3Rr3 wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl and 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2c groups.
  • A specific value for Z2 is selected from (C2-C8)alkynyl, phenyl, 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heterocycle and —C(O)NRq3Rr3, wherein phenyl, 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl and 8-10 membered C-linked-bicyclic-heterocycle of Z2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2b or Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2c groups.
  • A specific value for Z2 is selected from (C2-C8)alkynyl, phenyl, 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heterocycle and —C(O)NRq3Rr3, wherein any yl, 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl and 8-10 membered C-linked-bicyclic-heterocycle of Z2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2c groups.
  • A specific value for Z2 is selected from (C2-C8)alkynyl, phenyl, 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heterocycle and —C(O)NRq3Rr3, wherein the 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl and 8-10 membered C-linked-bicyclic-heterocycle have 1-9 carbon atoms and 1-4 heteroatoms in the ring system, and wherein any phenyl, 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl, 8-10 membered and C-linked-bicyclic-heterocycle of Z2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2b or Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2c groups.
  • A specific value for Z2 is selected from (C2-C8)alkynyl, phenyl, 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heterocycle and —C(O)NRq3Rr3, wherein the 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl and 8-10 membered C-linked-bicyclic-heterocycle have 1-9 carbon atoms and 1-4 heteroatoms in the ring system, and wherein any phenyl, 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl, 8-10 membered and C-linked-bicyclic-heterocycle of Z2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2c groups.
  • A specific value for Z2 is selected from 4-methylpentynyl, phenyl, pyridinyl, 1H-2-oxo-pyridinyl, triazolyl, 1-oxoisoindolinyl, 1H-pyrrolo[2,3-b]pyridinyl and —C(O)NR-3Rr, wherein any phenyl, pyridinyl, 1H-2-oxo-pyridinyl, triazolyl, 1-oxoisoindolinyl and 1H-pyrrolo[2,3-b]pyridinyl of Z2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2b or Z2e groups, and wherein any 4-methylpentynyl of Z2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2c groups.
  • A specific value for Z2 is selected from 4-methylpentynyl, phenyl, pyridinyl, 1H-2-oxo-pyridinyl, triazolyl, 1-oxoisoindolinyl, 1H-pyrrolo[2,3-b]pyridinyl and —C(O)NRq3Rr3, wherein any phenyl, pyridinyl, 2-oxopyridinyl, triazolyl, 1-oxoisoindolinyl and 1H-pyrrolo[2,3-b]pyridinyl of Z2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2c groups, and wherein any 4-methylpentynyl of Z2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2c groups.
  • A specific value for Z2 is selected from 4-methylpentyn-1-yl, phenyl, pyridin-4-yl, 1H-2-oxo-pyridin-2-yl, triazol-4-yl, 1-oxoisoindolin-6-yl, 1H-pyrrolo[2,3-b]pyridine-5-yl and —C(O)NRq3Rr3, wherein any phenyl, pyridin-4-yl, 1H-2-oxo-pyridin-2-yl, triazol-4-yl, 1-oxoisoindolin-6-yl and 1H-pyrrolo[2,3-b]pyridine-5-yl of Z2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2b or Z2c groups, and wherein any 4-methylpentyn-1-yl of Z2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2c groups.
  • A specific value for Z2 is selected from 4-methylpentyn-1-yl, phenyl, pyridin-4-yl, 1H-2-oxo-pyridin-2-yl, triazol-4-yl, 1-oxoisoindolin-6-yl, 1H-pyrrolo[2,3-b]pyridine-5-yl and —C(O)NRq3Rr3, wherein any phenyl, pyridin-4-yl, 1H-2-oxo-pyridin-2-yl, triazol-4-yl, 1-oxoisoindolin-6-yl and 1H-pyrrolo[2,3-b]pyridine-5-yl of Z2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2c groups, and wherein any 4-methylpentyn-1-yl of Z2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2c groups.
  • A specific group of compounds of formula I are compounds wherein each Z2 is not substituted with Z2b.
  • A specific group of compounds of formula I are compounds wherein each Z2 is optionally substituted with one or more Z2c groups.
  • A specific value for each Z2c is independently selected from halogen, —ORn4 and —C(O)NRq4Rr4.
  • A specific group of compounds of formula I are compounds wherein Rn4 is H or methyl, and Rq4 and Rr4 are each H.
  • A specific value for Rn4 is H or methyl.
  • A specific value for each Rq4 and Rr4 is H.
  • A specific value for Z2 is selected from:
  • Figure US20210009555A1-20210114-C00028
  • A specific value for A-Z1 is selected from:
  • Figure US20210009555A1-20210114-C00029
    Figure US20210009555A1-20210114-C00030
    Figure US20210009555A1-20210114-C00031
  • A specific value for A-Z is selected from:
  • Figure US20210009555A1-20210114-C00032
  • A specific value for R1 is a 5-12 membered heteroaryl, wherein any 5-12 membered heteroaryl of R is optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) Z4 groups.
  • A specific value for R1 is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl, wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R1 is optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) Z4 groups.
  • A specific value for R1 is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl, wherein the 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl have 4-10 carbon atoms and 1-5 heteroatoms in the ring system, and wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R1 is optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) Z4 groups.
  • A specific value for R1 is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl, wherein the 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl contains at least one partially unsaturated ring, and wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z4 groups.
  • A specific value for R1 has the following formula IIa:
  • Figure US20210009555A1-20210114-C00033
  • wherein:
  • C together with the two carbon atoms of ring B to which it is attached forms a 3-7 membered monocyclic-carbocycle, 5-8 membered bicyclic-carbocycle, 3-7 membered monocyclic-heterocycle or 5-8 membered bicyclic heterocycle, wherein any 3-7 membered monocyclic-carbocycle, 5-8 membered bicyclic-carbocycle, 3-7 membered monocyclic-heterocycle or 5-8 membered bicyclic heterocycle of C is optionally substituted with one or more (e.g. 1, 2, 3, 4 or 5) Z4 groups; and
  • B is a 5 or 6 membered monocyclic-heteroaryl with 1, 2 or 3 nitrogen atoms, wherein B is optionally substituted with one or more or (e.g. 1, 2, 3, 4 or 5) Z4 groups.
  • A specific value for R1 has the following IIIb:
  • Figure US20210009555A1-20210114-C00034
  • wherein:
  • C together with the two carbon atoms of ring B to which it is attached forms a 3-7 membered monocyclic-carbocycle, 5-8 membered bicyclic-carbocycle, 3-7 membered monocyclic-heterocycle or 5-8 membered bicyclic heterocycle, wherein any 3-7 membered monocyclic-carbocycle, 5-8 membered bicyclic-carbocycle, 3-7 membered monocyclic-heterocycle or 5-8 membered bicyclic heterocycle of C is optionally substituted with one or more (e.g. 1, 2, 3, 4 or 5) Z4 groups; and
  • B is a 5 or 6 membered monocyclic-heteroaryl having 1, 2 or 3 nitrogen atoms;
  • V is C or N;
  • W is CZ4c, NZ4c or N;
  • X is CZ4c, NZ4c or N;
  • Y is CZ4c, N or absent;
  • the dashed bonds are selected from single bonds and double bonds, wherein the dashed bonds, V, W, X and Y are selected so that the 5 or 6 membered monocyclic-heteroaryl B is aromatic; and
  • each Z4c is independently selected from H or Z4.
  • A specific value for R1 has the following formula IIc:
  • Figure US20210009555A1-20210114-C00035
  • wherein:
  • C together with the two carbon atoms of ring B to which it is attached forms a 3-7 membered monocyclic-carbocycle, 5-8 membered bicyclic-carbocycle, 3-7 membered monocyclic-heterocycle or 5-8 membered bicyclic heterocycle, wherein any 3-7 membered monocyclic-carbocycle, 5-8 membered bicyclic-carbocycle, 3-7 membered monocyclic-heterocycle or 5-8 membered bicyclic heterocycle of C is optionally substituted with one or more (e.g. 1, 2, 3, 4 or 5) Z4 groups; and
  • B is a 5 or 6 membered monocyclic-heteroaryl having 1, 2 or 3 nitrogen atoms;
  • V is C or N;
  • W is CZ4c or N;
  • X is CZ4c, NZ4c or N;
  • Y is CZ4c, N or absent;
  • the dashed bonds are selected from single bonds and double bonds, wherein the dashed bonds, V, W, X and Y are selected so that the 5 or 6 membered monocyclic-heteroaryl B is aromatic; and
  • each Z4c is independently selected from H or Z4.
  • A specific value for R1 has the following R1 has the following formula IId:
  • Figure US20210009555A1-20210114-C00036
  • wherein:
  • C together with the two carbon atoms to which it is attached forms a 3-7 membered monocyclic-carbocycle, 5-9 membered bicyclic-carbocycle, 3-7 membered monocyclic-heterocycle or 5-9 membered bicyclic heterocycle, wherein any 3-7 membered monocyclic-carbocycle, 5-9 membered bicyclic-carbocycle, 3-7 membered monocyclic-heterocycle or 5-9 membered bicyclic heterocycle of C is optionally substituted with one or more (e.g. 1, 2, 3, 4 or 5) Z4 groups; and
  • each Z4c is independently selected from H or Z4.
  • A specific value for each Z4 is independently selected from (C1-C6)alkyl and halogen, wherein any (C1-C6)alkyl of Z4 is optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) halogen.
  • A specific value for each Z4 is independently selected from fluoro, trifluoromethyl and difluoromethyl.
  • A specific value for R is selected from:
  • Figure US20210009555A1-20210114-C00037
  • A specific value for R1 is selected from:
  • Figure US20210009555A1-20210114-C00038
  • A specific value for R1 is
  • Figure US20210009555A1-20210114-C00039
  • A specific value for R1 is
  • Figure US20210009555A1-20210114-C00040
  • A specific value for R1 is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl, wherein the 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl has 4-9 carbon atoms and 1-5 heteroatoms in the ring system, and wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z4 groups.
  • A specific value for R1 is a 8-12 membered bicyclic-heteroaryl, wherein the 8-12 membered bicyclic-heteroaryl has 6-9 carbon atoms and 1-3 heteroatoms in the ring system, and wherein any 8-12 membered bicyclic-heteroaryl of R1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z4 groups.
  • A specific value for R1 is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl, wherein the 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl has 6-9 carbon atoms and 1-3 heteroatoms in the ring system, and wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z4 groups.
  • A specific value for R1 is selected from indolyl and 4,5,6,7-tetrahydro-indazolyl, wherein any indolyl and 4,5,6,7-tetrahydro-indazolyl of R1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z4 groups.
  • A specific value for R1 is selected from indolyl, 4,5,6,7-tetrahydro-indazolyl, 3b,4,4a,5-tetrahydro-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole and 1,4,5,5a,6,6a-hexahydrocyclopropa[g]indazole, wherein any indolyl, 4,5,6,7-tetrahydro-indazolyl, 3b,4,4a,5-tetrahydro-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole and 1,4,5,5a,6,6a-hexahydrocyclopropa[g]indazole of R1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z4 groups.
  • A specific value for R1 is selected from indol-3-yl and 4,5,6,7-tetrahydro-1H-indazol-1-yl, wherein any indol-3-yl and 4,5,6,7-tetrahydro-1H-indazol-1-yl of R1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z4 groups.
  • A specific value for R1 is selected from indol-3-yl, 4,5,6,7-tetrahydro-1H-indazol-1-yl, 3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl and 1,4,5,5a,6,6a-hexahydrocyclopropa[g]indazol-1-yl, wherein any indol-3-yl, 4,5,6,7-tetrahydro-1H-indazol-1-yl, 3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl and 1,4,5,5a,6,6a-hexahydrocyclopropa[g]indazol-1-yl of R1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z4 groups.
  • A specific value for each Z4 is independently selected from (C1-C6)alkyl and halogen, wherein any (C1-C6)alkyl of Z4 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) halogen.
  • A specific value for each Z4 is independently selected from (C1-C6)alkyl, —CN and halogen, wherein any (C1-C6)alkyl of Z4 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) halogen.
  • A specific value for each Z4 is independently selected from fluoro, trifluoromethyl and difluoromethyl.
  • A specific value for each Z4 is independently selected from fluoro, trifluoromethyl, —CN and difluoromethyl.
  • A specific value for R1 is selected from:
  • Figure US20210009555A1-20210114-C00041
  • A specific value for R1 is selected from:
  • Figure US20210009555A1-20210114-C00042
  • A specific value for R1 is selected from:
  • Figure US20210009555A1-20210114-C00043
  • A specific value for R1 is
  • Figure US20210009555A1-20210114-C00044
  • A specific value for R1
  • Figure US20210009555A1-20210114-C00045
  • In one variation of formula I, A is pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; and R1 is a 5-12 membered heteroaryl, optionally substituted with 1, 2, 3, 4 or 5 Z4 groups, which may be the same or different. In another variation, A is pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; and R1 is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl, wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R1 is optionally substituted with 1, 2, 3, 4, or 5 Z4 groups. In another variation, A is pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; R1 is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl, wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R1 is optionally substituted with 1, 2, 3, 4, or 5 Z4 groups; and each Z4 is independently fluoro, trifluoromethyl, or difluoromethyl.
  • In one variation of formula I, A is pyridinyl; and R1 is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl, wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R is optionally substituted with 1, 2, 3, 4, or 5 Z4 groups.
  • In one variation of formula I, A is pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; and R2 is 3,5-difluorophenyl. In another variation, A is pyridinyl; and R2 is 3,5-difluorophenyl. In another variation, A is pyrimidinyl; and R2 is 3,5-difluorophenyl. In another variation, A is pyrazinyl; and R2 is 3,5-difluorophenyl. In another variation, A is pyridazinyl; and R2 is 3,5-difluorophenyl.
  • In one variation of formula I, A is pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; and Z1 is phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle wherein any phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups. In another variation, A is pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; and Z1 is phenyl, optionally substituted with 1, 2, 3, 4 or 5 Z1a groups. In another variation, A is pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; and Z1 is 5-6 membered monocyclic-heteroaryl or 8-10 membered bicyclic-heteroaryl, wherein any 5-6 membered monocyclic-heteroaryl or 8-10 membered bicyclic-heteroaryl of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups. In another variation, A is pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; and Z1 is 8-10 membered bicyclic-heterocycle or 9-12 membered tricyclic-heterocycle wherein any 8-10 membered bicyclic-heterocycle or 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups.
  • In one variation of formula I, A is pyridinyl; and Z1 is phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle wherein any phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups. In another variation, A is pyridinyl; and Z1 is phenyl, optionally substituted with 1, 2, 3, 4 or 5 Z1a groups. In another variation, A is pyridinyl; and Z1 is 5-6 membered monocyclic-heteroaryl or 8-10 membered bicyclic-heteroaryl, wherein any 5-6 membered monocyclic-heteroaryl or 8-10 membered bicyclic-heteroaryl of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups. In another variation, A is pyridinyl; and Z1 is 8-10 membered bicyclic-heterocycle or 9-12 membered tricyclic-heterocycle wherein any 8-10 membered bicyclic-heterocycle or 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups.
  • In one variation of formula I, A is pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; and Z2 is (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, or —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, or 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2c groups. In another variation, A is pyridinyl; and Z2 is (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, or —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, or 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2c groups. In another variation, A is pyrimidinyl; and Z2 is (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, or —C(O)NRq3Rr3 wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, or 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2c groups. In another variation, A is pyrazinyl; and Z2 is (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, or —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, or 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2c groups. In another variation, A is pyridazinyl; and Z2 is (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, or —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, or 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2c groups.
  • In one variation of formula I, A is pyridinyl substituted with one Z1 moiety, one Z2 moiety and no (zero) Z3 moieties; and Z2 is (C2-C8)alkynyl or aryl, which Z2 may be optionally substituted as provided by formula I. In another variation, A is pyridinyl substituted with one Z moiety, one Z2 moiety and no (zero) Z3 moieties; and Z2 is (C2-C8)alkynyl, which Z2 may be optionally substituted as provided by formula I. In a particular variation, A is pyridinyl substituted with one Z1 moiety, one Z2 moiety at the position alpha to the nitrogen atom of the pyridinyl ring, and no (zero) Z3 moieties, wherein Z2 is (C2-C8)alkynyl, which Z2 may be optionally substituted as provided by formula I.
  • In one variation of formula I, R1 is a 5-12 membered heteroaryl optionally substituted with 1, 2, 3, 4 or 5 Z4 groups, which may be the same or different; and Z1 is phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle wherein any phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups. In another variation, R1 is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl, wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R1 is optionally substituted with 1, 2, 3, 4, or 5 Z4 groups; and Z1 is phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle wherein any phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups.
  • In one variation of formula I, R1 is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl, wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R1 is optionally substituted with 1, 2, 3, 4, or 5 Z4 groups; and Z1 is 8-10 membered bicyclic-heteroaryl or 8-10 membered bicyclic-heterocycle wherein any 8-10 membered bicyclic-heteroaryl or 8-10 membered bicyclic-heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups.
  • In one variation of formula I, R1 is a 5-12 membered heteroaryl optionally substituted with 1, 2, 3, 4 or 5 Z4 groups, which may be the same or different; and Z2 is (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, or —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, or 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2 groups. In another variation, R1 is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R1 is optionally substituted with 1, 2, 3, 4, or 5 Z4 groups; and Z2 is (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, or —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, or 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2c group.
  • In one variation of formula I, Z1 is phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle wherein any phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups; and Z2 is (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, or —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, or 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2c groups.
  • In one variation of formula I, Z1 is bicyclic-heteroaryl optionally substituted with 1, 2, 3, 4 or 5 Z1a groups; and Z2 is (C2-C8)alkynyl optionally substituted with 1, 2, 3, 4 or 5 Z2c groups.
  • In one variation of formula I, R1 is a 5-12 membered heteroaryl; Z1 is phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle wherein any phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups; and Z2 is (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, or —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, or 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2 groups.
    • Compounds of Formula III.
  • The present disclosure provides compounds of formula III:
  • Figure US20210009555A1-20210114-C00046
  • wherein
  • A is a 6-membered monocyclic-heteroaryl with one or two nitrogen atoms, wherein the 6-membered monocyclic-heteroaryl is substituted with one Z1 group at the position shown, one Z2 group, and optionally substituted with 1 or 2 Z3 groups, wherein the Z3 groups are the same or different;
  • R1 is 6-12 membered aryl, 5-12 membered heteroaryl, or 3-12 membered heterocycle, wherein any 6-12 membered aryl, 5-12 membered heteroaryl, or 3-12 membered heterocycle of R is optionally substituted with 1, 2, 3, 4 or 5 Z4 groups, wherein the Z4 groups are the same or different;
  • R2 is phenyl optionally substituted with 1, 2, 3, 4 or 5 halogen, which are the same or different;
  • each R3a and R3h is independently H or (C1-C3)alkyl;
  • Z1 is 6-12 membered aryl, 5-14 membered heteroaryl, or 3-14 membered heterocycle, wherein any 6-12 membered aryl, 5-14 membered heteroaryl, or 3-14 membered heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a or Z1b, wherein the Z1a and Z1b groups are the same or different;
  • each Z1a is independently (C3-C7)carbocycle, 5-12 membered heteroaryl, 3-12 membered heterocycle, halogen, —CN, —ORn1, —OC(O)Rp1, —OC(O)NRq1Rr, —SRn1, —S(O)Rp1, —S(O)2OH, —S(O)2Rp1, —S(O)2NRq1Rr1, —NRq1Rr1, —NRn1CORp1, —NRn1CO2Rp1, —NRn1CONRq1Rr1, —NRn1S(O)2Rp1, —NRn1S(O)2ORp1, —NRn1S(O)2NRq1Rr1, —C(O)Rn1, —C(O)ORn1, —C(O)NRq1Rr1 and —S(O)2NRn1 CORp1, wherein any (C3-C7)carbocycle, 5-12 membered heteroaryl and 3-12 membered heterocycle of Z1a is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different;
  • each Z1b is independently (C1—C)alkyl optionally substituted with 1, 2, 3, 4 or 5 halogen, which are the same or different;
  • each Z1c is independently halogen, —CN, —OH, —NH2, —C(O)NRq2Rr2, or (C1-C8)heteroalkyl;
  • each Z1d is independently (C1-C8)alkyl or (C1-C8)haloalkyl;
  • each Rn1 is independently H, (C1-C8)alkyl, (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl of Rn1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different, and wherein any (C1-C8)alkyl of Rn1 is optionally substituted with 1, 2, 3, 4 or 5 Z1 groups, wherein the Z1c groups are the same or different;
  • each Rp1 is independently (C1-C8)alkyl, (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl of Rp1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different, and wherein any (C1-C8)alkyl of Rp1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c groups, wherein the Z1c groups are the same or different;
  • each Rq1 and Rr1 is independently H, (C1-C8)alkyl, (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl of Rq1 or Rr1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different, and wherein any (C1-C8)alkyl of Rq1 or Rr1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c groups, wherein the Z1c groups are the same or different, or Rq1 and Rr1 together with the nitrogen to which they are attached form a 5, 6 or 7-membered heterocycle, wherein the 5, 6 or 7-membered heterocycle is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different;
  • each Rq2 and Rr2 is independently H, (C1-C8)alkyl, (C3-C7)carbocycle, or Rq2 and Rr2 together with the nitrogen to which they are attached form a 5, 6, or 7-membered heterocycle;
  • Z2 is (C2-C8)alkenyl, (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, —C(O)Rn3, or —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, or 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, wherein the Z2b and Z2c groups are the same or different, and wherein any (C2-C8)alkenyl or (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4, or 5 Z2c groups, wherein the Z2c groups are the same or different;
  • each Rn3 is independently H or (C1-C4)alkyl;
  • each Rq3 and Rr3 is independently H or (C1-C4)alkyl;
  • each Z2b is independently oxo, (C1-C4)alkyl, (C1-C4)heteroalkyl, or (C1-C4)haloalkyl;
  • each Z2c is independently oxo, halogen, —CN, —ORn4,—OC(O)Rp4, —OC(O)NRq4Rr4, —SRn4, —S(O)Rp4, —S(O)2OH, —S(O)2Rp4, —S(O)2NRq4Rr4, —NRn4CORp4, —NRn4CO2Rp4, —NRn4CONRq4Rr4, —NRn4S(O)2Rp4, —NRn4S(O)2ORp4, —NRn4S(O)2NRq4Rr4, —NO2, —C(O)Rn4, —C(O)ORn4, or —C(O)NRq4Rr4;
  • each Rn4 is independently H, (C1-C4)alkyl, (C1-C4)haloalkyl, or (C1-C4)heteroalkyl;
  • each Rp4 is independently (C1-C8)alkyl, (C1-C4)haloalkyl, or (C1-C4)heteroalkyl;
  • each Rq4 and Rr4 is independently H, (C1-C4)alkyl, (C1-C4)haloalkyl, or (C1-C4)heteroalkyl;
  • each Z3 is independently a (C1-C4)heteroalkyl or halogen;
  • each Z4 is independently oxo, (C1-C8)alkyl, (C3-C7)carbocycle, halogen, —CN, —ORn5,—NRq5Rr5, —NRn5CORp5, —NRn5CO2Rp5, —C(O)Rn5, —C(O)ORn5, or —C(O)NRq5Rr5 wherein any (C3-C7)carbocycle or (C1-C8)alkyl of Z4 is optionally substituted with 1, 2, 3, 4 or 5 Z4a groups, wherein the Z4a groups are the same or different;
  • each Z4a is independently halogen, —CN, or —ORn6; and
  • each Rn5, Rp5, Rq5, Rr5, and Rn6 is independently H or (C1-C4)alkyl;
  • or a pharmaceutically acceptable salt thereof.
  • In certain embodiments, a compound of formula III is a compound of formula IIIa.
  • Figure US20210009555A1-20210114-C00047
  • or a pharmaceutically acceptable salt thereof.
  • In certain embodiments, a compound of formula III is a compound of formula IIIb.
  • Figure US20210009555A1-20210114-C00048
  • or a pharmaceutically acceptable thereof.
  • In certain embodiments, a compound of formula III is a compound of formula IIIc.
  • Figure US20210009555A1-20210114-C00049
  • or a pharmaceutically acceptable thereof.
  • The present disclosure provides compounds of formula IIId:
  • Figure US20210009555A1-20210114-C00050
  • wherein
  • A1 is CH, C—Z3, or nitrogen;
  • A2 is CH or nitrogen;
  • R1 is 6-12 membered aryl, 5-12 membered heteroaryl, or 3-12 membered heterocycle, wherein any 6-12 membered aryl, 5-12 membered heteroaryl, or 3-12 membered heterocycle of R is optionally substituted with 1, 2, 3, 4 or 5 Z4 groups, wherein the Z4 groups are the same or different;
  • each R3a and R3b is independently H or (C1-C3)alkyl;
  • Z1 is 6-12 membered aryl, 5-14 membered heteroaryl, or 3-14 membered heterocycle, wherein any 6-12 membered aryl, 5-14 membered heteroaryl, or 3-14 membered heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a or Z1b, wherein the Z1a and Z1b groups are the same or different;
  • each Z1a is independently (C3-C7)carbocycle, 5-12 membered heteroaryl, 3-12 membered heterocycle, halogen, —CN, —ORn1, —OC(O)Rp1, —OC(O)NRq1Rr1, —SRn1, —S(O)Rp1, —S(O)2OH, —S(O)2Rp1, —S(O)2NRq1Rr1, —NRq1Rr1, —NRn1CORp1, —NRn1CO2Rp1, —NRn1 CONRq1Rr1, —NRn1 S(O)2Rp1, —NRn1S(O)2ORp1, —NRn1S(O)2NRq1Rr1, —C(O)Rn1, —C(O)ORn1, —C(O)NRq1Rr1 and —S(O)2NRn1CORp1, wherein any (C3-C7)carbocycle, 5-12 membered heteroaryl and 3-12 membered heterocycle of Z1a is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different;
  • each Z1b is independently (C1—C)alkyl optionally substituted with 1, 2, 3, 4 or 5 halogen, which are the same or different;
  • each Z1c is independently halogen, —CN, —OH, —NH2, —C(O)NRq2Rr2, or (C1-C8)heteroalkyl;
  • each Z1d is independently (C1-C8)alkyl or (C1—C)haloalkyl;
  • each Rn1 is independently H, (C1-C8)alkyl, (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl of Rn1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different, and wherein any (C1-C8)alkyl of Rn1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c groups, wherein the Z1c groups are the same or different;
  • each Rp1 is independently (C1-C8)alkyl, (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl of Rp1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different, and wherein any (C1-C8)alkyl of Rp1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c groups, wherein the Z1c groups are the same or different;
  • each Rq1 and Rr1 is independently H, (C1-C8)alkyl, (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl of Rq or Rr is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different, and wherein any (C1-C8)alkyl of Rq1 or Rr1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c groups, wherein the Z1c groups are the same or different, or Rq1 and Rr1 together with the nitrogen to which they are attached form a 5, 6 or 7-membered heterocycle, wherein the 5, 6 or 7-membered heterocycle is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different;
  • each Rq2 and Rr2 is independently H, (C1-C8)alkyl, (C3-C7)carbocycle, or Rq2 and Rr2 together with the nitrogen to which they are attached form a 5, 6, or 7-membered heterocycle;
  • Z2 is (C2-C8)alkenyl, (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, —C(O)Rn3, or —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, or 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, wherein the Z2b and Z2c groups are the same or different, and wherein any (C2-C8)alkenyl or (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4, or 5 Z2c groups, wherein the Z2c groups are the same or different;
  • each Rn3 is independently H or (C1-C4)alkyl;
  • each Rq3 and Rr3 is independently H or (C1-C4)alkyl;
  • each Z2b is independently oxo, (C1-C4)alkyl, (C1-C4)heteroalkyl or (C1-C4)haloalkyl;
  • each Z2c is independently oxo, halogen, —CN, —ORn4, —OC(O)Rp4, —OC(O)NRq4Rr4, —SRn4, —S(O)Rp4, —S(O)2OH, —S(O)2Rp4,—S(O)2NRq4Rr4, —NRq4Rr4, —NRn4CORp4, —NRn4CO2Rp4, —NRn4CONRq4Rr4, —NRn4S(O)2 p4, —NRn4S(O)2ORp4, —NRn4S(O)2NRq4Rr4, —NO2, —C(O)Rn4, —C(O)ORn4, or —C(O)NRq4Rr4;
  • each Rn4 is independently H, (C1-C4)alkyl, (C1-C4)haloalkyl, or (C1-C4)heteroalkyl;
  • each Rp4 is independently (C1-C8)alkyl, (C1-C4)haloalkyl, or (C1-C4)heteroalkyl;
  • each Rq4 and Rr4 is independently H, (C1-C4)alkyl, (C1-C4)haloalkyl, or (C1-C4)heteroalkyl;
  • each Z3 is independently a (C1-C4)heteroalkyl;
  • each Z4 is independently oxo, (C1-C8)alkyl, (C3-C7)carbocycle, halogen, —CN, —ORn5, —NRq5Rr5, —NRn5CORp5, —NRn5CO2Rp5, —C(O)Rn5, —C(O)ORn5, or —C(O)NRq5Rr5, wherein any (C3-C7)carbocycle or (C1-C8)alkyl of Z4 is optionally substituted with 1, 2, 3, 4 or 5 Z4a groups, wherein the Z4a groups are the same or different;
  • each Z4a is independently halogen, —CN, or —ORn6;
  • each Rn5, Rp5, Rq5, Rr5 and Rn6 is independently H or (C1-C4)alkyl;
  • each Z5 is independently halogen, which may be same or different; and
  • n is 0, 1, 2, or 3;
  • or a pharmaceutically acceptable salt thereof.
  • In certain embodiments, a compound of formula IIId is a compound of formula IIIe.
  • Figure US20210009555A1-20210114-C00051
  • or a pharmaceutically acceptable salt thereof.
  • The present disclosure provides compounds of formula IIIf:
  • Figure US20210009555A1-20210114-C00052
  • wherein
  • A1 is CH, C—Z3, or nitrogen;
  • A2 is CH or nitrogen;
  • R1 is 6-12 membered aryl, 5-12 membered heteroaryl, or 3-12 membered heterocycle, wherein any 6-12 membered aryl, 5-12 membered heteroaryl, or 3-12 membered heterocycle of R1 is optionally substituted with 1, 2, 3, 4 or 5 Z4 groups, wherein the Z4 groups are the same or different;
  • each R3a and R3b is independently H or (C1-C3)alkyl;
  • Z1 is 6-12 membered aryl, 5-14 membered heteroaryl, or 3-14 membered heterocycle, wherein any 6-12 membered aryl, 5-14 membered heteroaryl, or 3-14 membered heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a or Z1b, wherein the Z1a and Z1b groups are the same or different;
  • each Z1a is independently (C3-C7)carbocycle, 5-12 membered heteroaryl, 3-12 membered heterocycle, halogen, —CN, —ORn1, —OC(O)Rp1, —OC(O)NRq1Rr1, —SRn1, —S(O)Rp1, —S(O)2OH, —S(O)2Rp1, —S(O)2NRq1Rr1, —NRq1Rr1, —NRn1CORp1, —NRn1CO2Rp1, —NRn1CONRq1Rr1, —NRn1S(O)2Rp1, —NRn1S(O)2ORp1, —NRn1S(O),NRq1Rr1, —C(O)Rn1, —C(O)ORn1, —C(O)NRq1Rr1 and —S(O)2NRnCORP, wherein any (C3-C7)carbocycle, 5-12 membered heteroaryl and 3-12 membered heterocycle of Z1a is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different;
  • each Z1b is independently (C1-C8)alkyl optionally substituted with 1, 2, 3, 4 or 5 halogen, which are the same or different;
  • each Z1c is independently halogen, —CN, —OH, —NH2, —C(O)NRq2Rr2, or (C1-C8)heteroalkyl;
  • each Z1d is independently (C1-C8)alkyl or (C1-C8)haloalkyl;
  • each Rn1 is independently H, (C1-C8)alkyl, (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl of Rn1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different, and wherein any (C1-C8)alkyl of Rn1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c groups, wherein the Z1c groups are the same or different;
  • each Rp1 is independently (C1-C8)alkyl, (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl of Rp1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different, and wherein any (C1-C8)alkyl of Rp1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c groups, wherein the Z1c groups are the same or different;
  • each Rq1 and Rr1 is independently H, (C1-C8)alkyl, (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl of Rq1 or Rr1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different, and wherein any (C1-C8)alkyl of Rq1 or Rr1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c groups, wherein the Z1c groups are the same or different, or Rq1 and Rr1 together with the nitrogen to which they are attached form a 5, 6 or 7-membered heterocycle, wherein the 5, 6 or 7-membered heterocycle is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different;
  • each Rq2 and Rr2 is independently H, (C1-C8)alkyl, (C3-C7)carbocycle, or Rq2 and Rr2 together with the nitrogen to which they are attached form a 5, 6, or 7-membered heterocycle;
  • Z2 is (C2-C8)alkenyl, (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, —C(O)Rn3, or —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, or 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, wherein the Z2b and Z2c groups are the same or different, and wherein any (C2-C8)alkenyl or (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4, or 5 Z2c groups, wherein the Z2c groups are the same or different;
  • each Rn3 is independently H or (C1-C4)alkyl;
  • each Rq3 and Rr3 is independently H or (C1-C4)alkyl;
  • each Z2b is independently oxo, (C1-C4)alkyl, (C1-C4)heteroalkyl or (C1-C4)haloalkyl;
  • each Z2c is independently oxo, halogen, —CN, —ORn4, —OC(O)Rp4, —OC(O)NRq4Rr4, —SRn4, —S(O)Rp4, —S(O)2OH, —S(O)2Rp4, —S(O)2NRq4Rr4, —NRq4Rr4, —NRn4CORp4, —NRn4CO2Rp4, —NRn4CONRq4Rr4, —NRn4S(O)2Rp4, —NRn4S(O)2ORp4, —NRn4S(O)2NRq4Rr4, —NO2, —C(O)Rn4, —C(O)ORn4, or —C(O)NRq4Rr4;
  • each Rn4 is independently H, (C1-C4)alkyl, (C1-C4)haloalkyl, or (C1-C4)heteroalkyl;
  • each Rp4 is independently (C1-C8)alkyl, (C1-C4)haloalkyl, or (C1-C4)heteroalkyl;
  • each Rq4 and Rr4 is independently H, (C1-C4)alkyl, (C1-C4)haloalkyl, or (C1-C4)heteroalkyl;
  • each Z3 is independently a (C1-C4)heteroalkyl;
  • each Z4 is independently oxo, (C1-C8)alkyl, (C3-C7)carbocycle, halogen, —CN, —ORn5,—NRq5Rr5, —NRn5CORp5, —NRn5CO2Rp5, —C(O)ORn5, or —C(O)ORn5, —C(O)NRq5Rr5, wherein any (C3-C7)carbocycle or (C1-C8)alkyl of Z4 is optionally substituted with 1, 2, 3, 4 or 5 Z4a groups, wherein the Z4a groups are the same or different;
  • each Z4a is independently halogen, —CN, or —ORn6;
  • each Rn5, Rp5, Rr5, and Rn6 is independently H or (C1-C4)alkyl;
  • each Z5 is independently halogen, which may be same or different; and
  • n is 0, 1, 2, or 3;
  • or a pharmaceutically acceptable salt thereof.
  • In certain embodiments, a compound of formula IIIf is a compound of formula IIg.
  • Figure US20210009555A1-20210114-C00053
  • or a pharmaceutically acceptable salt thereof.
  • The present disclosure provides compounds of formula IIIh:
  • Figure US20210009555A1-20210114-C00054
  • wherein
  • A1 is CH, C—Z3, or nitrogen;
  • A2 is CH or nitrogen;
  • C together with the two carbon atoms to which it is attached forms a 3-7 membered monocyclic-carbocycle or 5-9 membered bicyclic-carbocycle, wherein any 3-7 membered monocyclic-carbocycle or 5-9 membered bicyclic-carbocycle of C is optionally substituted with 1, 2, 3, 4 or 5 Z4 groups, wherein the Z4 groups are the same or different;
  • each Z1w is independently Z1a, Z1b or H;
  • each Z1a is independently (C3-C7)carbocycle, 5-12 membered heteroaryl, 3-12 membered heterocycle, halogen, —CN, —ORn1, —OC(O)Rp1, —OC(O)NRq1Rr1, —SRn1, —S(O)Rp1, —S(O)2OH, —S(O)2Rp1, —S(O)2NRq1Rr1, —NRq1Rr1, —NRn1 CORp1, —NRn1CO2Rp1, —NRn1CONRq1Rr1, —NRn1S(O)2Rp1, —NRn1S(O)2ORp1, —NRn1S(O)2NRq1Rr1, —C(O)Rn1, —C(O)ORn1, —C(O)NRq1Rr1 and —S(O)2NRn1CORp1, wherein any (C3-C7)carbocycle, 5-12 membered heteroaryl and 3-12 membered heterocycle of Z1a is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different;
  • each Z1b is independently (C1-C8)alkyl optionally substituted with 1, 2, 3, 4 or 5 halogen, which are the same or different;
  • each Z1c is independently halogen, —CN, —OH, —NH2, —C(O)NRq2Rr2, or (C1-C8)heteroalkyl;
  • each Z1d is independently (C1-C8)alkyl or (C1—C)haloalkyl;
  • each Rn1 is independently H, (C1-C8)alkyl, (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl of Rn1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different, and wherein any (C1-C8)alkyl of Rn1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c groups, wherein the Z1c groups are the same or different;
  • each Rp1 is independently (C1-C8)alkyl, (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl of Rp1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different, and wherein any (C1-C8)alkyl of Rp1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c groups, wherein the Z1c groups are the same or different;
  • each Rq1 and Rr1 is independently H, (C1-C8)alkyl, (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl of Rq1 or Rr1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different, and wherein any (C1-C8)alkyl of Rq1 or Rr1 is optionally substituted with 1, 2, 3, 4 or 5 Z1c groups, wherein the Z1c groups are the same or different, or Rq1 and Rr1 together with the nitrogen to which they are attached form a 5, 6 or 7-membered heterocycle, wherein the 5, 6 or 7-membered heterocycle is optionally substituted with 1, 2, 3, 4 or 5 Z1c or Z1d groups, wherein the Z1c and Z1d groups are the same or different;
  • each Rq2 and Rr2 is independently H, (C1-C8)alkyl, (C3-C7)carbocycle, or Rq2 and Rr2 together with the nitrogen to which they are attached form a 5, 6, or 7-membered heterocycle;
  • Z2 is (C2-C8)alkenyl, (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, —C(O)Rn3, or —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, or 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, wherein the Z2b and Z2c groups are the same or different, and wherein any (C2-C8)alkenyl or (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4, or 5 Z2c groups, wherein the Z2c groups are the same or different;
  • each Rn3 is independently H or (C1-C4)alkyl;
  • each Rq3 and Rr3 is independently H or (C1-C4)alkyl;
  • each Z2b is independently oxo, (C1-C4)alkyl, (C1-C4)heteroalkyl or (C1-C4)haloalkyl;
  • each Z2c is independently oxo, halogen, —CN, —ORn4, —OC(O)Rp4, —OC(O)NRq4Rr4, —SR4, —S(O)Rp4, —S(O)2OH, —S(O)2Rp4, —S(O)2NRq4Rr4, —NRq4Rr4, —NRn4CORp4, —NR4CO2Rp4, —NRn4CONRq4Rr4, —NRn4S(O)2Rp4, —NRn4S(O)2ORp4, —NRn4S(O)2NRq4Rr4, —NO2, —C(O)Rn4, —C(O)ORn4, or —C(O)NRq4Rr4;
  • each Rn4 is independently H, (C1-C4)alkyl, (C1-C4)haloalkyl, or (C1-C4)heteroalkyl;
  • each Rp4 is independently (C1-C8)alkyl, (C1-C4)haloalkyl, or (C1-C4)heteroalkyl;
  • each Rq4 and Rr4 is independently H, (C1-C4)alkyl, (C1-C4)haloalkyl, or (C1-C4)heteroalkyl;
  • Z3 is independently a (C1-C4)heteroalkyl;
  • each Z4 is independently oxo, (C1-C8)alkyl, (C3-C7)carbocycle, halogen, —CN, —ORn5, —NRq5Rr5, —NRn5CORp5, —NRn5CO2Rp5, —C(O)Rn5, —C(O)ORn5, or —C(O)NRq5Rr5, wherein any (C3-C7)carbocycle or (C1-C8)alkyl of Z4 is optionally substituted with 1, 2, 3, 4 or 5 Z4a groups, wherein the Z4a groups are the same or different;
  • each Z4a is independently halogen, —CN, or —ORn6;
  • each Rn5, Rp5Rq5, Rr5, and Rn6 is independently H or (C1-C4)alkyl; and
  • Z5a is H or halogen;
  • or a pharmaceutically acceptable salt thereof.
  • In certain embodiments, a compound of formula IIIh is a compound of formula IIIi.
  • Figure US20210009555A1-20210114-C00055
  • or a pharmaceutically acceptable salt thereof.
  • The present disclosure provides compounds of formula IIj:
  • Figure US20210009555A1-20210114-C00056
  • wherein
  • A1 is CH, C—Z3, or nitrogen;
  • A2 is CH or nitrogen;
  • Z1x is H or (C1-C8)alkyl;
  • Z1y is —NRn1S(O)2Rp1, —NRn1S(O)2NRq1Rr1, —NRq1Rr1, —NRn1CORp1, —NRn1CONRq1Rr1, or —NRn1CO2Rp1;
  • Zz is H, halogen, —CN, —ORn1, (C1-C8)alkyl, wherein the (C1-C8)alkyl is optionally substituted with 1, 2, or 3 halogen, which are the same or different;
  • each Rn1 is independently H or (C1-C8)alkyl;
  • each Rp1 is independently (C1-C8)alkyl;
  • each Rq1 and Rr1 is independently H or (C1-C8)alkyl;
  • Z3 is (C1-C4)heteroalkyl;
  • Z2 is (C2-C8)alkynyl, optionally substituted with 1, 2, 3, 4, or 5 Z2c group, wherein the Z2c groups are the same or different; wherein Z2c is independently halogen, —ORn4, —NRn4CO2Rp4, —C(O)ORn4, or —NRq4Rr4;
  • each Rn4 is independently H or (C1-C4)alkyl;
  • each Rp4 is independently (C1-C4)alkyl;
  • each Rq4 and Rr4 is independently H, (C1-C4)alkyl, or (C1-C4)heteroalkyl;
  • Z4 is hydrogen, (C1-C8)alkyl, halogen, —CN, —C(O)Rn5, —C(O)ORn5, —C(O)NRq5Rr5, —NRn5CORp5, —NRq5Rr5, or (C3-C7)carbocycle, wherein any (C3-C7)carbocycle or (C1-C8)alkyl of Z4 is optionally substituted with halogen or hydroxyl;
  • each Rn5 is independently H or (C1-C4)alkyl;
  • each Rp5 is independently H or (C1-C4)alkyl;
  • each Rq5 and Rr5 is independently H or (C1-C4)alkyl; and
  • Z5a is H or halogen;
  • or a pharmaceutically acceptable salt thereof.
  • In certain embodiments, a compound of formula IIIj is a compound of formula IIIk.
  • Figure US20210009555A1-20210114-C00057
  • or a pharmaceutically acceptable salt thereof.
  • Specific values listed below are values for compounds of formula III as well as all related formulas (e.g., formulas IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IIIg, IIIh, IIIi, IIIj, and IIIk) where applicable. For example, values recited below as applying to formula III apply equally to all related formulas of formula III (e.g., formulas IIIa, IIIb, IIIc, IIId, IIIe, IIIf, IIIg, IIIh, IIIi, IIIj, and IIIk) that permit the presence of such variable. It is to be understood that two or more values may combined. Thus, it is to be understood that any variable for compounds of formula III may be combined with any other variable for compounds of formula III the same as if each and every combination of variables were specifically and individually listed. For example, it is understood that any specific value of R1 detailed herein for compounds of formula III may be combined with any other specific value for one or more of the variables A, Z1, R2, R3a or R3b of formula III the same as if each and every combination were specifically and individually listed.
  • In certain embodiments of formula III, A1 is CH. In certain embodiments, A1 is C—Z3. In certain embodiments, A1 is nitrogen.
  • In certain embodiments of formula III, A2 is CH. In certain embodiments, A2 is nitrogen.
  • In certain embodiments of formula III, A1 is CH; and A2 is CH. In certain embodiments, A1 is C—Z3; and A2 is CH. In certain embodiments, A1 is nitrogen; and A2 is CH.
  • In certain embodiments of formula III, A1 is CH; and A2 is nitrogen. In certain embodiments, A1 is C—Z3; and A2 is nitrogen. In certain embodiments, A1 is nitrogen; and A2 is nitrogen.
  • In certain embodiments of formula III, Z5 is F. In certain embodiments of formula III, n is one. In certain embodiments, n is two. In certain embodiments of formula III, n is one and Z5 is F. In certain embodiments, n is two and each Z5 is F.
  • In certain embodiments of formula III, Z5a is H. In certain embodiments, Z5a is F.
  • In certain embodiments of formula III, each Z1w is independently Z1a or Z1b, wherein the Z1a and Z1b groups may be the same or different. In certain embodiments, each Z1w is independently (C1-C8)alkyl, halogen, or —NRn1S(O)2Rp1, which may be same or different.
  • In certain embodiments of formula III, Z1x is H. In certain embodiments, Z1x is (C1-C8)alkyl. In certain embodiments, Z1x is (C1-C4)alkyl. In certain embodiments, Z1x is (C1-C3)alkyl. In certain embodiments, Z1x is methyl.
  • In certain embodiments of formula III, Z1y is —NRn1S(O)2Rp1, —NRn1S(O)2NRq1Rr1, or —NRq1Rr1. In certain embodiments, Z1y is —NRn1S(O)2Rp1 or —NRn1S(O)2NRq1Rr1. In certain embodiments, Z1y is —NRn1S(O)2Rp1. In certain embodiments, Z1y is —NRn1S(O)2NRq1Rr1. In certain embodiments, Z1y is —NRq1Rr1.
  • In certain embodiments of formula III, Z1z is H or halogen. In certain embodiments, Z1z is H. In certain embodiments, Z1z is halogen. In certain embodiments, Z1z is Cl. In certain embodiments, Z1z is F. In certain embodiments, Z1z is Br.
  • In certain embodiments of formula III, Z is —NR1yS(O)2Rp1 or —NRn1S(O)2NRq1Rr1 and Z1z is halogen. In certain embodiments, Z1y is —NRn1S(O)2Rp1 and Z1z is halogen. In certain embodiments, Z1x is (C1-C4)alkyl; Z1y is —NRn1S(O)2Rp1 or —NRn1S(O)2NRq1Rr1; and Z1z is halogen. In certain embodiments, Z1x is (C1-C4)alkyl; Z1y is —NRn1S(O)2Rp1; and Z1z is halogen.
  • In certain embodiments of formula III, A is pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, wherein any pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl of A is substituted with one Z1 group at the position shown, one Z2 group and optionally substituted with 1 or 2 Z3 groups. In certain embodiments, A is pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, wherein any pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl of A is substituted with one Z1 group at the position shown, one Z2 group and optionally substituted with 1 Z3 group.
  • In certain embodiments, A is pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein any pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl of A is substituted with one Z1 group at the position shown and one Z2 group. In one aspect, A is not substituted with a Z3 group.
  • In certain embodiments, A is pyridinyl, wherein any pyridinyl of A is substituted with one Z1 group at the position shown, one Z2 group, and optionally substituted with 1 or 2 Z3 groups. In certain embodiments, A is pyridinyl, wherein any pyridinyl of A is substituted with one Z1 group at the position shown, one Z2 group, and optionally substituted with 1 Z3 group.
  • In certain embodiments, A is pyridinyl, wherein any pyridinyl of A is substituted with one Z1 group at the position shown and one Z2 group. In one aspect, the Z2 group attached at the position alpha to the nitrogen of the pyridinyl group. In a further aspect, A is not substituted with a Z3 group.
  • In certain embodiments, A is pyrimidinyl, wherein any pyridinyl of A is substituted with one Z1 group at the position shown, one Z2 group, and optionally substituted with 1 or 2 Z3 groups. In certain embodiments, A is pyrimidinyl, wherein any pyridinyl of A is substituted with one Z1 group at the position shown, one Z2 group, and optionally substituted with 1 Z3 group.
  • In certain embodiments, A is pyrimidinyl, wherein any pyridinyl of A is substituted with one Z1 group at the position shown and one Z2 group. In one aspect, A is not substituted with a Z3 group.
  • In certain embodiments, A is pyrazinyl, wherein any pyridinyl of A is substituted with one Z1 group at the position shown, one Z2 group, and optionally substituted with 1 or 2 Z3 groups. In certain embodiments, A is pyrazinyl, wherein any pyridinyl of A is substituted with one Z1 group at the position shown, one Z2 group, and optionally substituted with 1 Z3 group.
  • In certain embodiments, A is pyrazinyl, wherein any pyridinyl of A is substituted with one Z1 group at the position shown and one Z2 group. In one aspect, A is not substituted with a Z3 group.
  • In certain embodiments, A is:
  • Figure US20210009555A1-20210114-C00058
  • In certain embodiments, A is:
  • Figure US20210009555A1-20210114-C00059
  • In certain embodiments, A is:
  • Figure US20210009555A1-20210114-C00060
  • In certain embodiments, A is:
  • Figure US20210009555A1-20210114-C00061
  • In certain embodiments, A is:
  • Figure US20210009555A1-20210114-C00062
  • In certain embodiments of formula III, R2 is phenyl optionally substituted with 1, 2, or 3 halogens, which may be the same or different. In certain embodiments, R2 is phenyl optionally substituted with 1 or 2 halogens, which may be the same or different. In certain embodiments, R2 is phenyl optionally substituted with 2 halogens, which may be the same or different. In certain embodiments, R2 is phenyl optionally substituted with 1 halogen.
  • In certain embodiments, R2 is 3,5-difluorophenyl or 3-fluorophenyl. In certain embodiments, R2 is 3,5-difluorophenyl. In certain embodiments, R2 is 3-fluorophenyl.
  • In certain embodiments, the moiety
  • Figure US20210009555A1-20210114-C00063
  • wherein Z is H or halogen.
  • In certain embodiments of formula III, each Z3, where present, is independently methoxy, dimethylamino, or methylamino. In certain embodiments, Z3, where present, is methoxy. In certain embodiments, Z3, where present, is dimethylamino. In certain embodiments, Z3, where present, is methylamino. In certain embodiments, Z3, where present, is halogen. In certain embodiments, Z3, where present, is fluoro. In certain embodiments, Z3, where present, is chloro. In certain embodiments, Z3, where present, is bromo.
  • In certain embodiments of formula III, each R3a and R3b are each H. In certain embodiments, R3a is methyl and R3b is H.
  • In certain embodiments of formula III, Z2 is (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, or —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, or 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2c groups.
  • In certain embodiments, Z2 is (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, or —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, or 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2c groups.
  • In certain embodiments, Z2 is (C2-C8)alkynyl, phenyl, 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heterocycle, or —C(O)NRq3Rr3, wherein any phenyl, 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl, or 8-10 membered C-linked-bicyclic-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2c groups.
  • In certain embodiments, Z2 is (C2-C8)alkynyl, phenyl, 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heterocycle, or —C(O)NRq3Rr3, wherein any phenyl, 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl, or 8-10 membered C-linked-bicyclic-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2c groups.
  • In certain embodiments, Z2 is (C2-C8)alkynyl, phenyl, 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heterocycle, or —C(O)NRq3Rr3, wherein the 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl, or 8-10 membered C-linked-bicyclic-heterocycle have 1-9 carbon atoms and 1-4 heteroatoms in the ring system, and wherein any phenyl, 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl, 8-10 membered and C-linked-bicyclic-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2c groups.
  • In certain embodiments, Z2 is (C2-C8)alkynyl, phenyl, 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heterocycle, or —C(O)NRq3Rr3, wherein the 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl, or 8-10 membered C-linked-bicyclic-heterocycle have 1-9 carbon atoms and 1-4 heteroatoms in the ring system, and wherein any phenyl, 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl, 8-10 membered, or C-linked-bicyclic-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2c groups.
  • In certain embodiments of formula III, Z2 is (C2-C8)alkynyl, optionally substituted with 1, 2, 3, 4, or 5 Z2c groups. In certain embodiments, Z2 is (C2-C8)alkynyl, optionally substituted with 1, 2, 3, or 4 Z2c groups. In certain embodiments, Z2 is (C2-C8)alkynyl, optionally substituted with 1, 2, or 3 Z2c groups. In certain embodiments, Z2 is (C2-C8)alkynyl, optionally substituted with 1 or 2 Z2c groups.
  • In certain embodiments, Z2 is of the formula:
  • Figure US20210009555A1-20210114-C00064
  • wherein each of the (C1-C4)alkyl moieties of Z2, if present, is optionally substituted with 1, 2 or 3 Z2c groups, wherein the Z2b groups may be the same or different.
  • In certain embodiments, Z2 is of the formula:
  • Figure US20210009555A1-20210114-C00065
  • wherein each of the (C1-C4)alkyl moieties of Z2 is optionally substituted with 1, 2 or 3 Z2c groups, wherein the Z2b groups may be the same or different.
  • In certain embodiments, Z2 is of the formula:
  • Figure US20210009555A1-20210114-C00066
  • wherein each of the (C1-C4)alkyl moieties of Z2 is optionally substituted with 1, 2 or 3 Z2c groups, wherein the Z2b groups may be the same or different.
  • In certain embodiments of formula III, Z2 is substituted with 1, 2, 3, or 4 Z2b or Z2c groups, wherein the Z2b and Z2c groups may be the same or different. In certain embodiments, Z2 is substituted with 1, 2, or 3 Z2b or Z2c groups, wherein the Z2b and Z2c groups may be the same or different. In certain embodiments, Z2 is substituted with 1 or 2 Z2b or Z2c groups, wherein the Z2b and Z2c groups may be the same or different. In certain embodiments, Z2 is substituted with 1 Z2b or Z2c group.
  • In certain embodiments of formula III, Z2 is optionally substituted with 1, 2, or 3 Z2b or Z2c groups, wherein the Z2b and Z2c groups may be the same or different. In certain embodiments, Z2 is substituted with 1 Z2b or Z2c group. In certain embodiments, Z2 is substituted with 2 Z2b or Z2c groups, wherein the Z2b and Z2c groups may be the same or different. In certain embodiments, Z2 is substituted with 3 Z2b or Z2c groups, wherein the Z2b and Z2c groups may be the same or different.
  • In certain embodiments of formula III, Z2 is substituted with 1, 2, 3, or 4 Z2c groups, wherein the Z2c groups may be the same or different. In certain embodiments, Z2 is substituted with 1, 2, or 3 Z2c groups, wherein the Z2c groups may be the same or different. In certain embodiments, Z2 is substituted with 1 or 2 Z2c groups, wherein the Z2c groups may be the same or different. In certain embodiments, Z2 is substituted with 1 Z2c group.
  • In certain embodiments of formula III, Z2 is optionally substituted with 1, 2, or 3 Z2c groups, wherein the Z2c groups may be the same or different. In certain embodiments, Z2 is substituted with 1 Z2c group. In certain embodiments, Z2 is substituted with 2 Z2c groups, wherein the Z2c groups may be the same or different. In certain embodiments, Z2 is substituted with 3 Z2c groups, wherein the Z2c groups may be the same or different.
  • In certain embodiments, each Z2c is independently halogen, —ORn4, NRq4Rr4, —NRn4CO2Rp4, —C(O)ORn4, or —C(O)NRq4Rr4. In certain embodiments, each Z2c is independently halogen or —ORn4.
  • In certain embodiments, Z2 optionally substituted with 1, 2, 3, 4, or 5 Z2b or Z2c groups is
  • Figure US20210009555A1-20210114-C00067
    Figure US20210009555A1-20210114-C00068
    Figure US20210009555A1-20210114-C00069
    Figure US20210009555A1-20210114-C00070
    Figure US20210009555A1-20210114-C00071
  • In certain embodiments, Z2 optionally substituted with 1, 2, 3, 4, or 5 Z2b or Z2c groups is —C(O)NH2,
  • Figure US20210009555A1-20210114-C00072
  • In certain embodiments, Z2 optionally substituted with 1, 2, 3, 4, or 5 Z2b or Z2c groups is
  • Figure US20210009555A1-20210114-C00073
  • In certain embodiments, Z2 optionally substituted with 1, 2, 3, 4, or 5 Z2b or Z2c groups is
  • Figure US20210009555A1-20210114-C00074
    Figure US20210009555A1-20210114-C00075
    Figure US20210009555A1-20210114-C00076
    Figure US20210009555A1-20210114-C00077
  • In certain embodiments, Z2 optionally substituted with 1, 2, 3, 4, or 5 Z2b or Z2c groups is
  • Figure US20210009555A1-20210114-C00078
    Figure US20210009555A1-20210114-C00079
  • In certain embodiments, Z2 optionally substituted with 1, 2, 3, 4, or 5 Z2b or Z2c groups is
  • Figure US20210009555A1-20210114-C00080
  • In certain embodiments of formula III, R is a 5-12 membered heteroaryl, wherein any 5-12 membered heteroaryl of R1 is optionally substituted with 1, 2, 3, 4, or 5 Z4 groups.
  • In certain embodiments of formula III, R1 is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl, wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R1 is optionally substituted with 1, 2, 3, 4, or 5 Z4 groups.
  • In certain embodiments, R1 is a 8-12 membered tricyclic-heteroaryl, wherein the 8-12 membered tricyclic-heteroaryl of R1 is optionally substituted with 1, 2, 3, 4, or 5 Z4 groups.
  • In certain embodiments, R1 is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl, wherein the 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl have 4-10 carbon atoms and 1-5 heteroatoms in the ring system, and wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R1 is optionally substituted with 1, 2, 3, 4, or 5 Z4 groups.
  • In certain embodiments, R1 is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl, wherein the 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl contains at least one partially unsaturated ring, and wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R is optionally substituted with 1, 2, 3, 4 or 5 Z4 groups.
  • In certain embodiments, R1 is a 8-12 membered tricyclic-heteroaryl, wherein the 8-12 membered tricyclic-heteroaryl contains at least one partially unsaturated ring, and wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R1 is optionally substituted with 1, 2, 3, 4 or 5 Z4 groups.
  • In certain embodiments of formula III, R1 is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl, wherein the 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl has 4-9 carbon atoms and 1-5 heteroatoms in the ring system, and wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R1 is optionally substituted with 1, 2, 3, 4 or 5 Z4 groups.
  • In certain embodiments, R1 is a 8-12 membered bicyclic-heteroaryl, wherein the 8-12 membered bicyclic-heteroaryl has 6-9 carbon atoms and 1-3 heteroatoms in the ring system, and wherein any 8-12 membered bicyclic-heteroaryl of R is optionally substituted with 1, 2, 3, 4 or 5 Z4 groups.
  • In certain embodiments, R1 is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl, wherein the 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl has 6-9 carbon atoms and 1-3 heteroatoms in the ring system, and wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R1 is optionally substituted with 1, 2, 3, 4 or 5 Z4 groups.
  • In certain embodiments of formula III, R has the following formula IIa:
  • Figure US20210009555A1-20210114-C00081
  • wherein:
  • C together with the two carbon atoms of ring B to which it is attached forms a 3-7 membered monocyclic-carbocycle, 5-8 membered bicyclic-carbocycle, 3-7 membered monocyclic-heterocycle, or 5-8 membered bicyclic heterocycle, wherein any 3-7 membered monocyclic-carbocycle, 5-8 membered bicyclic-carbocycle, 3-7 membered monocyclic-heterocycle or 5-8 membered bicyclic heterocycle of C is optionally substituted with 1, 2, 3, 4 or 5 Z4 groups, wherein the Z4 groups are the same or different; and
  • B is a 5 or 6 membered monocyclic-heteroaryl with 1, 2 or 3 nitrogen atoms, wherein B is optionally substituted with 1, 2, 3, 4 or 5 Z4 groups, wherein the Z4 groups are the same or different.
  • In certain embodiments of formula III, R1 has the following formula IIIb:
  • Figure US20210009555A1-20210114-C00082
  • wherein:
  • C together with the two carbon atoms of ring B to which it is attached forms a 3-7 membered monocyclic-carbocycle, 5-8 membered bicyclic-carbocycle, 3-7 membered monocyclic-heterocycle, or 5-8 membered bicyclic heterocycle, wherein any 3-7 membered monocyclic-carbocycle, 5-8 membered bicyclic-carbocycle, 3-7 membered monocyclic-heterocycle or 5-8 membered bicyclic heterocycle of C is optionally substituted with 1, 2, 3, 4 or 5 Z4 groups, wherein the Z4 groups are the same or different; and
  • B is a 5 or 6 membered monocyclic-heteroaryl having 1, 2 or 3 nitrogen atoms;
  • V is C or N;
  • W is CZ4c, NZ4c or N;
  • X is CZ4c NZ4c or N;
  • Y is CZ4c, N or absent;
  • the dashed bonds are selected from single bonds and double bonds, wherein the dashed bonds, V, W, X and Y are selected so that the 5 or 6 membered monocyclic-heteroaryl B is aromatic; and
  • each Z4c is independently selected from H or Z4, wherein the Z4 groups are the same or different.
  • In certain embodiments of formula iii, R1 has the following formula IIc:
  • Figure US20210009555A1-20210114-C00083
  • wherein:
  • C together with the two carbon atoms of ring B to which it is attached forms a 3-7 membered monocyclic-carbocycle, 5-8 membered bicyclic-carbocycle, 3-7 membered monocyclic-heterocycle, or 5-8 membered bicyclic heterocycle, wherein any 3-7 membered monocyclic-carbocycle, 5-8 membered bicyclic-carbocycle, 3-7 membered monocyclic-heterocycle or 5-8 membered bicyclic heterocycle of C is optionally substituted with 1, 2, 3, 4 or 5 Z4 groups, wherein the Z4 groups are the same or different; and
  • B is a 5 or 6 membered monocyclic-heteroaryl having 1, 2 or 3 nitrogen atoms;
  • V is C or N;
  • W is CZ4c or N;
  • X is CZ4c, NZ4c or N;
  • Y is CZ4c, N or absent;
  • the dashed bonds are selected from single bonds and double bonds, wherein the dashed bonds, V, W, X and Y are selected so that the 5 or 6 membered monocyclic-heteroaryl B is aromatic; and
  • each Z4c is independently selected from H or Z4, wherein the Z4 groups are the same or different.
  • In certain embodiments of formula III, R1 has the following formula IId:
  • Figure US20210009555A1-20210114-C00084
  • wherein:
  • C together with the two carbon atoms to which it is attached forms a 3-7 membered monocyclic-carbocycle, 5-9 membered bicyclic-carbocycle, 3-7 membered monocyclic-heterocycle, or 5-9 membered bicyclic heterocycle, wherein any 3-7 membered monocyclic-carbocycle, 5-9 membered bicyclic-carbocycle, 3-7 membered monocyclic-heterocycle or 5-9 membered bicyclic heterocycle of C is optionally substituted with 1, 2, 3, 4 or 5 Z4 groups, wherein the Z4 groups are the same or different; and
  • each Z4c is independently selected from H or Z4, wherein the Z4 groups are the same or different.
  • In certain embodiments of formula III, R has the following formula:
  • Figure US20210009555A1-20210114-C00085
  • wherein:
  • C together with the two carbon atoms to which it is attached forms a 3-7 membered monocyclic-carbocycle or 5-9 membered bicyclic-carbocycle, wherein any 3-7 membered monocyclic-carbocycle or 5-9 membered bicyclic-carbocycle of C is optionally substituted with 1, 2, 3, 4 or 5 Z4 groups, wherein the Z4 groups are the same or different.
  • In certain embodiments of formula III, R1 has the following formula:
  • Figure US20210009555A1-20210114-C00086
  • In certain embodiments of formula III, C together with the two carbon atoms to which it is attached forms a 5-7 membered monocyclic-carbocycle or 5-7 membered bicyclic-carbocycle, wherein any 5-7 membered monocyclic-carbocycle or 5-7 membered bicyclic-carbocycle of C is optionally substituted with 1, 2, 3, or 4 Z4 groups, wherein the Z4 groups are the same or different.
  • In certain embodiments of formula III, each Z4 is independently (C1-C8)alkyl, (C3-C7)carbocycle, halogen, —CN, —NRq5Rr5, —NRn5CORp5, —NRn5CO2Rp5, —C(O)ORn5, or —C(O)NRq5Rr5, wherein any (C3-C7)carbocycle or (C1-C8)alkyl of Z4 is optionally substituted with 1, 2, 3, 4 or 5 Z4a groups.
  • In certain embodiments, each Z4 is independently (C1-C6)alkyl or halogen, wherein any (C1-C6)alkyl of Z4 is optionally substituted with 1, 2, 3, 4 or 5 halogen, which may be the same or different. In certain embodiments, each Z4 is independently (C1-C4)alkyl or halogen, wherein any (C1-C6)alkyl of Z4 is optionally substituted with 1, 2, 3, 4 or 5 halogen, which may be the same or different. In certain embodiments, each Z4 is independently (C1-C3)alkyl or halogen, wherein any (C1-C3)alkyl of Z4 is optionally substituted with 1, 2, 3, 4 or 5 halogen, which may be the same or different.
  • In certain embodiments, each Z4 is independently fluoro, trifluoromethyl, or difluoromethyl.
  • In certain embodiments of formula III, R optionally substituted with 1, 2, 3, 4, or 5 Z4 groups is
  • Figure US20210009555A1-20210114-C00087
    Figure US20210009555A1-20210114-C00088
    Figure US20210009555A1-20210114-C00089
  • In certain embodiments, R1 optionally substituted with 1, 2, 3, 4, or 5 Z4 groups is
  • Figure US20210009555A1-20210114-C00090
  • In certain embodiments, R1 optionally substituted with 1, 2, 3, 4, or 5 Z4 groups is
  • Figure US20210009555A1-20210114-C00091
  • In certain embodiments, R1 optionally substituted with 1, 2, 3, 4,or 5Z4 groups is
  • Figure US20210009555A1-20210114-C00092
  • In certain embodiments, R1 optionally substituted with 1, 2, 3, 4,or 5Z4 groups is
  • Figure US20210009555A1-20210114-C00093
  • In certain embodiments, R1 optionally substituted with 1, 2, 3, 4, or 5 Z4 groups is
  • Figure US20210009555A1-20210114-C00094
  • In certain embodiments, R1 optionally substituted with 1, 2, 3, 4, or 5 Z4 groups is
  • Figure US20210009555A1-20210114-C00095
  • In certain embodiments, R1 optionally substituted with 1, 2, 3, 4, or 5 Z4 groups is
  • Figure US20210009555A1-20210114-C00096
  • In certain embodiments, R1 is
  • Figure US20210009555A1-20210114-C00097
    Figure US20210009555A1-20210114-C00098
  • optionally substituted with 1, 2, 3, 4 or 5 Z4 groups.
  • In certain embodiments, R is
  • Figure US20210009555A1-20210114-C00099
  • optionally substituted with 1, 2, 3, 4 or 5 Z4 groups.
  • In certain embodiments of formula III, each Z4 is independently (C1-C6)alkyl or halogen, wherein any (C1-C6)alkyl of Z4 is optionally substituted with 1, 2, 3, 4 or 5 halogen, which may the same or different.
  • In certain embodiments, each Z4 is independently (C1-C6)alkyl, —CN, or halogen, wherein any (C1-C6)alkyl of Z4 is optionally substituted with 1, 2, 3, 4 or 5 halogen, which may the same or different.
  • In certain embodiments, each Z4 is independently fluoro, trifluoromethyl, or difluoromethyl.
  • In certain embodiments, each Z4 is independently fluoro, trifluoromethyl, —CN, or difluoromethyl.
  • In certain embodiments of Formula III, Z1 is phenyl, 5-14 membered heteroaryl, or 3-14 membered heterocycle, wherein any phenyl, 5-14 membered heteroaryl, or 3-14 membered heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a or Z1b groups.
  • In certain embodiments, Z1 is phenyl, 5-12 membered heteroaryl, or 3-12 membered heterocycle, wherein any phenyl, 5-12 membered heteroaryl, or 3-12 membered heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a or Z1b groups.
  • In certain embodiments, Z1 is phenyl, 5-14 membered heteroaryl, or 3-14 membered heterocycle, wherein any phenyl, 5-14 membered heteroaryl, or 3-14 membered heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups.
  • In certain embodiments, Z1 is phenyl, 5-12 membered heteroaryl, or 3-12 membered heterocycle, wherein any phenyl, 5-12 membered heteroaryl, or 3-12 membered heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups.
  • In certain embodiments, Z1 is phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle wherein any phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a or Z1b groups.
  • In certain embodiments, Z1 is phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle wherein any phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups.
  • In certain embodiments, Z1 is phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle, wherein the 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle have 1-11 carbon atoms and 1-5 heteroatoms in the ring system, and wherein any phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a or Z1b groups.
  • In certain embodiments, Z1 is phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle, wherein the 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle have 1-11 carbon atoms and 1-5 heteroatoms in the ring system, and wherein any phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups.
  • In certain embodiments, Z1 is phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle, wherein the 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle have 4-11 carbon atoms and 1-3 heteroatoms in the ring system, and wherein any phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a or Z1b groups.
  • In certain embodiments, Z1 is phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle, wherein the 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle have 4-11 carbon atoms and 1-3 heteroatoms in the ring system, and wherein any phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups.
  • In certain embodiments, Z1 is 8-10 membered bicyclic-heteroaryl or 8-10 membered bicyclic-heterocycle, wherein any from 8-10 membered bicyclic-heteroaryl or 8-10 membered bicyclic-heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a or Z1b groups.
  • In certain embodiments, Z1 is 8-10 membered bicyclic-heteroaryl or 8-10 membered bicyclic-heterocycle, wherein any from 8-10 membered bicyclic-heteroaryl or 8-10 membered bicyclic-heterocycle of Z is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups.
  • In certain embodiments, Z1 is 8-10 membered bicyclic-heteroaryl or 8-10 membered bicyclic-heterocycle, wherein the 8-10 membered bicyclic-heteroaryl or 8-10 membered bicyclic-heterocycle has 3-9 carbon atoms and 1-5 heteroatoms in the ring system, and wherein any 8-10 membered bicyclic-heteroaryl or 8-10 membered bicyclic-heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a or Z1b groups.
  • In certain embodiments, Z1 is 8-10 membered bicyclic-heteroaryl or 8-10 membered bicyclic-heterocycle, wherein the 8-10 membered bicyclic-heteroaryl or 8-10 membered bicyclic-heterocycle has 3-9 carbon atoms and 1-5 heteroatoms in the ring system, and wherein any 8-10 membered bicyclic-heteroaryl or 8-10 membered bicyclic-heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups.
  • In certain embodiments of formula III, Z1 is not substituted with Z1b.
  • In certain embodiments of formula III, each Z1a is independently oxo, (C3-C7)carbocycle, halogen, —CN, —O—(C1-C8)alkyl, —NR1cRp1, —NRn1,CORp1, —NRn1CO2Rp1, —NRn1CONRq1Rr1, —NRn1 S(O)2Rp1, —NRn1S(O)2NRq1Rr1, or —C(O)NRq1Rr1.
  • In certain embodiments, each Z1a is independently —NRn1S(O)2Rp1, —NRn1S(O)2NRq1Rr1 or halogen. In certain embodiments, each Z1a is independently halogen or —NRn1S(O)2Rp1. In certain embodiments, each Z1a is independently halogen or —NRn1S(O)2NRq1Rr1.
  • In certain embodiments, Z1 is substituted with 2 Z1a groups, wherein each Z1a is independently —NRn1S(O)2Rp1, —NRn1S(O)2NRq1Rr1, or halogen.
  • In certain embodiments, each Z1a is independently halogen or —NRn1S(O)2Rp1 and each Z1b is (C1-C8)alkyl, which may be same or different.
  • In certain embodiments, Z1a is —NRn1S(O)2Rp1 or —NRn1S(O)2NRq1Rr1. In certain embodiments, Z1a is halogen. In certain embodiments, Z1a is —NRq1Rr1, —NRn1CORp1, —NRn1CO2Rp1, or —NRn1,CONRq1Rr1.
  • In certain embodiments, Z1a is halogen, —ORn1, or —C(O)NRq1Rr1.
  • In certain embodiments, Z1a is halogen or —C(O)NRq1Rr1.
  • In certain embodiments, Z1a is halogen, —OH, or —C(O)NH2.
  • In certain embodiments, Z1a is fluoro, —OH, or —C(O)NH2.
  • In certain embodiments, each Z1b is (C1-C8)alkyl, which may be same or different.
  • In certain embodiments, each Z1b is independently methyl or difluoromethyl.
  • In certain embodiments of formula III, Z1 is
  • Figure US20210009555A1-20210114-C00100
  • optionally substituted with 1, 2, 3, 4 or 5 Z1a or Z1b.
  • In certain embodiments, Z1 is
  • Figure US20210009555A1-20210114-C00101
  • wherein each Z1w is independently Z1a, Z1b, or H. In certain embodiments, each Z1a is independently halogen, —CN, —ORn1, —NRn1S(O)2Rp1, —NRn1S(O)2NRq1Rr1, —NRq1Rr1, —NRn1CORp1, —NRn1CONRq1Rr1, or —NRn1CO2Rp1; each Z1b is independently (C1-C8alkyl), wherein the (C1-C8alkyl) is optionally substituted with 1, 2, or 3 halogen, which are the same or different; and at least one of Z1w is Z1a or Z1b. In certain embodiments, at least two of Z1w are independently Z1a. In certain embodiments, each Z1a is independently halogen, —NRn1S(O)2Rp1, or —NRn1S(O)2NRq1Rr1.
  • In certain embodiments, Z1 is
  • Figure US20210009555A1-20210114-C00102
  • wherein each Z1a is independently halogen, —NRn1SS(O)2Rp1 or —NRn1S(O)2NRq1Rr1.
  • In certain embodiments, Z1 is
  • Figure US20210009555A1-20210114-C00103
  • optionally substituted with 1, 2, 3, or 4 Z1a or Z1b.
  • In certain embodiments, Z1 is
  • Figure US20210009555A1-20210114-C00104
  • In certain embodiments, Z1 optionally substituted with 1, 2, 3, 4, or 5 Z1a or Z1b groups is
  • Figure US20210009555A1-20210114-C00105
    Figure US20210009555A1-20210114-C00106
    Figure US20210009555A1-20210114-C00107
    Figure US20210009555A1-20210114-C00108
    Figure US20210009555A1-20210114-C00109
    Figure US20210009555A1-20210114-C00110
    Figure US20210009555A1-20210114-C00111
    Figure US20210009555A1-20210114-C00112
  • In certain embodiments, Z1 optionally substituted with 1, 2, 3, 4, or 5 Z1a or Z1b groups is
  • Figure US20210009555A1-20210114-C00113
  • In certain embodiments, Z1 optionally substituted with 1, 2, 3, 4, or 5 Z1a or Z1b groups is
  • Figure US20210009555A1-20210114-C00114
    Figure US20210009555A1-20210114-C00115
    Figure US20210009555A1-20210114-C00116
    Figure US20210009555A1-20210114-C00117
    Figure US20210009555A1-20210114-C00118
    Figure US20210009555A1-20210114-C00119
    Figure US20210009555A1-20210114-C00120
    Figure US20210009555A1-20210114-C00121
  • In certain embodiments, Z1 optionally substituted with 1, 2, 3, 4, or 5 Z1a or Z1b groups is
  • Figure US20210009555A1-20210114-C00122
  • In certain embodiments, Z optionally substituted with 1, 2, 3, 4, or 5 Z1a or Z1b groups is
  • Figure US20210009555A1-20210114-C00123
  • In certain embodiments, Z1 is
  • Figure US20210009555A1-20210114-C00124
  • In certain embodiments, Z2-A-Z1 is:
  • Figure US20210009555A1-20210114-C00125
  • In one variation of formula III, A is pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; and R1 is a 5-12 membered heteroaryl, optionally substituted with 1, 2, 3, 4 or 5 Z4 groups, which may be the same or different. In another variation, A is pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; and R is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl, wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R1 is optionally substituted with 1, 2, 3, 4, or 5 Z4 groups. In another variation, A is pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; R is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl, wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R is optionally substituted with 1, 2, 3, 4, or 5 Z4 groups; and each Z4 is independently fluoro, trifluoromethyl, or difluoromethyl.
  • In one variation of formula III, A is pyridinyl; and R1 is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl, wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R1 is optionally substituted with 1, 2, 3, 4, or 5 Z4 groups, which may be the same or different.
  • In one variation of formula III, A is pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; and R2 is 3,5-difluorophenyl. In another variation, A is pyridinyl; and R2 is 3,5-difluorophenyl. In another variation, A is pyrimidinyl; and R2 is 3,5-difluorophenyl. In another variation, A is pyrazinyl; and R2 is 3,5-difluorophenyl. In another variation, A is pyridazinyl; and R2 is 3,5-difluorophenyl.
  • In one variation of formula III, A is pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; and Z1 is phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle wherein any phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups, which may be the same or different. In another variation, A is pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; and Z1 is phenyl, optionally substituted with 1, 2, 3, 4 or 5 Z1a groups. In another variation, A is pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; and Z1 is 5-6 membered monocyclic-heteroaryl or 8-10 membered bicyclic-heteroaryl, wherein any 5-6 membered monocyclic-heteroaryl or 8-10 membered bicyclic-heteroaryl of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups. In another variation, A is pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; and Z1 is 8-10 membered bicyclic-heterocycle or 9-12 membered tricyclic-heterocycle wherein any 8-10 membered bicyclic-heterocycle or 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups.
  • In one variation of formula III, A is pyridinyl; and Z1 is phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle wherein any phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups, which may be the same or different. In another variation, A is pyridinyl; and Z1 is phenyl, optionally substituted with 1, 2, 3, 4 or 5 Z1a groups. In another variation, A is pyridinyl; and Z1 is 5-6 membered monocyclic-heteroaryl or 8-10 membered bicyclic-heteroaryl, wherein any 5-6 membered monocyclic-heteroaryl or 8-10 membered bicyclic-heteroaryl of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups. In another variation, A is pyridinyl; and Z1 is 8-10 membered bicyclic-heterocycle or 9-12 membered tricyclic-heterocycle wherein any 8-10 membered bicyclic-heterocycle or 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups.
  • In one variation of formula III, A is pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; and Z2 is (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, or —C(O)NRq3Rr3 wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, or 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, which may be the same or different, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2c groups, which may be the same or different. In another variation, A is pyridinyl; and Z2 is (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, or —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, or 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2c groups. In another variation, A is pyrimidinyl; and Z2 is (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, or —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, or 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2c groups. In another variation, A is pyrazinyl; and Z2 is (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, or —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, or 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2c groups. In another variation, A is pyridazinyl; and Z2 is (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, or —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, or 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2c groups.
  • In one variation of formula III, A is pyridinyl substituted with one Z moiety, one Z2 moiety and no (zero) Z3 moieties; and Z2 is (C2-C8)alkynyl or aryl, which Z2 may be optionally substituted as provided by formula III. In another variation, A is pyridinyl substituted with one Z1 moiety, one Z2 moiety and no (zero) Z3 moieties; and Z2 is (C2-C8)alkynyl, which Z2 may be optionally substituted as provided by formula III. In a particular variation, A is pyridinyl substituted with one Z1 moiety, one Z2 moiety at the position alpha to the nitrogen atom of the pyridinyl ring, and no (zero) Z3 moieties, wherein Z2 is (C2-C8)alkynyl, which Z2 may be optionally substituted as provided by formula III.
  • In one variation of formula III, R1 is a 5-12 membered heteroaryl optionally substituted with 1, 2, 3, 4 or 5 Z4 groups, which may be the same or different; and Z1 is phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle wherein any phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups, which may be the same or different. In another variation, R1 is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl, wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R1 is optionally substituted with 1, 2, 3, 4, or 5 Z4 groups; and Z is phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle wherein any phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle of Z is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups.
  • In one variation of formula III, R1 is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl, wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R1 is optionally substituted with 1, 2, 3, 4, or 5 Z4 groups, which may be the same or different; and Z is 8-10 membered bicyclic-heteroaryl or 8-10 membered bicyclic-heterocycle wherein any 8-10 membered bicyclic-heteroaryl or 8-10 membered bicyclic-heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups, which may be the same or different.
  • In one variation of formula III, R1 is a 5-12 membered heteroaryl optionally substituted with 1, 2, 3, 4 or 5 Z4 groups, which may be the same or different; and Z2 is (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, or —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, or 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2c groups, which may be the same or different. In another variation, R1 is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R1 is optionally substituted with 1, 2, 3, 4, or 5 Z4 groups; and Z2 is (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, or —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, or 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2c group.
  • In one variation of formula III, Z is phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle wherein any phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups, which may be the same or different; and Z2 is (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, or —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, or 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, which may be the same or different, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2c groups, which may be the same or different.
  • In one variation of formula III, Z is bicyclic-heteroaryl optionally substituted with 1, 2, 3, 4 or 5 Z1a groups, which may be the same or different; and Z2 is (C2-C8)alkynyl optionally substituted with 1, 2, 3, 4 or 5 Z2c groups, which may be the same or different.
  • In one variation of formula III, R is a 5-12 membered heteroaryl; Z is phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle wherein any phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle, or 9-12 membered tricyclic-heterocycle of Z is optionally substituted with 1, 2, 3, 4 or 5 Z1a groups, which may be the same or different; and Z2 is (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, or —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, or 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, which may be the same or different, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2c groups, which may be the same or different.
  • In certain embodiments of formula III,
  • A is a 6-membered monocyclic-heteroaryl with one or two nitrogen atoms, wherein the 6-membered monocyclic-heteroaryl is substituted with one Z1 group at the position shown, one Z2 group, and optionally substituted with 1 or 2 Z3 groups, which may be the same or different;
  • R1 is 6-12 membered aryl, 5-12 membered heteroaryl, or 3-12 membered heterocycle, wherein any 6-12 membered aryl, 5-12 membered heteroaryl, or 3-12 membered heterocycle of R1 is optionally substituted with 1, 2, 3, 4 or 5 Z4 groups, which may be the same or different;
  • R2 is phenyl optionally substituted with 1, 2, 3, 4 or 5 halogen, which may be the same or different;
  • each R3a and R3b is independently H or (C1-C3)alkyl;
  • Z1 is 6-12 membered aryl, 5-14 membered heteroaryl, or 3-14 membered heterocycle, wherein any 6-12 membered aryl, 5-14 membered heteroaryl, or 3-14 membered heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a or Z1b, which may be the same or different;
  • each Z1a is independently oxo, (C3-C7)carbocycle, halogen, —CN, —O—(C1-C8)alkyl, —OC(O)Rp1, —OC(O)NRq1Rr1, —NRq1Rr1, —NRn1CORp1, —NRn1CO2Rp1, —NRn1CONRq1Rr1, —NRn1S(O)2Rp1, —NRn1S(O)2NRq1Rr1, —C(O)Rn1, —C(O)ORn6, or —C(O)NRq1Rr1;
  • each Z1b is independently (C1-C8)alkyl optionally substituted with 1, 2, 3, 4 or 5 halogen, which may be the same or different;
  • each Rn1 is independently H or (C1-C8)alkyl;
  • each Rp1 is independently (C1-C8)alkyl, (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl of Rp1 is optionally substituted with 1, 2, 3, 4 or 5 (C1-C8)alkyl, which may be the same or different, and wherein any (C1-C8)alkyl of Rp1 is optionally substituted with 1, 2, 3, 4 or 5 halogen, hydroxyl, —O(C1-C8)alkyl, or —NRq2Rr2, which may be the same or different;
  • each Rq1 and Rr1 is independently H, (C1-C8)alkyl, (C3-C7)carbocycle, or 3-7-membered heterocycle, wherein any (C1-C8)alkyl of Rq1 or Rr1 is optionally substituted with 1, 2, 3, 4 or 5 halogen or —CN, which may be the same or different, or Rq1 and Rr1 together with the nitrogen to which they are attached form a 5, 6, or 7-membered heterocycle, wherein the 5, 6, or 7-membered heterocycle is optionally substituted with 1, 2, 3, 4 or 5 (C1-C8)alkyl, which may be the same or different;
  • each Rq2 and Rr2 is independently H, (C1-C8)alkyl, (C3-C7)carbocycle, or Rq2 and Rr2 together with the nitrogen to which they are attached form a 5, 6, or 7-membered heterocycle;
  • Z2 is (C2-C8)alkenyl, (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, —C(O)Rn3, or —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, or 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, which may be the same or different, and wherein any (C2-C8)alkenyl or (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4, or 5 Z2c groups, which may be the same or different;
  • each Rn3 is independently H or (C1-C4)alkyl;
  • each Rq3 and Rr3 is independently H or (C1-C4)alkyl;
  • each Z2b is independently oxo, (C1-C4)alkyl, (C1-C4)heteroalkyl or (C1-C4)haloalkyl;
  • each Z2c is independently oxo, halogen, —CN, —ORn4, NRq4Rr4, —NRn4CORp4, —NRn4CO2Rp4, —NRn4S(O)2Rp4, —C(O)Rn4, —C(O)ORn4 or —C(O)NRq4Rr4;
  • each Rn4 is independently H, (C1-C4)alkyl, or (C1-C4)heteroalkyl;
  • each Rp4 is independently (C1-C8)alkyl;
  • each Rq4 and Rr4 is independently H, (C1-C4)alkyl, or (C1-C4)heteroalkyl;
  • each Z3 is independently a (C1-C4)heteroalkyl or halogen;
  • each Z4 is independently oxo, (C1-C8)alkyl, (C3-C7)carbocycle, halogen, —CN, —ORn5, —NRq5Rr5, —NRn5CORp5, —NRn5CO2Rp5, —C(O)Rn5, —C(O)ORn5, or —C(O)NRq5Rr5 wherein any (C3-C7)carbocycle or (C1-C8)alkyl of Z4 is optionally substituted with 1, 2, 3, 4 or 5 Z4a groups, which may be the same or different;
  • each Z4a is independently halogen, —CN, or —ORn6; and
  • each Rn5, Rp5, Rq5, Rr5, and Rn6 is independently H or (C1-C4)alkyl.
  • In certain embodiments of formula III,
  • A1 is CH, C—Z3, or nitrogen;
  • A2 is CH or nitrogen;
  • R1 is 6-12 membered aryl, 5-12 membered heteroaryl, or 3-12 membered heterocycle, wherein any 6-12 membered aryl, 5-12 membered heteroaryl, or 3-12 membered heterocycle of R1 is optionally substituted with 1, 2, 3, 4 or 5 Z4 groups, which may be the same or different;
  • each R3a and R3b is independently H or (C1-C3)alkyl;
  • Z1 is 6-12 membered aryl, 5-14 membered heteroaryl, or 3-14 membered heterocycle, wherein any 6-12 membered aryl, 5-14 membered heteroaryl, or 3-14 membered heterocycle of Z1 is optionally substituted with 1, 2, 3, 4 or 5 Z1a or Z1b, which may be the same or different;
  • each Z1a is independently oxo, (C3-C7)carbocycle, halogen, —CN, —O—(C1-C8)alkyl, —OC(O)Rp1, —OC(O)NRq1Rr1, —NRq1Rr1, —NRn1 CORp1, —NRn1CO2Rp1, —NRn1CONRq1Rr1, —NRn1 S(O)2Rp1, —NRn1S(O)2NRq1Rr1, —C(O)Rn1, —C(O)ORn1, or —C(O)NRq1Rr1;
  • each Z1b is independently (C1-C8)alkyl optionally substituted with 1, 2, 3, 4 or 5 halogen, which may be the same or different;
  • each Rn1 is independently H or (C1-C8)alkyl;
  • each Rp1 is independently (C1-C8)alkyl, (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, or 5-6 membered monocyclic-heteroaryl of Rp1 is optionally substituted with 1, 2, 3, 4 or 5 (C1-C8)alkyl, which may be the same or different, and wherein any (C1-C8)alkyl of Rp1 is optionally substituted with 1, 2, 3, 4 or 5 halogen, hydroxyl, —O(C1-C8)alkyl, or —NRq2Rr2, which may be the same or different;
  • each Rq1 and Rr1 is independently H, (C1-C8)alkyl, (C3-C7)carbocycle, or 3-7-membered heterocycle, wherein any (C1-C8)alkyl of Rq1 or Rr1 is optionally substituted with 1, 2, 3, 4 or 5 halogen or —CN, which may be the same or different, or Rq1 and Rr1 together with the nitrogen to which they are attached form a 5, 6, or 7-membered heterocycle, wherein the 5, 6, or 7-membered heterocycle is optionally substituted with 1, 2, 3, 4 or 5 (C1-C8)alkyl, which may be the same or different;
  • each Rq2 and Rr2 is independently H, (C1-C8)alkyl, (C3-C7)carbocycle, or Rq2 and Rr2 together with the nitrogen to which they are attached form a 5, 6, or 7-membered heterocycle;
  • Z2 is (C2-C8)alkenyl, (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, —C(O)Rn3, or —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, or 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with 1, 2, 3, 4 or 5 Z2b or Z2c groups, which may be the same or different, and wherein any (C2-C8)alkenyl or (C2-C8)alkynyl of Z2 is optionally substituted with 1, 2, 3, 4, or 5 Z2c groups, which may be the same or different;
  • each Rn3 is independently H or (C1-C4)alkyl;
  • each Rq3 and Rr3 is independently H or (C1-C4)alkyl;
  • each Z2b is independently oxo, (C1-C4)alkyl, (C1-C4)heteroalkyl or (C1-C4)haloalkyl;
  • each Z2c is independently oxo, halogen, —CN, —ORn4, NRq4Rr4, —NRn4CORp4, —NRn4CO2Rp4, —NRn4S(O)2Rp4, —C(O)Rn4, —C(O)ORn4 or —C(O)NRq4Rr4;
  • each Rn4 is independently H, (C1-C4)alkyl, or (C1-C4)heteroalkyl;
  • each Rp4 is independently (C1-C8)alkyl;
  • each Rq4 and Rr4 is independently H, (C1-C4)alkyl, or (C1-C4)heteroalkyl;
  • Z3 is independently a (C1-C4)heteroalkyl or halogen;
  • each Z4 is independently oxo, (C1-C8)alkyl, (C3-C7)carbocycle, halogen, —CN, —ORn5, —NRq5Rr5, —NRn5CORp5, —NRn5CO2Rp5, —C(O)Rn5, —C(O)ORn5, or —C(O)NRq5Rr5, wherein any (C3-C7)carbocycle or (C1-C8)alkyl of Z4 is optionally substituted with 1, 2, 3, 4 or 5 Z4a groups, which may be the same or different;
  • each Z4a is independently halogen, —CN, or —ORn6; and
  • each Rn5, Rp5Rq5, Rr5, and Rn6 is independently H or (C1-C4)alkyl;
  • each Z5 is independently halogen, which may be same or different; and
  • n is 0, 1, 2,or 3.
  • In one embodiment the compound of formula I is selected from:
  • Figure US20210009555A1-20210114-C00126
    Figure US20210009555A1-20210114-C00127
    Figure US20210009555A1-20210114-C00128
    Figure US20210009555A1-20210114-C00129
    Figure US20210009555A1-20210114-C00130
  • and pharmaceutically acceptable salts thereof.
  • In certain embodiments, a compound is:
  • Figure US20210009555A1-20210114-C00131
  • or a pharmaceutically acceptable salt thereof.
  • In certain embodiments, a compound is:
  • Figure US20210009555A1-20210114-C00132
  • or a pharmaceutically acceptable salt thereof.
  • In certain embodiments, a compound or a pharmaceutically acceptable salt thereof is:
  • Figure US20210009555A1-20210114-C00133
    Figure US20210009555A1-20210114-C00134
    Figure US20210009555A1-20210114-C00135
    Figure US20210009555A1-20210114-C00136
    Figure US20210009555A1-20210114-C00137
    Figure US20210009555A1-20210114-C00138
    Figure US20210009555A1-20210114-C00139
    Figure US20210009555A1-20210114-C00140
    Figure US20210009555A1-20210114-C00141
    Figure US20210009555A1-20210114-C00142
    Figure US20210009555A1-20210114-C00143
    Figure US20210009555A1-20210114-C00144
    Figure US20210009555A1-20210114-C00145
    Figure US20210009555A1-20210114-C00146
    Figure US20210009555A1-20210114-C00147
    Figure US20210009555A1-20210114-C00148
    Figure US20210009555A1-20210114-C00149
    Figure US20210009555A1-20210114-C00150
    Figure US20210009555A1-20210114-C00151
    Figure US20210009555A1-20210114-C00152
    Figure US20210009555A1-20210114-C00153
    Figure US20210009555A1-20210114-C00154
    Figure US20210009555A1-20210114-C00155
    Figure US20210009555A1-20210114-C00156
    Figure US20210009555A1-20210114-C00157
    Figure US20210009555A1-20210114-C00158
    Figure US20210009555A1-20210114-C00159
    Figure US20210009555A1-20210114-C00160
    Figure US20210009555A1-20210114-C00161
    Figure US20210009555A1-20210114-C00162
    Figure US20210009555A1-20210114-C00163
    Figure US20210009555A1-20210114-C00164
    Figure US20210009555A1-20210114-C00165
    Figure US20210009555A1-20210114-C00166
    Figure US20210009555A1-20210114-C00167
    Figure US20210009555A1-20210114-C00168
    Figure US20210009555A1-20210114-C00169
    Figure US20210009555A1-20210114-C00170
    Figure US20210009555A1-20210114-C00171
    Figure US20210009555A1-20210114-C00172
    Figure US20210009555A1-20210114-C00173
    Figure US20210009555A1-20210114-C00174
    Figure US20210009555A1-20210114-C00175
    Figure US20210009555A1-20210114-C00176
    Figure US20210009555A1-20210114-C00177
    Figure US20210009555A1-20210114-C00178
    Figure US20210009555A1-20210114-C00179
    Figure US20210009555A1-20210114-C00180
    Figure US20210009555A1-20210114-C00181
    Figure US20210009555A1-20210114-C00182
    Figure US20210009555A1-20210114-C00183
    Figure US20210009555A1-20210114-C00184
    Figure US20210009555A1-20210114-C00185
    Figure US20210009555A1-20210114-C00186
    Figure US20210009555A1-20210114-C00187
    Figure US20210009555A1-20210114-C00188
    Figure US20210009555A1-20210114-C00189
    Figure US20210009555A1-20210114-C00190
    Figure US20210009555A1-20210114-C00191
    Figure US20210009555A1-20210114-C00192
  • In certain embodiments, a compound is:
  • Figure US20210009555A1-20210114-C00193
  • or a pharmaceutically acceptable salt thereof.
  • In certain embodiments, a compound is:
  • Figure US20210009555A1-20210114-C00194
  • or a pharmaceutically acceptable salt thereof.
  • In certain embodiments, a compound is:
  • Figure US20210009555A1-20210114-C00195
  • or a pharmaceutically acceptable salt thereof.
  • In certain embodiments, a compound is:
  • Figure US20210009555A1-20210114-C00196
  • or a pharmaceutically acceptable salt thereof.
  • In certain embodiments, a compound is:
  • Figure US20210009555A1-20210114-C00197
  • or a pharmaceutically acceptable salt thereof.
  • In certain embodiments, a compound is
  • Figure US20210009555A1-20210114-C00198
  • or a pharmaceutically acceptable salt thereof.
    • General Synthetic Procedures
  • The following schemes describe methods that are useful for preparing compounds of formula I. The following schemes similarly describe methods that are useful for preparing compounds of formula III.
  • Figure US20210009555A1-20210114-C00199
    Figure US20210009555A1-20210114-C00200
  • Scheme 1 describes a general stereoselective route which is used to prepare compounds of formula I. The scheme is also be used to prepare compounds of formula III. Heteroaryl acids of formula A1 (where X represents diversifiable chemical group such as NH2, SH, or halogen that are suitably protected) are converted to the corresponding aldehydes then condensed with a chiral auxiliary to provide a stereoselective addition of a nucleophilic reagent. Depicted in Scheme 1 is the conversion of a heteroaryl acid A1 containing two diversifiable functional groups (e.g., X and Br) to the corresponding aldehyde. This is followed by the condensation of the aldehyde A3 with (S) tert-butane sulfinamide and the addition of a Grignard reagent to provide a mixture of A5 and A6 enriched in A5. This mixture is separated by column chromatography on silica gel to provide pure diastereomers. Removal of the auxiliary provides amines A7 and A8 which are coupled to a variety of carboxylic acids to provide heteroaryl compounds of formula A9 and A10. Diversification of A9 and A10 is accomplished by a variety of methods including alkylation, acylation, cyanation, nucleophilic aromatic displacement, and metal catalyzed cross coupling reactions such as Suzuki couplings, Buchwald-Hartwig type couplings, and Sonogashira couplings.
  • Scheme 2 describes a general stereoselective route which can be used to prepare compounds of formulas I and III.
  • Figure US20210009555A1-20210114-C00201
  • Depicted in Scheme 2 is the protection of amine A7 to a compound of formula B1. This is followed by the conversion of the Br to the corresponding boronic acid. Diversification of the functional group X and boronic acid is accomplished by a variety of methods including alkylation, acylation, cyanation, nucleophilic aromatic displacement, and metal catalyzed cross coupling reactions such as Suzuki couplings, Buchwald-Hartwig type couplings, and Sonogashira couplings to provide compounds of formulas B3 and B4. Deprotection followed by amide formation with a variety of carboxylic acids provides compounds of formula I.
    • Combination Therapy
  • In one embodiment, the invention provides a method for treating an HIV infection, comprising administering to a patient in need thereof a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt, thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents which are suitable for treating an HIV infection.
  • A compound as disclosed herein (e.g., a compound of any of formulas I and III or a pharmaceutically acceptable salt thereof) may be combined with one or more additional therapeutic agents in any dosage amount of the compound (e.g., from 50 mg to 300 mg of compound).
  • In one embodiment, a method for treating or preventing an HIV infection in a human having or at risk of having the infection is provided, comprising administering to the human a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents.
  • In one embodiment, the invention provides pharmaceutical compositions comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with at least one additional therapeutic agent, and a pharmaceutically acceptable carrier. For example, the therapeutic agent used in combination with the compound disclosed herein can be any anti-HIV agent.
  • In one embodiment, combination pharmaceutical agents comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with one or more additional therapeutic agents are provided.
  • One embodiment provides pharmaceutical compositions comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with at least one additional therapeutic agent, and a pharmaceutically acceptable carrier. In one embodiment, the additional therapeutic agent may be an anti-HIV agent. For example, in some embodiments, the additional therapeutic agent is selected from the group consisting of HIV protease inhibiting compounds (HIV protease inhibitors), HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, entry inhibitors (e.g., CCR5 inhibitors, gp41 inhibitors (i.e., fusion inhibitors) and CD4 attachment inhibitors), CXCR4 inhibitors, gp120 inhibitors, G6PD and NADH-oxidase inhibitors, capsid polymerization inhibitors or capsid disrupting compounds such as those disclosed in US 2013/0165489 (University of Pennsylvania), and WO 2013/006792 (Pharma Resources), pharmacokinetic enhancers, and other drug for treating HIV, and combinations thereof.
  • In further embodiments, the additional therapeutic agent is selected from one or more of:
  • (1) HIV protease inhibitors selected from the group consisting of amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, ritonavir, nelfinavir, saquinavir, tipranavir, brecanavir, darunavir, TMC-126, TMC-114, mozenavir (DMP-450), JE-2147 (AG1776), L-756423, R00334649, KNI-272, DPC-681, DPC-684, GW640385X, DG17, PPL-100, DG35, and AG 1859:
  • (2) HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase selected from the group consisting of capravirine, emivirine, delaviridine, efavirenz, nevirapine, (+) calanolide A, etravirine, GW5634, DPC-083, DPC-961, DPC-963, MIV-150, TMC-120, rilpivirene, BILR 355 BS, VRX 840773, lersivirine (UK-453061), RDEA806, KM023 and MK-1439:
  • (3) HIV nucleoside inhibitors of reverse transcriptase selected from the group consisting of zidovudine, emtricitabine, didanosine, stavudine, zalcitabine, lamivudine, abacavir, amdoxovir, elvucitabine, alovudine, MIV-210, ±-FTC, D-d4FC, emtricitabine, phosphazide, fozivudine tidoxil, apricitibine (AVX754), amdoxovir, KP-1461, GS-9131 (Gilead Sciences) and fosalvudine tidoxil (formerly HDP 99.0003);
  • (4) HIV nucleotide inhibitors of reverse transcriptase selected from the group consisting of tenofovir, tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, tenofovir alafenamide, GS-7340 (Gilead Sciences), GS-9148 (Gilead Sciences), adefovir, adefovir dipivoxil, CMX-001 (Chimerix) or CMX-157 (Chimerix);
  • (5) HIV integrase inhibitors selected from the group consisting of curcumin, derivatives of curcumin, chicoric acid, derivatives of chicoric acid, 3,5-dicaffeoylquinic acid, derivatives of 3,5-dicaffeoylquinic acid, aurintricarboxylic acid, derivatives of aurintricarboxylic acid, caffeic acid phenethyl ester, derivatives of caffeic acid phenethyl ester, tyrphostin, derivatives of tyrphostin, quercetin, derivatives of quercetin, S-1360, AR-177, L-870812, and L-870810, raltegravir, BMS-538158, GSK364735C, BMS-707035, MK-2048, BA 011, elvitegravir, dolutegravir and GSK-744;
  • (6) HIV non-catalytic site, or allosteric, integrase inhibitors (NCINI) including, but not limited to, BI-224436, CX0516, CX05045, CX14442, compounds disclosed in WO 2009/062285 (Boehringer Ingelheim), WO 2010/130034 (Boehringer Ingelheim), WO 2013/159064 (Gilead Sciences), WO 2012/145728 (Gilead Sciences), WO 2012/003497 (Gilead Sciences), WO 2012/003498 (Gilead Sciences) each of which is incorporated by reference in its entirety herein;
  • (7) gp41 inhibitors selected from the group consisting of enfuvirtide, sifuvirtide, albuvirtide, FB006M, and TRI-1144;
  • (8) the CXCR4 inhibitor AMD-070;
  • (9) the entry inhibitor SP01A;
  • (10) the gp120 inhibitor BMS-488043;
  • (11) the G6PD and NADH-oxidase inhibitor immunitin;
  • (12) CCR5 inhibitors selected from the group consisting of aplaviroc, vicriviroc, maraviroc, cenicriviroc, PRO-140, INCB15050, PF-232798 (Pfizer), and CCR5mAb004;
  • (13) CD4 attachment inhibitors selected from the group consisting of ibalizumab (TMB-355) and BMS-068 (BMS-663068);
  • (14) pharmacokinetic enhancers selected from the group consisting of cobicistat, ritonavir, and SPI-452; and
  • (15) other drugs for treating HIV selected from the group consisting of BAS-100, SPI-452, REP 9, SP-01A, TNX-355, DES6, ODN-93, ODN-112, VGV-1, PA-457 (bevirimat), HRG214, VGX-410, KD-247, AMZ 0026, CYT 99007A-221 HIV, DEBIO-025, BAY 50-4798, MDX010 (ipilimumab), PBS 119, ALG 889, and PA-1050040 (PA-040).
  • In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with two, three, four or more additional therapeutic agents. In certain embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with two additional therapeutic agents. In other embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with three additional therapeutic agents. In further embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with four additional therapeutic agents. The two, three four or more additional therapeutic agents can be different therapeutic agents selected from the same class of therapeutic agents, or they can be selected from different classes of therapeutic agents. In a specific embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with an HIV nucleotide inhibitor of reverse transcriptase and an HIV non-nucleoside inhibitor of reverse transcriptase. In another specific embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with an HIV nucleotide inhibitor of reverse transcriptase, and an HIV protease inhibiting compound. In a further embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with an HIV nucleotide inhibitor of reverse transcriptase, an HIV non-nucleoside inhibitor of reverse transcriptase, and an HIV protease inhibiting compound. In an additional embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with an HIV nucleotide inhibitor of reverse transcriptase, an HIV non-nucleoside inhibitor of reverse transcriptase, and a pharmacokinetic enhancer.
  • In a specific embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with tenofovir, tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamide. In another specific embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir alafenamide. In a specific embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with emtricitibine, abacavir or lamivudine.
  • In a specific embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with one of: tenofovir, tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, tenofovir disoproxil, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamide and one of: emtricitibine, abacavir or lamivudine. In a specific embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with one of: tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, tenofovir alafenamide fumarate, or tenofovir alafenamide and one of: emtricitibine or abacavir.
  • In some embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with 5-30 mg tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamide and 200 mg emtricitabine. In some embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with 5-10; 5-15; 5-20; 5-25; 25-30; 20-30; 15-30; or 10-30 mg tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamide and 200 mg emtricitabine. In some embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with 10 mg tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamide and 200 mg emtricitabine. In some embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with 25 mg tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, or tenofovir alafenamide and 200 mg emtricitabine. A compound as disclosed herein (e.g., a compound of any of formulas I and III or a pharmaceutically acceptable salt thereof) may be combined with the agents provided herein in any dosage amount of the compound (e.g., from 50 mg to 300 mg of compound) the same as if each combination of dosages were specifically and individually listed.
  • In some embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with 200-400 mg tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir disoproxil and 200 mg emtricitabine. In some embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with 200-250; 200-300; 200-350; 250-350; 250-400; 350-400; 300-400; or 250-400 mg tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir disoproxil and 200 mg emtricitabine. In some embodiments, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with 300 mg tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, or tenofovir disoproxil and 200 mg emtricitabine. A compound as disclosed herein (e.g., a compound of any of formulas I and III or a pharmaceutically acceptable salt thereof) may be combined with the agents provided herein in any dosage amount of the compound (e.g., from 50 mg to 300 mg of compound) the same as if each combination of dosages were specifically and individually listed.
  • In some embodiments, one or more of the compounds disclosed herein are combined with one or more other active therapeutic agents in a unitary dosage form for simultaneous or sequential administration to a patient. In certain embodiments, a pharmaceutical composition including one or more of the compounds disclosed herein combined with one or more other active therapeutic agents is provided. In certain embodiments, the compounds disclosed herein are combined with one or more other active therapeutic agents in a solid dosage form. The combination therapy may be administered as a simultaneous or sequential regimen. When administered sequentially, the combination may be administered in two or more administrations.
  • In some embodiments, one or more of the compounds disclosed herein are co-administered with one or more other active therapeutic agents. Co-administration of a compound disclosed herein with one or more other active therapeutic agents generally refers to simultaneous or sequential administration of a compound disclosed herein and one or more other active therapeutic agents, such that therapeutically effective amounts of disclosed herein and one or more other active therapeutic agents are both present in the body of the patient.
  • In yet another embodiment, the present application provides a method for treating an HIV infection comprising administering to a patient in need thereof a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents such as those disclosed above.
    • Pharmaceutical Formulations
  • The compounds disclosed herein are formulated with conventional carriers (e.g., inactive ingredient or excipient material) which will be selected in accord with ordinary practice. Tablets will contain excipients including glidants, fillers, binders and the like. Aqueous formulations are prepared in sterile form, and when intended for delivery by other than oral administration generally will be isotonic. All formulations will optionally contain excipients such as those set forth in the Handbook of Pharmaceutical Excipients (1986). Excipients include ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid and the like. One embodiment provides the formulation as a solid dosage form including a solid oral dosage form. The pH of the formulations ranges from about 3 to about 11, but is ordinarily about 7 to 10.
  • While it is possible for the active ingredients to be administered alone it may be preferable to present them as pharmaceutical formulations (compositions). The formulations, both for veterinary and for human use, of the invention comprise at least one active ingredient, as above defined, together with one or more acceptable carriers and optionally other therapeutic ingredients. The carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and physiologically innocuous to the recipient thereof.
  • The formulations include those suitable for the foregoing administration routes. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Techniques and formulations generally are found in Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, Pa.). Such methods include the step of bringing into association the active ingredient with inactive ingredients (e.g., a carrier, pharmaceutical excipients, etc.) which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
  • Formulations described herein that are suitable for oral administration may be presented as discrete units including but not limited to capsules, cachets or tablets each containing a predetermined amount of the active ingredient.
  • Pharmaceutical formulations disclosed herein comprise one or more compounds disclosed herein together with one or more pharmaceutically acceptable carriers or excipients and optionally other therapeutic agents. Pharmaceutical formulations containing the active ingredient may be in any form suitable for the intended method of administration. When used for oral use for example, tablets, troches, lozenges, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs may be prepared. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents including sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide a palatable preparation. Tablets containing the active ingredient in admixture with non-toxic pharmaceutically acceptable excipient which are suitable for manufacture of tablets are acceptable. These excipients may be, for example, inert diluents, such as calcium or sodium carbonate, lactose, lactose monohydrate, croscarmellose sodium, povidone, calcium or sodium phosphate; granulating and disintegrating agents, such as maize starch, or alginic acid; binding agents, such as cellulose, microcrystalline cellulose, starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or may be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.
  • The amount of active ingredient that is combined with the inactive ingredients to produce a dosage form will vary depending upon the host treated and the particular mode of administration. For example, in some embodiments, a dosage form for oral administration to humans contains approximately 1 to 1000 mg of active material formulated with an appropriate and convenient amount of carrier material (e.g., inactive ingredient or excipient material). In some embodiments, a dosage form (e.g., for oral administration to humans) contains: from 10 mg to 1000 mg or from 50 mg to 1000 mg or from 100 mg to 1000 mg or from 200 mg to 1000 mg or from 300 mg to 1000 mg or from 10 mg to 800 mg or from 10 mg to 600 mg or from 10 mg to 500 mg or from 10 mg to 400 mg or from 10 mg to 300 mg or from 50 mg to 800 mg or from 100 mg to 600 mg or from 150 mg to 500 mg or from 200 mg to 400 mg or from 50 mg to 500 mg or from 10 mg to 300 mg or from 50 mg to 300 mg or from 10 mg to 200 mg or from 50 mg to 200 mg or from 100 mg to 300 mg or from 100 mg to 200 mg or from 200 mg to 300 mg of active material (e.g., a compound of any of formulae I or III). In some embodiments, a dosage form for oral administration to humans contains at least any of 10, 25, 50, 100, 150, 200, 250 or 300 mg and no more than 500 or 800 or 1000 mg of active material (e.g., from at least 50 mg to no more than 500 mg). In some embodiments, a dosage form for oral administration to humans contains at least any of 10, 25, 50, 100, 150, 200, 250 or 300 mg or no more than 500 or 800 or 1000 mg of active material. In some embodiments, a dosage form for oral administration to humans contains any of 10, 25, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 1000 mg of active material. It is understood that a dosage form in an amount provided herein may be administered to a patient (e.g., a human in need thereof) in accordance with a dosing regimen provided herein, such as once, twice or thrice daily dosing. In one aspect, a dosing regimen provides for administration of at least 10 mg and no more that 1,000 mg of active material (e.g., a compound of any of formulas I or III) daily, and it is understood that the amount may be provided in any suitable dosage form and amount (e.g., 500 mg twice daily or 1,000 mg once daily would provide the same amount of 1,000 mg/day dosing). The invention embraces once daily dosing to an individual (e.g., a human in need thereof) of a dosage form of compound (e.g., a compound of any of formulas I or III) containing at least 50 mg and not more than 300 mg of compound. In certain embodiments, the carrier material varies from about 5 to about 95% of the total compositions (weight:weight).
  • It should be understood that in addition to the ingredients particularly mentioned above the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
  • The invention further provides veterinary compositions comprising at least one active ingredient as above defined together with a veterinary carrier.
  • Veterinary carriers are materials useful for the purpose of administering the composition and may be solid, liquid or gaseous materials which are otherwise inert or acceptable in the veterinary art and are compatible with the active ingredient. These veterinary compositions may be administered orally, parenterally or by any other desired route.
  • Effective dose of active ingredient depends at least on the nature of the condition being treated, toxicity, whether the compound is being used prophylactically (lower doses), the method of delivery, and the pharmaceutical formulation, and will be determined by the clinician using conventional dose escalation studies.
    • Routes of Administration
  • One or more compounds disclosed herein (herein referred to as the active ingredients) are administered by any route appropriate to the condition to be treated. Suitable routes include oral, rectal, nasal, topical (including buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), and the like. It will be appreciated that the preferred route may vary with for example the condition of the recipient. An advantage of the compounds disclosed herein is that they are orally bioavailable and can be dosed orally.
    • Dosing Regimen
  • The compound, such as a compound of any of Formulas I and III, may be administered to an individual in accordance with an effective dosing regimen for a desired period of time or duration, such as at least about one month, at least about 2 months, at least about 3 months, at least about 6 months, or at least about 12 months or longer. In one variation, the compound is administered on a daily or intermittent schedule for the duration of the individual's life.
  • The dosage or dosing frequency of a compound of any of Formulas I and III may be adjusted over the course of the treatment, e.g., based on the judgment of the administering physician.
  • The compound may be administered to an individual (e.g., a human) in an effective amount. In one aspect, the compound is administered once daily. In one aspect, the compound is administered twice a day. In one aspect, the compound is administered three times daily. It is understood that the compound may be administered in any dosage amount provided herein, such as a dosage amount that would provide at least 10 mg/day dosing and no more than 1,000 mg/day dosing. Once daily oral dosing is embraced, such as by administering a dosage form containing from 50 mg to 300 mg of compound.
  • The antiviral properties of a compound of the invention may be determined using Test A described below.
    • Test A: Antiviral Assay in MT4 Cells
  • For the antiviral assay, 40 μL of a concentration required to achieve a final effective 1× test concentration of 3-fold serially diluted compound in culture medium with 10% FBS was added to each well of a 384-well plate (10 concentrations) in quadruplicate. MT-4 cells were next mixed with HIV-IIIb at an m.o.i of 0.003 for 1 hour, after which time 35 μL of virus/cell mixture (2000 cells) was immediately added to each well containing 40 μL of diluted compound. The plates were then incubated at 37° C. for 5 days. After 5 days of incubation, 25 μl of 2× concentrated CellTiter-Glo™ Reagent (catalog #G7571, Promega Biosciences, Inc., Madison, Wis.) was added to each well containing MT-4 cells. Cell lysis was carried out by incubating at room temperature for 10 min and then chemiluminescence was read. EC50 values were calculated as the compound concentration that caused a 50% decrease in luminescence signal, a measure of HIV-1 replication. Percent inhibition of virus-induced cell killing calculated from the dose response curve at 2 μM and 0.2 μM drug concentration is shown in the table below.
    • Test B: Cytotoxicity Assay
  • Compound cytotoxicity and the corresponding CC50 values was determined using the same protocol as described in the antiviral assay (Test A) except that uninfected cells were used.
  • Compounds of the present invention demonstrate antiviral activity (Test A) as depicted in the table below. Shown below are the corresponding values for CC50 and percent inhibition of virus-induced cell killing in the presence of 2 μM and 0.2 μM drug concentration.
  • % inhibition at % inhibition at CC50
    Compound 2 μM 0.2 μM (nM)
     1B 77 17 8569
     2 90 79 14347
     3D 82 82 4149
     4H 74 8 22793
     5G 58 3 >53192
     6 73 5 >53192
     7 92 8 5664
     8C 86 6 21955
     9B 95 92 14557
     10B 85 1 >53192
     11 66 3 >53192
     12 58 1 >53192
     13 0 — >53192
     14E 89 87 6824
     15 94 93 10261
     16C 65 23 3670
     17 80 95 12556
     18 90 96 6934
     19G 93 97 19626
     20 80 96 11162
     21H 92 92 7628
     22C 92 92 4949
     23B 88 83 7619
     24B 83 78 5921
     25 89 89 9139
     26 100 84 10014
     27G 89 89 10412
     28 84 71 12175
     29B 81 80 15266
     30 91 1 8582
     31 89 89 8034
     32 84 84 9177
     33F 93 93 12867
     34 78 78 8758
     35D 91 28 14204
     36C 92 88 3150
     37F 90 90 6352
     38 96 96 13516
     39C 91 7 26475
     40 87 87 8719
     41 98 98 7631
     42 100 100 11765
     43 100 100 15419
     44 94 94 6816
     45G 92 92 10401
     46 89 87 10490
     47 100 100 21441
     48 88 88 23969
     49 87 87 23967
     50 96 95 11736
     51 95 95 11128
     52 93 92 31753
     53 92 92 8026
     54 98 98 8076
     55C 92 92 9559
     56F 97 97 18961
     57 93 93 7634
     58G 95 95 8440
     59B 94 94 22443
     60 96 86 14337
     61B 96 96 14309
     62 100 100 5695
     63 91 91 8888
     64 98 98 7696
     65 100 85 19301
     66 97 97 6956
     67I 94 94 21471
     68G 96 96 9638
     69 77 77 718
     70 94 94 9976
     71 87 87 9509
     72 87 85 5865
     73 86 86 4494
     74D 99 99 6905
     75 93 92 >40267
     76F 98 98 22571
     77E 97 96 11804
     78 98 98 14418
     79 100 100 4716
     80 100 96 8579
     81 100 100 12466
     82 99 99 9698
     83 94 94 9935
     84 100 100 8734
     85 96 96 7850
     86 99 99 6471
     87 96 95 6803
     88 100 100 8488
     89 95 95 7773
     90D 97 97 7620
     91E 100 100 9382
     92 100 100 6244
     93 92 92 4809
     94 100 100 7577
     95 93 93 6513
     96 100 100 6998
     97 100 100 7596
     98 100 100 8410
     99B 100 100 6366
    100 99 99 5136
    101 95 95 6526
    102 100 100 5815
    103 100 100 6792
    104 100 100 7463
    105E 74 — 31484
    106E 96 95 12404
    107B 95 95 5303
    108C 94 94 >53076
    109 97 97 29567
    110E 98 15 >53192
    111 90 89 9593
    112D 97 97 13891
    113D 97 — 1092
    114G 100 100 14834
    115C 91 84 9313
    116A 93 62 10484
    117F 100 93 27833
    118 96 96 23924
    119C 99 99 9242
    120H 88 51 11699
    121 98 46 9184
    122 88 88 9072
    123 90 90 7904
    124 97 97 9145
    125D 97 96 13628
    126 92 92 15507
    127 92 92 8762
    128B 94 93 4181
    129 82 54 12115
    130 85 80 23158
    131E 96 95 22533
    132C 92 92 24161
    133 90 90 16784
    134 83 82 28027
    135B 93 93 14242
    136D — — 7427
    137C 100 93 7881
    138 83 61 33392
    139B 94 94 15437
    140M 98 98 20364
    141D 100 100 19761
    142 92 92 12621
    143 98 98 11253
    144 95 95 16236
    145 99 99 8687
    146I — — 33468
    147 — — >53192
    148B 83 83 23264
    149 86 86 26728
    150 87 87 28895
    151 92 92 25316
    152 89 89 11872
    153 98 98 18649
    154 97 97 12488
    155I 99 99 26782
    156E 78 78 25584
    157G 87 87 10904
    158G 71 71 26745
    159 95 95 27427
    160 100 100 20477
    161 84 84 21843
    162 81 81 22412
    163 86 79 8853
    164 97 96 40504
    165 72 72 5456
    166 92 92 24421
    167 93 93 34110
    168B 90 90 >53192
    169 92 92 12421
    170 88 88 16958
    171D — — >42470
    172 — — 61
    173 92 92 >43678
    174 85 85 >53192
    175 95 95 >46082
    176 100 100 17402
    177D 100 100 >53192
    178 100 95 13999
    179 100 100 15481
    180C 100 100 21252
    181C 100 100 >53192
    182L 100 100 9829
    183F 84 84 12400
    184 90 90 7694
    185C 89 89 18160
    186D 87 87 1517
    187G 84 84 19776
    188 92 92 26275
    189 88 88 17249
    190 98 98 13907
    191 91 91 10142
    192 98 95 28776
    193 92 92 23055
    194 99 84 21268
    195 90 88 11235
    196 92 76 10783
    197 63 — 15373
    198 98 64 23690
    199 95 95 22472
    200 90 89 12230
  • The data above represent an average over time of each assay for each compound. For certain compounds, multiple assays have been conducted over the life of the project. Thus, the data reported in the tables include the data reported in the priority document, as well as data from assays run in the intervening period. In the above table, percent inhibition values have been normalized to 100% where the calculation of percent inhibition would have resulted in a value greater than 100.
  • In one embodiment, the compounds demonstrate >10% inhibition at 2 μM. In one embodiment, the compounds demonstrate >30% inhibition at 2 μM. In one embodiment, the compounds demonstrate >50% inhibition at 2 μM. In one embodiment, the compounds demonstrate >70% inhibition at 2 μM. In one embodiment, the compounds demonstrate >75% inhibition at 2 μM. In one embodiment, the compounds demonstrate >80% inhibition at 2 μM. In one embodiment, the compounds demonstrate >85% inhibition at 2 μM. In one embodiment, the compounds demonstrate >90% inhibition at 2 μM. In one embodiment, the compounds demonstrate >95% inhibition at 2 μM. It is to be understood that the compounds disclosed herein can be grouped according to their % inhibition as described above.
  • In one embodiment, the compounds demonstrate >10% inhibition at 0.2 μM. In one embodiment, the compounds demonstrate >30% inhibition at 0.2 μM. In one embodiment, the compounds demonstrate >50% inhibition at 0.2 μM. In one embodiment, the compounds demonstrate >70% inhibition at 0.2 μM. In one embodiment, the compounds demonstrate >75% inhibition at 0.2 μM. In one embodiment, the compounds demonstrate >80% inhibition at 0.2 μM. In one embodiment, the compounds demonstrate >85% inhibition at 0.2 μM. In one embodiment, the compounds demonstrate >90% inhibition at 0. μM. In one embodiment, the compounds demonstrate >95% inhibition at 0. μM. It is to be understood that the compounds disclosed herein can be grouped according to their % inhibition as described above.
  • In one variation, a compound is of any formulae provided herein, wherein the compound exhibits from 85%-100% inhibition of virus-induced cell killing at 2 μM. In one variation, a compound is of any formulae provided herein, wherein the compound exhibits from 85%-100% inhibition of virus-induced cell killing at 0. μM. In other embodiments, a compound is of any formulae provided herein wherein the compound exhibits from 50-100, 60-100, 70-100, 80-100, or 90-100% inhibition of virus-induced cell killing at 2 μM or at 0.2 μM.
  • It is understood that % inhibition may be evaluated by techniques known in the art. In a particular variation, a compound is of any formulae provided herein wherein the compound exhibits from 85%-110% inhibition of virus-induced cell killing at 2 μM or at 0.2 μM as measured by the method provided in the Test A and Test B sections discussed above.
  • Percent inhibition was also calculated for certain compounds as compared to previously published compounds (WO 2013/006738) and is shown below. The percent inhibition of virus-induced cell killing at 2 μM and 0.2 μM was measured by the method provided in the Test A and Test B sections discussed above.
  • Compound Response at 2 μM Response at 0.2 μM
    Figure US20210009555A1-20210114-C00202
         		94 21
    Figure US20210009555A1-20210114-C00203
         		84 71
    Figure US20210009555A1-20210114-C00204
         		58 3
    Figure US20210009555A1-20210114-C00205
         		91 65
    Figure US20210009555A1-20210114-C00206
         		90 96
  • The specific pharmacological responses observed may vary according to and depending on the particular active compound selected and whether there are present pharmaceutical carriers and/or pharmaceutically active compounds, as well as the type of formulation and mode of administration employed, and such expected variations or differences in the results are contemplated in accordance with practice of the present invention.
  • The Examples provided herein describe the synthesis of compounds disclosed herein as well as intermediates used to prepare the compounds. It is to be understood that individual steps described herein may be combined. It is also to be understood that separate batches of a compound may be combined and then carried forth in the next synthetic step.
    • Example 1
  • Figure US20210009555A1-20210114-C00207
    • Synthesis of (S)-5-bromo-6-(1-(2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)picolinamide (A)
  • Compound 5F (100 mg, 0.15 mmol) and CuCN (16 mg, 0.18 mmol) was dissolved in 0.3 mL of DMF. The reaction mixture was heated at 100° C. overnight. After cooled down to room temperature it was diluted with water and extracted with EtOAc. The organic phase was dried (Na2SO4), filtered and concentrated. The crude material was purified on reverse phase HPLC eluting with acetonitrile and water (with 0.1% TFA) to afford (S)—N-(1-(3-bromo-6-cyanopyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide and the title product (A). MS (m/z) 640.05 [M+H]+.
    • Synthesis of (S)-6-(1-(2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)-5-(1H-pyrrolo[2,3-b]pyridin-5-yl)picolinamide (1B)
  • The title compound (B) was prepared according to the method presented for the synthesis of compound 4H of Example 4 utilizing 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine and IA. H NMR (400 MHz, CD3OD) δ 9.00 (d, J=8.5 Hz, 1H), 8.12 (d, J=7.9 Hz, 1H), 8.01 (s, 1H), 7.92-7.77 (m, 2H), 7.56 (d, J=3.5 Hz, 1H), 6.97-6.53 (m, 3H), 6.26 (d, J=6.1 Hz, 2H), 5.53 (m, 1H), 5.11 (s, 2H), 3.07 (m, 2H), 2.63-2.25 (m, 4H).MS (m/z) 678.08 [M+H]+.
    • Example 2
  • Figure US20210009555A1-20210114-C00208
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(4-oxo-3,4-dihydroquinazolin-8-yl)pyridin-2-yl)ethyl)acetamide (2)
  • The title compound (2) was prepared according to the method presented for the synthesis of compound 4H of Example 4 utilizing (4-oxo-3,4-dihydroquinazolin-8-yl)boronic acid and 14D. 1H NMR (400 MHz, CD3OD) δ 8.27 (m, 1H), 7.82 (m, 1H), 7.75 (m, 1H), 7.50 (s, 1H), 7.44 (m, 2H), 6.86 (m, 1H), 6.61 (m, 2H), 6.32 (m, 1H), 6.15 (m, 2H), 5.21 (m, 1H), 4.76 (s, 2H), 3.11 (m, 2H), 2.92 (m, 2H), 2.48 (m, 4H), 1.62 (d, J=6.6 Hz, 6H), 1.33 (m, 1H), 1.12 (m, 1H).MS (m/z) 725.14 [M+H]+.
    • Example 3
  • Figure US20210009555A1-20210114-C00209
    Figure US20210009555A1-20210114-C00210
    • Synthesis of 3′-oxospiro[cyclopropane-1,1′-isoindolin]-5′-yl trifluoromethanesulfonate (3B)
  • The mixture of compound 3A (1 g, 5.7 mmol, prepared according to the method presented in Tetrahedron Letters 50 (2009) 1267-1269), DCM (20 mL), and Et3N (0.9 mL, 6.8 mmol) was cooled to 0° C. using an ice/water bath. Trifluoromethanesulfonyl chloride (0.91 mL, 8.5 mmol) was added dropwise via syringe. The mixture was then stirred for 1 h in ambient temperature. More Trifluoromethanesulfonyl chloride (0.8 mL) was added and the mixture was stirred at ambient temperature for another hour. Then diluted with DCM (150 mL) and washed with 1.0 N HCl (50 mL), saturated aqueous sodium bicarbonate (1×50 mL), and saturated aqueous sodium chloride (1×50 mL). The organic layer was dried over MgSO4, filtered through Celite.®, and concentrated in vacuo to give the title product (3B). MS (m/z) 308.29 [M+H]+.
    • Synthesis of 5′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)spiro[cyclopropane-1,1′-isoindolin]-3′-one (3C)
  • In a microwave tube were charged 3B (200 mg, 0.65 mmol), bis(pinacolato)diboron (330 mg, 1.3 mmol) and potassium acetate (191 mg, 1.95 mmol), [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II)(14 mg, 0.02 mmol) and 1,4-dioxane (8 mL) The mixture was heated up to 150° C. for 20 min in a Microwave Synthesizer. Upon completion the solution was diluted in EtOAc and the organic layer was washed with water and a saturated NaCl solution, dried over MgSO4 and concentrated in vacuum to give the title compound as a dark brown solid. A half amount of the product was purified by silica gel chromatography eluting with EtOAc/hexanes to afford the title product. MS (m/z) 286.23 [M+H]+.
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(3′-oxospiro[cyclopropane-1,1′-isoindolin]-5′-yl)pyridin-2-yl)ethyl)acetamide (3D)
  • In a microwave tube were charged with 14D (33 mg, 0.05 mmol), 3C (21 mg, 0.075 mmol), LiCl (6 mg, 0.15 mmol), K2CO3 (21 mg, 0.15 mmol), Pd(PPh3)2Cl2 (3 mg) and Pd(dppf)Cl2 (3 mg). To the mixture was added 1 mL of DME and 0.2 mL of H2O. The mixture was heated up to 165° C. for 12 min in a Microwave Synthesizer. After cooled down and filtered through a syringe filter, purified on reverse phase HPLC eluting with acetonitrile and water (with 0.1% TFA) to afford the title product. 1H NMR (400 MHz, CD3OD) δ 8.77 (d, J=8.4 Hz, 1H), 7.55 (d, J=8.0 Hz, 1H), 7.46 (d, J=8.0 Hz, 1H), 7.40 (d, J=7.8 Hz, 1H), 7.32-7.16 (m, 2H), 6.64 (t, J=9.2 Hz, 1H), 6.24 (d, J=6.5 Hz, 2H), 5.39 (t, J=7.3 Hz, 1H), 4.86 (s, 2H), 3.08-2.92 (m, 2H), 2.58-2.31 (m, 2H), 1.62 (s, 6H), 1.60-1.33 (m, 5H), 1.12 (m, 1H).
  • MS (m/z) 738.15 [M+H]+.
    • Example 4
  • Figure US20210009555A1-20210114-C00211
    Figure US20210009555A1-20210114-C00212
    • Synthesis of (S)—N-((3,5-dibromopyridin-2-yl)methylene)-2-methylpropane-2-sulfinamide (4B)
  • To 3,5-dibromopicolinaldehyde (1.9 g, 7.17 mmol) in DCM (30 mL) was added (S)-2-methylpropane-2-sulfinamide (870 mg, 7.17 mmol) and CuSO4 (2.29 g, 14.3 mmol). The reaction mixture was stirred for 15 h. Solids were filtered over celite. The solvents were removed in vacuo and the residue purified by column chromatography on silica to provide 2.6 g of the title compound. MS (m/z) 368.9 [M+H]+.
    • Synthesis of (S)—N—((S)-1-(3,5-dibromopyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-methylpropane-2-sulfinamide (4C)
  • (S)—N-((3,5-dibromopyridin-2-yl)methylene)-2-methylpropane-2-sulfinamide (2.6 g, 7.1 mmol) was dissolved in THF (24 mL) and cooled to −78° C. (3,5-difluorobenzyl)magnesium bromide (34 mL, 0.2 μM in Et2O) was added dropwise. The reaction was stirred at −78° C. for 3 hr then let warm to 0° C. and quenched. The reaction was partitioned between EtOAc and aq. NH4Cl. The organics were separated, dried, and removed in vacuo. The residue purified by column chromatography on silica to provide the title compound. MS (m/z) 496.6 [M+H]+. Synthesis of (S)-1-(3,5-dibromopyridin-2-yl)-2-(3,5-difluorophenyl)ethanamine (4D):
  • To (S)—N—((S)-1-(3,5-dibromopyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-methylpropane-2-sulfinamide (650 mg) dissolved in DCM (3 mL) was added 4N HCl in dioxanes (4 mL). The reaction was stirred for 2 hr at ambient temperature. Solvents were removed in vacuo and the crude desired product was used without further purification. MS (m/z) 393.0 [M+H]+.
    • Synthesis of (S)-tert-butyl 1-(3,5-dibromopyridin-2-yl)-2-(3,5-difluorophenyl)ethylcarbamate (4E)
  • (S)-1-(3,5-Dibromopyridin-2-yl)-2-(3,5-difluorophenyl)ethanamine (780 mg, 1.84 mmol) was combined with di-tert-butyl dicarbonate (400 mg, 1.84 mmol) and TEA (515 μL, 3.7 mmol) in DCM (9 mL). The reaction was stirred for 2 hr at ambient temperature. The reaction was partitioned between EtOAc and H2O. The organics were separated, dried, and removed in vacuo. The residue purified by column chromatography on silica to provide the title compound. MS (m/z) 492.9 [M+H]+.
    • Synthesis of (S)-tert-butyl 1-(3-bromo-5-(3-hydroxy-3-methylbut-1-ynyl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethylcarbamate (4F)
  • To (S)-tert-butyl 1-(3,5-dibromopyridin-2-yl)-2-(3,5-difluorophenyl)ethylcarbamate (140 mg, 0.29 mmol) in THF (18 mL) was added 2-methylbut-3-yn-2-ol (42 μL, 0.43 mmol), TEA (0.9 mL), Pd(PPh3)2Cl2 (30 mg) and CuI (16 mg). The reaction was stirred for 2 hr at ambient temperature and then partitioned between EtOAc and H2O. The organics were separated, dried, and removed in vacuo. The residue purified by column chromatography on silica to provide the title compound as a mixture with 4E which was used in the next step. MS (m/z) 496.7 [M+H]+.
    • Synthesis of (S)—N-(1-(3-bromo-5-(3-hydroxy-3-methylbut-1-ynyl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide (4G)
  • A mixture of (S)-tert-butyl 1-(3-bromo-5-(3-hydroxy-3-methylbut-1-ynyl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethylcarbamate and (S)-tert-butyl 1-(3,5-dibromopyridin-2-yl)-2-(3,5-difluorophenyl)ethylcarbamate (105 mg) obtained from the previous step was dissolved in DCM (3 mL) and treated with 4N HCl in dioxanes (4 mL). The reaction was stirred for 2 hr then solvents removed in vacuo. The residue purified by column chromatography on silica to provide 18 mg of (S)-4-(6-(1-amino-2-(3,5-difluorophenyl)ethyl)-5-bromopyridin-3-yl)-2-methylbut-3-yn-2-ol (MS (m/z) 395.0 [M+H]+). To (S)-4-(6-(1-amino-2-(3,5-difluorophenyl)ethyl)-5-bromopyridin-3-yl)-2-methylbut-3-yn-2-ol (18 mg, 0.046 mmol) in DMF (1 mL) was added 2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetic acid (15 mg, 0.05 mmol), iPr2NEt (17 μL, 0.1 mmol) and HATU (26 mg, 0.07 mmol). The reaction was stirred 30 min and then partitioned between EtOAc and H2O. The organics were separated, dried, and removed in vacuo. The crude product was used directly in the next reaction. MS (m/z) 679.2 [M+H]+.
    • Synthesis of (S)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)-N-(2-(3,5-difluorophenyl)-1-(5-(3-hydroxy-3-methylbut-1-ynyl)-3-(3-oxoisoindolin-5-yl)pyridin-2-yl)ethyl)acetamide (4H)
  • To (S)—N-(1-(3-bromo-5-(3-hydroxy-3-methylbut-1-ynyl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide (16 mg, 0.02 mmol) in DME (0.7 mL) was added 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one (7 mg, 0.03 mmol), Pd(PPh3)2C2 (2 mg), LiCl (1 mg), and aq 2M K2CO3 (30 μL). The reaction was heated in a microwave reactor to 150° C. for 20 min. The reaction was purified by RP HPLC to provide the desired product. 1H NMR (400 MHz, Methanol-d4) δ 8.69 (d, 1H), 7.62-7.49 (m, 2H), 7.43 (s, 1H), 7.28 (s, 1H), 6.98-6.58 (m, 4H), 6.26 (d, 2H), 5.34 (d, 2H), 5.18 (s, 1H), 5.05 (s, 2H), 4.48 (s, 2H), 3.02 (t, J=7.5 Hz, 3H), 2.49 (s, 7H), 1.56 (s, 5H). MS (m/z) 732.1 [M+H]+.
    • Example 5
  • Figure US20210009555A1-20210114-C00213
    Figure US20210009555A1-20210114-C00214
    • Synthesis of 3,6-dibromo-2-(dibromomethyl)pyridine (5A)
  • To a solution of 3,6-dibromo-2-methylpyridine (5.2 g, 21 mmol) in CCl4 (50 mL) was added N-bromosuccinimide (7.57 g, 42 mmol) and 2,2′-azobis(2-methylpropionitrile) (0.70 g, 4.3 mmol). The mixture was heated at 80° C. overnight and cooled to room temperature. The solid was removed by filtration and the filtrate was concentrated under reduced pressure. The product (5A) was obtained after flash chromatography eluding with 0-10 percent EtOAc in hexane (7.36 g). MS (m/z): 409.66 [M+H]+
    • Synthesis of 3,6-dibromopicolinaldehyde (5B)
  • A solution of silver nitrate (7.6 g, 45 mmol) in water (24 mL) was added dropwise to a solution of 5A (7.36 g, 18 mmol) in refluxing EtOH (90 mL). The mixture was stirred at 80° C. for 5 hours. After the mixture was cooled to room temperature, it was diluted with water (100 mL), extracted with EtOAc (3 times), dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product (5B, 4.6 G) was directly used for next step. MS (m/z): 265.96. [M+H]+
    • Synthesis of (S,Z)—N-((3,6-dibromopyridin-2-yl)methylene)-2-methylpropane-2-sulfinamide (5C)
  • The title compound (5C) was prepared according to the method presented for the synthesis of compound 4B of Example 4 utilizing 5B. MS (m/z) 368.86 [M+H]+
    • Synthesis of (S)—N—((S)-1-(3,6-dibromopyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-methylpropane-2-sulfinamide (5D)
  • The title compound (5D) was prepared according to the method presented for the synthesis of compound 4C of Example 4 utilizing 5C. MS (m/z) 496.99 [M+H]+
    • Synthesis of (S)-1-(3,6-dibromopyridin-2-yl)-2-(3,5-difluorophenyl)ethanamine hydrochloride(5E)
  • The title compound (5E) was prepared according to the method presented for the synthesis of compound 4D of Example 4 utilizing 5D. MS (m/z) 393.29 [M+H]+
    • Synthesis of (S)—N-(1-(3,6-dibromopyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide (5F)
  • The title compound (5F) was prepared according to the method presented for the synthesis of compound 10A of Example 10 utilizing 5E. MS (m/z) 676.96 [M+H]+.
    • Synthesis of (S)-5,5′-(6-(1-(2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)pyridine-2,5-diyl)bis(2-fluorobenzamide) (5G)
  • In a microwave tube was charged with 5F (100 mg, 0.15 mmol), (3-carbamoyl-4-fluorophenyl)boronic acid (81 mg, 0.45 mmol), LiCl (19 mg, 0.45 mmol), Na2CO3 (50 mg, 0.6 mmol) and 5 mg of Pd(PPh3)2C2. To the mixture was added 1.4 mL of 1,4-dioxane/methanol/H2O (5/1/1). The mixture was heated up to 170° C. for 15 min in a Microwave Synthesizer. After cooled down and filtered through a syringe filter, purified on reverse phase HPLC eluting with acetonitrile and water (with 0.1% TFA) to afford the title compound. 1H NMR (400 MHz, CD3OD) δ 8.90 (d, J=8.6 Hz, 1H), 8.74 (dd, J=7.2, 2.4 Hz, 1H), 8.51-8.30 (m, 1H), 7.91 (d, J=8.1 Hz, 1H), 7.64 (d, J=8.1 Hz, 1H), 7.41 (m, 2H), 7.23 (dd, J=10.7, 8.5 Hz, 1H), 7.02-6.49 (m, 2H), 6.35 (d, J=6.2 Hz, 2H), 5.45 (m, 1H), 5.16-5.02 (m, 2H), 3.23-2.97 (m, 2H), 2.49 (m, 4H).MS (m/z) 793.19 [M+H]+.
    • Example 6
  • Figure US20210009555A1-20210114-C00215
    • Synthesis of (S)—N-(1-(3,6-bis(3-oxoisoindolin-5-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide (6)
  • The title compound (6) was prepared according to the method presented for the synthesis of compound 5G of Example 5 utilizing 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one and 5F. 1H NMR (400 MHz, CD3OD) δ 8.84 (d, J=8.1 Hz, 1H), 8.72 (s, 1H), 8.49 (d, J=7.9 Hz, 1H), 7.98 (d, J=8.1 Hz, 2H), 7.72 (dd, J=23.8, 8.0 Hz, 2H), 7.60 (d, J=7.9 Hz, 1H), 7.49 (d, J=8.0 Hz, 1H), 7.39 (s, 1H), 6.97-6.57 (m, 2H), 6.33 (m, 2H), 5.49 (m, 2H), 5.10 (s, 2H), 4.57 (s, 2H), 4.49 (s, 2H), 3.24-2.95 (m, 2H), 2.47 (m, 4H).MS (m/z) 781.02[M+H]+.
    • Example 7
  • Figure US20210009555A1-20210114-C00216
    • Synthesis of (S)—N-(1-(3,6-bis(1H-pyrrolo[2,3-b]pyridin-5-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide (7)
  • The title compound (7) was prepared according to the method presented for the synthesis of compound 5G of Example 5 utilizing 6 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine and 5F. 1H NMR (400 MHz, CD3OD) δ 9.23-9.17 (m, 2H), 9.04 (d, J=8.1 Hz, 1H), 8.03 (m, 3H), 7.75 (d, J=8.1 Hz, 1H), 7.61 (dd, J=7.3, 3.5 Hz, 2H), 6.93-6.52 (m, 4H), 6.34 (d, J=6.2 Hz, 2H), 5.45 (m, 1H), 5.10 (m, 2H), 3.27-3.06 (m, 2H), 2.48 (m, 4H).MS (m/z) 751.22 [M+H]+.
    • Example 8
  • Figure US20210009555A1-20210114-C00217
    Figure US20210009555A1-20210114-C00218
    • Synthesis of (S)—N-(1-(5-bromo-2′-methoxy-[2,4′-bipyridin]-6-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide (8A) and (S)—N-(1-(2′,5′-di(methoxy-[2,4′-bipyridin]-6-yl))-2-(3,5-difluorophenyl)ethyl)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide (8B)
  • The title compounds (8A and 8B) were prepared according to the method presented for the synthesis of compound 5G of Example 5 utilizing 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine(2 equiv.) and 5F.
    • Synthesis of (S)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)-N-(2-(3,5-difluorophenyl)-1-(2′-methoxy-5-(3-oxoisoindolin-5-yl)-[2,4′-bipyridin]-6-yl)ethyl)acetamide (8C)
  • The title compound (8C) was prepared according to the method presented for the synthesis of compound 4H of Example 4 utilizing 8A. 1H NMR (400 MHz, CD3OD) δ 8.85 (d, J=8.1 Hz, 1H), 8.33 (d, J=5.7 Hz, 1H), 8.06 (d, J=8.0 Hz, 1H), 7.91 (d, J=5.7 Hz, 1H), 7.82 (s, 1H), 7.74 (d, J=8.0 Hz, 1H), 7.61 (d, J=6.3 Hz, 1H), 7.53 (d, J=7.8 Hz, 1H), 7.38 (s, 1H), 6.91-6.44 (m, 2H), 6.29 (d, J=6.3 Hz, 2H), 5.51 (dd, J=14.8, 8.2 Hz, 1H), 5.18-4.98 (m, 2H), 4.50 (s, 2H), 4.09 (s, 3H), 3.12 (m, 2H), 2.49 (m, 4H).MS (m/z) 757.25 [M+H]+.
    • Example 9
  • Figure US20210009555A1-20210114-C00219
    • Synthesis of (S)—N-(1-(3-bromo-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide (9A)
  • The title compound (9A) was prepared according to the method presented for the synthesis of compound 4F of Example 4 utilizing 2-methylbut-3-yn-2-ol and 5F. MS (m/z) 681.17 [M+H]+.
    • Synthesis of (S)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)-N-(2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(3-oxoisoindolin-5-yl)pyridin-2-yl)ethyl)acetamide (9B)
  • The title compound (9B) was prepared according to the method presented for the synthesis of compound 4H of Example 4 utilizing 9A. 1H NMR (400 MHz, CD3OD) δ 7.63-7.53 (m, 2H), 7.50-7.40 (m, 2H), 7.30 (s, 1H), 6.95-6.56 (m, 2H), 6.28 (d, J=6.3 Hz, 2H), 5.39 (t, J=7.4 Hz, 1H), 5.05 (s, 2H), 4.48 (s, 2H), 3.13-2.91 (m, 2H), 2.66-2.35 (m, 4H), 1.61 (s, 6H).MS (m/z) 732.23 [M+H]+.
    • Example 10
  • Figure US20210009555A1-20210114-C00220
    • Synthesis of (S)—N-(1-(3,5-dibromopyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide (10A)
  • To (S)-1-(3,5-dibromopyridin-2-yl)-2-(3,5-difluorophenyl)ethanamine (380 mg, 0.97 mmol) dissolved in DMF (10 mL) was added iPr2NEt (350 μL, 2 mmol) and 2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetic acid (293 mg, 0.97 mmol). HATU (442 mg, 1.16 mmol) was added and the reaction stirred for 30 min. The reaction was partitioned between EtOAc and H2O. The organics were separated, dried, and removed in vacuo. The residue purified by column chromatography on silica to provide the title compound. MS (m/z) 677.1 [M+H]+.
    • Synthesis of (S)—N-(1-(3,5-bis(3-oxoisoindolin-5-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide (10B)
  • To (S)—N-(1-(3,5-dibromopyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide (50 mg, 0.074 mmol) in DME (0.8 mL) and DMF (0.2 mL) was added 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one (48 mg, 0.19 mmol), Pd(PPh3)2C2 (5 mg), LiCl (2 mg), and aq 2M K2CO3 (110 μL). The reaction was heated in a microwave reactor to 150° C. for 20 min. The reaction was purified by RP HPLC to provide the desired product. 1H NMR (400 MHz, Methanol-d4) δ 9.02 (d, 1H), 8.11 (d, 1H), 7.97 (dd, 1.7 Hz, 1H), 7.89 (d, 1H), 7.72 (d, 1H), 7.67-7.48 (m, 3H), 7.42 (d, 1H), 6.70-6.61 (m, 2H), 6.37-6.30 (m, 2H), 5.44 (t, 1H), 5.07 (s, 2H), 4.51 (d, 4H), 3.18-3.01 (m, 3H), 2.50 (dd, 4H). MS (m/z) 798.1[M+H]+.
    • Example 11
  • Figure US20210009555A1-20210114-C00221
    • Synthesis of (S)—N-(1-(3,5-di(1H-pyrrolo[2,3-b]pyridin-5-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide (11)
  • The title compound was prepared according to the method presented for the synthesis of 10B of Example 10 utilizing 10A and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine. 1H NMR (400 MHz, Methanol-d4) δ 9.10 (s, 1H), 8.62 (s, 1H), 8.56 (s, 1H), 8.14 (s, 1H), 8.05-7.94 (m, 2H), 7.58 (dd, 2H), 6.99-6.61 (m, 4H), 6.36 (d, 2H), 5.47-5.27 (m, 2H), 5.15-5.00 (m, 2H), 3.24-3.01 (m, 3H), 2.66-2.32 (m, 5H). MS (m/z) 751.1 [M+H]+.
    • Example 12
  • Figure US20210009555A1-20210114-C00222
    • Synthesis of (S)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)-N-(2-(3,5-difluorophenyl)-1-(2′-oxo-5-(3-oxoisoindolin-5-yl)-1′,2′-dihydro-[2,4′-bipyridin]-6-yl)ethyl)acetamide (12)
  • In a microwave tube were charged with (S)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)-N-(2-(3,5-difluorophenyl)-1-(2′-methoxy-5-(3-oxoisoindolin-5-yl)-[2,4′-bipyridin]-6-yl)ethyl)acetamide (8C, 5 mg), HCl in 1,4-dioxane (4N, 0.3 mL) and ethanol (0.3 mL). The mixture was heated up to 100° C. for 20 min in a Microwave Synthesizer. After cooled down, After cooled down, the solvent was removed and the residue was purified on reverse phase HPLC eluting with acetonitrile and water (with 0.1% TFA) to afford the title product. 1H NMR (400 MHz, CD3OD) δ 8.88 (m, 1H), 7.96 (d, J=8.0 Hz, 1H), 7.73 (d, J=8.0 Hz, 1H), 7.60 (m, 2H), 7.53 (m, 1H), 7.43 (s, 1H), 7.37 (s, 1H), 7.27 (d, J=6.8 Hz, 1H), 6.96-6.53 (m, 2H), 6.30 (d, J=6.2 Hz, 2H), 5.49 (m, 1H), 5.09 (s, 2H), 4.49 (s, 2H), 3.12 (m, 2H), 2.48 (m, 4H). MS (m/z) 742.99 [M+H]+.
    • Example 13
  • Figure US20210009555A1-20210114-C00223
    • Synthesis of (S)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)-N-(2-(3,5-difluorophenyl)-1-(2,2″-dioxo-1,1″,2,2″-tetrahydro-[4,2′:5′,4″-terpyridin]-6′-yl)ethyl)acetamide (13)
  • The title compound (13) was prepared according to the method presented for the synthesis of compound 12 of Example 12 utilizing 8B. 1H NMR (400 MHz, CD3OD) δ 8.95 (d, J=7.8 Hz, 1H), 7.95 (d, J=8.1 Hz, 1H), 7.71 (d, J=8.1 Hz, 1H), 7.60 (d, J=6.8 Hz, 1H), 7.43 (d, J=7.2 Hz, 1H), 7.25 (d, J=6.9 Hz, 1H), 6.98-6.61 (m, 2H), 6.45 (d, J=6.3 Hz, 2H), 6.33 (d, J=6.6 Hz, 1H), 6.19 (s, 1H), 5.51 (m, 1H), 5.08 (m, 2H), 3.15 (m, 2H), 2.49 (m, 4H).MS (m/z) 705.00 [M+H]+.
    • Example 14
  • Figure US20210009555A1-20210114-C00224
    Figure US20210009555A1-20210114-C00225
    • Synthesis of (S)-tert-butyl 1-(3,6-dibromopyridin-2-yl)-2-(3,5-difluorophenyl)ethylcarbamate (14A)
  • The title compound was prepared according to the method presented for the synthesis of compound 4E of Example 4 utilizing 5E.
    • Synthesis of (S)-tert-butyl (1-(3-bromo-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (14B)
  • The title compound (14B) was prepared according to the method presented for the synthesis of compound 4F of Example 4 utilizing 2-methylbut-3-yn-2-ol and (S)-tert-butyl (1-(3,6-dibromopyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate. MS (m/z) 496.90 [M+H]+. Synthesis of (S)-4-(6-(1-amino-2-(3,5-difluorophenyl)ethyl)-5-bromopyridin-2-yl)-2-methylbut-3-yn-2-ol compound with 2-methylbut-3-yn-2-ol (1:1) hydrochloride (14C):
  • The title compound (14C) was prepared according to the method presented for the synthesis of compound 4G of Example 4 utilizing 14B. MS (m/z) 397.09 [M+H]+.
    • Synthesis of N—((S)-1-(3-bromo-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (14D)
  • The title compound (14D) was prepared according to the method presented for the synthesis of compound 4G of Example 4 utilizing 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid and 14C. MS (m/z) 659.23 [M+H]+.
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(1-oxoisoindolin-4-yl)pyridin-2-yl)ethyl)acetamide (14E)
  • The title compound (14E) was prepared according to the method presented for the synthesis of compound 4H of Example 4 utilizing 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine and 14D. H NMR (400 MHz, CD3OD) δ 8.92 (d, J=8.7 Hz, 1H), 8.00 (s, 2H), 7.85 (s, 1H), 7.59 (m, 2H), 7.48 (d, J=7.9 Hz, 1H), 6.77-6.56 (m, 2H), 6.28 (d, J=6.3 Hz, 2H), 5.33 (m, 1H), 4.87 (s, 2H), 3.17-2.99 (m, 4H), 2.48 (m, 4H), 1.6 (s, 6H), 1.40 (m, 1H), 1.10 (m, 1H).MS (m/z) 697.28 [M+H]+.
    • Example 15
  • Figure US20210009555A1-20210114-C00226
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(1-oxoisoindolin-4-yl)pyridin-2-yl)ethyl)acetamide (15)
  • The title compound (15) was prepared according to the method presented for the synthesis of compound 4H of Example 4 utilizing 14D and 2,3-dihydro-1H-isoindol-1-one-4-boronic acid pinacol ester. 1H NMR (400 MHz, CD3OD) δ 7.82 (m, 1H), 7.53 (m, 4H), 6.78 (m, 1H), 6.30 (m, 2H), 5.35 (m, 1H), 4.83 (m, 2H), 4.17 (m, 2H), 3.16-3.04 (m, 1H), 2.98 (m, 1H), 2.48 (m, 2H), 1.53 (s, 6H), 1.43 (m, 1H), 1.08 (m, 1H).MS (m/z) 712.18 [M+H]+.
    • Example 16
  • Figure US20210009555A1-20210114-C00227
    • Synthesis of (S)—N-(1-(3-bromo-6-((trimethylsilyl)ethynyl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide (16A)
  • The title compound (16A) was prepared according to the method presented for the synthesis of compound 4F of Example 4 utilizing ethynyltrimethylsilane and 5F. MS (m/z) 694.59 [M+H]+.
    • Synthesis of (S)—N-(1-(3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-6-((trimethylsilyl)ethynyl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide (16B)
  • The title compound (16B) was prepared according to the method presented for the synthesis of compound 4H of Example 4 utilizing 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine and 16A. MS (m/z) 731.22 [M+H]+.
    • Synthesis of (S)—N-(1-(3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-6-(1H-1,2,3-triazol-4-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide (16C)
  • Compound 16B (75 mg, 0.1 mmol), NaN3 (13 mg, 0.2 mmol) and NH4Cl (5 mg, 0.1 mmol) were dissolved in DMF (0.5 mL) and stirred at 100° C. for overnight. The reaction mixture was cooled down to room temperature and diluted with water and extracted with EtOAc. The organic phase was dried (Na2SO4), filtered and concentrated. The crude material was purified on reverse phase HPLC eluting with acetonitrile and water (with 0.1% TFA) to afford the title product. 1H NMR (400 MHz, CD3OD) δ 9.01 (d, J=7.7 Hz, 1H), 8.54 (s, 1H), 7.99 (m, 3H), 7.73 (d, J=8.0 Hz, 1H), 7.59 (d, J=3.5 Hz, 1H), 6.97-6.55 (m, 3H), 6.31 (d, J=6.3 Hz, 2H), 5.45 (m, 1H), 5.11 (s, 2H), 3.13 (m, 2H), 2.49 (m, 4H).MS (m/z) 702.02 [M+H]+.
    • Example 17
  • Figure US20210009555A1-20210114-C00228
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(3-(2,4-dioxo-1,2,3,4-tetrahydroquinazolin-8-yl)-6-(3-hydroxy-3-methylbut-1-ynyl)pyridin-2-yl)ethyl)acetamide (17)
  • The title compound was prepared according to the method presented for the synthesis of compound 4F of Example 4 utilizing 8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazoline-2,4(1H,3H)-dione and 14D. 1H NMR (400 MHz, DMSO) δ 11.36 (d, 1H), 10.12 (d, 1H), 8.87 (m, 1H), 7.98 (d, 1H), 7.75-6.70 (m, 7H), 6.47-6.57 (m, 2H), 4.74-4.50 (m, 2H), 3.01-2.90 (m, 2H), 2.48-2.60 (m, 2H), 1.49 (s, 6H), 1.45-1.24 (m, 1H), 0.96 (m, 1H). MS (m/z) 741.1 [M+H]+.
    • Example 18
  • Figure US20210009555A1-20210114-C00229
    • Synthesis of 5-(2-((S)-1-(2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-2-fluorobenzamide (18)
  • The title compound was prepared according to the method presented for the synthesis of compound 4F of Example 4 utilizing (3-carbamoyl-4-fluorophenyl)boronic acid and 14D. H NMR (400 MHz, DMSO) δ 9.08 (d, 1H), 7.79-7.14 (m, 8H), 6.92 (m, 1H), 6.62 (d, 2H), 5.12 (m, 1H), 4.77-4.83 (m, 2H), 3.01 (m, 2H), 2.55 (m, 1H), 1.51 (s, 6H), 1.38 (m, 1H), 0.98 (m, 1H). MS (m/z) 718.2 [M+H]+.
    • Example 19
  • Figure US20210009555A1-20210114-C00230
    Figure US20210009555A1-20210114-C00231
    • Synthesis of 7-bromo-4-chloro-1-methyl-1H-indazol-3-amine (19B)
  • To 3-bromo-6-chloro-2-fluorobenzonitrile (10 g, 42.7 mmol) in EtOH (100 mL) was added methylhydrazine (9 ml, 171 mmol). The reaction mixture was stirred for 4 hours at 110° C. The reaction was allowed to slowly cool over 4 hours, then the solids were filtered off and used with no further purification to provide 7 g of the title compound (including minor amounts of the other regioisomer). MS (m/z) 262.0 [M+H]+.
    • Synthesis of 4-chloro-1-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (19C)
  • To 7-bromo-4-chloro-1-methyl-1H-indazol-3-amine (3 g, 11.5 mmol) in dioxane (40 mL) and DMF (25 ml) was added bis (pinacolato) diborane (8.8 g, 34.6 mmol), potassium acetate (3.4 g, 34.6 mmol), and trans-dichlorobis(triphenylphosphine)palladium (II) (486.35 mg, 0.69 mmol). The reaction mixture was stirred for 3 hours at 130° C. The reaction was cooled, diluted with EtOAc, and then the solids were filtered off over Celite and silica gel eluting with EtOAc. The mixture was concentrated and purified by flash column chromatography to provide 1.8 g of the title compound. MS (m/z) 308.3 [M+H]+.
    • Synthesis of N-(4-chloro-1-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-yl)methanesulfonamide (19D)
  • To 7-bromo-4-chloro-1-methyl-1H-indazol-3-amine (2.6 g, 8.5 mmol) in DCM (30 mL) was added N,N-Diisopropylethylamine (5.9 ml, 33.8 mmol) then the reaction was cooled in an ice bath and methansulfonyl chloride (2 ml, 25.4 mmol) was added. The reaction mixture was stirred for 20 minutes at 0° C. The reaction was diluted with water and extracted 2× with DCM. The organic layer was dried over sodium sulfate and concentrated. The resulting mixture was taken up in EtOH (30 ml) and 8 ml of 10N NaOH was added. The reaction was followed by LC/MS and once done (10 minutes) the reaction was diluted with water and quenched with concentrated HCl to pH 2. The mixture was extracted 3× with DCM. The organic layer was dried over sodium sulfate and concentrated until solid starts to fall out. The mixture is then cooled in a brine/ice bath for 20 minutes and filtered to recover desired as two lots and used with no further purification to provide 2.1 g of the title compound. MS (m/z) 386.4 [M+H]+.
    • Synthesis of (S)-tert-butyl 1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-ynyl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethylcarbamate (19E)
  • To N-(4-chloro-1-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-yl)methanesulfonamide (39 mg, 0.1 mmol) in dioxane (5 mL) and DMF (0.3 ml) was added 14B (50 mg, 0.1 mmol), 1N sodium bicarbonate (0.9 ml, 0.9 mmol), and dichlorobis(tricyclohexylphosphine)palladium (11) (1.9 mg, 0.003 mmol). The reaction mixture was stirred for 4 hours at 140° C. The reaction was cooled, diluted with EtOAc and brine. The mixture was extracted 2× with EtOAc, the organic layer was dried over sodium sulfate, was concentrated and purified by flash column chromatography to provide 30 mg of the title compound. MS (m/z) 674.7 [M+H]+.
    • Synthesis of (S)—N-(7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-ynyl)pyridin-3-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide TFA salt (19F)
  • To (S)-tert-butyl 1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-ynyl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethylcarbamate (30 mg, 0.04 mmol) in DCM (4 mL) was added TFA (2 ml). The reaction mixture was stirred for 0.5 hours at RT. The reaction was concentrated and used with no further purification to provide the title compound. MS (m/z) 574.4 [M+H]+.
    • Synthesis of (S)—N-(1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-ynyl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(difluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (19G)
  • The title compound (19G) was prepared according to the method presented for the synthesis of compound 4G of Example 4 utilizing 2-((3bS,4aR)-5,5-difluoro-3-(difluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid and (S)—N-(7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-ynyl)pyridin-3-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide to provide 20 mg of the title compound. H NMR (400 MHz, Methanol-d4) δ 8.69 (t, 1H), 7.69 (dd, 1H), 7.53 (dd, 1H), 7.17 (s, 1H), 7.06 (d, 1H), 6.88-6.52 (m, 2H), 6.44-6.33 (m, 2H), 5.28 (d, 1H), 5.02-4.92 (m, 1H), 4.78-4.64 (m, 2H), 3.33 (s, 3H), 3.24 (d, 3H), 3.19-3.08 (m, 2H), 3.05-2.92 (m, 2H), 2.44 (ddd, 2H), 1.64 (d, 6H), 1.38 (dt, 1H), 1.02 (s, 1H).
  • MS (m/z) 820.8 [M+H]+.
    • Example 20
  • Figure US20210009555A1-20210114-C00232
    • Synthesis of (S)—N-(1-(3-(1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-ynyl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(difluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (20)
  • The title compound was prepared according to the method presented for the synthesis of compound 19G of utilizing N-(1-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-yl)methanesulfonamide and compound 14B. 1H NMR (400 MHz, Methanol-d4) δ 8.69 (t, 1H), 7.88-7.80 (dd, 1H), 7.69 (dd, 1H), 7.53 (dd, 1H), 7.20 (s, 1H), 7.09 (d, 1H), 6.88-6.52 (m, 2H), 6.38-6.27 (m, 2H), 5.35 (m, 1H), 5.02-4.95 (m, 1H), 4.80-4.65 (m, 2H), 3.33 (s, 3H), 3.19-3.08 (m, 4H), 3.05-2.92 (m, 2H), 2.44 (m, 2H), 1.64 (d, 6H), 1.38 (m, 1H), 1.02 (m, 1H).
  • MS (m/z) 786.1 [M+H]+.
    • Example 21
  • Figure US20210009555A1-20210114-C00233
    Figure US20210009555A1-20210114-C00234
    • Synthesis of 5-bromo-N-methoxy-N-methyl-2-(methylthio)pyrimidine-4-carboxamide (21A)
  • To a mixture of 5-bromo-2-(methylthio)pyrimidine-4-carboxylic acid (5 g, 20 mmol), N,O-dimethylhydroxylamine hydrochloride (2.9 g, 30 mmol) and HATU (9.1 g, 24 mmol) in 100 mL of CH2Cl2 at 0° C. was added N,N-diisopropylethylamine (17.4 mL, 100 mmol). The reaction mixture was allowed to stir at 0° C. for 30 min and then diluted with CH2Cl2. It was washed with water and half brine. The organic layer was separated, dried over MgSO4, filtered and concentrated. The crude product was purified by silica gel chromatography to afford the title compound 21A. MS (m/z) 292.16 [M+H]+.
    • Synthesis of 5-bromo-2-(methylthio)pyrimidine-4-carbaldehyde (21B)
  • A solution of 5-bromo-N-methoxy-N-methyl-2-(methylthio)pyrimidine-4-carboxamide (21A, 8.2 g, 28 mmol) in THF (120 mL) was added dropwise to a suspension of lithium aluminum hydride (1.06 g, 28 mmol) and THF (120 mL) at −78° C. The mixture was stirred for 10 minutes after addition finish. H2O (1.06 mL), 15% aqueous NaOH solution (1.06 mL) and H2O (3.18 mL) were successively added to the mixture at 0° C. very slowly. The resulting precipitate was filtered and washed with THF. The filtrate was concentrated in vacuo to afford crude of the title compound. MS (m/z): 233.14, [M+H]+.
    • Synthesis of (S)—N-((5-bromo-2-(methylthio)pyrimidin-4-yl)methylene)-2-methylpropane-2-sulfinamide (21C)
  • Copper(II) sulfate (anhydrous, 8.9 g, 56 mmol) was added to a solution of 5-bromo-2-(methylthio)pyrimidine-4-carbaldehyde (21B, ˜28 mmol) and (S)-2-methylpropane-2-sulfinamide (3.4 g, 28 mmol) in CH2Cl2 (100 mL). The suspension was stirred for 3 days at room temperature. The reaction was filtered and washed with CH2Cl2 (3×20 ml). The filtrate was concentrated. The crude product was purified by silica gel chromatography to yield the title compound 21C. MS (m/z) 337.7 [M+H]+
    • Synthesis of (S)—N—((S)-1-(5-bromo-2-(methylthio)pyrimidin-4-yl)-2-(3,5-difluorophenyl)ethyl)-2-methylpropane-2-sulfinamide (21D)
  • To a solution of (S)—N-((5-bromo-2-(methylthio)pyrimidin-4-yl)methylene)-2-methylpropane-2-sulfinamide (21C, 2.97 g. 8.8 mmol) in THF (18 mL) cooled to −78° C. was drop wise added 3,5-Difluorobenzylmagnesium bromide (53 mL, 0.25 M in Ether, 13.3 mmol). After stirring at −78° C. for 10 min, NH4Cl (sat. aq.) (10 ml) was added to the reaction and warmed up to ambient temperature. Extracted with EtOAc and the organic layer was dried over Na2SO4(s).The solvent was removed and the residue was purified by silica gel chromatography to yield 1.44 g of the title compound 21D MS (m/z) 465.87 [M+H]+
    • Synthesis of (S)-1-(5-bromo-2-(methylthio)pyrimidin-4-yl)-2-(3,5-difluorophenyl)ethanamine hydrochloride (21E)
  • Compound 21D (8 g, 17.23 mmol) was dissolved in 35 mL of methanol and cooled to 0° C. To it was added 4N HCl/1,4-dioxane (10.7 mL). The reaction mixture was allowed to stir for 20 minutes and to it was added diethyl ether. The resulting precipitate was collected by vacuum filtration then dried to afford the title product 21E. MS (m/z) 362.02 [M+H]+.
    • Synthesis of (S)—N-(1-(5-bromo-2-(methylthio)pyrimidin-4-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide (21F)
  • A mixture of 2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetic acid (604 mg, 2 mmol), compound 21E (793 mg, 2 mmol) and HATU (912 mg, 2.4 mmol) in 10 mL of DMF was cooled to 0° C. To it was drop wise added N,N-diisopropylethylamine (1.05 mL, 6 mmol). The reaction mixture was allowed to stir at 0° C. for 10 minutes then slowly poured it into ice water with stirring. The resulting precipitate was collected by vacuum filtration then dried to afford the title product 21F. MS (m/z) 644.22 [M+H]+.
    • Synthesis of (S)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)-N-(2-(3,5-difluorophenyl)-1-(2-(methylthio)-5-(3-oxoisoindolin-5-yl)pyrimidin-4-yl)ethyl)acetamide (21G)
  • In a microwave tube were charged with compound 21F (300 mg, 0.47 mmol), 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one (181 mg, 0.7 mmol) and PdCl2[P(Cy)3]2 (17 mg, 0.023 mmol). To the mixture was added 10 mL of 1,4-dioxane and 1.4 mL of sodium bicarbonate aqueous solution (1M). The mixture was heated to 155° C. for 25 min in a microwave synthesizer. After cooled to room temperature, it was partitioned between EtOAc and water. The organic layer was separated and washed with brine, then dried over MgSO4, filtered and concentrated. The residue was purified by silica gel chromatography to afford the title compound 21G. MS (m/z) 697.32 [M+H]+).
    • Synthesis of (S)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)-N-(2-(3,5-difluorophenyl)-1-(2-(3-hydroxy-3-methylbut-1-yn-1-yl)-5-(3-oxoisoindolin-5-yl)pyrimidin-4-yl)ethyl)acetamide (21H)
  • To the mixture of solid CuI (3.3 mg, 0.017 mmol), Pd(dppf)Cl2 (7 mg, 0.009 mmol), 2-methylbut-3-yn-2-ol (22 mg, 0.26 mmol) and compound 21G (60 mg, 0.086 mmol) were added THF (1 mL) and Et3N (0.06 mL, 0.4 mmol). The reaction mixture was heated in a microwave at 160° C. for 20 min. After cooled to room temperature it was diluted with EtOAc. To it was added Si-Thiol (130 mg, 1.37 mmol/g) and the mixture was stirred at 40° C. for 1 hour. Then it was filtered and the filtrate was washed with 10% aqueous NH4OH, water and brine. The organic layer was dried over MgSO4, filtered, concentrated, and purified by reverse phase HPLC to afford the title compound (21H). 1H NMR (400 MHz, Methanol-d4): δ 9.09 (d), 8.54 (s), 7.64 (dd), 7.58 (dd), 7.40 (d), 6.78 (t), 6.67 (tt), 6.43-6.20 (m), 5.40 (q), 4.50 (s), 3.05 (d), 2.50 (tdd), 1.62 (s). MS (m/z): 732.99 [M+H]+.
    • Example 22
  • Figure US20210009555A1-20210114-C00235
    • Synthesis of N—((S)-1-(5-bromo-2-(methylthio)pyrimidin-4-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (22A)
  • The title compound (22A) was prepared according to the method presented for the synthesis of compound 21F of Example 21 utilizing 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid and compound 21E. MS (m/z) 624.13 [M+H]+.
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(2-(methylthio)-5-(3-oxoisoindolin-5-yl)pyrimidin-4-yl)ethyl)acetamide (22B)
  • The title compound (22B) was prepared according to the method presented for the synthesis of compound 21G of Example 21 utilizing compound 22A and 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one. MS (m/z) 677.05 [M+H]+.
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(2-(3-hydroxy-3-methylbut-1-yn-1-yl)-5-(3-oxoisoindolin-5-yl)pyrimidin-4-ylethyl)acetamide (22C)
  • The title compound (22C) was prepared according to the method presented for the synthesis of compound 21H of Example 21 utilizing compound 22B and 2-methylbut-3-yn-2-ol. H NMR (400 MHz, Methanol-d4): δ 9.05 (d), 8.53 (s), 7.63 (dd), 7.58 (dd), 7.37 (d), 6.75-6.55 (m), 6.41-6.21 (m), 5.41 (q), 4.85 (s), 4.50 (s), 3.05 (dd), 2.48-2.45 (m), 1.62 (s), 1.38 (q), 1.18-0.97 (m, 1H). MS (m/z) 713.01 [M+H]+.
    • Example 23
  • Figure US20210009555A1-20210114-C00236
    • Synthesis of 5-(4-((S)-1-(2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)-2-(methylthio)pyrimidin-5-yl)-2-fluorobenzamide (23A)
  • The title compound (23A) was prepared according to the method presented for the synthesis of compound 21G of Example 21 utilizing compound 22A and 2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide. MS (m/z) 683.06 [M+H]+.
    • Synthesis of 5-(4-((S)-1-(2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)-2-(3-hydroxy-3-methylbut-1-yn-1-yl)pyrimidin-5-yl)-2-fluorobenzamide (23B)
  • The title compound (23B) was prepared according to the method presented for the synthesis of compound 21H of Example 21 utilizing compound 23A and 2-methylbut-3-yn-2-ol. H NMR (400 MHz, Methanol-d4): δ 9.09 (t), 8.51 (d), 7.46 (ddq), 7.27 (ddd), 6.69 (tt), 6.40 (h), 5.36 (q), 4.84 (s), 3.10-3.01 (m), 2.48-2.45 (m), 1.61 (s), 1.38 (q), 1.07 (dd). MS (m/z) 719.06 [M+H]+.
    • Example 24
  • Figure US20210009555A1-20210114-C00237
    • Synthesis of 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinolin-1(2H)-one (24A)
  • To 5-bromoisoquinolin-1(2H)-one (40 mg, 0.18 mmol) in dioxane (1 mL) was added bis(pinacolato)diboron (63 mg, 0.25 mmol), and PdCl2[P(Ph)3]2 (6 mg, 0.01 mmol). The reaction mixture sealed and heated to 100° C. for 1 h. The reaction was cooled to room temperature and telescoped to the next reaction. MS (m/z) 272.3 [M+H]+.
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(1-oxo-1,2-dihydroisoquinolin-5-yl)pyridin-2-yl)ethyl)acetamide (24B)
  • To the reaction vial containing 24A (0.18 mmol) was added 14D (50 mg, 0.07 mmol), PdCl2[P(Ph)3]2 (5 mg, 0.01 mmol), LiCl (11 mg, 0.22 mmol) and aq 1M NaHCO3 (0.22 mL, 0.22 mmol). The reaction mixture was sealed and heated in a microwave reactor to 160° C. for 20 min. Upon cooling, the reaction mixture was diluted with EtOAc and washed with three portions of brine. The organic layer were dried over Na2SO4, filtered, concentrated in vacuo, and purified by reverse phase HPLC to provide the title compound 24B as a mixture of atropisomers. MS (m/z) 724.2 [M+H]+. HPLC retention time 6.95 min and 7.09 min (2-98% acetonitrile: water with 0.1% trifluoroacetic acid, 8.5 min gradient on a Phenomonex Kinetex C18 column).
    • Example 25
  • Figure US20210009555A1-20210114-C00238
    • Synthesis of N—((S)-1-(3-(3-amino-1-methyl-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (25)
  • The title compound (25) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 33F of Example 33 utilizing 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid and 37A. 1H NMR (400 MHz, cd3od) δ 9.04-8.52 (m), 7.7-7.61 (m), 7.52 (dd), 7.17 (d), 7.04 (t), 7.00-6.90 (m), 6.77-6.66 (m), 6.60 (t), 6.48 9 (d), 6.40-6.25 (m), 5.32-5.25 (m), 5.11-5.04 (m), 4.80-4.79 (m), 3.22-3.06 (m), 2.96-2.85 (m), 2.52-2.46 (m), 1.64 (s), 1.43-1.39 (m), 1.14-1.07 (m). MS (m/z) 726.2 [M+H]+.
    • Example 26
  • Figure US20210009555A1-20210114-C00239
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-6-yl)pyridin-2-yl)ethyl)acetamide (26)
  • The title compound (26) was prepared according to the method presented for the synthesis of compound 24B of Example 24 utilizing 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one MS (m/z) 714.1 [M+H]+. HPLC retention time 6.58 min (2-98% acetonitrile: water with 0.1% trifluoroacetic acid, 8.5 min gradient on a Phenomonex Kinetex C18 column).
    • Example 27
  • Figure US20210009555A1-20210114-C00240
    Figure US20210009555A1-20210114-C00241
    • Synthesis of 3-bromo-6-hydrazinyl-2-methylpyridine (27B)
  • To 3-bromo-6-chloro-2-methylpyridine (1.53 g, 7.41 mmol) in dioxane (4.5 ml) was added hydrazine hydrate (1.8 ml, 37 mmol). The reaction was heated in a microwave reactor at 160° C. for 55 min. After cooling to ambient temperature, the reaction mixture was partitioned between EtOAc and saturated aqueous NaCl. The organics were separated and evaporated in vacuo. The product was used directly in the following step. MS (m/z) 202.0 [M+H]+.
    • Synthesis of 6-bromo-5-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (27C)
  • 3-bromo-6-hydrazinyl-2-methylpyridine (4.55 g, 22.52 mmol) was dissolved in DCE (35 ml) to which trichloromethyl chloroformate (2.72 ml, 22.52 mmol) was added. The reaction was stirred at ambient temperature for 1 h. Hexanes (15 ml) was added and the solids filtered to provide the desired product. The eluent was reduced in a volume and a second crop of precipitate was isolated. The combined solids were used without further purification. MS (m/z) 228.0 [M+H]+.
    • Synthesis of 5-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (27D)
  • 6-bromo-5-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (3.62 g, 15.87 mmol) was combined with bis(pinacolato)diboron (6.05 g, 23.81 mmol), KOAc (3.12 g, 31.75 mmol), and PdCl2(PCy3)2 (0.23 g, 0.32 mmol) in dioxane (80 ml). Argon was bubbled into the reaction solution for 15 min. The reaction was then heated to 85 deg C. for 15 h. Additional PdCl2(PCy3)2 (250 mg) was added and the temperature was raised to 125 deg C. Heated for 15 h. After cooling to ambient temperature, the reaction was partitioned between EtOAc and water. The organics were separated, dried, and removed in vacuo. The residue was suspended in EtOAc (50 ml) and the resultant solids filtered to provide the title compound. MS (m/z) 276.2 [M+H]+.
    • Synthesis of (S)-tert-butyl (2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-1-yl)-3-(5-methyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-6-yl)pyridin-2-yl)ethyl)carbamate (27E)
  • In a microwave reaction vessel, 14B (66 mg, 0.13 mmol) and 5-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (55 mg, 0.2 mmol) were dissolved in dioxane (2 mL) and treated with aqueous 1M NaHCO3 (0.4 mL) and PdCl2(PCy3)2 (10 mg). The mixture was heated to 150° C. for 20 min. After cooling to ambient temperature, the reaction was partitioned between EtOAc and water. The organics were separated, dried, and removed in vacuo and the residue was purified by column chromatography on silica to provide the title compound as a mixture of atropisomers. MS (m/z) 563.8 [M+H]+.
    • Synthesis of (S)-6-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-5-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (27F)
  • The title compound (27F) was prepared as a mixture of atropisomers according to the method presented for the synthesis of 19F in Example 19 utilizing 27E. MS (m/z) 464.1 [M+H]+.
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(5-methyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-6-yl)pyridin-2-yl)ethyl)acetamide (27G)
  • The title compound (27G) was prepared as a mixture of atropisomers according to the method presented for the synthesis of 37E in Example 37 utilizing 27F and 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. 1H NMR (400 MHz, Methanol-d4) δ 8.75 (dd), 7.44-7.54 (m), 6.83-6.92 (m), 6.68-6.80 (m), 6.47-6.56 (dd), 5.98 (d), 5.16-5.24 (m), 3.13-3.26 (m), 3.03-3.08 (m), 2.45-2.51 (m), 2.37 (s), 2.11 (s), 1.36-1.43 (m), 1.05-1.15 (m). MS (m/z) 728.0 [M+H]+.
    • Example 28
  • Figure US20210009555A1-20210114-C00242
    • Synthesis of (S)-5-(2-(1-(2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-2-fluorobenzamide (28)
  • The title compound (28) was prepared according to the method presented for the synthesis of compound 33F of Example 33 utilizing (3-carbamoyl-4-fluorophenyl)boronic acid and 2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetic acid. H NMR (400 MHz, cd3od) δ 8.88 (d), 7.55 (d), 7.50-7.36 (m), 7.32 (s), 7.23 (dd), 6.94 (d), 6.82 (d), 6.72-6.62 (m), 6.40-6.31 (m), 5.40-5.32 (m), 5.22 (s), 5.06 (s), 4.36-4.29 (m), 3.75-3.57 (m), 3.14-2.98 (m), 2.66-2.42 (m), 1.62 (s). MS (m/z) 738.2 [M+H]+.
    • Example 29
  • Figure US20210009555A1-20210114-C00243
    • Synthesis of 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (29A)
  • To 7-bromo-1H-indazol-3-amine (75 mg, 0.35 mmol) in dioxane (3 mL) was added bis(pinacolato)diboron (126 mg, 0.5 mmol), and PdCl2[P(Ph)3]2 (12 mg, 0.01 mmol). The reaction mixture sealed and heated to 100° C. for 16 h. The reaction was cooled to room temperature and telescoped to the next reaction. MS (m/z) 260.2 [M+H]+.
    • Synthesis of N—((S)-1-(3-(3-amino-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (29B)
  • The title compound (29) was prepared according to the method presented for the synthesis of compound 24B of Example 24 utilizing 29A. MS (m/z) 712.4 [M+H]+. PLC retention time 6.02 min (2-98% acetonitrile: water with 0.1% trifluoroacetic acid, 8.5 min gradient on a Phenomonex Kinetex C18 column).
    • Example 30
  • Figure US20210009555A1-20210114-C00244
    • Synthesis of 5-(2-((S)-1-(2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-2,3-difluorobenzamide (30)
  • The title compound (30) was prepared according to the method presented for the synthesis of compound 33F of Example 33 utilizing 5-bromo-2,3-difluorobenzamide and 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. 1H NMR (400 MHz, cd3od) δ 8.80 (d), 7.71-7.65 (m), 7.60-7.50 (m), 7.49-7.40 (m), 7.25-7.18 (m), 7.17-7.10 (m), 6.79-6.65 (m), 6.43-6.31 (m), 5.33 (m, 1H), 5.03 (s), 4.33-4.30 (m), 3.20-3.00 (m), 2.59-2.45 (m), 1.65-1.55 (m), 1.49-1.37 (m), 1.15-1.04 (m). MS (m/z) 736.1 [M+H]+.
    • Example 31
  • Figure US20210009555A1-20210114-C00245
    • Synthesis of (S)—N-(1-(3-(3-amino-1-methyl-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide (31)
  • The title compound (31) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 33F of Example 33 utilizing 37A and 2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetic acid. H NMR (400 MHz, cd3od) δ 8.85 (m), 7.87-7.85 (m), 7.70 (d), 7.54-7.46 (d), 7.33 (d), 7.25-7.15 (m), 6.81-6.71 (m), 6.40-6.32 (m), 5.35-5.24 (m), 5.03-4.98 (m), 3.19 (s), 3.08-2.95 (m), 2.61-2.40 (m), 1.64 (s). MS (m/z) 746.2 [M+H]+.
    • Example 32
  • Figure US20210009555A1-20210114-C00246
    • Synthesis of N—((S)-1-(3-(3-amino-1-methyl-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (32)
  • The title compound (32) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 33F of Example 33 utilizing 37A. H NMR (400 MHz, cd3od) δ 8.68 (d), 7.89-7.79 (m), 7.74-7.65 (m), 7.59-7.48 (m), 7.29 (d), 7.16-7.11 (m), 6.79-6.60 (m), 6.39 (d), 6.35-6.28 (m), 5.27-5.22 (m), 5.06-4.95 (m), 4.73 (d), 3.16 (s), 3.13-3.03 (m), 3.02-2.84 (m), 2.50-2.39 (m), 1.64 (s), 1.42-1.34 (m), 1.03 (s). MS (m/z) 708.2 [M+H]+.
    • Example 33
  • Figure US20210009555A1-20210114-C00247
    Figure US20210009555A1-20210114-C00248
    • Synthesis of 7-bromo-1-methyl-1H-indazol-3-amine (33A)
  • In a microwave vial a solution of 3-bromo-2-fluorobenzonitrile (2 g, 10 mmol) ethanol (10 mL) was treated with methylhydrazine (2.1 mL, 40 mmol), sealed, and heated to 120° C. in a microwave reactor for 35 minutes. The reaction was concentrated in vacuo and the crude product dissolved with EtOAc (30 mL) and washed with water (30 mL), then 2M NaCl (aq, 30 mL). The organics were dried with Na2SO4, filtered, and concentrated. Product was purified by silica chromatography to give the title compound. MS (m/z) 227.1 [M+H]+.
    • Synthesis of N-(7-bromo-1-methyl-1H-indazol-3-yl)methanesulfonamide (33B)
  • To a stirred solution of 33A (500 mg, 2.21 mmol), 4-Dimethylaminopyridine (13.5 mg, 0.11 mmol), and N,N-diisopropylethylamine (714.6 mg, 5.53 mmol) in DCM (20 ml) was added dropwise methanesulfonyl chloride (532.0 mg, 4.64 mmol) at 0° C. The reaction was warmed to RT and stirred for 2 h. The reaction was washed with water, dried with Na2SO4, filtered, and concentrated. The crude product dissolved with EtOH (10 mL) and treated with 8N NaOH (1.65 ml). The reaction mixture was heated at 60° C. for 0.5 h. The ethanol was removed under vacuum, pH to ˜2 with 1.0 HCl then, extracted with EtOAc. The organics were dried with Na2SO4, filtered, and concentrated. The product was purified by silica chromatography to give the title compound. MS (m/z) 305.9 [M+H]+.
    • Synthesis of N-(1-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-yl)methanesulfonamide (33C)
  • To 33B (1.2 g, 3.9 mmol) in dioxane (15 mL) was added bis(pinacolato)diboron (1.9 mg, 5.5 mmol), and PdCl2[P(Ph)3]2 (138 mg, 0.19 mmol). The reaction mixture sealed and heated to 100° C. for 1 h. The reaction was cooled to rt and filtered through Celite using ethyl acetate to rinse the pad. The collected organic phase was concentrated in vacuo and purified by silica gel chromatography to give the title compound. MS (m/z) 352.1 [M+H]+.
    • Synthesis of (S)-tert-butyl (2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)ethyl)carbamate (33D)
  • To 14B (250 mg, 0.5 mmol) in dioxane (12 mL) was added N-(1-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-yl)methanesulfonamide (33C, 253 mg, 0.72 mmol), PdCl2[P(Ph)3]2 (35 mg, 0.05 mmol), and aq 1M NaHCO3 (1.5 mL, 1.5 mmol). The reaction mixture sealed and heated in a microwave reactor to 150° C. for 20 min. Upon cooling, the reaction mixture was diluted with EtOAc and washed with three portions of brine. The organic layer were dried over Na2SO4, filtered, concentrated in vacuo, and purified by silica gel column chromatography, eluting with 0-100% EtOAc in hexanes to give the title compound 33D as a mixture of atropisomers.
    • Synthesis of (S)—N-(7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-1-methyl-1H-indazol-3-yl)methanesulfonamide (33E)
  • To a solution of 33D (47 mg, 0.07 mmol) in DCM was added 4M HCl in dioxane (0.7 mL, 2.9 mmol). The reaction mixture was stirred at room temperature for 0.5 hours. Upon complete removal of the Boc protecting group, the reaction was concentrated in vacuo to give the title compound 33E as a mixture of atropisomers.
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)ethyl)acetamide (33F)
  • To a solution of 33E (70 mg) in DMA (3 mL) was added triethylamine (0.046 mL, 0.32 mmol), followed by 2-((3bS,4aR)-3-(trifluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid (31 mg, 0.1 mmol) and HATU (46 mg, 0.12 mmol). After stirring for 30 minutes, the reaction mixture was filtered and purified by reverse phase HPLC to provide the product 33F as a mixture of atropisomers. 1H NMR (400 MHz, cd3od) δ 7.83 (dd), 7.72-7.64 (m), 7.50-7.55 (m), 7.32-7.07 (m), 6.78-6.70 (m), 6.52-6.48 (m), 6.33-6.31 (m), 5.35-5.28 (m), 5.05-4.37 (m), 3.56 (s), 3.21-3.09 (m), 3.00-2.90 (m), 2.54-2.40 (m), 1.64 (s), 1.50-1.39 (m), 1.10-0.88 (m). MS (m/z) 804.1 [M+H]+.
    • Example 34
  • Figure US20210009555A1-20210114-C00249
    • Synthesis of N—((S)-1-(3-(3-amino-1-methyl-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(difluoromethyl)-5,5a,6,6a-tetrahydrocyclopropa[g]indazol-1(4H)-yl)acetamide (34)
  • The title compound (34) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 33F of Example 33 utilizing 37A and 2-(3-(difluoromethyl)-5,5a,6,6a-tetrahydrocyclopropa[g]indazol-1(4H)-yl)acetic acid (WO2013006738). 1H NMR (400 MHz, cd3od) δ 7.91-7.86 (m), 7.71 (dd), 7.54 (dd), 7.22-7.17 (m), 6.87-6.69 (m), 6.66-6.56 (m), 6.41-6.30 (m), 5.35-5.25 (m), 5.08-4.97 (m), 4.90-4.71 (m), 4.36-4.29 (m), 3.76-3.66 (m), 3.65-3.57 (m), 3.18-3.13 (m), 3.07 (dt), 3.01-2.90 (m), 2.75-2.64 (m), 2.21-2.04 (m), 1.76-1.61 (m), 1.10-1.03 (m), 1.00-0.90 (m), 0.75-0.70 (m), 0.69-0.62 (m). MS (m/z) 686.2 [M+H]+.
    • Example 35
  • Figure US20210009555A1-20210114-C00250
    • Synthesis of 6-bromo-N-(oxetan-3-yl)imidazo[1,2-a]pyridine-8-carboxamide (35B)
  • 6-bromoimidazo[1,2-a]pyridine-8-carboxylic acid hydrochloride (235 mg, 0.85 mmol) and HATU (386.16 mg, 1.02 mmol) were combined in DMF (4 ml) and treated with iPr2NEt (0.37 ml, 2.12 mmol). 3-Oxetamine hydrochloride (92.31 mg, 0.85 mmol) was added and the reaction stirred at ambient temperature for 1 h. Water (2 ml) was added and a solid precipitated. The solids were collected by filtration to provide the desired product. MS (m/z) 296.0 [M+H]+.
    • Synthesis of (8-(oxetan-3-ylcarbamoyl)imidazo[1,2-a]pyridin-6-yl)boronic acid (35C)
  • The title compound (35C) was prepared according to the method presented for the synthesis of 27D in Example 27 utilizing 35B wherein the boronic ester hydrolyzed and the corresponding boronic acid was isolated. MS (m/z) 262.1 [M+H]+.
  • Figure US20210009555A1-20210114-C00251
    • Synthesis of 6-(2-((S)-1-(2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-N-(oxetan-3-yl)imidazo[1,2-a]pyridine-8-carboxamide (35D)
  • The title compound (35D) was prepared according to the method presented for the synthesis of 27G in Example 27 utilizing 14B and 35C. 1H NMR (400 MHz, Methanol-d4) δ 9.15 (d), 8.80 (d), 8.27 (d), 8.11 (d), 7.84-7.69 (m), 7.65 (dd), 7.53 (dd), 6.89-6.64 (m), 6.53-6.37 (m), 5.34-5.13 (m), 4.73-4.49 (m), 4.49-4.34 (m), 3.96-3.58 (m), 3.25-3.03 (m), 2.59-2.36 (m), 1.51-1.29 (m), 1.18-0.95 (m). MS (m/z) 796.2 [M+H]+.
    • Example 36
  • Figure US20210009555A1-20210114-C00252
    • Synthesis of (4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)boronic acid (36B)
  • In a microwave vessel, 5-bromo-4-fluoro-1H-pyrrolo[2,3-b]pyridine (100 mg, 0.47 mmol) was combined with bis(pinacolato)diboron (177 mg, 0.7 mmol), KOAc (91 mg, 0.93 mmol), and PdCl2(PCy3)2 (34 mg) in dioxane (4.5 ml). Argon was bubbled into the reaction solution for 15 min. The reaction was heated in a microwave reactor at 155° C. for 15 min. After cooling to ambient temperature, the reaction was partitioned between EtOAc and water. The organics were separated, dried, and removed in vacuo to provide the title compound. MS (m/z) 181.1 [M+H]+.
  • Figure US20210009555A1-20210114-C00253
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(3-(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)ethyl)acetamide (36C)
  • The title compound (36C) was prepared according to the method presented for the synthesis of 27G in Example 27 utilizing 14B and 36B. H NMR (400 MHz, Methanol-d4) δ 8.71 (s), 7.63 (s), 7.53-7.42 (m), 6.64 (s), 6.57 (s), 6.32 (s), 3.14-2.97 (m), 2.56-2.40 (m), 1.62 (s), 1.42-1.34 (m), 1.16-1.04 (m). MS (m/z) 715.1 [M+H]+.
    • Example 37
  • Figure US20210009555A1-20210114-C00254
    Figure US20210009555A1-20210114-C00255
    • Synthesis of 1-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (37A)
  • The title compound (37A) was prepared according to the method presented for the synthesis of compound 39B of Example 39 utilizing 33A. MS (m/z) 274.2 [M+H]+.
    • Synthesis of (S)-tert-butyl (1-(5-bromo-2-(methylthio)pyrimidin-4-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (37B)
  • To compound 21E (310 mg, 0.78 mmol) in dichloromethane (3 ml) was added triethylamine (217 μL, 1.56 mmol) and di-tert-butyldicarbonate (170 mg, 0.78 mmol). The mixture was stirred for one hour at ambient temperature then concentrated in vacuo.
  • The residue was purified by silica gel chromatography to afford the title compound (37B). MS (m/z) 459.86 [M+H]+.
    • Synthesis of (S)-tert-butyl (1-(5-(3-amino-1-methyl-1H-indazol-7-yl)-2-(methylthio)pyrimidin-4-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (37C)
  • The title compound (37C) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 21G of Example 21 utilizing compound 37B and 37A. MS (m/z) 526.81 [M+H]+.
    • Synthesis of (S)-7-(4-(1-amino-2-(3,5-difluorophenyl)ethyl)-2-(methylthio)pyrimidin-5-yl)-1-methyl-1H-indazol-3-amine hydrochloride (37D)
  • Compound 37C (78 mg, 0.15 mmol) was dissolved in 2 mL of 1,4-dioxane and cooled to 0° C. To it was added 4N HC/1,4-dioxane (2 mL). The reaction mixture was stirred at room temperature for 7 hours. The solvent was removed and dried to afford the title compound 37D as a mixture of atropisomers. MS (m/z) 427.01 [M+H]+.
    • Synthesis of (S)—N-(1-(5-(3-amino-1-methyl-1H-indazol-7-yl)-2-(methylthio)pyrimidin-4-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide (37E)
  • A mixture of 2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetic acid (44 mg, 0.14 mmol), compound 37D (69 mg, 0.15 mmol) and HATU (68 mg, 0.18 mmol) in 1.5 mL of DMF was cooled to 0° C. To it was added N,N-diisopropylethylamine (0.1 mL, 0.6 mmol). The reaction mixture was allowed to stir at 0° C. for 5 minutes then partitioned between EtOAc and 5% aqueous LiCl solution. The organic layer was separated, washed with brine and concentrated. The residue was purified by reverse phase HPLC) to afford the title product 37E as a mixture of atropisomers. MS (m/z) 710.95 [M+H]+.
    • Synthesis of (S)—N-(1-(5-(3-amino-1-methyl-1H-indazol-7-yl)-2-(3-hydroxy-3-methylbut-1-yn-1-yl)pyrimidin-4-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide (37F)
  • The title compound (37F) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 21H of Example 21 utilizing compound 37E and 2-methylbut-3-yn-2-ol. 1H NMR (400 MHz, Methanol-d4) δ 9.01 (d), 8.69 (d), 7.88-7.78 (m), 7.70-7.41 (m), 7.40-7.28 (m), 7.10 (dt), 6.96-6.52 (m), 6.35 (d), 5.41-5.23 (m), 5.15-5.05 (m), 5.04-4.91 (m), 3.45-3.47 (m), 3.20 (s), 3.13-2.83 (m), 2.62-2.35 (m), 1.62 (s). MS (m/z) 747.03 [M+H]+.
    • Example 38
  • Figure US20210009555A1-20210114-C00256
    • Synthesis of 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(5-methyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-6-yl)pyridin-2-yl)ethyl)acetamide (38)
  • The title compound (38) was prepared as a mixture of atropisomers according to the method presented for the synthesis of 27G in Example 27 utilizing 27F and 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. HPLC retention time 6.48 min and 6.58 min corresponding to each atropisomer (2-98% acetonitrile: water with 0.1% trifluoroacetic acid, 8.5 min gradient on a Phenomonex Kinetex C18 column 4.6×100 mm). MS (m/z) 710.1 [M+H]+.
    • Example 39
  • Figure US20210009555A1-20210114-C00257
    • Synthesis of N-(7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]isoxazol-3-yl)methanesulfonamide (39B)
  • To 39A (prepared similarly to 33B of example 33 utilizing 7-bromobenzo[d]isoxazol-3-amine instead of 7-bromo-1-methyl-1H-indazol-3-amine) (87 mg, 0.3 mmol) in dioxane (3 mL) was added bis(pinacolato)diboron (107 mg, 0.4 mmol), and PdCl2[P(Ph)3]2 (21 mg, 0.03 mmol). The reaction mixture sealed and heated to 100° C. for 16 h. The reaction was cooled to room temperature and telescoped to the next reaction. MS (m/z) 260.2 [M+H]*.
  • Figure US20210009555A1-20210114-C00258
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(3-(methylsulfonamido)benzo[d]isoxazol-7-yl)pyridin-2-yl)ethyl)acetamide (39C)
  • The title compound (39C) was prepared according to the method presented for the synthesis of compound 33F of Example 33 utilizing 39B and 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. MS (m/z) 791.1 [M+H]+. HPLC retention time 7.25 min (2-98% acetonitrile: water with 0.1% trifluoroacetic acid, 8.5 min gradient on a Phenomonex Kinetex C18 column).
    • Example 40
  • Figure US20210009555A1-20210114-C00259
    • Synthesis of (S)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)-N-(2-(3,5-difluorophenyl)-1-(2-(3-hydroxy-3-methylbut-1-yn-1-yl)-5-(1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyrimidin-4-yl)ethyl)acetamide (40)
  • The title compound (40) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 37F of Example 37 utilizing compound 37B and N-(1-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-yl)methanesulfonamide (compound 33C). 1H NMR (400 MHz, Methanol-d4): δ 8.73 (d), 7.90 (ddd), 7.48-7.40 (m), 7.25 (dd), 7.18 (dd), 7.04-6.53 (m), 6.44-6.25 (m), 5.42-5.38 (m), 5.09-4.88 (m), 3.41 (s), 3.19 (s), 3.14-2.90 (m), 2.63-2.20 (m), 1.64 (d). MS (m/z) 824.90 [M+H]+
    • Example 41
  • Figure US20210009555A1-20210114-C00260
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(2-(3-hydroxy-3-methylbut-1-yn-1-yl)-5-(1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyrimidin-4-yl)ethyl)acetamide (41)
  • The title compound (41) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 23B of Example 23 utilizing compound 22A and N-(1-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-yl)methanesulfonamide (33C). 1H NMR (400 MHz, Methanol-d4) δ 9.12-8.90 (m), 8.73 (dd), 7.90 (dd), 7.42 (d), 7.24 (t), 7.17 (t), 6.87-6.68 (m), 6.61 (t), 6.37 (dd), 5.47-5.35 (m), 5.02 (q), 4.85-4.46 (m), 3.40 (d), 3.19 (d), 3.12 (dd), 3.07-2.83 (m), 2.62-2.33 (m) 1.64 (d), 1.48-1.31 (m), 1.16-0.95 (m). MS (m/z) 804.85 [M+H]+.
    • Example 42
  • Figure US20210009555A1-20210114-C00261
    • Synthesis of (S)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)-N-(2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(l-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)ethyl)acetamide (42)
  • The title compound (42) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 33F of Example 33 utilizing 2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetic acid. 1H NMR (400 MHz, cd3od) δ 8.80 (d), 7.82 (d), 7.75-7.69 (m), 7.59-7.51 (m), 7.40-7.20 (m), 7.19-7.05 (m), 6.80 (d), 6.60-6.52 (m), 6.30 (d), 5.08-4.97 (m), 4.90-4.71 (m), 3.34 (s), 3.25-3.00 (m),2.90-2.75 (m), 2.76-2.64 (m), 2.25-2.00 (m, 5H), 1.64 (s). MS (m/z) 824.2 [M+H]+.
    • Example 43
  • Figure US20210009555A1-20210114-C00262
    • Synthesis of 2-(3-(difluoromethyl)-5,5a,6,6a-tetrahydrocyclopropa[g]indazol-1(4H)-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)ethyl)acetamide (43)
  • The title compound (43) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 33F of Example 33 utilizing 20C and 2-(3-(difluoromethyl)-5,5a,6,6a-tetrahydrocyclopropa[g]indazol-1(4H)-yl)acetic acid. 1H NMR (400 MHz, cd3od) δ 7.80 (d), 7.45 (d), 7.51 (d), 7.25-7.20 (m, 1H), 6.80-6.52 (m), 6.45 (d), 5.35-5.25 (m), 5.08-4.97 (m), 4.90-4.71 (m), 3.34 (s), 3.25-3.02 (m), 2.98-2.64 (m), 2.75-2.35 (m), 2.25-2.00 (m), 1.80-1.70 (m), 1.64 (d), 1.00-0.90 (m), 0.65-0.58 (m). MS (m/z) 764.2 [M+H]+.
    • Example 44
  • Figure US20210009555A1-20210114-C00263
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(1-methyl-3-(sulfamoylamino)-1H-indazol-7-yl)pyridin-2-yl)ethyl)acetamide (44)
  • To a stirred solution of 25 (31 mg, 0.04 mmol) and pyridine (0.024 mL, 0.03 mmol) in dichloroethane (0.5 mL) was added a solution of sulfamoyl chloride (12 mg, 0.1 mmol) in dichloroethane (˜0.2 mL). The reaction was heated at 60° C. for 1 h. Upon cooling, the reaction mixture was concentrated in vacuo, diluted with EtOAc and washed with water then 1 M HCl. The organic layer was dried over Na2SO4, filtered, concentrated in vacuo, and purified by reverse phase HPLC to provide the title compound 44 as a mixture of atropisomers. 1H NMR (400 MHz, cd3od) 8.86-6.25 (m, 8H), 5.38-4.97 (m, 1H), 4.85-4.73 (m, 2H), 3.26-3.06 (m, 1H), 3.04-2.90 (m, 2H), 2.63-2.37 (m, 2H), 1.69-1.56 (m, 6H), 1.52-1.32 (m, 1H), 1.19-0.98 (m, 1H). MS (m/z) 805.1 [M+H]+.
    • Example 45
  • Figure US20210009555A1-20210114-C00264
    Figure US20210009555A1-20210114-C00265
    • Synthesis of 2-(7-bromo-1H-indazol-3-yl)isoindoline-1,3-dione (45B)
  • To 7-bromo-1H-indazol-3-amine (45A, 1.2 g, 5.5 mmol) in toluene (30 mL) was added phthalic acid (990 mg, 6.0 mmol). The flask was fitted with a Dean-Stark trap and the reaction mixture was stirred for 12 hours at 180° C. The reaction was allowed to cool, the solids were filtered off and used with no further purification to provide the title compound. MS (m/z) 343.1 [M+H]+.
    • Synthesis of 7-bromo-1-ethyl-1H-indazol-3-amine (45C)
  • To 45B (100 mg, 0.3 mmol) in DMF (2 mL) was added Cs2CO3 (95.2 mg, 0.3 mmol) and iodoethane (0.028 ml, 0.35 mmol). The reaction mixture was stirred for 10 minutes. The reaction mixture was diluted with EtOAc and brine, extracted 2× with EtOAc, organic layer dried over sodium sulfate, and concentrated. To the crude mixture was added EtOH (2 ml) and hydrazine hydrate (1 ml) the reaction mixture was stirred for 30 minutes. The mixture was concentrated and purified by flash column chromatography to provide the title compound. MS (m/z) 240.1 [M+H]+.
    • Synthesis of 1-ethyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (45D)
  • To 45C (80 mg, 0.3 mmol) in dioxane (5 mL) was added bis(pinacolato)diboron (84.6 mg, 0.3 mmol), potassium acetate (32.7 mg, 0.3 mmol), and Pd(PCy3)2Cl2 (12.3 mg, 0.02 mmol). The reaction mixture was heated in the microwave for 30 minutes at 150° C. The reaction was cooled and the solids were filtered off. The mixture was concentrated and purified by flash column chromatography to provide the title compound. MS (m/z) 288.2 [M+H]+.
    • Synthesis of (S)-tert-butyl (1-(3-(3-amino-1-ethyl-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (45E)
  • To 45D (40 mg, 0.1 mmol) in dioxane (4 mL) and MeOH (0.75 ml) was added 14B (69 mg, 0.1 mmol), 2M K2CO3 (0.4 ml), LiCl (17.7 mg, 0.4 mmol) and Pd(PPh3)2Cl2 (4.9 mg, 0.007 mmol). The reaction mixture was heated in the microwave for 30 minutes at 150° C. The reaction was cooled, diluted with EtOAc and brine, and extracted 2× EtOAc. The organic layer was dried over sodium sulfate, concentrated and purified by flash column chromatography to provide the title compound as a mixture of atropisomers. MS (m/z) 576.0 [M+H]+.
    • Synthesis of (S)-4-(5-(3-amino-1-ethyl-1H-indazol-7-yl)-6-(1-amino-2-(3,5-difluorophenyl)ethyl)pyridin-2-yl)-2-methylbut-3-yn-2-ol (45F)
  • The title compound (45F) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 19F of Example 19 utilizing 45E. MS (m/z) 476.1 [M+H]+.
    • Synthesis of N—((S)-1-(3-(3-amino-1-ethyl-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (45G)
  • The title compound (45G) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 10A of Example 10 utilizing 45F and 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. 1H NMR 1H NMR (400 MHz, Methanol-d4) δ 8.67 (d), 7.87-7.75 (m), 7.71 (d), 7.59-7.50 (m), 7.26-7.19 (m), 7.18-7.12 (m), 7.12-7.04 (m), 6.76-6.63 (m), 6.60 (d), 6.47-6.41 (m), 6.27 (d), 5.11-5.01 (m), 4.81 (d), 4.72 (d), 3.67-3.55 (m), 3.51-3.43 (m), 3.39-3.24 (m), 3.15-3.10 (m), 3.09-2.84 (m), 2.56-2.40 (m), 1.64 (s), 1.45-1.33 (m), 1.31-1.25 (m), 1.14-1.03 (m), 0.87 (dt). MS (m/z) 740.2 [M+H]+.
    • Example 46
  • Figure US20210009555A1-20210114-C00266
    • Synthesis of N—((S)-1-(3-(3-amino-1H-indazol-5-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (46)
  • The title compound (46) was prepared according to the method presented for the synthesis of compound 33F of Example 33 utilizing 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine and 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. 1H NMR (400 MHz, cd3od) δ 8.99 (d), 7.62-7.54 (m),7.51-7.40 (m), 7.33 (d), 6.72-6.62 (m), 6.29-6.22 (m), 5.53-5.43 (m), 4.92 (d), 3.03 (d), 2.60-2.45 (m), 1.63 (s), 1.48-1.37 (m), 1.16-1.04 (m). MS (m/z) 712.1 [M+H]+.
    • Example 47
  • Figure US20210009555A1-20210114-C00267
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(1-methyl-3-(1-methyl-1H-imidazole-4-sulfonamido)-1H-indazol-7-yl)pyridin-2-yl)ethyl)acetamide (47)
  • To a solution of N—((S)-1-(3-(3-amino-1-methyl-H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (25, 10 mg, 0.014 mmol) in dichloromethane (0.2 mL) was added pyridine (6.6 μL, 0.083 mmol), followed by 1-methyl-H-imidazole-4-sulfonyl chloride (3.7 mg, 0.021 mmol). After stirring for 1 h, the reaction mixture was concentrated and purified by reverse phase HPLC to provide the title product as a mixture of atropisomers. 1H NMR (400 MHz, Methanol-d4) δ 7.75 (dd), 7.71-7.63 (m), 7.57-7.48 (m), 7.30 (s), 7.14-7.03 (m), 6.79-6.70 (m), 6.66-6.55 (m), 6.38-6.26 (m), 5.25 (dd), 4.96 (dd), 4.87-4.72 (m), 3.67 (s), 3.46 (s), 3.27 (s), 3.25-3.18 (m), 3.09-3.02 (m), 3.00-2.87 (m), 2.58-2.43 (m), 1.64 (s), 1.64 (s), 1.50-1.37 (m), 1.16-1.06 (m). MS (m/z) 870.10 [M+H]+.
    • Example 48
  • Figure US20210009555A1-20210114-C00268
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(1-methyl-3-(1-methyl-1H-pyrazole-4-sulfonamido)-1H-indazol-7-yl)pyridin-2-yl)ethyl)acetamide (48)
  • The title compound (48) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound (47) of Example 47 utilizing 1-methyl-1H-pyrazole-4-sulfonyl chloride. 1H NMR (400 MHz, Methanol-d4) δ 7.95 (s), 7.77-7.66 (m), 7.61 (s), 7.57-7.48 (m), 7.24-7.18 (m), 7.17-7.10 (m), 7.07 (dd), 6.78-6.68 (m), 6.63 (dd), 6.60-6.50 (m), 6.40-6.26 (m), 5.26 (dd), 5.02 (dd), 4.88-4.71 (m), 3.83 (s), 3.60 (s), 3.29 (s), 3.27-3.21 (m), 3.09-3.01 (m), 3.00-2.87 (m), 2.58-2.39 (m), 1.64 (s), 1.49-1.36 (m), 1.16-1.04 (m). MS (m/z) 870.03 [M+H]+.
    • Example 49
  • Figure US20210009555A1-20210114-C00269
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(1-methyl-3-(1H-pyrazole-4-sulfonamido)-1H-indazol-7-yl)pyridin-2-yl)ethyl)acetamide (49)
  • The title compound (49) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound (47) of Example 47 utilizing 1H-pyrazole-4-sulfonyl chloride. 1H NMR (400 MHz, Methanol-d4) δ 8.74 (d), 8.60 (q), 7.91 (s), 7.83 (s), 7.76-7.63 (m), 7.57-7.47 (m), 7.21 (dd), 7.13 (dd), 7.03 (dd), 6.79-6.68 (m), 6.61-6.50 (m), 6.46 (dd), 6.38-6.25 (m), 5.34-5.22 (m), 5.05-4.94 (m), 4.87-4.78 (m), 3.28 (s), 3.26-3.16 (m), 3.15-3.07 (m), 3.00-2.90 (m), 2.58-2.43 (m), 1.64 (s), 1.64-1.64 (m), 1.49-1.37 (m), 1.17-1.07 (m). MS (m/z) 856.03 [M+H]+.
    • Example 50
  • Figure US20210009555A1-20210114-C00270
    • Synthesis of N—((S)-1-(3-(3-(3-cyclopropylureido)-1-methyl-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (50)
  • To a solution of N—((S)-1-(3-(3-amino-1-methyl-H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (25, 10 mg, 0.014 mmol) and DIPEA (3.5 μL, 0.021 mmol) in dichloromethane (0.1 mL) was added triphosgene (4.5 mg, 0.015 mmol). After stirring for 1 minute cyclopropylamine (3.5 μL, 0.055 mmol) was added. After stirring for 15 minutes, the reaction mixture was concentrated and purified by reverse phase HPLC to provide the title product as a mixture of atropisomers. 1H NMR (400 MHz, Methanol-d4) δ 7.87 (m), 7.68 (dd), 7.53 (dd), 7.23 (dd), 7.13 (dd), 7.02 (dd), 6.77-6.68 (m), 6.63-6.54 (m), 6.49 (dd), 6.38-6.32 (m), 6.32-6.25 (m), 5.25 (dd), 5.01 (t), 4.79 (t), 3.26 (s), 3.25-3.19 (m), 3.14-3.04 (m), 3.00-2.89 (m), 2.73-2.64 (m), 2.56-2.41 (m), 1.64 (s), 1.64 (s), 1.49-1.36 (m), 1.17-1.04 (m), 0.81-0.71 (m), 0.61-0.51 (m). MS (m/z) 809.12 [M+H]−.
    • Example 51
  • Figure US20210009555A1-20210114-C00271
    • Synthesis of N-(7-(2-((S)-1-(2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-1-methyl-1H-indazol-3-yl)-4-methylpiperazine-1-carboxamide (51)
  • The title compound (51) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound (50) of Example 50 utilizing 1-methylpiperazine, 1H NMR (400 MHz, Methanol-d4) δ 7.79-7.66 (m), 7.54 (dd), 7.23 (dd), 7.16 (dd), 7.09 (dd), 6.78-6.68 (m), 6.66-6.57 (m), 6.43-6.36 (m), 6.36-6.28 (m), 5.29 (dd), 5.02 (dd), 4.85-4.71 (m), 4.39 (s), 3.67-3.45 (m), 3.27-3.22 (m), 3.14-3.06 (m), 3.03-2.89 (m), 2.58-2.41 (m), 1.65 (s), 1.64 (s), 1.49-1.36 (m), 1.17-1.10 (m), 1.10-1.04 (m). MS (m/z) 852.11 [M+H]+.
    • Example 52
  • Figure US20210009555A1-20210114-C00272
    • Synthesis of N-(7-(2-((S)-1-(2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-1-methyl-1H-indazol-3-yl)morpholine-4-carboxamide (52)
  • The title compound (52) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound (50) of Example 50 utilizing morpholine. 1H NMR (400 MHz, Methanol-d4) δ 7.77-7.66 (m), 7.54 (dd), 7.22 (dd), 7.15 (dd), 7.08 (dd), 6.77-6.69 (m), 6.66-6.60 (m), 6.58 (dd), 6.42-6.36 (m), 6.36-6.29 (m), 5.32 (dd), 5.03 (dd), 4.85-4.79 (m), 4.79-4.71 (m), 3.74 (dd), 3.61-3.53 (m), 3.27-3.20 (m), 3.15-3.07 (m), 3.02 (s), 3.00-2.90 (m), 2.58-2.41 (m), 1.65 (s), 1.64 (s), 1.49-1.35 (m), 1.16-1.10 (m), 1.10-1.04 (m). MS (m/z) 839.13 [M+H]+.
    • Example 53
  • Figure US20210009555A1-20210114-C00273
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(3-(3-((N-ethylsulfamoyl)amino)-1-methyl-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)ethyl)acetamide (53)
  • The title compound (53) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound (44) of Example 44 utilizing ethyl sulfamoylchloride. 1H NMR (400 MHz, Methanol-d4) δ 8.84-8.74 (m), 7.95-7.85 (m), 7.69 (dd), 7.54 (dd), 7.23 (dd), 7.15 (dd), 7.09 (dd), 6.79-6.69 (m), 6.66-6.56 (m), 6.39-6.34 (m), 6.34-6.26 (m), 5.35-5.25 (m), 5.07-4.98 (m), 4.86-4.71 (m), 3.23 (m), 3.15-3.02 (m), 3.00 (s), 2.98-2.88 (m), 2.58-2.40 (m), 1.65 (s), 1.64 (s), 1.49-1.36 (m), 1.12 (t), 1.10-1.02 (m). MS (m/z) 833.14 [M+H]+.
    • Example 54
  • Figure US20210009555A1-20210114-C00274
    • Synthesis of 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(1-methyl-3-(sulfamoylamino)-1H-indazol-7-yl)pyridin-2-yl)ethyl)acetamide (54)
  • The title compound (54) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 44 of Example 44 utilizing and 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. 1H NMR (400 MHz, cd3od) δ 8.75 (d), 8.01-7.93 (m), 7.72-7.63 (m), 7.53 (dd), 7.28-7.05 (m), 6.87-6.51 (m), 6.34 (m), 5.35-5.25 (m), 5.07-4.96 (m), 4.80-4.65 (m), 3.33 (s), 3.24-2.88 (m), 2.53-2.38 (m), 1.64 (d), 1.45-1.32 (m), 1.13-0.99 (m). MS (m/z) 787.1 [M+H]+.
    • Example 55
  • Figure US20210009555A1-20210114-C00275
    Figure US20210009555A1-20210114-C00276
    • Synthesis of (S)-tert-butyl (1-(3-(3-amino-4-chloro-1-methyl-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (55A)
  • To 19C (1.5 g, 4.8 mmol) in dioxane (100 mL) was added 14B (1.6 g, 3.2 mmol), 1N sodium bicarbonate (8.4 ml, 8.4 mmol), and PdCl2(PCy3)2 (238 mg, 0.3 mmol). The reaction mixture was stirred for 30 minutes at 125° C. The reaction was cooled, diluted with EtOAc and brine. The mixture was extracted 2× with EtOAc, the organic layer was dried over sodium sulfate, was concentrated and purified by flash column chromatography to provide the title compound as a mixture of atropisomers. MS (m/z) 596.7 [M+H]+.
    • Synthesis of (S)-4-(6-(1-amino-2-(3,5-difluorophenyl)ethyl)-5-(3-amino-4-chloro-1-methyl-H-indazol-7-yl)pyridin-2-yl)-2-methylbut-3-yn-2-ol (55B)
  • The title compound (55B) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 19F of Example 19 utilizing 55A. MS (m/z) 496.5 [M+H]+.
    • Synthesis of N—((S)-1-(3-(3-amino-4-chloro-1-methyl-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-ylacetamide (55C)
  • The title compound (55C) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 10A of Example 10 utilizing 55B and 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. 1H NMR (400 MHz, Methanol-d4) δ 8.83-8.69 (m), 7.65 (d), 7.53 (d), 7.13-7.06 (m), 7.07-6.99 (m), 6.96 (d), 6.81-6.71 (m), 6.67-6.56 (m), 6.48-6.39 (m), 6.41-6.30 (m), 5.30-5.19 (m), 5.07-4.96 (m), 4.83-4.71 (m), 3.27-3.22 (m), 3.17 (s), 3.10 (s), 3.04-2.91 (m), 2.81 (s), 2.61-2.39 (m), 1.63 (s), 1.49-1.37 (m), 1.37-1.24 (m), 1.23-1.00 (m). MS (m/z) 760.3 [M+H]+.
    • Example 56
  • Figure US20210009555A1-20210114-C00277
    Figure US20210009555A1-20210114-C00278
    • Synthesis of 2,5-dioxopyrrolidin-1-yl 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetate (56A)
  • To a stirring solution of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid (1.00 g, 3.54 mmol), N-hydroxysuccinimide (0.61 g, 5.32 mmol), and pyridine (0.968 mL, 12.1 mmol) was added dropwise at −5° C. thionyl chloride (0.439 mL, 6.02 mmol). After stirring at −5° C. for 20 min, 2.0M aqueous NaCl (10 mL) was added and the product was extracted with two portions of ethyl acetate (12 mL). The combined organic layers were dried over Na2SO4, filtered, concentrated in vacuo, and purified by silica gel column chromatography to give the title compound. 1H NMR (400 MHz, DMSO-d) δ 5.88-5.63 (m, 4H), 2.77-2.55 (m, 2H), 1.56-1.31 (m, 2H), 1.12-0.98 (m, 2H).
    • Synthesis of N-(7-bromo-1-methyl-1H-indazol-3-yl)-4-methylpiperazine-1-sulfonamide (56B)
  • To a stirring solution of 7-bromo-1-methyl-1H-indazol-3-amine (33A, 250 mg, 1.11 mmol) and DABCO (310 mg, 2.77 mmol) in acetonitrile was added 4-methylpiperazine-1-sulfonyl chloride HCl (650 mg, 2.77 mmol). After stirring at 50° C. for 3 h, the reaction was concentrated, diluted with water and extracted with ethyl acetate. The organic layer was dried over Na2SO4, filtered, concentrated in vacuo, and purified by silica gel column chromatography to give the title compound. MS (m/z) 387.97 [M+H]+.
    • Synthesis of 4-methyl-N-(1-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-yl)piperazine-1-sulfonamide (56C)
  • The title compound (56C) was prepared according to the method presented for the synthesis of compound (19D) of Example 19 utilizing N-(7-bromo-1-methyl-H-indazol-3-yl)-4-methylpiperazine-1-sulfonamide (56B). MS (m/z) 436.18 [M+H]+.
    • Synthesis of (S)-tert-butyl (2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(1-methyl-3-(4-methylpiperazine-1-sulfonamido)-1H-indazol-7-yl)pyridin-2-yl)ethyl)carbamate (56D)
  • The title compound (56D) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound (19E) of Example 19 utilizing 4-methyl-N-(1-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-yl)piperazine-1-sulfonamide (56C).
    • Synthesis of (S)—N-(7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-1-methyl-1H-indazol-3-yl)-4-methylpiperazine-1-sulfonamide (56E)
  • The title compound (56E) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound (14C) of Example 14 utilizing (S)-tert-butyl (2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(1-methyl-3-(4-methylpiperazine-1-sulfonamido)-1H-indazol-7-yl)pyridin-2-yl)ethyl)carbamate (56D). The resulting crude product was basified to pH-8 with 1M aqueous NaHCO3 and extracted with ethyl acetate. The organic layer was dried over Na2SO4, filtered, concentrated in vacuo, and taken to the next step without further purification.
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(1-methyl-3-(4-methylpiperazine-1-sulfonamido)-1H-indazol-7-yl)pyridin-2-yl)ethyl)acetamide (56F)
  • To a solution of crude (S)—N-(7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-1-methyl-H-indazol-3-yl)-4-methylpiperazine-1-sulfonamide (56E, 62.9 mg, 0.101 mmol assuming 100% purity) and DIPEA (17.5 μL, 0.101 mmol) in acetonitrile (2 mL) was 2,5-dioxopyrrolidin-1-yl 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetate (56A, 38.3 mg, 0.101 mmol). After stirring for 1 h, the reaction mixture was filtered and purified by reverse phase HPLC to provide the title product as a mixture of atropisomers. 1H NMR (400 MHz, Methanol-d4) 8.01 (dd), 7.87-7.77 (m), 7.73-7.52 (m), 7.28-7.15 (m), 6.95 (dd), 6.76-6.61 (m), 6.46-6.41 (m), 6.19-6.11 (m), 5.24 (dd), 5.03-4.90 (m), 4.78 (d), 3.91-3.67 (m), 3.36 (s), 3.13 (dq), 3.00 (s), 2.94-2.87 (m), 2.75 (dd), 2.70 (s), 2.60-2.45 (m), 1.65 (s), 1.64 (s), 1.49-1.38 (m), 1.15-0.94 (m). MS (m/z) 888.35 [M+H]+.
    • Example 57
  • Figure US20210009555A1-20210114-C00279
    • Synthesis of N—((S)-1-(3-(3-amino-4-chloro-1-methyl-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (57)
  • The title compound (57) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 10A of Example 10 utilizing 55B and 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. 1H NMR (400 MHz, Chloroform-d) δ 8.02 (s), 7.54-7.37 (m), 7.10 (d), 7.07-6.99 (m), 6.75 (d), 6.72 (t), 6.67-6.56 (m), 6.51-6.44 (m), 6.25-6.13 (m), 6.02 (d), 5.56 (q), 5.01 (td), 4.75-4.69 (m), 3.08 (s), 2.98-2.86 (m), 2.80 (s), 2.55-2.39 (m), 1.71 (s), 1.42 (q), 1.22-1.14 (m). MS (m/z) 742.8 [M+H]+.
    • Example 58
  • Figure US20210009555A1-20210114-C00280
    Figure US20210009555A1-20210114-C00281
    • Synthesis of 7-bromo-4-iodo-1-methyl-1H-indazol-3-amine (58B)
  • The title compound (58B) was prepared according to the method presented for the synthesis of compound 19B of Example 19 utilizing 58A. MS (m/z) 352.4 [M+H]+.
    • Synthesis of 7-bromo-1,4-dimethyl-1H-indazol-3-amine (58C)
  • To 58B (3.0 g, 8.5 mmol) in dioxane (10 mL) and DMF (10 ml) was added Trimethylboroxine (4.8 ml, 34.1 mmol), 2M K2CO3 in water (8.5 ml), and Pd(PPh3)2Cl2 (600 mg, 0.8 mmol). The reaction mixture was stirred for 5 hours at 160° C. The reaction was cooled, diluted with EtOAc and brine. The mixture was extracted 2× with EtOAc, the organic layer was dried over sodium sulfate, concentrated and purified by flash column chromatography to provide the title compound. MS (m/z) 240.1 [M+H]+.
    • Synthesis of 1,4-dimethyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (58D)
  • The title compound (58D) was prepared according to the method presented for the synthesis of compound 19C of Example 19 utilizing 58C. MS (m/z) 288.2 [M+H]+.
    • Synthesis of (S)-tert-butyl (1-(3-(3-amino-1,4-dimethyl-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (58E)
  • The title compound (58E) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 19E of Example 19 utilizing 58D. MS (m/z) 576.2 [M+H]+.
    • Synthesis of (S)-4-(5-(3-amino-1,4-dimethyl-1H-indazol-7-yl)-6-(1-amino-2-(3,5-difluorophenyl)ethyl)pyridin-2-yl)-2-methylbut-3-yn-2-ol (58F)
  • The title compound (58F) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 19F of Example 19 utilizing 58E. MS (m/z) 476.1 [M+H]+.
    • Synthesis of N—((S)-1-(3-(3-amino-1,4-dimethyl-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (58G)
  • The title compound (58G) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 10A of Example 10 utilizing 58F and 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. 1H NMR (Methanol-d4) δ: 8.68-8.57 (m), 7.69-7.45 (m), 7.06 (d), 6.85 (d), 6.80 (d), 6.76-6.66 (m), 6.66-6.53 (m), 6.45 (d), 6.38 (d), 6.31 (d), 5.26 (s), 5.08-4.98 (m), 4.73 (d), 3.27-3.19 (m), 3.16 (s), 3.06 (dd), 2.91 (dd), 2.84 (s), 2.74-2.66 (m), 2.53-2.38 (m), 1.64 (d), 1.43-1.24 (m), 1.12-0.98 (m). MS (m/z) 722.2 [M+H]+.
    • Example 59
  • Figure US20210009555A1-20210114-C00282
    • Synthesis of (R)-tert-butyl 4-((5-bromo-6-((S)-1-(2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)pyridin-2-yl)ethynyl)-2,2-dimethyloxazolidine-3-carboxylate (59A)
  • The title compound was prepared similarly to compound 14D in example 14 utilizing (R)-tert-butyl 4-ethynyl-2,2-dimethyloxazolidine-3-carboxylate instead of 2-methylbut-3-yn-2-ol. MS (m/z) 799 [M−H]−.
    • Synthesis of N—((S)-1-(6-((R)-3-amino-4-hydroxybut-1-yn-1-yl)-3-(1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (59B)
  • To a solution of 59A (110 mg, 0.13 mmol) in dioxane (3 mL) was added 20C (67 mg, 0.19 mmol), sodium bicarbonate (1M, 0.41 mL) followed by PdCl2[P(Ph)3]2 (4.8 mg, 0.06 mmol). The reaction was sealed and heated in a microwave reactor for 20 min at 150° C. Upon cooling, the reaction mixture was first diluted with EtOAc and washed with brine (2×10 mL), dried over Na2SO4, filtered and concentrated. The crude material purified by reverse phase HPLC. Fractions containing the product were pooled and treated with neat TFA to give the title compound 59B as a mixture of atropisomers. 1H NMR (400 MHz, cd3od) δ 7.89-7.73 (m), 7.69-7.60 (m), 7.32-7.27 (m), 7.25-7.15 (m), 7.10-7.07 (m), 6.80-6.70 (m), 6.69-6.47 (m), 6.50 (d), 6.40-6.28 (m), 5.32-5.25 (m), 5.05-4.96 (m), 4.80-4.72 (d), 4.52-4.44 (m), 4.09-3.98 (m), 3.94-3.84 (m), 3.21-3.08 (m), 3.05-2.89 (m), 2.59-2.37 (m), 1.46-1.35 (m), 1.11 (s), 1.04 (s). MS (m/z) 805.1 [M+H]+.
    • Example 60
  • Figure US20210009555A1-20210114-C00283
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(1-methyl-1H-pyrazol-4-yl)-3-(1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)ethyl)acetamide (60)
  • In a microwave tube were charged with compound 61A (20 mg, 0.026 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (11 mg, 0.053 mmol) and PdCl2[PPh3]2 (2 mg, 0.003 mmol). To the mixture was added 0.5 mL of 1,4-dioxane and 0.1 mL of sodium bicarbonate aqueous solution (1M). The mixture was heated to 120° C. for 4 minutes in a microwave synthesizer. After cooled to room temperature, it was partitioned between EtOAc and water. The organic layer was separated and washed with brine, then dried over MgSO4, filtered and concentrated. The residue was purified by reverse phase HPLC to afford the title compound 60 as a mixture of atropisomers. 1H NMR (400 MHz, Methanol-d4) δ 8.43-8.29 (m), 8.28-8.09 (m), 7.91-7.72 (m), 7.76-7.58 (m), 7.15-7.00 (m), 6.82-6.68 (m), 6.53 (dd), 6.36-6.14 (m), 5.39-5.18 (m), 5.08-4.91 (m), 4.84 (d), 4.02 (d), 3.38 (s), 3.23-3.14 (m), 3.14 (s), 3.01 (d), 2.93 (dd), 2.63-2.30 (m), 1.50-1.26 (m), 1.17-0.79 (m). MS (m/z): 802.16 [M+H]+
    • Example 61
  • Figure US20210009555A1-20210114-C00284
    • Synthesis of N—((S)-1-(6-chloro-3-(1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (61A)
  • The title compound (61A) was prepared according to the method presented for the synthesis of compound 157F of Example 157 utilizing N-(1-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-yl)methanesulfonamide (33C) instead of 19D. MS (m/z) 756.1 [M+H]+.
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-(dimethylamino)prop-1-yn-1-yl)-3-(1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)ethyl)acetamide (61B)
  • To the reaction vial containing 61A (20 mg, 0.026 mmol) in DMF (0.2 mL) was added N,N-dimethylprop-2-yn-1-amine (11 mg, 0.13 mmol), PdCl2[P(Ph)3]2 (1.87 mg, 0.003 mmol), and diethylamine (0.02 mL, 0.26 mmol). The reaction mixture was flushed with argon gas for 5 min then sealed and heated in a microwave reactor to 125° C. for 15 min. Upon cooling, the reaction mixture was filtered and purified by reverse phase HPLC to provide the title product as a mixture of atropisomers. 1H NMR δ 8.70 (m), 7.90-7.76 (m), 7.70 (d), 7.16 (m), 6.75 (tt), 6.57 (dd), 6.41-6.28 (m), 5.35-5.25 (m), 5.08-4.97 (m), 4.82-4.68 (m), 4.47 (d), 3.30-3.06 (m), 3.05-2.88 (m), 2.54-2.43 (m), 1.48-1.35 (m), 1.15-1.11 (m), 1.09-1.00 (m). MS (m/z) 803.2 [M+H]+.
    • Example 62
  • Figure US20210009555A1-20210114-C00285
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N-((1S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3,4-dimethylpent-1-yn-1-yl)-3-(1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)ethyl)acetamide (62)
  • The title compound (62) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 61 of Example 61 utilizing 3,4-dimethylpent-1-yn-3-ol. 1H NMR (400 MHz, cd3od) δ 8.73 (m), 7.83-7.79 (m), 7.75-7.70 (m), 7.60-7.54 (m), 7.277.12 (m), 7.05 (t), 6.65 (t), 6.61 (t), 6.52 (t), 6.35-6.21 (m), 5.35-5.21 (m), 5.06-4.97 (m), 4.85-4.70 (m), 3.34 (s), 3.20-3.08 (m), 3.01-2.88 (m), 2.56-2.38 (m), 2.01-1.89 (m), 1.60-1.54 (d), 1.46-1.34 (m), 1.21-1.09 (m), 1.08-1.03 (m). MS (m/z) 832.1 [M+H]+.
    • Example 63
  • Figure US20210009555A1-20210114-C00286
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(4-hydroxy-3,3-dimethylbut-1-yn-1-yl)-3-(1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)ethyl)acetamide (63)
  • The title compound (63) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 61 of Example 61 utilizing 2,2-dimethylbut-3-yn-1-ol. 1H NMR (400 MHz, cd3od) δ 8.65 (d), 7.83 (m), 7.66 (dd), 7.51 (dd), 7.08 (dd), 6.73 (tt), 6.50 (dt), 6.38-6.26 (m), 5.35-5.25 (m), 4.98 (t), 4.85-4.71 (m), 3.57 (s), 3.33 (s), 3.15 (d), 3.04-2.87 (m), 2.54-2.43 (m), 1.36 (s), 1.12-1.02 (m). MS (m/z) 818.2 [M+H]+.
    • Example 64
  • Figure US20210009555A1-20210114-C00287
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N-((1S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-4-methylpent-1-yn-1-yl)-3-(1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)ethyl)acetamide (64)
  • The title compound (64) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 61 of Example 61 utilizing 4-methylpent-1-yn-3-ol. 1H NMR (400 MHz, cd3od) δ 8.74 (d), 8.67 (d), 7.88-7.79 (m), 7.75-7.66 (m), 7.60-7.50 (m), 7.14-7.05 (m), 6.78-6.68 (m), 6.53 (ddt), 6.41-6.29 (m),5.31-5.25 (m), 5.06-4.95 (m), 4.78 (d), 4.45-4.38 (m), 3.34 (s), 3.15 (d), 3.03-2.88 (m), 2.55-2.43 (m), 2.06-1.91 (m), 1.39 (q), 1.18-1.10 (m), 1.07 (d). MS (m/z) 818.1 [M+H]+.
    • Example 65
  • Figure US20210009555A1-20210114-C00288
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(3-(1-methyl-3-(1-methyl-1H-imidazole-4-sulfonamido)-1H-indazol-7-yl)-6-vinylpyridin-2-yl)ethyl)acetamide (65)
  • Argon was bubbled through a solution of N—((S)-1-(6-chloro-3-(1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (61A, 100 mg, 0.13 mmol), potassium vinyltrifluoroborate (35.4 mg, 0.26 mmol), dichloro 1,1′-bis(diphenylphosphino)ferrocene palladium (II) dichloromethane (10.8 mg, 0.01 mmol), and triethylamine (0.06 ml, 0.43 mmol) in EtOH (2.6 ml) for 5 mins. The reaction was heated in a microwave reactor at 150° C. for 20 mins. The product was solid loaded onto silica and purified by silica gel chromatography followed by re-purification by reverse phase HPLC to provide the title product as a mixture of atropisomers. 1H NMR (400 MHz, Methanol-d4) δ 7.85-7.78 (m), 7.67-7.62 (m), 7.55-7.48 (m), 7.24-7.14 (m), 7.11-7.05 (m), 7.04-6.94 (m), 6.76-6.67 (m), 6.64-6.56 (m), 6.56-6.34 (m), 6.33-6.24 (m), 5.67-5.58 (m), 5.31-5.23 (m), 5.03-4.95 (m), 4.86-4.75 (m), 3.34 (s), 3.32-3.28 (m), 3.24-3.09 (m), 3.02-2.85 (m),2.57-2.41 (m), 1.41 (m), 1.35-1.24 (m), 1.17-1.10 (m), 1.10-1.03 (m). MS (m/z) 748.15 [M+H]+.
    • Example 66
  • Figure US20210009555A1-20210114-C00289
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-ethyl-3-hydroxypent-1-yn-1-yl)-3-(1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)ethyl)acetamide (66)
  • The title compound (66) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 61 of Example 61 utilizing 3-ethylpent-1-yn-3-ol. 1H NMR (400 MHz, cd3od) δ 7.83 (td), 7.74-7.65 (m), 7.54 (dd), 7.28-7.05 (m), 6.78-6.67 (m), 6.62 (s), 6.54 (dd), 6.35 (ddd), 5.00 (t), 5.32-5.25 (m), 4.84-4.70 (m), 3.34 (s), 3.15 (d), 3.03-2.88 (m), 2.55-2.42 (m), 1.93-1.73 (m), 1.41 (dq), 1.16 (td), 1.10-1.01 (m). MS (m/z) 832.1 [M+H]+.
    • Example 67
  • Figure US20210009555A1-20210114-C00290
    Figure US20210009555A1-20210114-C00291
    • Synthesis of 1-(allyloxy)but-3-en-2-ol (67B)
  • The epoxide 67A (3.5 g, 50 mmol) and allyl alcohol (5.8 g, 100 mmol) were dissolved in DMF (100 mL) in a pressure bottle. After cooled to 0° C., NaH (60% suspension in mineral oil, 2.4 g) was added portionwise, stirred for 20 min under argon. The bottle was sealed and heated at 60° C. overnight. The reaction was cooled to 0° C. in an ice bath, quenched with 100 mL 2N HCl. The aqueous layer was extracted 3 times with ether (3×100 mL). The combined ether were washed with 5% LiCl and brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column to yield the title compound 67B. 1H NMR (400 MHz, Chloroform-d) δ 6.00-5.74 (m, 2H), 5.45-5.08 (m, 4H), 4.31 (tdd, J=7.0, 3.2, 1.5 Hz, 1H), 4.02 (dt, J=5.7, 1.4 Hz, 2H), 3.49 (dd, J=9.7, 3.4 Hz, 1H), 3.32 (dd, J=9.7, 7.9 Hz, 1H), 2.56 (s, 1H).
    • Synthesis of 3,6-dihydro-2H-pyran-3-ol (67C)
  • The title compound (67C) was prepared according to reference: Angew. Chem. Intl. Ed. 2005, 44, 5306-5310. 1H NMR data: 1H NMR (400 MHz, Chloroform-d) δ 6.06-5.81 (m, 2H), 4.19-3.99 (m, 2H), 3.98-3.89 (m, 1H), 3.86-3.66 (m, 2H), 2.77-2.57 (m, 1H).
    • Synthesis of 2H-pyran-3(6H)-one (67D)
  • The title compound (67D) was prepared according to reference: Angew. Chem. Intl. Ed. 2005, 44, 5306-5310.
    • Synthesis of 3-oxabicyclo[4.1.0]heptan-5-one (67E)
  • To a suspension of NaH (60% in mineral oil, 0.19 g) in DMSO (20 mL) was added trimethylsulfonium iodide (1.75 g, 8 mmol) at room temperature. After stirring for 15 min, a solution of 67D (0.6 g, 6 mmol) in DMSO (5 mL) was added. After stirring at room temperature for 5 min, the reaction mixture was diluted with ethyl acetate and washed with 5% LiCl aqueous solution. The organic layers were dried over Na2SO4, filtered, concentrated in vacuo, and purified by silica gel column chromatography to give the title compound. 1H NMR (400 MHz, Chloroform-d) δ 4.22-4.03 (m, 2H), 3.80 (s, 1H), 3.76 (d, J=6.0 Hz, 1H), 1.95 (ddd, J=9.8, 7.5, 4.7 Hz, 1H), 1.85-1.71 (m, 2H), 1.23 (ddd, J=9.8, 7.1, 4.4 Hz, 1H).
    • Synthesis of 3-(trifluoromethyl)-5,5a,6,6a-tetrahydro-1H-cyclopropa[4,5]pyrano[3,2-c]pyrazole (67F)
  • A solution of compound 67E (90 mg, 0.8 mmol) and ethyl trifluoroacetate (0.16 g, 1.2 mmol) in ether was cooled to −78° C. LiHMDS (0.18 g, 1 mmol) was added in one portion. The resulting mixture was stirred at −78° C. for 2 h. The reaction was poured into 1 N HCl aqueous solution and the aqueous layer was extracted with ether. The organic layers were dried over Na2SO4, filtered, concentrated in vacuo to give the title compound which was used without further purification. MS (m/z) 209.06 [M+H]+.
  • To a solution of crude from last step in ethanol (20 mL) was added concentrated sulfuric acid (0.5 mL) and hydrazine monohydrate (1 mL). The resulting mixture was heated at 90° C. for 5 min. Upon completion of the reaction, the volatiles were removed in vacuo to give the title compound which was used in the next step. MS (m/z) 205.18 [M+H]+.
    • Synthesis of ethyl 2-(3-(trifluoromethyl)-5,5a,6,6a-tetrahydro-1H-cyclopropa[4,5]pyrano[3,2-c]pyrazol-1-yl)acetate (67G)
  • To a solution of compound 67F (100 mg, 0.49 mmol) in DMF (2 mL) was added bromoethyl acetate (98 mg, 0.59 mmol) and cesium carbonate (160 mg, 0.5 mmol) at 0° C. The reaction was heated at 50° C. overnight. Upon cooling, the mixture was purified by reverse phase HPLC to give the title compound. MS (m/z) 291.19 [M+H]+.
    • Synthesis of 2-(3-(trifluoromethyl)-5,5a,6,6a-tetrahydro-1H-cyclopropa[4,5]pyrano[3,2-c]pyrazol-1-yl)acetic acid (67H)
  • To a solution of compound 67G (16 mg, 0.055 mmol) in a mixture of THF:water:MeOH (1 mL: 0.5 mL: 0.5 mL) was added solid LiOH monohydrate (7 mg, 0.165 mmol) at 0° C. After stirring at room temperature for 10 min, the reaction mixture was poured into EtOAc and the organic was washed with 2 N HCl. The organic layers were dried over Na2SO4, filtered, concentrated in vacuo to give the title compound which was used in the next step. MS (m/z) 263.04 [M+H]+.
    • Synthesis of N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)ethyl)-2-(3-(trifluoromethyl)-5,5a,6,6a-tetrahydro-1H-cyclopropa[4,5]pyrano[3,2-c]pyrazol-1-yl)acetamide (671)
  • The title compound (671) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 10A of Example 10 utilizing 2-(3-(trifluoromethyl)-5,5a,6,6a-tetrahydro-1H-cyclopropa[4,5]pyrano[3,2-c]pyrazol-1-yl)acetic acid (67H) and compound 33E. 1H NMR (400 MHz, Methanol-d4) δ 7.93-7.78 (m), 7.75-7.65 (m), 7.61-7.45 (m), 7.39-6.98 (m), 6.73 (tq), 6.68-6.56 (m), 6.34 (tdd), 5.43-4.93 (m), 4.83-4.71 (m), 4.30-3.97 (m), 3.22-3.00 (m), 3.02-2.76 (m), 2.10-1.70 (m), 1.16 (dddd), 0.86-0.64 (m). MS (m/z) 784.34 [M+H]+.
    • Example 68
  • Figure US20210009555A1-20210114-C00292
    Figure US20210009555A1-20210114-C00293
    • Synthesis of N-(7-bromo-1-methyl-H-indazol-3-yl)-2,2,2-trifluoroacetamide (68A)
  • To a solution of 7-bromo-1-methyl-1H-indazol-3-amine (33A, 500 mg, 2.21 mmol) and N,N-diisopropylethylamine (0.578 mL, 3.32 mmol) in dichloromethane (5 ml) was added dropwise at 0° C. trifluoroacetic anhydride (697 mg, 3.32 mmol). The reaction was warmed to room temperature and stirred for 30 min. The reaction mixture was washed with water. The aqueous layer was back-extracted with dichloromethane. The combined organic layers were dried over Na2SO4, filtered, concentrated in vacuo, and purified by silica gel column chromatography to give the title compound. 1H NMR (400 MHz, Chloroform-d) δ 8.51 (s, 1H), 7.87 (d, 1H), 7.60 (d, 1H), 7.01 (t, 1H), 4.37 (s, 3H).
    • Synthesis of N-(7-bromo-1-methyl-1H-indazol-3-yl)-2,2,2-trifluoro-N-methylacetamide (68B)
  • To a stirred solution of N-(7-bromo-1-methyl-H-indazol-3-yl)-2,2,2-trifluoroacetamide (68A, 100 mg, 0.31 mmol) in DMF (0.6 ml) was added potassium t-butoxide (36.6 mg, 0.33 mmol). The reaction was sonicated until the solution became homogeneous and the reaction was stirred at room temperature for 30 mins. To the reaction was added iodomethane (29 μL, 0.47 mmol). After stirring for 1 h, the reaction was diluted with ethyl acetate and washed with water, followed by 0.5M aqueous NaCl. The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The crude product was used in the next step without further purification.
    • Synthesis of 7-bromo-N,1-dimethyl-1H-indazol-3-amine (68C)
  • To a solution of N-(7-bromo-1-methyl-H-indazol-3-yl)-2,2,2-trifluoro-N-methylacetamide (68B, 104 mg) in methanol (3 ml) was added 8M NaOH (46.6 μl). After stirring for 30 mins, the solution was concentrated, extracted with ethyl acetate (4 mL) and washed water (4 mL), followed by 2M aqueous NaCl (4 mL). The organic layer was dried over Na2SO4, filtered, and concentrated in vacuo. The crude product was used in the next step without further purification. MS (m/z) 240.15 [M+H]+.
    • Synthesis of N,1-dimethyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (68D)
  • The title compound (68D) was prepared according to the method presented for the synthesis of compound 19C of Example 19 utilizing 7-bromo-N,1-dimethyl-1H-indazol-3-amine (68C). MS (m/z) 288.22 [M+H]+.
    • Synthesis of ((S)-tert-butyl (2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(1-methyl-3-(methylamino)-1H-indazol-7-yl)pyridin-2-yl)ethyl)carbamate (68E)
  • The title compound (68E) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 55A of Example 55 utilizing N,1-dimethyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (68D). MS (m/z) 576.06 [M+H]+.
    • Synthesis of (S)-4-(6-(1-amino-2-(3,5-difluorophenyl)ethyl)-5-(1-methyl-3-(methylamino)-1H-indazol-7-yl)pyridin-2-yl)-2-methylbut-3-yn-2-ol (68F)
  • The title compound (68F) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 14C of Example 14 utilizing ((S)-tert-butyl (2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(1-methyl-3-(methylamino)-1H-indazol-7-yl)pyridin-2-yl)ethyl)carbamate (68E). MS (m/z) 476.13 [M+H]+.
    • Synthesis of 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(I-methyl-3-(methylamino)-1H-indazol-7-yl)pyridin-2-yl)ethyl)acetamide (68G)
  • The title compound (68G) was prepared according to the method presented for the synthesis of compound 33F of Example 33 utilizing (S)-4-(6-(1-amino-2-(3,5-difluorophenyl)ethyl)-5-(1-methyl-3-(methylamino)-1H-indazol-7-yl)pyridin-2-yl)-2-methylbut-3-yn-2-ol (68F) and 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. 1H NMR (400 MHz, Methanol-d4) δ 7.90-7.86 (m), 7.86-7.80 (m), 7.71 (dd), 7.55 (dd), 7.34 (d), 7.22-7.12 (m), 6.84-6.77 (m), 6.77-6.70 (m), 6.70-6.67 (m), 6.66-6.62 (m), 6.56 (s), 6.54 (s), 6.47-6.41 (m), 6.36-6.29 (m), 5.22 (dd), 5.05 (t), 4.76 (d), 4.71 (s), 3.30-3.22 (m), 3.14-3.03 (m), 3.03-2.91 (m), 2.85 (s), 2.46 (ddt), 1.64 (s), 1.44-1.33 (m), 1.11-0.97 (m). MS (m/z) 722.18 [M+H]+.
    • Example 69
  • Figure US20210009555A1-20210114-C00294
    • Synthesis of N—((S)-1-(3-(3-aminobenzo[d]isoxazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (69)
  • The title compound (69) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 33F of Example 33 utilizing tert-butyl (7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]isoxazol-3-yl)carbamate and 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. 1H NMR (400 MHz, cd3od) δ 7.80 (dd), 7.69 (d), 7.54-7.40 (m), 7.33 (dt), 6.57 (ddd), 6.36-6.27 (m), 5.31 (t), 4.82 (s), 3.13-2.96 (m), 2.52-2.43 (m), 1.63 (s), 1.45-1.35 (m), 1.15-1.07 (m). MS (m/z) 713.3 [M+H]+.
    • Example 70
  • Figure US20210009555A1-20210114-C00295
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(sulfamoylamino)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (70)
  • Compound 57 (20 mg, 0.03 mmol) was dissolved in ACN (0.5 ml) and cooled in a salt-ice bath to −10° C. The reaction solution was treated with DABCO (6 mg, 0.05 mmol) then a solution of sulfamoyl chloride (5 mg, 0.04 mmol) in ACN (0.2 ml) and let warm to ambient temperature. After 1 h, an additional aliquot of DABCO (2 eq) and sulfamoyl chloride (1.5 eq) were added. After another 1.5 hr, the reaction was diluted with KH2PO4 buffer and partitioned between brine and EtOAc. The organics were separated, dried, and removed in vacuo. The residue was purified by reverse phase HPLC to provide the title compound as a mixture of atropisomers. 1H NMR (400 MHz, Methanol-d4) δ 8.69 (d), 7.68 (dd), 7.53 (dd), 7.19-7.10 (m), 7.06 (d), 6.87-6.52 (m), 6.49-6.31 (m), 5.35-5.22 (m), 5.05-4.94 (m), 4.79-4.65 (m), 3.24 (dd), 3.12 (dd), 3.04-2.91 (m), 2.45 (ddt), 1.64 (d), 1.44-1.32 (m), 1.12-0.99 (m). MS (m/z) 820.9 [M+H]+.
    • Example 71
  • Figure US20210009555A1-20210114-C00296
    • Synthesis of 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(3-(1,4-dimethyl-3-(sulfamoylamino)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)ethyl)acetamide (71)
  • The title compound (71) was prepared as a mixture of atropisomers according to the method presented for the synthesis of 70 in Example 70 utilizing compound 58. 1H NMR (400 MHz, Methanol-d4) δ 8.71-8.54 (m), 7.73-7.60 (m), 7.57-7.45 (m), 7.08 (d), 7.00-6.89 (m), 6.89-6.77 (m), 6.77-6.64 (m), 6.66-6.56 (m), 6.54 (s), 6.44 (d), 6.41-6.33 (m), 6.33-6.25 (m), 5.40-5.29 (m), 5.08-4.94 (m), 4.75-4.67 (m), 3.12-2.86 (m), 2.86-2.74 (m), 2.54-2.35 (m), 1.44-1.29 (m), 1.12-0.98 (m). MS (m/z) 801.0 [M+H]+.
    • Example 72
  • Figure US20210009555A1-20210114-C00297
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(1H-indazol-4-yl)pyridin-2-yl)ethyl)acetamide (72)
  • The title compound (72) was prepared according to the method presented for the synthesis of compound 33F of Example 33 utilizing 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole and 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. 1H NMR (400 MHz, cd3od) δ 8.74 (d), 8.61 (m), 7.63 (dd), 7.56-7.46 (m), 7.39 (dd), 7.32 (dd), 6.99 (d), 6.72 (tt), 6.56-6.45 (m), 6.31 (d), 6.27-6.20 (m), 5.44-5.34 (m), 5.10-4.99 (m), 4.93-4.83 (m), 4.76 (s), 3.18-3.04 (m), 2.97-2.83 (m), 2.58-2.42 (m), 1.86 (s), 1.67-1.57 (m), 1.48-1.33 (m), 1.15 (s), 1.08 (s). MS (m/z) 697.2 [M+H]+.
    • Example 73
  • Figure US20210009555A1-20210114-C00298
    • Synthesis of N—((S)-1-(3-(1-aminoisoquinolin-5-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (73)
  • The title compound (73) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 33F of Example 33 utilizing 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinolin-1-amine and 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid, 1H NMR (400 MHz, cd3od) δ 8.89 (d), 8.76 (d), 8.47 (d), 7.90-7.84 (m), 7.81-7.73 (m), 7.68-7.50 (m), 7.32 (dd), 7.07 (dd), 6.81-6.69 (m), 6.63-6.53 (m), 6.48 (dd), 6.35-6.25 (m), 6.05 (dd), 5.07 (td), 4.86-4.71 (m), 3.25-3.09 (m), 3.03-2.92 (m), 2.55-2.45 (m), 1.65 (s), 1.48-1.38 (m), 1.16-1.07 (m). MS (m/z) 723.3 [M+H]+.
    • Example 74
  • Figure US20210009555A1-20210114-C00299
    • Synthesis of N-(7-bromo-1-methyl-1H-indazol-3-yl)-N-(2,2-difluoroethyl)-2,2,2-trifluoroacetamide (74A)
  • To N-(7-bromo-1-methyl-1H-indazol-3-yl)-2,2,2-trifluoroacetamide (150 mg, 0.47 mmol) in DCE (2 ml) was added iPr2NEt (0.122 ml, 0.7 mmol) followed by 2,2-difluoroethyl trifluoromethanesulfonate (100 mg, 0.47 mmol). The reaction was stirred 15 h at ambient temperature. The reaction was partitioned between EtOAc and water. The organics were separated, dried, and removed in vacuo to provide the title compound which was used directly in the next reaction. MS (m/z) 387.9 [M+H]+.
    • Synthesis of 7-bromo-N-(2,2-difluoroethyl)-1-methyl-1H-indazol-3-amine (74B)
  • N-(7-bromo-1-methyl-1H-indazol-3-yl)-N-(2,2-difluoroethyl)-2,2,2-trifluoroacetamide (0.18 g, 0.47 mmol) was dissolved in MeOH (2 ml) and treated with aqueous NaOH (1M, 3 ml). After 10 min, the reaction was neutralized and partitioned between EtOAc and 20% aqueous KH2PO4. The organics were separated, dried, and removed in vacuo to provide the title compound which was used directly in the next reaction. MS (m/z) 290.1 [M+H]+.
    • Synthesis of N-(2,2-difluoroethyl)-1-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (74C)
  • The title compound (74C) was prepared according to the method presented for the synthesis of 27D in Example 27 utilizing 74B. MS (m/z) 338.1 [M+H]+.
  • Figure US20210009555A1-20210114-C00300
    • Synthesis of N—((S)-1-(3-(3-((2,2-difluoroethyl)amino)-1-methyl-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (74D)
  • The title compound (36C) was prepared as a mixture of atropisomers according to the method presented for the synthesis of 27G in Example 27 utilizing 14B and 74C. 1H NMR (400 MHz, Methanol-d4) δ 7.75 (d), 7.67 (dd), 7.52 (dd), 7.18 (d), 7.04 (t), 6.95 (t), 6.85-6.49 (m), 6.39-6.26 (m), 6.26-6.20 (m), 6.12-6.04 (m), 5.99-5.91 (m), 5.32-5.22 (m), 5.05 (t), 4.74 (s), 3.79-3.56 (m), 3.23-3.11 (m), 3.07 (dd), 3.00-2.89 (m), 2.88 (s), 2.54-2.38 (m), 1.64 (s), 1.44-1.27 (m), 1.13-0.94 (m).
  • MS (m/z) 772.5 [M+H]+.
    • Example 75
  • Figure US20210009555A1-20210114-C00301
    • Synthesis of 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(3-(4-fluoro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)ethyl)acetamide (75)
  • The title compound (75) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 132C of Example 132 utilizing 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. 1H NMR (400 MHz, cd3od) δ 8.68 (dd), 7.72-7.65 (m), 7.54 (d), 7.51 (d), 7.21 (dd), 6.87-6.81 (m), 6.80-6.71 (m), 6.69 (s), 6.66-6.59 (m), 6.58 (s), 6.55 (s), 6.45-6.34 (m), 5.35-5.27 (m), 5.03-4.96 (m), 4.88 (s), 4.77 (s), 4.72 (d), 3.27-3.08 (m), 3.03-2.92 (m), 2.56-2.37 (m), 1.94 (s), 1.64 (d), 1.44-1.26 (m), 1.13-1.06 (m), 1.05-0.98 (m). MS (m/z) 804.1 [M+H]+.
    • Example 76
  • Figure US20210009555A1-20210114-C00302
    • Synthesis of 2-(3-bromopyridin-2-yl)-N-methylhydrazinecarbothioamide (76B)
  • 3-Bromo-2-hydrazinylpyridine (1500 mg, 7.98 mmol) was dissolved in DCM (50 ml) and treated with dropwise addition of methyl isothiocyanate (700 mg, 9.57 mmol) in DCM. The reaction was heated to 45° C. and stirred for 2 hr. After cooling to ambient temperature, the solids were filtered to provide the title compound. MS (m/z) 261.0 [M+H]+.
    • Synthesis of 8-bromo-N-methyl-[1,2,4]triazolo[4,3-a]pyridin-3-amine (76C)
  • 2-(3-Bromopyridin-2-yl)-N-methylhydrazinecarbothioamide (1.6 g, 6.1 mmol) was treated with EDCI HCl (1.76 g, 9 mmol) in toluene and heated to 105° C. After 1 hr, the hot toluene was decanted. To the residue was added H2O (50 ml). The slurry was mixed thoroughly and heated to 100° C. for 15 min. After cooling to 0° C., the resultant solids were filtered to provide the title compound. MS (m/z) 227.1 [M+H]+.
    • Synthesis of tert-butyl (8-bromo-[1,2,4]triazolo[4,3-a]pyridin-3-yl)(methyl)carbamate (76D)
  • 8-bromo-N-methyl-[1,2,4]triazolo[4,3-a]pyridin-3-amine (0.55 g, 2.42 mmol) was dissolved in DMF (10 ml) and treated with KHMDS (0.58 g, 2.91 mmol). Di-tert-butyl dicarbonate (0.79 g, 3.63 mmol) was then added. The reaction was stirred at ambient temperature for 2 d. The reaction was partitioned between EtOAc and water. The organics were separated, dried, and removed in vacuo and the residue was purified by column chromatography on silica to provide the title compound. MS (m/z) 326.9 [M+H]+.
    • Synthesis of (3-((tert-butoxycarbonyl)(methyl)amino)-[1,2,4]triazolo[4,3-a]pyridin-8-yl)boronic acid (76E)
  • tert-Butyl (8-bromo-[1,2,4]triazolo[4,3-a]pyridin-3-yl)(methyl)carbamate (0.46 g, 1.41 mmol) was combined with bis (pinacolato) diboron (0.54 g), KOAc (0.41 g, 0 mol), and PdCl2(PCy3)2 (0.05 g) in dioxane and DMF. Argon was bubbled into the reaction mixture for 10 min and then heated to 140 deg C. for 2 h. The reaction was partitioned between EtOAc and water. The organics were separated, dried, and removed in vacuo to provide the title compound as a crude product contaminated with byproducts. The material was used directly in the following reaction. MS (m/z) 293.0 [M+H]+.
  • Figure US20210009555A1-20210114-C00303
    • Synthesis of 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(3-(methylamino)-[1,2,4]triazolo[4,3-a]pyridin-8-yl)pyridin-2-yl)ethyl)acetamide (76F)
  • The title compound (76F) was prepared according to the method presented for the synthesis of 27G in Example 27 utilizing 14B and 76E. 1H NMR (400 MHz, Methanol-d4) δ 8.88 (d), 8.22 (d), 7.75 (d), 7.56 (d), 7.37 (s), 7.18 (t), 6.67 (t), 6.70-6.59 (m), 6.55-6.44 (m), 5.31-5.17 (m), 4.69 (d), 3.23-3.08 (m), 2.55-2.39 (m), 1.63 (s), 1.46-1.25 (m), 1.08-1.00 (m). MS (m/z) 709.2 [M+H]+.
    • Example 77
  • Figure US20210009555A1-20210114-C00304
    Figure US20210009555A1-20210114-C00305
    • Synthesis of 3-amino-7-bromo-1-methyl-1H-indazole-4-carbonitrile (77A)
  • To 58B (3 g, 8.5 mmol) in dioxane (32 mL) and DMF (32 ml) was added zinc (6.7 g, 102.3 mmol) and Pd(PPh3)2C2 (600 mg, 0.9 mmol). The reaction mixture was stirred at 160° C. and ZnCN2 (500 mg, 4.3 mmol) was added to the reaction. After an hour another aliquot of ZnCN2(500 mg, 4.3 mmol) was added. The reaction was cooled, diluted with EtOAc and brine. The mixture was extracted 2× with EtOAc, the organic layer was dried over sodium sulfate, was concentrated and purified by flash column chromatography to provide the title compound. MS (m/z) 251.1 [M+H]+.
    • Synthesis of 3-amino-1-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole-4-carbonitrile (77B)
  • The title compound (77B) was prepared according to the method presented for the synthesis of compound 19C of Example 19 utilizing 77A. MS (m/z) 299.3 [M+H]+.
    • Synthesis of (S)-tert-butyl (1-(3-(3-amino-4-cyano-1-methyl-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (77C)
  • The title compound (77C) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 19E of Example 19 utilizing 77B. MS (m/z) 587.0 [M+H]+.
    • Synthesis of (S)-3-amino-7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-1-methyl-1H-indazole-4-carbonitrile (77D)
  • The title compound (77D) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 19F of Example 19 utilizing 77C. MS (m/z) 487.2 [M+H]+.
    • Synthesis of N—((S)-1-(3-(3-amino-4-cyano-1-methyl-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (77E)
  • The title compound (77E) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 10A of Example 10 utilizing 77D and 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. 1H NMR (Chloroform-d) δ: 7.54 (t), 7.52-7.45 (m), 7.33 (d), 7.19 (t), 6.85 (t), 6.71-6.62 (m), 6.49 (d), 6.24-6.17 (m), 6.15 (d), 5.47 (d), 4.99-4.88 (m), 4.78-4.68 (m), 3.12 (s), 3.03-2.94 (m), 2.92 (s), 2.56-2.39 (m), 1.72 (s), 1.42 (q), 1.21-1.10 (m) MS (m/z) 733.3 [M+H]+.
    • Example 78
  • Figure US20210009555A1-20210114-C00306
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (78)
  • The title compound (78) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 19G of Example 19 utilizing 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. 1H NMR (Chloroform-d) δ: 7.60-7.46 (m), 7.32-7.24 (m), 7.24-7.15 (m), 6.92 (d), 6.71-6.62 (m), 6.48 (s), 6.27-6.17 (m), 6.08 (d), 5.55 (d), 4.98 (q), 4.79 (d), 4.73 (d), 3.56 (d), 3.40 (d), 3.27 (s), 3.07-2.91 (m), 2.66-2.40 (m), 1.71 (s), 1.44 (q), 1.28-1.15 (m). MS (m/z) 838.9 [M+H]+.
    • Example 79
  • Figure US20210009555A1-20210114-C00307
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(3-methyl-1H-indazol-4-yl)pyridin-2-yl)ethyl)acetamide (79)
  • The title compound (79) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 20F of Example 20 utilizing (3-carbamoyl-4-chlorophenyl)boronic acid and 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. H NMR (400 MHz, cd3od) δ 8.75 (d), 8.61 (d), 7.63 (dd), 7.56-7.46 (m), 7.39 (dd), 7.32 (dd), 6.99 (d), 6.72 (tt), 6.56-6.45 (m), 6.31 (d), 6.27-6.20 (m), 5.39 (dt), 5.10-4.99 (m), 4.76 (s), 3.18-3.04 (m), 2.97-2.83 (m), 2.58-2.42 (m), 1.86 (s), 1.64 (d), 1.60 (s), 1.48-1.33 (m), 1.18-1.11 (m), 1.11-1.03 (m). MS (m/z) 711.7 [M+H]+.
    • Example 80
  • Figure US20210009555A1-20210114-C00308
    • Synthesis of 2-chloro-5-(2-((S)-1-(2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)benzamide (80)
  • The title compound (80) was prepared according to the method presented for the synthesis of compound 33F of Example 33 utilizing (3-carbamoyl-4-chlorophenyl)boronic acid and 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. 1H NMR (400 MHz, cd3od) δ 8.86 (d), 7.54 (d), 7.46 (dd), 7.17 (d), 7.07-6.99 (m), 6.70 (tt), 6.44-6.34 (m), 5.35 (dd), 4.84 (d), 3.19-3.00 (m), 2.57-2.42 (m), 1.62 (s), 1.46-1.36 (m), 1.15-1.06 (m). MS (m/z) 736.0 [M+H]−.
    • Example 81
  • Figure US20210009555A1-20210114-C00309
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylamino)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (81)
  • The title compound (81) was prepared as a mixture of atropisomers according to the method presented in Example 68 utilizing 7-bromo-4-chloro-1-methyl-H-indazol-3-amine (19B) in place of 7-bromo-1-methyl-1H-indazol-3-amine (33A). 1H NMR (400 MHz, Methanol-d4) δ 7.90-7.86 (m), 7.86-7.80 (m), 7.71 (dd), 7.55 (dd), 7.34 (d), 7.22-7.12 (m), 6.84-6.77 (m), 6.77-6.70 (m), 6.70-6.67 (m), 6.66-6.62 (m), 6.56 (s), 6.54 (s), 6.47-6.41 (m), 6.36-6.29 (m), 5.22 (dd), 5.05 (t), 4.76 (d), 4.71 (s), 3.30-3.22 (m), 3.14-3.03 (m), 3.03-2.91 (m), 2.85 (s), 2.46 (ddt), 1.64 (s), 1.44-1.33 (m), 1.11-0.97 (m). MS (m/z) 756.14 [M+H]+.
    • Example 82
  • Figure US20210009555A1-20210114-C00310
    • Synthesis of (S)—N-(1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide (82)
  • The title compound (82) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 19G of Example 19 utilizing 2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetic acid. H NMR (Chloroform-d) δ: 7.60-7.47 (m), 7.31-7.16 (m), 7.02-6.80 (m), 6.72-6.59 (m), 6.51-6.43 (m), 6.27-6.12 (m), 5.66-5.52 (m), 5.08-4.97 (m), 4.94 (d), 3.40 (s), 3.38 (s), 3.28 (t), 3.07 (s), 3.01-2.89 (m), 2.63-2.42 (m), 2.03 (s), 1.71 (s). MS (m/z) 858.8 [M+H]+.
    • Example 83
  • Figure US20210009555A1-20210114-C00311
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(difluoromethyl)-5,5a,6,6a-tetrahydrocyclopropa[g]indazol-1(4H)-yl)acetamide (83)
  • The title compound (83) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 19G of Example 19 utilizing 2-(3-(difluoromethyl)-5,5a,6,6a-tetrahydrocyclopropa[g]indazol-1(4H)-yl)acetic acid. 1H NMR (Chloroform-d): 7.55-7.43 (m), 7.38 (d), 7.29 (d), 7.18 (d), 6.96 (dd), 6.86 (d), 6.72 (d), 6.67-6.59 (m), 6.57 (d), 6.29 (d), 6.18 (td), 4.94 (dq), 4.84-4.79 (m), 4.76 (s), 3.39 (d), 3.30 (s), 3.24 (s), 3.07 (d), 3.01-2.89 (m), 2.89-2.74 (m), 2.63-2.47 (m), 2.29-2.08 (m), 1.82-1.62 (m), 1.71 (d), 1.05 (td), 0.96 (td), 0.74 (q), 0.65 (q). MS (m/z) 798.9 [M+H]+.
    • Example 84
  • Figure US20210009555A1-20210114-C00312
    • Synthesis of N—((S)-1-(3-(4-chloro-3-(2-methoxyacetamido)-1-methyl-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (84)
  • To the reaction vial containing 57 (13 mg, 0.017 mmol) in THF (0.25 mL) was added 2-methoxyacetyl chloride (2 mg, 0.019 mmol), and triethylamine (0.004 mL, 0.026 mmol). The reaction mixture was stirred at room temperature until the majority of 57 was consumed. The reaction mixture was concentrated in vacuo and dissolved in methanol and treated with several drops of 2 M NaOH for 30 min. The reaction mixture was then acidified with TFA and purified by reverse phase HPLC to provide the title compound 84 as a mixture of atropisomers. H NMR (400 MHz, cd3od) δ 8.72-8.67 (m), 7.70 (dd), 7.54 (dd), 7.22-7.13 (m), 7.08 (d), 6.87-6.59 (m), 6.50-6.36 (m), 5.32-5.25 (m), 5.02-4.94 (m), 4.72 (dd), 4.14 (d), 3.56 (s), 3.34 (s), 3.15 (dd), 3.05-2.93 (m), 2.51-2.38 (m), 1.64 (d), 1.45-1.31 (m), 1.11-1.05 (m), 1.06-0.97 (m). MS (m/z) 815.2 [M+H]+.
    • Example 85
  • Figure US20210009555A1-20210114-C00313
    • Synthesis of N-(4-chloro-7-(2-((S)-1-(2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-1-methyl-1H-indazol-3-yl)-3-methoxypropanamide (85)
  • The title compound (85) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 84 of Example 84 utilizing 3-methoxypropanoyl chloride. 1H NMR (400 MHz, cd3od) δ 8.75-8.65 (m),7.69 (dd), 7.53 (dd), 7.21-7.12 (m), 7.07 (d), 6.87-6.52 (m), 6.47-6.35 (m),5.35-5.25 (m), 4.98 (t), 4.79-4.63 (m), 3.79-3.73 (m), 3.39 (s), 3.14 (dd), 3.05-2.93 (m), 2.76-2.68 (m), 2.51-2.39 (m), 1.64 (d), 1.45-1.32 (m), 1.11-1.05 (m), 1.06-0.97 (m). MS (m/z) 829.2 [M+H]+.
    • Example 86
  • Figure US20210009555A1-20210114-C00314
    • Synthesis of N-(4-chloro-7-(2-((S)-1-(2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-1-methyl-1H-indazol-3-yl)cyclopropanecarboxamide (86)
  • The title compound (86) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 84 of Example 84 utilizing cyclopropanecarbonyl chloride. 1H NMR (400 MHz, cd3od) δ 8.75-8.52 (m),7.69 (dd), 7.53 (dd), 7.16 (d), 7.06 (d), 6.87-6.52 (m), 6.46-6.35 (m), 5.35-5.21 (m), 4.98 (t), 4.79-4.63 (m), 3.14 (dd), 3.00 (d), 2.53-2.39 (m), 1.90 (s), 1.64 (d), 1.45-1.32 (m), 1.06-0.96 (m), 0.90 (s). MS (m/z) 811.2 [M+H]+.
    • Example 87
  • Figure US20210009555A1-20210114-C00315
    • Synthesis of N-(4-chloro-7-(2-((S)-1-(2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-1-methyl-1H-indazol-3-yl)isoxazole-5-carboxamide (87)
  • The title compound (87) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 84 of Example 84 utilizing isoxazole-5-carbonyl chloride. 1H NMR (400 MHz, cd3od) δ 8.71 (t), 8.60 (s), 7.72 (dd), 7.55 (dd), 7.24-7.07 (m), 6.87-6.61 (m), 6.60-6.37 (m), 5.35-5.25 (m), 5.00 (t), 4.79-4.64 (m), 3.37 (s), 3.21-3.12 (m), 3.08-2.95 (m), 2.52-2.39 (m), 1.92 (d), 1.64 (d), 1.42-132 (m), 1.08 (s), 1.02 (s). MS (m/z) 838.1 [M+H]+.
    • Example 88
  • Figure US20210009555A1-20210114-C00316
    • Synthesis of N—((S)-1-(3-(4-chloro-3-(2-hydroxyacetamido)-1-methyl-H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (88)
  • The title compound (88) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 84 of Example 84 utilizing 2-chloro-2-oxoethyl acetate. 1H NMR (400 MHz, cd3od) δ 7.74-7.66 (m), 7.54 (dd), 7.23-7.13 (m), 7.08 (d), 6.87-6.58 (m), 6.50-6.35 (m), 5.25-5.31 (m), 4.99 (t), 4.76 (d), 4.68 (s), 4.21 (d), 3.34 (s), 3.30-3.11 (m), 3.04-2.94 (m), 2.51-2.38 (m), 1.64 (d), 1.45-1.33 (m), 1.11-1.05 (m), 1.06-0.97 (m). MS (m/z) 802.1 [M+H]+.
    • Example 89
  • Figure US20210009555A1-20210114-C00317
    • Synthesis of N-(4-chloro-7-(2-((S)-1-(2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-1-methyl-1H-indazol-3-yl)-2-hydroxy-2-methylpropanamide (89)
  • The title compound (89) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 84 of Example 84 utilizing 1-chloro-2-methyl-1-oxopropan-2-yl acetate. H NMR (400 MHz, cd3od) δ 8.75-8.65 (m),7.70 (t), 7.54 (dd), 7.22-7.12 (m), 7.07 (d), 6.87-6.66 (m), 6.49-6.36 (m), 5.30-5.22 (m), 4.99 (t), 4.75 (d), 4.67 (s), 3.35 (s), 3.28-3.12 (m), 3.04-2.93 (m), 2.49-2.38 (m), 1.64 (d), 1.51 (dd), 1.43-1.33 (m), 1.08 (s), 1.05-0.98 (m). MS (m/z) 829.2 [M+H]+.
    • Example 90
  • Figure US20210009555A1-20210114-C00318
    Figure US20210009555A1-20210114-C00319
    • Synthesis of (S)-tert-butyl (1-(3-bromo-6-(3-((tert-butyldimethylsilyl)oxy)-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (90A)
  • The title compound (90A) was prepared according to the method presented for the synthesis of compound (14B) of Example 14 utilizing tert-butyldimethyl((2-methylbut-3-yn-2-yl)oxy)silane. MS (m/z) 609.10 [M+H]+.
    • Synthesis of (S)-tert-butyl (1-(3-(3-amino-4-chloro-1-methyl-1H-indazol-7-yl)-6-(3-((tert-butyldimethylsilyl)oxy)-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (90B)
  • The title compound (90B) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound (19E) of Example 19 utilizing (S)-tert-butyl (1-(3-bromo-6-(3-((tert-butyldimethylsilyl)oxy)-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (90A) and 4-chloro-1-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (19C). MS (m/z) 710.01 [M+H]+.
    • Synthesis of (S)-methyl (7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-4-chloro-1-methyl-1H-indazol-3-yl)carbamate (90C)
  • To a solution of (S)-tert-butyl (1-(3-(3-amino-4-chloro-1-methyl-1H-indazol-7-yl)-6-(3-((tert-butyldimethylsilyl)oxy)-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (90B) (20 mg, 0.03 mmol) and DIPEA (0.08-1, 0.06 mmol) in dichloromethane (0.5 ml) was added methyl chloroformate (3.27 μl, 0.04 mmol). After stirring overnight, trifluoroacetic acid (0.5 ml) was added and the reaction was stirred at room temperature for 1 hour. The reaction was concentrated, extracted with ethyl acetate, and basified with 2 M aqueous K2CO3. The organic layer was washed with 0.5 M NaCl and the organic layer was dried with Na2SO4, filtered, and concentrated. The crude product as a mixture of atropisomers was taken to the next step without further purification. MS (m/z) 554.13 [M+H]+.
    • Synthesis of methyl (4-chloro-7-(2-((S)-1-(2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-1-methyl-H-indazol-3-yl)carbamate (90D)
  • The title compound (90D) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound (33F) of Example 33 utilizing (S)-methyl (7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-4-chloro-1-methyl-1H-indazol-3-yl)carbamate (90C) and 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. 1H NMR (400 MHz, Methanol-d4) δ 8.72 (d), 8.66 (d), 7.74-7.63 (m), 7.59-7.48 (m), 7.20-7.14 (m), 7.07 (d), 6.87-6.53 (m), 6.46-6.33 (m), 5.35-5.26 (m), 5.05-4.95 (m), 4.80-4.64 (m), 3.75 (d), 3.33 (s), 3.28-3.07 (m), 2.99 (q), 2.53-2.39 (m), 1.64 (s), 1.50-1.28 (m), 1.09 (d), 1.06-0.99 (m). MS (m/z) 800.15 [M+H]+.
    • Example 91
  • Figure US20210009555A1-20210114-C00320
    Figure US20210009555A1-20210114-C00321
    • Synthesis of (S′)-tert-butyl (1-(6-(3-((tert-butyldimethylsilyl)oxy)-3-methylbut-1-yn-1-yl)-3-(4-chloro-1-methyl-3-(2,2,2-trifluoroacetamido)-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (91A)
  • To a solution of (S)-tert-butyl (1-(3-(3-amino-4-chloro-1-methyl-1H-indazol-7-yl)-6-(3-((tert-butyldimethylsilyl)oxy)-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (90B) (93 mg. 0.13 mmol) in dichloromethane (0.5 ml) was added DIPEA (34.14 μl, 0.2 mmol), followed by trifluoroacetic anhydride (25.5 μl, 0.18 mmol). After stirring at room temperature for 1 h, the product was extracted with dichloromethane and water. The organic layer was dried with Na2SO4, filtered, concentrated in vacuo, and purified by silica gel chromatography to provide the title compound. MS (m/z) 806.04 [M+H]+.
    • Synthesis of (S)-tert-butyl (1-(6-(3-((tert-butyldimethylsilyl)oxy)-3-methylbut-1-yn-1-yl)-3-(4-chloro-3-(N-ethyl-2,2,2-trifluoroacetamido)-1-methyl-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (91B)
  • To a solution of (S)-tert-butyl (1-(6-(3-((tert-butyldimethylsilyl)oxy)-3-methylbut-1-yn-1-yl)-3-(4-chloro-1-methyl-3-(2,2,2-trifluoroacetamido)-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (91A) (20 mg, 0.02 mmol) in DMF (0.5 ml) was added cesium carbonate (20.2 mg, 0.06 mmol), followed by diethylsulfate (4.6 mg, 0.03 mmol). After stirring at room temperature overnight, the reaction mixture was extracted with ethyl acetate and water. The organic layer was dried with Na2SO4, filtered, and concentrated in vacuo. The crude product was taken to the next step without further purification.
    • Synthesis of (S)-tert-butyl (1-(6-(3-((tert-butyldimethylsilyl)oxy)-3-methylbut-1-yn-1-yl)-3-(4-chloro-3-(ethylamino)-1-methyl-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (91C)
  • To a solution of (S)-tert-butyl (1-(6-(3-((tert-butyldimethylsilyl)oxy)-3-methylbut-1-yn-1-yl)-3-(4-chloro-3-(N-ethyl-2,2,2-trifluoroacetamido)-1-methyl-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (21 mg) (91B) in methanol (0.5 mL) was added 2M aqueous K2CO3 (0.25 mL). After stirring at room temperature for 2 h, the reaction mixture was concentrated in vacuo. The mixture was extracted with ethyl acetate and water. The organic layer was dried with Na2SO4, filtered, and concentrated in vacuo. The crude product was taken to the next step without further purification.
    • Synthesis of (S)-4-(6-(1-amino-2-(3,5-difluorophenyl)ethyl)-5-(4-chloro-3-(ethylamino)-1-methyl-1H-indazol-7-yl)pyridin-2-yl)-2-methylbut-3-yn-2-ol (91D)
  • The title compound (91D) was prepared according to the method presented for the synthesis of compound (90C) of Example 90 utilizing (S)-tert-butyl (1-(6-(3-((tert-butyldimethylsilyl)oxy)-3-methylbut-1-yn-1-yl)-3-(4-chloro-3-(ethylamino)-1-methyl-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (91C). MS (m/z) 524.55 [M+H]+.
    • Synthesis of N—((S)-1-(3-(4-chloro-3-(ethylamino)-1-methyl-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (91E)
  • The title compound (91E) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound (90D) of Example 90 utilizing (S)-4-(6-(1-amino-2-(3,5-difluorophenyl)ethyl)-5-(4-chloro-3-(ethylamino)-1-methyl-1H-indazol-7-yl)pyridin-2-yl)-2-methylbut-3-yn-2-ol (91D). 1H NMR (400 MHz, Methanol-d4) δ 7.73-7.60 (m), 7.58-7.48 (m), 7.12 (d), 7.04 (d), 6.93 (d), 6.85-6.79 (m), 6.78-6.71 (m), 6.71-6.66 (m), 6.67-6.58 (m), 6.58-6.53 (m), 6.49-6.32 (m), 6.32-6.28 (m), 5.26-5.20 (m), 5.04 (t), 4.80-4.67 (m), 4.10 (q), 3.42-3.28 (m), 3.27-3.17 (m), 3.17-3.05 (m), 3.05-2.91 (m), 2.82 (s), 2.53-2.40 (m), 2.01 (s), 1.64 (s), 1.41-1.21 (m), 0.96-0.82 (m). MS (m/z) 770.15 [M+H]+.
    • Example 92
  • Figure US20210009555A1-20210114-C00322
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-ureido-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (92)
  • To a solution of N—((S)-1-(3-(3-amino-4-chloro-1-methyl-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (57) (30 mg, 0.04 mmol) in acetic acid (0.4 ml) was added a solution of potassium cyanate (3.9 mg, 0.049 mmol) in water (0.05 ml). After stirring at 50° C. for 2 h, the reaction was concentrated and purified by reverse phase HPLC to provide the title product as a mixture of atropisomers. 1H NMR (400 MHz, Methanol-d4) δ 8.72 (dd), 7.69 (dd), 7.54 (dd), 7.22-7.10 (m), 7.04 (d), 6.88-6.52 (m), 6.47-6.32 (m), 5.31-5.22 (m), 5.03-4.92 (m), 4.76 (s), 4.72 (d), 3.28 (s), 3.18-3.10 (m), 3.04-2.94 (m), 2.94 (s), 2.53-2.40 (m), 1.64 (s), 1.46-1.25 (m), 1.12-1.05 (m), 1.05-0.99 (m). MS (m/z) 785.15 [M+H]+.
    • Example 93
  • Figure US20210009555A1-20210114-C00323
    • Synthesis of N—((S)-1-(3-(4-chloro-3-((cyanomethyl)amino)-1-methyl-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (93)
  • The title compound (93) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound (91D) of Example 91 utilizing bromoacetonitrile in place of diethyl sulfate during the synthesis of compound (91B). 1H NMR (400 MHz, Methanol-d4) δ 8.69 (d), 8.63-8.55 (m), 7.67 (dd), 7.56-7.48 (m), 7.11 (d), 6.99 (d), 6.86 (dd), 6.78-6.72 (m), 6.70 (d), 6.67-6.60 (m), 6.57 (d), 6.45-6.31 (m), 5.35-5.28 (m), 5.08-5.00 (m), 4.77 (s), 4.73 (s), 4.35-4.23 (m), 3.20 (s), 3.12 (dd), 3.05-2.92 (m), 2.89 (s), 2.54-2.39 (m), 1.64 (s), 1.44-1.30 (m), 1.12-1.07 (m), 1.07-1.01 (m). MS (m/z) 828.18 [M+H]+.
    • Example 94
  • Figure US20210009555A1-20210114-C00324
    • Synthesis of N—((S)-1-(3-(3-acetamido-4-chloro-1-methyl-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (94)
  • The title compound (94) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 84 of Example 84 utilizing acetyl chloride. 1H NMR (Chloroform-d) δ: 7.63-7.57 (m), 7.54-7.48 (m), 7.25-7.22 (m), 6.97 (d), 6.70 (t), 6.70-6.63 (m), 6.48 (t), 6.24 (d), 6.19 (d), 6.15 (d), 5.63-5.55 (m), 4.99 (q), 4.76 (d), 4.70 (d), 3.29 (s), 3.09-2.94 (m), 2.55-2.40 (m), 2.30 (d), 1.72 (d), 1.41 (q), 1.21-1.12 (m). MS (m/z) 784.9 [M+H]+.
    • Example 95
  • Figure US20210009555A1-20210114-C00325
    • Synthesis of N-(4-chloro-7-(2-((S)-1-(2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-1-methyl-1H-indazol-3-yl)propionamide (95)
  • The title compound (95) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 84 of Example 84 utilizing propionyl chloride. H NMR (Chloroform-d) δ: 7.62-7.43 (m), 7.35-7.17 (m), 6.95 (d), 6.71 (t), 6.69-6.62 (m), 6.53-6.44 (m), 6.30-6.16 (m), 6.12 (d), 5.61-5.50 (m), 4.96 (q), 4.75 (d), 4.70 (d), 3.28 (s), 3.07 (s), 2.95 (d), 2.56 (qd), 2.61-2.36 (m), 1.71 (s), 1.41 (q), 1.36-1.21 (m), 1.20-1.08 (m). MS (m/z) 798.9 [M+H]+.
    • Example 96
  • Figure US20210009555A1-20210114-C00326
    • Synthesis of N-(4-chloro-7-(2-((S)-1-(2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-1-methyl-1H-indazol-3-yl)isobutyramide (96)
  • The title compound (96) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 84 of Example 84 utilizing isobutyryl chloride. 1H NMR (Chloroform-d) δ: 7.59-7.52 (m), 7.48 (dd), 7.31-7.23 (m), 7.22 (s), 6.94 (d), 6.70 (t), 6.69-6.61 (m), 6.48 (d), 6.22 (d), 6.18 (d), 6.11 (d), 5.56 (d), 4.96 (q), 4.75 (d), 4.69 (d), 3.28 (s), 3.15 (s), 3.09 (s), 2.96 (d), 2.72 (s), 2.55-2.40 (m), 1.71 (s), 1.41 (q), 1.33 (s), 1.21-1.13 (m). MS (m/z) 813.1 [M+H]+.
    • Example 97
  • Figure US20210009555A1-20210114-C00327
    • Synthesis of N-(4-chloro-7-(2-((S)-1-(2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-1-methyl-1H-indazol-3-yl)-2,2-difluoroacetamide (97)
  • The title compound (97) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 84 of Example 84 utilizing 2,2-difluoroacetic anhydride. 1H NMR (Chloroform-d) δ: 8.80 (d), 7.63-7.55 (m), 7.54-7.46 (m), 7.43-7.30 (m), 7.30-7.23 (m), 6.99 (d), 6.71 (t), 6.70-6.63 (m), 6.53-6.46 (m), 6.25 (d), 6.19 (d), 6.17-6.11 (m), 6.04-5.95 (m), 5.65-5.53 (m), 4.98 (q), 4.79-4.73 (m), 4.69 (d), 3.33 (s), 3.12 (s), 3.07-2.94 (m), 2.60-2.34 (m), 1.71 (s), 1.41 (q), 1.26 (s), 1.23-1.12 (m) MS (m/z) 820.9 [M+H]+.
    • Example 98
  • Figure US20210009555A1-20210114-C00328
    • Synthesis N-(4-chloro-7-(2-((S)-1-(2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-1-methyl-1H-indazol-3-yl)-2,2,2-trifluoroacetamide (98)
  • The title compound (98) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 84 of Example 84 utilizing 2,2,2-trifluoroacetic anhydride. 1H NMR (Chloroform-d) δ: 8.77-8.72 (m), 8.69-8.63 (m), 7.56-7.43 (m), 7.31-7.19 (m), 7.18-7.06 (m), 7.01-6.95 (m), 6.71 (t), 6.70-6.61 (m), 6.52-6.45 (m), 6.24-6.16 (m), 6.11 (d), 5.60-5.52 (m), 4.93 (q), 4.75 (d), 4.69 (d), 3.32 (s), 3.10 (s), 3.01-2.91 (m), 2.57-2.38 (m), 2.23-2.02 (m), 1.72 (s), 1.47-1.37 (m), 1.25 (s), 1.22-1.12 (m). MS (m/z) 838.8 [M+H]+.
    • Example 99
  • Figure US20210009555A1-20210114-C00329
    • Synthesis of 2-bromo-N-(4-chloro-7-(2-((S)-1-(2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-1-methyl-1H-indazol-3-yl)acetamide (99A)
  • To the reaction vial containing 57 (32 mg, 0.043 mmol) in THF (0.25 mL) was added 2-bromoacetyl chloride (7 mg, 0.047 mmol), and triethylamine (0.009 mL, 0.06 mmol). The reaction mixture was stirred at room temperature until the majority of 57 was consumed. The reaction mixture was concentrated in vacuo and telescoped to the next reaction. MS (m/z) 862.1 [M+H]+.
    • Synthesis of N—((S)-1-(3-(4-chloro-3-(2-(dimethylamino)acetamido)-1-methyl-H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (99B)
  • The crude 99A material was dissolved in DMF (0.1 mL) and treated with excess dimethylamine at room temperature for 30 min. The reaction mixture was then acidified with TFA and purified by reverse phase HPLC to provide the title compound 99B as a mixture of atropisomers. 1H NMR (400 MHz, cd3od) δ 8.90-8.69 (m, 1H), 7.73-7.65 (m, 1H), 7.59-7.49 (m, 1H), 7.23-7.06 (m, 1H), 6.89-6.59 (m, 2H), 6.53-6.29 (m, 3H), 5.03-4.93 (m, 1H), 4.80-4.68 (m, 2H), 4.28 (s, 2H), 3.38-2.96 (m, 9H), 2.91-2.73 (m, 2H), 2.61-2.33 (m, 2H), 1.64 (s, 6H), 1.43-1.28 (m, 1H), 1.15-0.98 (m, 1H). MS (m/z) 829.2 [M+H]+.
    • Example 100
  • Figure US20210009555A1-20210114-C00330
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(2-(pyrrolidin-1-yl)acetamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (100)
  • The title compound (100) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 99B of Example 99 utilizing pyrrolidine. 1H NMR (400 MHz, cd3od) δ 8.87-8.69 (m), 7.73-7.68 (m), 7.59-7.49 (m), 7.20 (s), 7.10 (s), 6.90-6.69 (m), 6.45-6.32 (m), 5.30-5.25 (m), 5.03-4.98 (m), 4.79-4.63 (m), 4.37 (s), 3.82-3.64 (m), 3.35 (s), 3.24-3.19 (m), 3.01 (s), 2.51-2.43 (m, 2H), 2.30-2.13 (m), 1.64 (d), 1.42-1.25 (m), 1.10 (s), 1.00 (s). MS (m/z) 854.4 [M+H]+.
    • Example 101
  • Figure US20210009555A1-20210114-C00331
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(2-(methylamino)acetamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (101)
  • The title compound (101) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 99B of Example 99 utilizing methylamine. 1H NMR (400 MHz, cd3od) δ 8.85-8.65 (m), 7.79-7.62 (m), 7.60-7.50 (m), 7.21-7.15 (m), 7.13-7.09 (m), 6.91-6.50 (m), 6.45-6.23 (m), 5.32-5.21 (m), 5.00-4.98 (m), 4.82-4.68 (m), 4.20-4.15 (s), 4.14-4.08 (s), 3.35 (s), 3.13-3.08 (m), 3.03-2.98 (m), 2.81 (s), 2.48-2.43 (m), 1.64 (d), 1.50-1.29 (m), 1.12-1.05 (m), 1.03-0.98 (m). MS (m/z) 814.2 [M+H]+.
    • Example 102
  • Figure US20210009555A1-20210114-C00332
    • Synthesis of N—((S)-1-(3-(4-chloro-3-(2-(cyclopropylamino)acetamido)-1-methyl-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (102)
  • The title compound (102) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 99B of Example 99 utilizing cyclopropylamine. H NMR (400 MHz, cd3od) δ 8.74-8.69 (m), 7.74-7.65 (m), 7.59-7.49 (m), 7.19 (s), 7.12 (s) 6.91-6.53 (m), 6.38 (m),5.35-5.20 (m), 5.01-4.94 (m), 4.79-4.64 (m), 4.21 (s), 3.35 (s), 3.03-2.98 (m), 2.91-2.86 (m), 2.53-2.38 (m), 1.64 (s), 1.45-1.36 (m), 1.11-0.70 (m). MS (m/z) 840.2 [M+H]+.
    • Example 103
  • Figure US20210009555A1-20210114-C00333
    • Synthesis of (S)—N-(4-chloro-7-(2-((S)-1-(2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-1-methyl-1H-indazol-3-yl)-2-hydroxypropanamide (103)
  • The title compound (103) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 84 of Example 84 utilizing (S)-1-chloro-1-oxopropan-2-yl acetate. 1H NMR (400 MHz, cd3od) δ 8.72-8.64 (m), 7.70 (dd), 7.54 (dd), 7.22-7.12 (m), 7.07 (d), 6.87-6.66 (m), 6.50-6.36 (m), 5.30-5.25 9 (m), 4.99 (t), 4.75 (d), 4.68 (s), 4.38-4.28 (m), 3.33 (s), 3.26-3.12 (m)), 3.04-2.93 (m), 2.52-2.38 (m), 1.64 (d), 1.50 (dd), 1.43-1.31 (m), 1.10-1.05 (m), 1.04-0.98 (m). MS (m/z) 815.2 [M+H]+.
    • Example 104
  • Figure US20210009555A1-20210114-C00334
    • Synthesis of N—((S)-1-(6-(3-amino-3-methylbut-1-yn-1-yl)-3-(1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (104)
  • The title compound (104) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound (61) of Example 61 utilizing 2-methylbut-3-yn-2-amine. 1H NMR (400 MHz, Methanol-d4) δ 8.71 (d), 7.89-7.81 (m), 7.78 (t), 7.63 (dd), 7.27 (dd), 7.20 (dd), 7.10 (dd), 6.79-6.71 (m), 6.68-6.58 (m), 6.52 (dd), 6.40-6.27 (m), 5.33-5.24 (m), 5.02 (q), 4.80-4.68 (m), 3.32 (s), 3.28-3.20 (m), 3.18 (s), 3.16-3.10 (m), 3.04-2.91 (m), 2.58-2.40 (m), 1.83 (s), 1.47-1.36 (m), 1.15-1.10 (m), 1.08-1.02 (m). MS (m/z) 803.13 [M+H]+.
    • Example 105
  • Figure US20210009555A1-20210114-C00335
    Figure US20210009555A1-20210114-C00336
    • Synthesis of (S)-tert-butyl (2-(3,5-difluorophenyl)-1-(6′-hydrazinyl-6-(3-hydroxy-3-methylbut-1-yn-1-yl)-[3,3′-bipyridin]-2-yl)ethyl)carbamate (105A)
  • In a microwave tube were charged with compound 14B (50 mg, 0.1 mmol), 2-hydrazinyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (36 mg, 0.15 mmol), potassium carbonate (42 mg, 0.3 mmol) and dichlorobis(tricyclohexylphosphine)palladium(II) (4 mg, 0.005 mmol). To the mixture was added was added 1,4-dioxane (2 mL), water (0.5 mL) and MeOH (0.3 mL). The mixture was heated to 150° C. for 10 minutes in a microwave synthesizer. After cooling to room temperature, the reaction was partitioned between EtOAc and water. The organic layer was separated and washed with brine, then dried over MgSO4, filtered and concentrated. The residue was purified by silica gel chromatography to afford the title compound 105A. MS (m/z): 524.10 [M+H]+;
    • Synthesis of Boc-(S)-ethyl (6-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)carbamate (105B)
  • To a reaction mixture of compound 105A (28 mg, 0.053 mmol) in 0.5 mL 2-methyltetrahydrofuran was added ethoxycarbonyl isothiocyanate (7 mg, 0.053 mmol) and the reaction was allowed to stir at room temperature for 1 min. The solvent was removed in vacuo. The residue was dissolved in 0.5 mL of methylene chloride and to it was added 2-chloro-1-methylpyridinium iodide (12 mg, 0.046 mmol) followed by triethylamine (0.08 mL, 0.057 mmol). The reaction mixture was stirred at room temperature for 1 min. The solvent was removed in vacuo and the residue was purified by silica gel chromatography to afford the title compound 105B. MS (m/z): 621.07 [M+H]+.
    • Synthesis of (S)-ethyl (6-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)carbamate (105C)
  • Compound 105B (14 mg, 0.023 mmol) was dissolved in 1 mL of methylene chloride and to it was added 0.15 mL of TFA. The reaction mixture was stirred at room temperature for 40 minutes. The solvent was removed to afford the title compound 105C as a TFA salt. MS (m/z): 521.09 [M+H]+.
    • Synthesis of ethyl (6-(2-((S)-1-(2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)carbamate (105D)
  • The title compound (105D) was prepared according to the method presented for the synthesis of compound 37E of Example 37 utilizing 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid and compound 105C. MS (m/z) 767.18 [M+H]+.
    • Synthesis of N—((S)-1-(3-(3-amino-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (105E)
  • Compound 105D (15.3 mg, 0.05 mmol) was dissolved in 2 mL of 1,4-dioxane and to it was added 0.5 mL of 1M sodium bicarbonate aqueous solution. The reaction mixture was heated in microwave for 1 hour at 140° C. The solvent was removed and the residue was purified by RP-HPLC to afford the title compound 105E. 1H NMR (400 MHz, Methanol-d4): δ 8.08 (s), 7.81-7.60 (m), 7.57-7.38 (m), 6.77-6.70 (m), 6.61 (t), 6.52-6.35 (m), 5.36 (t), 4.81 (d), 3.15 (d), 2.59-2.27 (m), 1.63 (s), 1.48-1.20 (m), 1.10-0.78 (m). MS (m/z): 695.30 [M+H]+.
    • Example 106
  • Figure US20210009555A1-20210114-C00337
    Figure US20210009555A1-20210114-C00338
    • Synthesis of 3-bromo-6-chloro-2-hydrazinylpyridine (106A)
  • To a mixture of 3-bromo-6-chloro-2-fluoropyridine (6 g, 28.5 mmol) in 200 mL ethanol was added 14 mL of hydrazine monohydrate. The reaction mixture was stir at room temperature for overnight and then removed most of the solvent. The precipitate was collected by vacuum filtration to afford the title compound 106A. MS (m/z): 223.97 [M+H]+.
    • Synthesis of ethyl (8-bromo-5-chloro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)carbamate (106B)
  • The title compound (106B) was prepared according to the method presented for the synthesis of compound 105B of Example 105 utilizing compound 106A. MS (m/z) 321.01 [M+H]+.
    • Synthesis of (S)-tert-butyl (1-(3-(3-amino-5-chloro-[1,2,4]triazolo[4,3-a]pyridin-8-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (106C)
  • In a microwave tube were charged with compound 117B (48 mg, 0.1 mmol), compound 106B (40 mg, 0.13 mmol), sodium carbonate (33 mg, 0.03 mmol) and PdCl2PPh3]2 (8 mg, 0.01 mmol). To the mixture was added 2.5 mL of 1,4-dioxane and 0.5 mL of water. The mixture was heated to 170° C. for 20 minutes in a microwave synthesizer. After cooling to room temperature, the reaction was partitioned between EtOAc and water. The organic layer was separated and washed with brine, then dried over MgSO4, filtered and concentrated. The residue was purified by reverse phase HPLC to afford the title compound 106C. MS (m/z): 583.01 [M+H]+
    • Synthesis of (S)-4-(6-(1-amino-2-(3,5-difluorophenyl)ethyl)-5-(3-amino-5-chloro-[1,2,4]triazolo[4,3-a]pyridin-8-yl)pyridin-2-yl)-2-methylbut-3-yn-2-ol (106D)
  • The title compound (106D) was prepared according to the method presented for the synthesis of compound 105C of Example 105 utilizing compound 106C. MS (m/z) 483.28 [M+H]+.
    • Synthesis of N—((S)-1-(3-(3-amino-5-chloro-[1,2,4]triazolo[4,3-a]pyridin-8-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (106E)
  • The title compound (106E) was prepared according to the method presented for the synthesis of compound 37E of Example 37 utilizing 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid and compound 106D. 1H NMR (400 MHz, Methanol-d4): δ 8.79 (d), 7.71 (d), 7.52 (d), 7.04 (d), 6.69-6.63 (m), 6.68 (t), 6.59-6.36 (m), 5.41-5.12 (m), 4.75-4.48 (m), 3.25-2.97 (m), 2.55-2.35 (m), 1.62 (s), 1.38 (q), 1.12-0.96 (m). MS (m/z): 729.24 [M+H]+.
    • Example 107
  • Figure US20210009555A1-20210114-C00339
    • Synthesis of 7-bromo-1-methyl-1H-indazol-3-ol (107A)
  • To the reaction vial containing methyl 3-bromo-2-fluorobenzoate (1 g, 4.5 mmol) in ethanol (5 mL) was added methylhydrazine (0.29 mL, 6 mmol). The reaction mixture was sealed and heated to 125° C. overnight. Upon cooling, the reaction mixture was treated with water and the resulting solid was collected by filtration to give the title product 107A. MS (m/z) 229.1 [M+2H]+.
  • Figure US20210009555A1-20210114-C00340
    • Synthesis of 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(1-methyl-3-oxo-2,3-dihydro-1H-indazol-7-yl)pyridin-2-yl)ethyl)acetamide (107B)
  • The title compound (107B) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 117F of Example 117 utilizing 107A and 117B. H NMR (400 MHz, cd3od) δ 8.61 (d), 7.79-7.63 (m), 7.52 (dd), 7.28-7.21 (m), 7.12 (t), 7.02 (t), 6.76-6.67 (m), 6.66-6.54 (m), 6.40 (d), 6.34-6.27 (m), 5.26 (t), 5.17-5.07 (m), 4.83-4.74 (m), 3.24 (dd), 3.12-2.88 (m), 2.75 (s), 2.55-2.42 (m), 1.64 (s), 1.45-1.35 (m), 1.14-1.06 (m). MS (m/z) 727.1 [M+H]+.
    • Example 108
  • Figure US20210009555A1-20210114-C00341
    • Synthesis of 7-bromo-4-chloro-1H-indazol-3-amine (108A)
  • In a microwave vial a solution of 3-bromo-2-fluorobenzonitrile (1 g, 4.26 mmol) ethanol (5 mL) was treated with hydrazine (0.85 mL, 17 mmol), sealed, and heated to 120° C. in a microwave reactor for 35 minutes. The reaction was concentrated in vacuo and the crude product dissolved with EtOAc (30 mL) and washed with water (30 mL), then 2M NaCl (aq, 30 mL). The organics were dried with Na2SO4, filtered, and concentrated. Product was purified by silica chromatography to give the title compound. MS (m/z) 247.1 [M+H]+.
    • Synthesis of N-(7-bromo-4-chloro-1H-indazol-3-yl)methanesulfonamide (108B)
  • To a stirred solution of 108A (161 mg, 0.65 mmol), 4-dimethylaminopyridine (4 mg, 0.03 mmol), and N,N-diisopropylethylamine (0.28 mL, 1.6 mmol) in DCM (5 ml) at, 0° C. was added drop wise methanesulfonyl chloride (156 mg, 1.3 mmol). The ice bath was removed immediately after the addition and the reaction was warmed to room temperature and stirred for 2 h. The reaction was washed with water, dried with Na2SO4, filtered, and concentrated. The crude product dissolved with EtOH (10 mL) and treated with 8N NaOH (3.3 ml). The reaction mixture was heated at 60° C. for 0.5 h. The ethanol was removed under vacuum, pH to 2 with 1.0 HCl then, extracted with EtOAc. The organics were dried with Na2SO4, filtered, and concentrated. The product was purified by silica chromatography to give the title compound. MS (m/z) 325.9 [M+H]+.
  • Figure US20210009555A1-20210114-C00342
    • Synthesis of N—((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (108C)
  • The title compound (108C) was prepared according to the method presented for the synthesis of compound 117F of Example 117 utilizing 108B and 117B. MS (m/z) 807.1 [M+H]+. HPLC retention time 6.96 min (2-98% acetonitrile: water with 0.1% trifluoroacetic acid, 8.5 min gradient on a Phenomonex Kinetex C18 column).
    • Example 109
  • Figure US20210009555A1-20210114-C00343
    • Synthesis of N—((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (109)
  • The title compound (109) was prepared according to the method presented for the synthesis of compound 117F of Example 117 utilizing 108B, 117B and 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. MS (m/z) 824.2 [M+H]+. HPLC retention time 7.16 min (2-98% acetonitrile: water with 0.1% trifluoroacetic acid, 8.5 min gradient on a Phenomonex Kinetex C18 column).
    • Example 110
  • Figure US20210009555A1-20210114-C00344
    Figure US20210009555A1-20210114-C00345
    • Synthesis of 8-bromo-5-chloro-[1,2,4]triazolo[4,3-a]pyridin-3-amine (110A)
  • To a solution of compound 106B (2.1 g, 6.6 mmol) in a mixture of dioxane (90 mL), water (15 mL) and DMF (9 mL) was added KOH (0.37 g, 6.6 mmol). The mixture was heated at 110° C. overnight. After removing volatiles in vacuo, the residue was purified by silica gel column to yield the title compound 110A. MS (m/z) 248.95 [M+H]+.
    • Synthesis of N-(8-bromo-5-chloro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)methanesulfonamide (110B)
  • To a solution of compound 110A (80 mg, 0.3 mmol) in DCM (5 mL) was added DIEA (0.42 g, 3 mmol) and methanesulfonyl chloride (0.19 g, 2 mmol). After stirred at room temperature for 5 min, the volatiles was removed in vacuo. The residue was dissolved in a mixture of THF (2 mL), MeOH (2 mL) and 2 N NaOH (2 mL) and stirred for 15 min. After removing volatiles, the residue was purified by reverse phase HPLC to yield the title compound. MS (m/z) 326.82 [M+H]+.
    • Synthesis of (S)-tert-butyl (1-(3-(5-chloro-3-(methylsulfonamido)-[1,2,4]triazolo[4,3-a]pyridin-8-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (11° C.)
  • The title compound (110C) was prepared according to the method presented for the synthesis of compound 117D of Example 117 utilizing compound 110B and 117B. MS (m/z) 661.02 [M+H]+.
    • Synthesis of (S)—N-(8-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-5-chloro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)methanesulfonamide TFA salt (110D)
  • The title compound (110D) was prepared according to the method presented for the synthesis of compound 19F of Example 19 utilizing compound 110C. MS (m/z) 561.00 [M+H]+.
    • Synthesis of N—((S)-1-(3-(5-chloro-3-(methylsulfonamido)-[1,2,4]triazolo[4,3-a]pyridin-8-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (110E)
  • The title compound (110E) was prepared according to the method presented for the synthesis of compound 10A of Example 10 utilizing compound HOD and 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. HPLC retention time 6.63 min (2-98% acetonitrile: water with 0.1% trifluoroacetic acid, 8.5 min gradient on a Phenomonex Kinetex C18 column 4.6×100 mm). MS (m/z) 807.16 [M+H]+.
    • Example 111
  • Figure US20210009555A1-20210114-C00346
    • Synthesis of N—((S)-1-(3-(3-amino-5-chloro-[1,2,4]triazolo[4,3-a]pyridin-8-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (111)
  • The title compound (111) was prepared according to the method presented for the synthesis of compound 106E of Example 106 utilizing 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid and 106D. 1H NMR (400 MHz, Methanol-d4): δ 8.83 (d), 7.72 (d), 7.51 (d), 6.98 (d), 6.64 (t), 6.58-6.44 (m), 5.41-5.18 (m), 4.74 (s), 3.27-2.96 (m), 2.67-2.18 (m), 1.62 (s), 1.40 (q), 1.17-0.99 (m). MS (m/z): 747.30 [M+H]+
    • Example 112
  • Figure US20210009555A1-20210114-C00347
    • Synthesis of N-(1,4-dimethyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-yl)methanesulfonamide (112A)
  • The title compound (112A) was prepared according to the method presented for the synthesis of compound 19D of Example 19 utilizing 58D. MS (m/z) 366.1 [M+H]+.
    • Synthesis of (S)-tert-butyl (2-(3,5-difluorophenyl)-1-(3-(1,4-dimethyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)ethyl)carbamate (112B)
  • The title compound (112B) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 19E of Example 19 utilizing 112A. MS (m/z) 654.4 [M+H]+.
    • Synthesis of (S)—N-(7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-1,4-dimethyl-1H-indazol-3-yl)methanesulfonamide (112C)
  • The title compound (112C) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 19F of Example 19 utilizing 112B. MS (m/z) 554.2[M+H]+.
    • Synthesis of 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(3-(1,4-dimethyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)ethyl)acetamide (112D)
  • The title compound (112D) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 10A of Example 10 utilizing 112C and 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. 1H NMR (Chloroform-d) δ: 8.16-8.10 (m), 8.00 (d), 7.76 (d), 7.58 (d), 7.38 (d), 7.06 (dd), 6.86 (dd), 6.67 (t), 6.64 (dt), 6.51-6.41 (m), 6.38 (d), 6.24 (dd), 6.13 (dd), 5.62 (q), 5.06 (q), 4.78 (d), 4.69 (s), 3.35 (s), 3.32 (s), 3.29 (s), 3.11 (s), 3.10-2.91 (m), 2.87-2.78 (m), 2.55-2.34 (m), 1.71 (s), 1.45-1.34 (m), 1.20-1.07 (m) MS (m/z) 800.6 [M+H]+.
    • Example 113
  • Figure US20210009555A1-20210114-C00348
    • Synthesis of (Z)-3-bromo-2-((1,2-dichlorovinyl)oxy)benzaldehyde (113A)
  • Trichloroethylene (2.68 mL, 30 mmol) was added drop wise over a period of 30 min to a solution of 3-bromo-2-hydroxybenzaldehyde (2 g, 9.9 mmol) suspended with K2CO3 (4.1 g, 30 mmol) in DMF (8 mL) at 60° C. under N2. The reaction was stirred for 15 h then cooled to room temperature and partitioned between 150 mL of ethylacetate and 100 mL of water. The organic phase was washed with brine 100 mL, dried over sodium sulfate, filtered and concentrated. The crude material was purified by silica gel to give the title compound.
    • Synthesis of 5-bromo-3-chloro-1H-benzofuro[3,2-c]pyrazolebenzaldehyde (113B)
  • Benzenesulfonylhydrazide (0.57 g, 3.3 mmol) was added all at once to a solution of the 113A (0.9 g, 3.0 mmol) in acetonitrile (13 mL) at room temperature. After stirring for 2 h, aqueous 2 M NaOH (3 mL, 6 mmol) was added drop wise over 10 min. The solution was heated to 50° C. and stirred for 1 h. After cooling to room temperature, the solvents were removed under vacuum. The residue was partitioned between 20 mL EtOAc and 15 mL H2O. The organic layer was dried over MgSO4, filtered and solvent removed under vacuum yielding the title compound 113B.
    • Synthesis of (3-chloro-1H-benzofuro[3,2-c]pyrazol-5-yl)boronic acid (113C)
  • To 113B (200 mg, 0.73 mmol) in dioxane (5 mL) was added bis(pinacolato)diboron (262 mg, 1 mmol), potassium acetate (0.144 g, 1 mmol), and Pd(PPh3)2Cl2 (26 mg, 0.03 mmol). The reaction mixture sealed and heated to 100° C. for 1 h. The reaction was cooled to room temperature and telescoped to the next reaction. MS (m/z) 237.1 [M+H]+.
  • Figure US20210009555A1-20210114-C00349
    • Synthesis of N—((S)-1-(3-(3-chloro-1H-benzofuro[3,2-c]pyrazol-5-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (113D)
  • The title compound (113D) was prepared according to the method presented for the synthesis of compound 33F of Example 33 utilizing 113C and 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. H NMR (400 MHz, cd3od) δ 8.88-8.60 (m, 1H), 7.80 (d), 7.70 (d), 7.51 (d), 7.35 (t), 6.44-6.17 (m), 5.50-5.27 (m), 4.80-4.74 (m), 3.12-2.72 (m), 2.55-2.48 (m), 1.64 (s), 1.45-1.35 (m), 1.14-1.06 (m). MS (m/z) 772.2 [M+H]+.
    • Example 114
  • Figure US20210009555A1-20210114-C00350
    Figure US20210009555A1-20210114-C00351
    • Synthesis of 4-methoxy-1-methyl-1H-indazol-3-amine (114B)
  • The title compound (114B) was prepared according to the method presented for the synthesis of compound 19B of Example 19 utilizing 114A. MS (m/z) 178.1 [M+H]+.
    • Synthesis of 7-bromo-4-methoxy-1-methyl-1H-indazol-3-amine (114C)
  • A flask was charged with 114B (3.7 g, 20.9 mmol) and H2SO4 (35 mL) and cooled to 0° C. in an ice bath. Then NBS (1.9 g, 10 mmol) was added. The reaction mixture was allowed to warm to room temperature and diluted with ice water and filtered to remove solids. The mother liquor was basified with saturated NaHCO3 and extracted 2×EtOAc. The organic layer was dried over sodium sulfate, concentrated, and purified by flash column chromatography to provide the title compound. MS (m/z) 256.2 [M+H]+.
    • Synthesis of 4-methoxy-1-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (114D)
  • The title compound (114D) was prepared according to the method presented for the synthesis of compound 19C of Example 19 utilizing 114C. MS (m/z 304.2 [M+H]+. Synthesis of (S)-tert-butyl (1-(3-(3-amino-4-methoxy-1-methyl-H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (114E):
  • The title compound (114E) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 19E of Example 19 utilizing 114D. MS (m/z 592.1 [M+H]+.
    • Synthesis of (S)-4-(6-(1-amino-2-(3,5-difluorophenyl)ethyl)-5-(3-amino-4-methoxy-1-methyl-1H-indazol-7-yl)pyridin-2-yl)-2-methylbut-3-yn-2-ol (114F)
  • The title compound (114F) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 19F of Example 19 utilizing 114E. MS (m/z) 492.2 [M+H]+.
    • Synthesis of N—((S)-1-(3-(3-amino-4-methoxy-1-methyl-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (114G)
  • The title compound (114G) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 10A of Example 10 utilizing 114F and 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. 1H NMR (Methanol-d4) δ: 8.72-8.62 (m), 7.66 (dd), 7.51 (dd), 7.19 (d), 6.87-6.65 (m), 6.65-6.51 (m), 6.44 (d), 6.40-6.30 (m), 5.34-5.26 (m), 5.11-4.99 (m), 4.79-4.71 (m), 4.02 (d), 3.28-3.22 (m), 3.14 (d), 3.07 (dd), 3.02-2.90 (m), 2.83 (s), 2.53-2.35 (m), 1.63 (d), 1.38 (q), 1.11-0.99 (m). MS (m/z) 738.6 [M+H]+.
    • Example 115
  • Figure US20210009555A1-20210114-C00352
    • Synthesis of (S)-(2-(1-((tert-butoxycarbonyl)amino)-2-(3,5-difluorophenyl)ethyl)-6-(3,3-dimethylbut-1-yn-1-yl)pyridin-3-yl)boronic acid (115A)
  • The title compound (115A) was prepared according to the method presented for the synthesis of compound 117B of Example 117 utilizing (S)-(6-bromo-2-(1-((tert-butoxycarbonyl)amino)-2-(3,5-difluorophenyl)ethyl)pyridin-3-yl)boronic acid (117A) and 3,3-dimethylbut-1-yne. MS (m/z): 459.22 [M+H]+.
    • Synthesis of (S)-tert-butyl (1-(3-(3-amino-5-chloro-[1,2,4]triazolo[4,3-a]pyridin-8-yl)-6-(3,3-dimethylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (115B)
  • The title compound (115B) was prepared according to the method presented for the synthesis of compound 106C of Example 106 utilizing compound 115A and compound 106B. MS (m/z): 581.14 [M+H]+.
    • Synthesis of N—((S)-1-(3-(3-amino-5-chloro-[1,2,4]triazolo[4,3-a]pyridin-8-yl)-6-(3,3-dimethylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (115C)
  • The title compound (115C) was prepared according to the method presented for the synthesis of compound 37E of Example 37 utilizing 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid and compound 115B. 1H NMR (400 MHz, Methanol-d4): δ 8.74 (d), 7.68 (d), 7.45 (d), 7.03 (d), 6.69-6.62 (m), 6.65 (t), 6.59-6.45 (m), 5.36-5.14 (m), 4.69 (s), 3.23-3.05 (m), 2.59-2.22 (m), 1.39 (s), 1.41-1.28 (m), 1.13-0.83 (m). MS (m/z): 727.41 [M+H]+.
    • Example 116
  • Figure US20210009555A1-20210114-C00353
    • Synthesis of N—((S)-1-(3-(3-amino-5-methyl-[1,2,4]triazolo[4,3-a]pyridin-8-yl)-6-(3,3-dimethylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (116A)
  • In a microwave tube were charged with compound 115C (15 mg, 0.02 mmol), trimethylboroxine (9 μL, 0.06 mmol), potassium carbonate (8.5 mg, 0.06 mmol) and PdCl2[PPh3]2 (1.5 mg, 0.002 mmol). To the mixture was added 1 mL of 1,4-dioxane and 0.1 mL of water. The mixture was heated to 160° C. for 20 minutes in a microwave synthesizer. After cooled to room temperature, it was partitioned between EtOAc and water. The organic layer was separated and washed with brine, then dried over MgSO4, filtered and concentrated. The residue was purified by reverse phase HPLC to afford the title compound 116A. 1H NMR (400 MHz, Methanol-d4) δ 8.82 (d), 7.67 (d), 7.47 (d), 6.87 (dd), 6.72-6.65 (m), 6.68 (t), 6.58-6.45 (m), 5.26-5.11 (m), 4.70 (s), 3.25-3.05 (m), 2.99 (d), 2.58-2.32 (m), 1.39 (s), 1.39-1.37 (m), 1.14-0.88 (m). MS (m/z) 707.30 [M+H]+.
  • Compound 116B was obtained as a side product. MS (m/z): 693.23 [M+H]+.
    • Example 117
  • Figure US20210009555A1-20210114-C00354
    Figure US20210009555A1-20210114-C00355
    • Synthesis of (S)-(6-bromo-2-(1-((tert-butoxycarbonyl)amino)-2-(3,5-difluorophenyl)ethyl)pyridin-3-yl)boronic acid (117A)
  • To a solution (S)-tert-butyl (1-(3,6-dibromopyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (14A) (6.2 g, 12.6 mmol) in 2-methyltetrahydrofuran (25 ml) was added dropwise 1M LiHMDS in THF (12.6 ml) at 0° C. After stirring at room temperature for 20 minutes, the reaction was concentrated in vacuo, dissolved in toluene (30 mL), concentrated in vacuo, and re-dissolved in 2-MeTHF (25 ml). To the resulting solution was added triisopropyl borate (7.11 ml, 37.8 mmol) at −78° C. followed by the dropwise addition of 1M n-butyllithium in hexanes (20 ml) over 15 minutes. After stirring for 5 minutes, the reactions were gradually warmed to 0° C., and quenched with 4M aqueous NH4Cl (75 mL). Additional 2-MeTHF (25 mL) was added and the organic layer was dried with Na2SO4, filtered, and concentrated in vacuo. The crude product was taken to the next step without further purification. MS (m/z) 456.87 [M+H]+.
    • Synthesis of (S)-(2-(1-((tert-butoxycarbonyl)amino)-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)boronic acid (117B)
  • A solution of (S)-(6-bromo-2-(1-((tert-butoxycarbonyl)amino)-2-(3,5-difluorophenyl)ethyl)pyridin-3-yl)boronic acid (117A) (5.76 g, 12.6 mmol), 2-methyl-3-butyn-2-ol (2.44 ml, 25.2 mmol), and triethylamine (7.0 ml, 50.4 mmol) in tetrahydrofuran (21 ml) was degassed with argon. To the reaction was added CuI (72 mg, 0.38 mmol) and PdCl2(PPh3)2 (2.65 g, 0.38 mmol) and the resulting mixture was stirred at room temperature for 1 h. The reaction was concentrated in vacuo and extracted with ethyl acetate and water. The organic layer was dried with Na2SO4, filtered, concentrated in vacuo, and purified by silica chromatography to give the title compound. MS (m/z) 460.11 [M+H]+.
    • Synthesis of 8-bromo-N-(2,2,2-trifluoroethyl)-[1,2,4]triazolo[4,3-a]pyridin-3-amine (117C)
  • The title compound (117C) was prepared according to the method presented for the synthesis of 76C in Example 76 utilizing 3-bromo-2-hydrazinylpyridine and 1,1,1-trifluoro-2-isothiocyanatoethane. MS (m/z) 295.0 [M+H]+.
    • Synthesis of (S)-tert-butyl (2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(3-((2,2,2-trifluoroethyl)amino)-[1,2,4]triazolo[4,3-a]pyridin-8-yl)pyridin-2-yl)ethyl)carbamate (117D)
  • In a microwave vial, (S)-(2-(1-((tert-butoxycarbonyl)amino)-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)boronic acid (117B, 30 mg, 0.07 mmol) was combined with 8-bromo-N-(2,2,2-trifluoroethyl)-[1,2,4]triazolo[4,3-a]pyridin-3-amine (117C, 19 mg, 0.07 mmol), PdCl2(PPh3)2 (2 mg, 5 mol %), K2CO3 (65 ml of 2 M aqueous solution), and LiCl (1 mg) in dioxane (1 ml). Argon was bubbled into the reaction solution for 5 min. The reaction was heated in a microwave reactor at 155° C. for 15 min. After cooling to ambient temperature, the reaction was partitioned between EtOAc and water. The organics were separated, dried, and removed in vacuo and the residue was purified by column chromatography on silica to provide the title compound (117D). MS (m/z) 631.0 [M+H]+.
    • Synthesis of (S)-4-(6-(1-amino-2-(3,5-difluorophenyl)ethyl)-5-(3-((2,2,2-trifluoroethyl)amino)-[1,2,4]triazolo[4,3-a]pyridin-8-yl)pyridin-2-yl)-2-methylbut-3-yn-2-ol (117E)
  • The title compound (117E) was prepared according to the method presented for the synthesis of compound 19F of Example 19 utilizing compound 117D.
    • Synthesis of 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(3-((2,2,2-trifluoroethylamino)-[1,2,4]triazolo[4,3-a]pyridin-8-yl)pyridin-2-yl)ethyl)acetamide (117F)
  • The title compound (117F) was prepared according to the method presented for the synthesis of compound 37E of Example 37 utilizing compound 117E. 1H NMR (400 MHz, Methanol-d4) δ 8.85 (d), 8.34 (d), 7.76 (d), 7.56 (d), 7.38 (s), 7.23 (t), 6.67 (t), 6.66-6.58 (m), 6.51-6.45 (m), 5.30-5.12 (m), 4.69 (s), 4.33-4.18 (m), 3.27-3.04 (m), 2.53-2.36 (m), 2.00 (d), 1.43-1.26 (m), 1.03 (s). MS (m/z) 777.1 [M+H]+.
    • Example 118
  • Figure US20210009555A1-20210114-C00356
    • Synthesis of N—((S)-1-(3-(5-chloro-3-(methylsulfonamido)-[1,2,4]triazolo[4,3-a]pyridin-8-yl)-6-(3,3-dimethylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (118)
  • The title compound (118) was prepared according to the method presented for the synthesis of compound 19D of Example 19 utilizing compound 115C. H NMR (400 MHz, Methanol-d4) δ 8.67 (d), 7.69 (d), 7.42 (d), 7.09-6.97 (m), 6.89 (d), 6.70 (t), 6.63 (t), 6.53-6.41 (m), 5.37-5.19 (m), 4.72 (s), 3.22-3.00 (m), 3.11 (s), 2.56-2.35 (m), 1.39 (s), 1.39-1.33 (m), 1.13-0.91 (m). MS (m/z): 805.78 [M+H]+.
    • Example 119
  • Figure US20210009555A1-20210114-C00357
    • Synthesis of (S)-tert-butyl (1-(3-(4-chloro-1-methyl-3-(sulfamoylamino)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (119A)
  • The title compound (119A) was prepared as a mixture of atropisomers according to the method presented for the synthesis of 70 in Example 70 utilizing 55A. MS (m/z) 675.0 [M+H]+.
    • Synthesis of 119B
  • The title compound (119B) was prepared as a mixture of atropisomers according to the method presented for the synthesis of 19F in Example 19 utilizing 119A. MS (m/z) 575.2 [M+H]+.
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(sulfamoylamino)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (119C)
  • The title compound (119C) was prepared as a mixture of atropisomers according to the method presented for the synthesis of 10A in Example 10 utilizing 119B and 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. 1H NMR (400 MHz, Methanol-d4) δ 8.76 (d), 7.68 (dd), 7.53 (dd), 7.14 (q), 7.05 (d), 6.82-6.69 (m), 6.69-6.57 (m), 6.46-6.40 (m), 6.40-6.30 (m), 5.33-5.21 (m), 5.05-4.92 (m), 4.81-4.76 (m), 3.52-3.43 (m), 3.29-3.20 (m), 3.12 (dd), 3.06-2.92 (m), 2.60-2.40 (m), 1.49-1.31 (m), 1.25 (dd), 1.17-1.03 (m). MS (m/z): 839.8 [M+H]+.
    • Example 120
  • Figure US20210009555A1-20210114-C00358
    Figure US20210009555A1-20210114-C00359
    • Synthesis of 5-bromo-3-methylimidazo[1,5-a]pyridine (120A)
  • 6-(Bromopyridin-2-yl)methylamine (4.0 g, 21.4 mmol) was added dropwise to acetic anhydride (10 ml) at 0° C. The reaction was warmed to room temperature and to the reaction was added p-toluenesulfonic acid (4.07 g, 20.4 mmol). The reaction was heated in a microwave reactor at 140° C. for 25 minutes. The reaction was concentrated in vacuo, the crude product was taken up in water, pH adjusted to ˜9 with 1N aqueous NaOH, and extracted with twice with ethyl acetate. The organic layers were dried with Na2SO4, filtered, concentrated in vacuo, and purified by silica gel chromatography to give the title compound. MS (m/z) 213.06 [M+H]+.
    • Synthesis of 5-bromo-3-methyl-1-nitroimidazo[1,5-a]pyridine (120B)
  • To 5-bromo-3-methylimidazo[1,5-a]pyridine (120A) (3.0 g, 14.2 mmol) in acetic acid (15 ml) was added dropwise a solution of 70% HNO3 (0.82 ml) and conc. H2SO4 (0.82 ml) in acetic acid (8 ml). An exotherm was produced during the reaction. After stirring at room temperature for 45 mins, the resulting solution was added to stirring mixture of ice and brine (150 mL). To the chilled solution was added 8M aqueous NaOH (4.3 mL). The yellow precipitate was filtered and washed with water. The crude product was taken to the next step without further purification. MS (m/z) 255.95 [M+H]+.
    • Synthesis of N-(5-bromo-3-methylimidazo[1,5-a]pyridin-1-yl)-2,2,2-trifluoroacetamide (120C)
  • To a solution of 5-bromo-3-methyl-1-nitroimidazo[1,5-a]pyridine (120B) (0.30 g, 1.17 mmol) and trifluoroacetic acid anhydride (0.5 ml, 3.51 mmol) in trifluoroacetic acid (4.2 ml) was added in portions zinc dust (0.15 g, 2.34 mmol). The reaction produces a strong exotherm. Upon completion, the reaction was concentrated in vacuo, and extracted with EtOAc and saturated aqueous NaHCO3. The organic layer was dried with Na2SO4, filtered, concentrated in vacuo, and purified by silica gel chromatography eluting with ethyl acetate and hexanes to give the title compound. MS (m/z) 322.018 [M+H]+.
    • Synthesis of 5-bromo-3-methylimidazo[1,5-a]pyridin-1-amine (120D)
  • A solution of N-(5-bromo-3-methylimidazo[1,5-a]pyridin-1-yl)-2,2,2-trifluoroacetamide (120C) (50 mg, 0.16 mmol) in 7N ammonia in methanol (1 ml) was heated in a microwave reactor at 70° C. for 30 minutes. The reaction was concentrated in vacuo. The resulting crude mixture was suspended in EtOAc, concentrated in vacuo, and dried under vacuum. The crude product was taken to the next step without further purification. MS (m/z) 228.12 [M+H]+.
    • Synthesis of N-(5-bromo-3-methylimidazo[1,5-a]pyridin-1-yl)methanesulfonamide (120E)
  • To a solution of 5-bromo-3-methylimidazo[1,5-a]pyridin-1-amine (120D) (35 mg) and triethylamine (48 ul, 0.34 mmol) in dichloromethane (0.5 ml) was added methanesulfonyl chloride (24 μl, 0.31 mmol). After stirring at room temperature for 30 minutes, 2M methylamine in THF (0.250 mL) was added, and the reaction was concentrated in vacuo. The crude product was dissolved in 2-propanol (2.0 mL) and to the reaction was added 1.0M aqueous NaOH (2.0 mL). After stirring at room temperature for 1.5 h, the reaction was acidified with AcOH (180 uL), and the resulting mixture was concentrated in vacuo. The mixture was extracted with ethyl acetate and water. The organic layers were dried with Na2SO4, filtered, concentrated in vacuo, and purified by silica gel chromatography to give the title compound. MS (m/z) 305.88 [M+H]+.
    • Synthesis of (S)-tert-butyl (2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(3-methyl-1-(methylsulfonamido)imidazo[1,5-a]pyridin-5-yl)pyridin-2-yl)ethyl)carbamate (120F)
  • A solution of N-(5-bromo-3-methylimidazo[1,5-a]pyridin-1-yl)methanesulfonamide (120E) (50 mg, 0.16 mmol), (S)-(2-(1-((tert-butoxycarbonyl)amino)-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)boronic acid (117B) (90.8 mg, 0.20 μmol), and dichlorobis(triphenylphosphine)palladium(II) (11.5 mg, 0.016 mmol) in dioxane (1.2 ml) was purged with argon. To the reaction was added 1M aqueous Na2CO3 (0.4 ml), solution was purged with argon, and heated in a microwave reactor for 30 mins at 120° C. To the resulting solution was added 5% AcOH in brine (10 mL) and was extracted twice with EtOAc. The organic layers were dried with Na2SO4, filtered, concentrated in vacuo, and purified by silica gel chromatography to give the title compound as a mixture of atropisomers. MS (m/z) 639.94 [M+H]+.
    • Synthesis of (S)—N-(5-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-3-methylimidazo[1,5-a]pyridin-1-yl)methanesulfonamide (120G)
  • (S)-tert-butyl (2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(3-methyl-1-(methylsulfonamido)imidazo[1,5-a]pyridin-5-yl)pyridin-2-yl)ethyl)carbamate (120F) (75 mg, 0.12 mmol) was dissolved in DCM (1.0 mL) and TFA (0.5 mL) and stirred at room temperature for 30 mins. The resulting solution was concentrated in vacuo and extracted with ethyl acetate and saturated aqueous NaHCO3 followed by water. The organic layer was dried with Na2SO4, filtered, and concentrated in vacuo. The crude product as a mixture of atropisomers was taken to the next step without further purification. MS (m/z) 540.12 [M+H]+.
    • Synthesis of 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(3-methyl-1-(methylsulfonamido)imidazo[1,5-a]pyridin-5-yl)pyridin-2-yl)ethyl)acetamide (120H)
  • The title compound (120H) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound (33F) of Example 33 utilizing (S)—N-(5-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-3-methylimidazo[1,5-a]pyridin-1-yl)methanesulfonamide (120G). H NMR (400 MHz, Methanol-d4) δ 8.88-8.81 (m), 8.75 (d), 7.84 (dd), 7.70-7.53 (m), 6.90 (dd), 6.83-6.74 (m), 6.73-6.65 (m), 6.58 (dd), 6.54-6.46 (m), 5.99 (dd), 5.31-5.22 (m), 5.01-4.92 (m), 4.74-4.61 (m), 3.41-3.28 (m), 3.24-3.12 (m), 3.10-2.99 (m), 2.53-2.39 (m), 1.87 (s), 1.65 (s), 1.64 (s), 1.43-1.33 (m), 1.11-1.04 (m), 1.05-0.97 (m). MS (m/z) 786.13 [M+H]+.
    • Example 121
  • Figure US20210009555A1-20210114-C00360
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-1-1-yl)-3-(3-methyl-1-(methylsulfonamido)imidazo[1,5-a]pyridin-5-yl)pyridin-2-yl)ethyl)acetamide (121)
  • The title compound (121) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound (33F) of Example 33 utilizing (S)—N-(5-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-3-methylimidazo[1,5-a]pyridin-1-yl)methanesulfonamide (120G) and 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. 1H NMR (400 MHz, Methanol-d4) 8.97 (d), 8.83 (d), 7.84 (dd), 7.70 (dd), 7.65-7.52 (m), 6.96-6.86 (m), 6.84-6.74 (m), 6.70-6.62 (m), 6.62-6.55 (m), 6.54-6.43 (m), 5.99 (dd), 5.32-5.22 (m), 5.01-4.89 (m), 4.81-4.66 (m), 3.51-3.36 (m), 3.26-3.15 (m), 3.14-2.97 (m), 2.55-2.43 (m), 1.88 (s), 1.65 (s), 1.64 (s), 1.46 (s), 1.45-1.36 (m), 1.13 (s), 1.09-1.04 (m). MS (m/z) 804.15 [M+H]+.
    • Example 122
  • Figure US20210009555A1-20210114-C00361
    • Synthesis of (S)—N-(1-(3-(4-chloro-1-methyl-3-(sulfamoylamino)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide (122)
  • The title compound (122) was prepared as a mixture of atropisomers according to the method presented for the synthesis of 10A in Example 10 utilizing 119B and 2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetic acid. H NMR (400 MHz, Methanol-d4) δ 8.91-8.81 (m), 7.69 (dd), 7.53 (dd), 7.22-7.12 (m), 7.06 (d), 6.98-6.59 (m), 6.50-6.32 (m), 5.36-5.24 (m), 4.99 (d), 3.34 (s), 3.24 (dd), 3.14 (dd), 3.02 (s), 2.97 (dd), 2.66-2.38 (m), 1.63 (s). MS (m/z): 859.3 [M+H]+.
    • Example 123
  • Figure US20210009555A1-20210114-C00362
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-((N-methylsulfamoyl)amino)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (123)
  • The title compound (123) was prepared as a mixture of atropisomers according to the method presented for the synthesis of 70 in Example 70 utilizing 57 and methylsulfamoyl chloride. 1H NMR (400 MHz, Methanol-d4) δ 8.75-8.67 (m), 7.68 (d), 7.57-7.51 (m), 7.15 (d), 7.06 (d), 6.86-6.52 (m), 6.48-6.29 (m), 5.33-5.23 (m), 4.96 (q), 4.80-4.64 (m), 3.21-3.05 (m), 3.05-2.89 (m), 2.78 (s), 2.72 (s), 2.55-2.39 (m), 1.64 (s), 1.48-1.28 (m), 1.11-0.95 (m). MS (m/z) 835.8 [M+H]+.
    • Example 124
  • Figure US20210009555A1-20210114-C00363
    • Synthesis of (S)—N-(1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide (124)
  • The title compound (124) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 10A of Example 10 utilizing (S)—N-(7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide (19F) and 2-(3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetic acid. 1H NMR (400 MHz, Methanol-d4) 8.68 (t), 7.71 (dd), 7.54 (dd), 7.25-7.14 (m), 7.11 (d), 6.80-6.73 (m), 6.69-6.60 (m), 6.53 (dd), 6.46-6.36 (m), 5.29-5.22 (m), 5.04-4.96 (m), 4.91-4.75 (m), 4.72 (d), 4.67 (d), 4.17 (s), 3.58 (s), 3.33 (s), 3.26 (s), 3.23 (s), 3.15 (dd), 3.04 (s), 3.02-2.94 (m), 2.65-2.43 (m), 2.40-2.28 (m), 1.85-1.69 (m), 1.64 (s), 1.64 (s). MS (m/z) 804.18 [M+H]+.
    • Examples 125 and 126
  • Figure US20210009555A1-20210114-C00364
    Figure US20210009555A1-20210114-C00365
    • Synthesis of 3-chloro-4,5,6,7-tetrahydro-1H-indazole (125A)
  • A solution of 4,5,6,7-tetrahydro-1H-indazol-3-ol (0.41 g, 3.0 mmol) in trichlorophosphate (1.5 ml) was heated in a microwave reactor under argon at 225° C. for 15 minutes. The reaction was concentrated in vacuo and carefully quenched with 1.0N aqueous NaOH at 0° C. and extracted with dichloromethane. The organic layer was dried with Na2SO4, filtered, concentrated in vacuo and purified by silica gel chromatography to give the title compound. MS (m/z) 157.14 [M+H]+.
    • Synthesis of a 1:5 mixture of ethyl 2-(3-chloro-4,5,6,7-tetrahydro-2H-indazol-2-yl)acetate and ethyl 2-(3-chloro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetate (125B)
  • To a solution of 3-chloro-4,5,6,7-tetrahydro-1H-indazole (125A) in DMF (1.6 ml) was added portionwise NaH (60% w/mineral oil) (74.9 mg, 1.95 mmol). After stirring at room temperature for 15 mins, ethyl bromoacetate (0.22 ml, 1.95 mmol) was added dropwise at 0° C. The reaction was warmed to room temperature and stirred for 2 h. The reaction was quenched with water and extracted with ethyl acetate. The organic layer was washed with water. The organic layer was dried with Na2SO4, filtered, concentrated in vacuo and purified by silica gel chromatography to give the title compounds as a 1:5 mixture of ethyl 2-(3-chloro-4,5,6,7-tetrahydro-2H-indazol-2-yl)acetate and ethyl 2-(3-chloro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetate (125B). MS (m/z) 243.11 [M+H]+.
    • Synthesis of a 1:5 mixture of 2-(3-chloro-4,5,6,7-tetrahydro-2H-indazol-2-yl)acetic acid and 2-(3-chloro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetic acid (125C)
  • To a 1:5 mixture of ethyl 2-(3-chloro-4,5,6,7-tetrahydro-2H-indazol-2-yl)acetate and ethyl 2-(3-chloro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetate (125B) (15 mg, 61.8 μmol) in methanol (250 μl) was added 2M aqueous LiOH (62 μl). The reaction was heated at 50° C. for 1.5 h. The mixture was concentrated in vacuo, extracted with 2-methyltetrahydrofuran (2 mL) and 0.1N HCl (1.3 mL). The organic layer was dried with Na2SO4, filtered, and concentrated in vacuo. The crude product was taken to the next step without further purification. MS (m/z) 215.14 [M+H]+.
    • Syntheses of (S)—N-(1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-chloro-4,5,6,7-tetrahydro-2H-indazol-2-yl)acetamide (125D) and of (S)—N-(1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-chloro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide (126)
  • The title compounds (125D and 126) were both prepared as mixtures of atropisomers according to the method presented for the synthesis of compound 33F of Example 33 utilizing the free base form of (S)—N-(7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide (19F) and 1:5 mixture of 2-(3-chloro-4,5,6,7-tetrahydro-2H-indazol-2-yl)acetic acid and 2-(3-chloro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetic acid (125C). The regioisomers were separated by reverse phase HPLC to provide the title products. (125D): 1H NMR (400 MHz, Methanol-d4) δ 8.56-8.45 (m), 7.70 (dd), 7.53 (dd), 7.27-7.14 (m), 7.10 (d), 6.79-6.71 (m), 6.66-6.59 (m), 6.53-6.47 (m), 6.44-6.33 (m), 5.32-5.22 (m), 5.05-4.92 (m), 4.71 (d), 4.67 (s), 3.36 (s), 3.25 (s), 3.23 (s), 3.21-3.16 (m), 3.16-3.07 (m), 3.03 (s), 3.01-2.90 (m), 2.64-2.53 (m), 2.44-2.30 (m), 1.76 (dd), 1.64 (s), 1.64 (s). MS (m/z) 770.24 [M+H]+. (126): 1H NMR (400 MHz, Methanol-d4) 7.71 (dd), 7.53 (dd), 7.27-7.14 (m), 7.11 (d), 6.82-6.7 (m), 6.68-6.60 (m), 6.54 (d), 6.47-6.34 (m), 5.26 (dd), 5.00 (t), 4.60 (s), 4.55 (s), 3.34 (s), 3.26 (s), 3.23 (s), 3.25-3.19 (m), 3.17-3.10 (m), 3.03 (s), 3.02-2.92 (m), 2.47-2.27 (m), 1.85-1.67 (m), 1.64 (s), 1.64 (s). MS (m/z) 770.24 [M+H]+.
    • Example 127
  • Figure US20210009555A1-20210114-C00366
    • Synthesis of N—((S)-1-(6-(3-amino-3-methylbut-1-yn-1-yl)-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (127)
  • The title compound (127) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 142 of Example 142 utilizing 2-methylbut-3-yn-2-amine. 1H NMR (400 MHz, cd3od) δ 8.79 (t), 7.79 (d), 7.76 (d), 7.64 (d), 7.61 (d), 7.22-7.15 (m), 7.08 (d), 6.82-6.75 (m), 6.70-6.63 (m), 6.45-6.40 (m), 6.40-6.35 (m), 5.30-5.21 (m), 5.04-4.95 (m), 4.78 (s), 4.75 (d), 3.32 (s), 3.26 (s), 3.23 (s), 3.20-3.13 (m), 3.06-2.95 (m), 2.94 (s), 2.50 (ddt), 1.82 (s), 1.82 (s), 1.48-1.28 (m), 1.14 (dd), 1.09-1.00 (m). MS (m/z) 838.3 [M+H]+.
    • Example 128
  • Figure US20210009555A1-20210114-C00367
    • Synthesis of N1,N1-dimethyl-N2-(2-methylbut-3-yn-2-yl)ethane-1,2-diamine (128A)
  • Argon was bubbled through a solution of 2-methylbut-3-yn-2-yl acetate (15.96 mg, 126.5 μmol), copper chloride (0.75 mg, 7.59 μmol), triethylamine (17.63 μl, 126.5 μmol), and N,N-dimethylethylenediamine (20.73 μl, 189.74 μmol) in DMF (0.2 ml). The reaction was heated in a microwave reactor at 110° C. for 5 min. The reaction was cooled to room temperature and telescoped to the next reaction.
    • Synthesis of N—((S)-1-(6-(3-amino-3-methylbut-1-yn-1-yl)-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (128B)
  • Into the reaction was added 157F (20 mg, 25.3 μmol) in DMF (0.2 mL), CuI (1 mg, 5.06 μmol), and PdCl2(PPh3)2 (3.55 mg, 5.06 μmol). Argon was bubbled through the reaction and diethylamine (39 μl, 379 μmol) was added. The reaction was heated in a microwave reactor for 15 mins at 125° C. The excess amines were removed under vacuum and the product was purified by reverse phase HPLC the title product 128B as a mixture of atropisomers. 1H NMR (400 MHz, cd3od) δ 8.76 (t), 7.76 (d), 7.73 (d), 7.64 (d), 7.61 (d), 7.21-7.16 (m), 7.07 (d), 6.82-6.74 (m), 6.69-6.62 (m), 6.45-6.40 (m), 6.37 (ddd), 5.30-5.24 (m), 4.99 (dd), 4.78 (s), 4.76 (d), 3.60-3.48 (m), 3.32 (s), 3.26 (s), 3.23 (s), 3.18-3.11 (m), 3.01 (s), 2.97 (s), 2.58-2.42 (m), 1.77 (s), 1.48-1.37 (m), 1.13 (tt), 1.10-1.03 (m). MS (m/z) 908.3 [M+H]+.
    • Example 129
  • Figure US20210009555A1-20210114-C00368
    • Synthesis of (S)—N-(1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(2,3-dichlorophenyl)acetamide (129)
  • The title compound (129) was prepared as a mixture of atropisomers according to the method presented in the synthesis of 10A in Example 10 utilizing 19F and 2-(2,3-dichlorophenyl)acetic acid. 1H NMR (400 MHz, Methanol-d4) δ 7.70 (dd), 7.53 (dd), 7.44 (dd), 7.39 (dd), 7.28-7.05 (m), 6.80-6.69 (m), 6.68-6.61 (m), 6.60 (d), 6.48-6.36 (m), 5.35-5.20 (m), 5.06-4.92 (m), 3.67 (s), 3.62 (s), 3.22 (s), 3.20-3.11 (m), 3.07 (s), 3.00 (dd), 1.64 (s). MS (m/z) 762.3 [M+H]+.
    • Example 130
  • Figure US20210009555A1-20210114-C00369
    • Synthesis of 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3,3-dimethylbut-1-yn-1-yl)-3-(5-methoxy-3-(methylsulfonamido)-[1,2,4]triazolo[4,3-a]pyridin-8-yl)pyridin-2-yl)ethyl)acetamide (130)
  • To compound 115C (15 mg, 0.2 mmol) dissolved in 0.5 mL of methylene chloride was added triethylamine (37 μL, 0.2 mmol) followed by methanesulfonyl chloride (8 μL, 0.1 mmol). The reaction mixture was allowed to stir at room temperature for 30 minutes. The reaction was diluted with methylene chloride and water. The organic layer was separated, dried over sodium sulfate, filtered and concentrated. The residue was dissolved in 1 mL of methanol and to it was added 0.1 mL of 15% NaOH aqueous solution. The mixture was stirred at 40° C. for overnight then 60° C. for 7 hours. The solvent was removed and the residue was purified by RP-HPLC to afford the title compound 130. 1H NMR (400 MHz, Methanol-d4) δ 7.68 (d), 7.43 (d), 7.22-7.11 (m), 6.70 (t), 6.63 (t), 6.53-6.43 (m), 6.27 (d), 5.28 (t), 4.71 (s), 4.12 (s), 3.26-2.89 (m), 3.18 (s), 2.52-2.40 (m), 1.40-1.31 (m), 1.39 (s), 1.09-1.00 (m). MS (m/z): 801.65 [M+H]+.
    • Example 131
  • Figure US20210009555A1-20210114-C00370
    • Synthesis of (S)-tert-butyl (1-(3-bromo-6-(3,3-dimethylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (131A)
  • The title compound (131A) was prepared according to the method presented for the synthesis of compound 4F of Example 4 utilizing compound 14A and 3,3-dimethylbut-1-yne. MS (m/z) 494.92 [M+H]+.
    • Synthesis of (S)-tert-butyl (1-(3-(3-amino-4-chloro-1-methyl-1H-indazol-7-yl)-6-(3,3-dimethylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (131B)
  • The title compound (131B) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 19E of Example 19 utilizing compound 131A and compound 19C. MS (m/z) 594.44 [M+H]+.
    • Synthesis of (S)-7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-6-(3,3-dimethylbut-1-yn-1-yl)pyridin-3-yl)-4-chloro-1-methyl-1H-indazol-3-amine (131C)
  • The title compound (131C) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 105C of Example 105 utilizing compound 131B. MS (m/z) 494.26 [M+H]+.
    • Synthesis of N—((S)-1-(3-(3-amino-4-chloro-1-methyl-1H-indazol-7-yl)-6-(3,3-dimethylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (131D)
  • The title compound 131D was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 37E of Example 37 utilizing 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid and compound 131C. MS (m/z) 740.35 [M+H]+.
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3,3-dimethylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (131E)
  • The title compound (131E) was prepared according to the method presented for the synthesis of compound 19D of Example 19 utilizing compound 131D. 1H NMR (400 MHz, Methanol-d4) δ 7.67-7.63 (m), 7.49-7.44 (m), 7.17 (d), 7.06 (d), 6.90-6.47 (m), 6.79 (t), 6.47-6.20 (m), 5.33-5.23 (m), 4.95 (t), 4.79-4.49 (m), 3.33 (s), 3.24 (d), 3.13 (dd), 3.05-2.83 (m), 3.00 (s), 2.58-2.14 (m), 1.43-1.31 (m), 1.41 (s), 1.13-0.93 (m). MS (m/z): 818.15 [M+H]+.
    • Example 132
  • Figure US20210009555A1-20210114-C00371
    • Synthesis of 7-bromo-4-fluoro-1-methyl-1H-indazol-3-amine (132A)
  • A solution of 4-fluoro-1-methyl-1H-indazol-3-amine (4.3 g, 26 mmol) in concentrated sulfuric acid (26 ml) was cooled to 0° C. then treated in three portions with N-bromosuccinimide (4.64 g, 26 mmol). The reaction was allowed to slowly reach room temperature and stirred for 15 h. The reaction was carefully quenched with water, filtered, and the filtrate was neutralized. The neutralized solution was then extracted with ethyl acetate, dried over sodium sulfate, filtered and concentrated. The crude material was purified by silica gel chromatography to give the title compound. MS (m/z) 246.1[M+H]+.
    • Synthesis of N-(7-bromo-4-fluoro-1-methyl-1H-indazol-3-yl)methanesulfonamide (132B)
  • The title compound was prepared similarly to 108B of Example 108 starting from 132A. MS (m/z) 320.3 [M−H]−.
  • Figure US20210009555A1-20210114-C00372
    • Synthesis of 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(3-(4-fluoro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)ethyl)acetamide (132C)
  • The title compound (132C) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 117F of Example 117 utilizing 132B, 117B and 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. 1H NMR (400 MHz, cd3od) δ 8.80-8.75 (m), 7.70 (d), 7.65-7.59 (m), 7.52 (d), 7.35-7.30 (m), 7.22-7.17 (m), 7.11-7.06 (m), 6.75-6.70 (m), 6.49-6.44 (m), 6.23-6.16 (m), 5.52-5.47 (m),5.00-4.95 (m), 4.86 (d), 3.26 (t), 3.02-2.97 (m), 2.52-2.47 (m), 1.63 (s), 1.45-1.36 (m), 1.33-1.27 (m), 1.15-1.10 (m). MS (m/z) 822.1 [M+H]+.
    • Example 133
  • Figure US20210009555A1-20210114-C00373
    • Synthesis of 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3,3-dimethylbut-1-yn-1-yl)-3-(5-methyl-3-(methylsulfonamido)-[1,2,4]triazolo[4,3-a]pyridin-8-yl)pyridin-2-yl)ethyl)acetamide (133)
  • The title compound (133) was prepared according to the method presented for the synthesis of compound 19D of Example 19 utilizing compound 116A. H NMR (400 MHz, Methanol-d4): δ 7.66 (d), 7.41 (dd), 7.02-6.90 (m), 6.71 (t), 6.63 (t), 6.56-6.37 (m), 5.41-5.23 (m), 4.74 (d), 3.23-2.75 (m), 3.06 (s), 2.92 (s), 2.46 (ddd), 1.45-1.32 (m), 1.39 (s), 1.11-1.01 (m). MS (m/z): 785.31 [M+H]+.
    • Example 134
  • Figure US20210009555A1-20210114-C00374
    • Synthesis of 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3,3-dimethylbut-1-yn-1-yl)-3-(3-(methylsulfonamido)-[1,2,4]triazolo[4,3-a]pyridin-8-yl)pyridin-2-yl)ethyl)acetamide (134)
  • The title compound (134) was prepared according to the method presented for the synthesis of compound 19D of Example 19 utilizing compound 116B. 1H NMR (400 MHz, Methanol-d4) δ 8.69 (d), 8.04 (dd), 7.71 (d), 7.43 (d), 7.21-7.12 (m), 6.91 (t), 6.70 (t), 6.62 (t), 6.50-6.41 (m), 5.41-5.26 (m), 4.74 (s), 3.25-3.10 (m), 3.06 (s), 2.55-2.36 (m), 1.43-1.21 (m), 1.40 (s), 1.14-0.96 (m). MS (m/z): 771.12 [M+H]+.
    • Example 135
  • Figure US20210009555A1-20210114-C00375
    • Synthesis of N—((S)-1-(5-amino-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (135A)
  • The title compound (135A) may be prepared analogously to the method presented for the synthesis of compound 139A of Example 139 utilizing 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid and compound 182H. MS (m/z): 853.26 [M+H]+.
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)-5-methoxypyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (135B)
  • To a solution of compound 135A (25 mg, 0.029 mmol) in MeOH (1 mL) was added t-butyl nitrite (15 mg, 0.15 mmol). The resulting solution was heated at 50° C. for 2 h. The volatiles were removed in vacuo and residue was purified by reverse phase HPLC to yield the title compound as a mixture of atropisomers. 1H NMR (400 MHz, Methanol-d4) δ 8.73 (dd), 7.69 (dd), 7.53 (dd), 7.34 (d), 7.22-7.10 (m), 7.05 (dd), 6.76 (t), 6.52-6.23 (m), 4.82-4.67 (m), 3.87 (d), 3.37 (s), 3.24 (d), 3.17-3.04 (m), 2.97 (q), 2.49 (s), 1.71-1.55 (m), 1.49-1.31 (m), 1.07 (s). MS (m/z) 868.24 [M+H]+.
    • Examples 136
  • Figure US20210009555A1-20210114-C00376
    • Synthesis of 7-bromo-4-chloro-1-methyl-1H-indazole (136A)
  • Compound 19B (150 mg, 0.58 mmol) was dissolved in Me-THF and treated with tert-butyl nitrite (0.21 ml, 1.73 mmol). The reaction was heated to 75° C. for 2 h. The reaction was diluted with EtOAc and saturated aqueous NaCl. The organics were separated, dried, and removed in vacuo and the residue was purified by column chromatography on silica to provide the title compound (136A). MS (m/z) 247.0 [M+H]+.
    • Synthesis of (S)-tert-butyl (1-(3-(4-chloro-1-methyl-1H-indazol-7-yl)-6-ethynylpyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (136B)
  • In a microwave vial, (S)-(2-(1-((tert-butoxycarbonyl)amino)-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)boronic acid (117B, 35 mg, 0.08 mmol) was combined with 7-bromo-4-chloro-1-methyl-1H-indazole (136A, 19 mg, 0.08 mmol), PdCl12(PCy3)2 (6 mg), and NaHCO3 (228 μl of 1 M aqueous solution) in dioxane (1 ml). Argon was bubbled into the reaction solution for 5 min. The reaction was heated in a microwave reactor at 155° C. for 15 min. After cooling to ambient temperature, the reaction was partitioned between EtOAc and water. The organics were separated, dried, and removed in vacuo and the residue was purified by column chromatography on silica to provide the title compound (136B). MS (m/z) 523.2 [M+H]+.
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-1H-indazol-7-yl)-6-ethynylpyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (136C)
  • The title compound (136C) was prepared according to the method presented for the synthesis of compound 19F of Example 19 utilizing compound 136B. MS (m/z): 423.1 [M+H]+.
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-1H-indazol-7-yl)-6-ethynylpyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (136D)
  • The title compound (136D) was prepared according to the method presented for the synthesis of compound 10A of Example 10 utilizing compound 136C and 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. 1H NMR (400 MHz, DMSO-d6) δ 8.89 (d), 8.23 (s), 7.87 (t), 7.66 (dd), 7.43 (d), 7.29 (d), 7.07-6.99 (m), 6.98-6.96 (m), 6.94 (t), 5.25-5.11 (m), 4.90-4.62 (m), 3.27-2.97 (m), 2.61-2.49 (m), 1.44-1.30 (m), 0.95-0.84 (m). MS (m/z): 669.1 [M+H]+.
    • Example 137
  • Figure US20210009555A1-20210114-C00377
    • Synthesis of (S)-tert-butyl (1-(3-(4-chloro-1-methyl-1H-indazol-7-yl)-6-ethynyl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (137A)
  • In a microwave vial, (S)-(2-(1-((tert-butoxycarbonyl)amino)-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)boronic acid (117B, 35 mg, 0.08 mmol) was combined with 7-bromo-4-chloro-1-methyl-1H-indazole (136A, 19 mg, 0.08 mmol), PdCl2(PPh3)2 (5 mg), and K2CO3 (95 μl of 2 M aqueous solution) in dioxane (1 ml). Argon was bubbled into the reaction solution for 5 min. The reaction was heated in a microwave reactor at 115° C. for 15 min. After cooling to ambient temperature, the reaction was partitioned between EtOAc and water. The organics were separated, dried, and removed in vacuo and the residue was purified by column chromatography on silica to provide the title compound as a mixture of atropisomers. MS (m/z) 581.0 [M+H]+.
    • Synthesis of (S)-4-(6-(1-amino-2-(3,5-difluorophenyl)ethyl)-5-(4-chloro-1-methyl-1H-indazol-7-yl)pyridin-2-yl)-2-methylbut-3-yn-2-ol (137B)
  • The title compound (137B) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 19F of Example 19 utilizing compound 137A. MS (m/z): 481.1 [M+H]+.
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (137C)
  • The title compound (137C) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 10A of Example 10 utilizing compound 137B and 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. 1H NMR (400 MHz, Methanol-d4) δ 8.75-8.70 (m), 8.70-8.62 (m), 8.10-8.05 (m), 7.69 (dd), 7.53 (dd), 7.18 (s), 7.08 (d), 6.89-6.52 (m), 6.42 (d), 6.39-6.30 (m), 5.31-5.20 (m), 5.04-4.91 (m), 4.70 (d), 3.48 (t), 3.40 (s), 3.19-3.07 (m), 3.04 (s), 2.96 (dd), 2.54-2.38 (m), 1.64 (d), 1.44-1.27 (m), 1.14-0.96 (m). MS (m/z): 727.1 [M+H]+.
    • Example 138
  • Figure US20210009555A1-20210114-C00378
    • Synthesis of 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-1-(3-(3-(difluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-8-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)acetamide (138)
  • The title compound (138) was prepared according to the method presented for the synthesis of compound 106E of Example 106 utilizing compound 117B and 8-bromo-5-chloro-3-(difluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine. H NMR (400 MHz, Methanol-d4) δ 8.61 (dd), 7.78 (dd), 7.55 (d), 7.48 (t), 7.46-7.37 (m), 7.33-7.18 (m), 6.83-6.74 (m), 6.67 (t), 6.62-6.47 (m), 6.46-6.35 (m), 5.38-5.03 (m), 4.75-4.57 (m), 3.26-3.17 (m), 3.17-2.98 (m), 2.44 (ddd), 1.61 (d), 1.42-1.30 (m), 1.06-0.96 (m, 1H). MS (m/z): 730.22 [M+H]+.
    • Example 139
  • Figure US20210009555A1-20210114-C00379
    • Synthesis of N—((S)-1-(5-amino-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (139A)
  • The title compound (139A) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 19G of Example 19 utilizing compound 182H. MS (m/z): 835.67 [M+H]+.
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)-5-methoxypyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (139B)
  • The title compound (139B) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 135A of Example 135 utilizing compound 139A. 1H NMR (400 MHz, Methanol-d4) δ 8.62 (t), 7.75-7.47 (m), 7.34 (d), 7.21-6.96 (m), 6.90-6.64 (m), 6.53-6.21 (m), 4.78-4.60 (m), 3.86 (d), 3.36 (s), 3.24 (d), 3.15-3.07 (m), 3.01-2.90 (m), 2.61-2.35 (m), 1.64 (d), 1.37 (q), 1.28 (d), 1.03 (d). MS (m/z) 850.52 [M+H]+.
    • Example 140
  • Figure US20210009555A1-20210114-C00380
    Figure US20210009555A1-20210114-C00381
    • Synthesis of tert-butyl(((1R,2S,3R,5R)-2-(methoxymethoxy)bicyclo[3.1.0]hexan-3-yl)oxy)dimethylsilane (140A)
  • To a solution of (1R,2S,3R,5R)-3-((tert-butyldimethylsilyl)oxy)bicyclo[3.1.0]hexan-2-ol (10.4 g, 45.6 mmol, synthesis previous reported in JACS, 2007, 129, 4456-4462), DIPEA (31.7 ml, 182.4 mmol), and DMAP (556 mg, 4.56 mmol) in dichloromethane (90 mL) was added chloromethyl methyl ether (14.6 ml, 182.4 mmol) at 0° C. The mixture was warmed to room temperature and stirred overnight. The resulting solution was concentrated in vacuo and extracted twice with EtOAc and water. The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude product was taken to next step without further purification. 1H NMR (400 MHz, Chloroform-d) δ 4.09-3.99 (m, 1H), 2.50-2.38 (m, 1H), 2.05-1.96 (m, 2H), 1.84-1.76 (m, 1H), 1.57 (s, 1H), 1.31-1.14 (m, 2H), 1.06-0.99 (m, 1H), 0.95-0.81 (m, 10H), 0.07 (dd, 6H).
    • Synthesis of (1R,2S,3R,5R)-2-(methoxymethoxy)bicyclo[3.1.0]hexan-3-ol (140B)
  • To a crude solution of tert-butyl(((1R,2S,3R,5R)-2-(methoxymethoxy)bicyclo[3.1.0]hexan-3-yl)oxy)dimethylsilane (140A) (12.4 g) in THF (100 ml) was added 1M tetrabutylammonium fluoride in THF (64 mL). After stirring at room temperature for 2 h, the mixture was partially concentrated in vacuo, and extracted twice with EtOAc and water. The combined organic layers were washed with brine, dried with MgSO4, filtered, and concentrated in vacuo. The resulting mixture was slurried in 25% EtOAc and hexanes, solids filtered, and the filtrate was purified by silica gel chromatography to give the title compound. 1H NMR (400 MHz, Chloroform-d) δ 4.85-4.73 (m, 2H), 4.01-3.92 (m, 1H), 3.87-3.74 (m, 1H), 3.47-3.41 (m, 3H), 2.16-2.06 (m, 1H), 1.73-1.61 (m, 1H), 1.52-1.35 (m, 2H), 0.53-0.42 (m, 1H), 0.19-0.11 (m, 1H).
    • Synthesis of (1R,2S,5R)-2-(methoxymethoxy)bicyclo[3.1.0]hexan-3-one (140C)
  • To a mixture of (1R,2S,3R,5R)-2-(methoxymethoxy)bicyclo[3.1.0]hexan-3-ol (140B) (5.8 g, 36.7 mmol) and NaHCO3 (4.62 g, 55.1 mmol) in dichloromethane (75 ml) was added in portions Dess-Martin periodinane (17.1 g, 40.37 mmol) at −15° C. The mixture was slowly warmed to room temperature and stirred for 1 h. Upon completion, the reaction was cooled to 0° C. and 1M aqueous NaHCO3 (150 ml) was added. The solution was stirred until evolution of gas ceased, and the organic layer was separated. The aqueous layer was back extracted twice with dichloromethane, the organic layers were combined, dried with Na2SO4, filtered, and concentrated in vacuo. The resulting mixture was slurried in 25% Et2O and hexanes, solids filtered, and the filtrate was concentrated in vacuo then, purified by silica gel chromatography to give the title compound. 1H NMR (400 MHz, Chloroform-d) δ 4.89-4.62 (m, 2H), 3.66 (s, 1H), 3.45-3.35 (m, 3H), 2.81-2.69 (m, 1H), 2.19-2.08 (m, 1H), 1.73-1.54 (m, 2H), 1.03-0.92 (m, 1H), −0.00-−0.11 (m, 1H).
    • Synthesis of (3bS,4aR)-ethyl 5-(methoxymethoxy)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carboxylate (140D)
  • To a solution of (1R,2S,5R)-2-(methoxymethoxy)bicyclo[3.1.0]hexan-3-one (140C) (4.4 g, 28.2 mmol) in ethanol (28 ml) was added a solution of 21% NaOEt in EtOH (11.0 ml, 29.6 mmol) at 0° C. After stirring at room temperature for 5 minutes, diethyl oxalate (4.02 ml, 29.6 mmol) was added, and the reaction was stirred at 70° C. for 45 minutes. Upon completion, the mixture was concentrated in vacuo, dissolved in acetic acid (15 ml) and water (2 ml), and hydrazine hydrate (2.82 g, 56.4 mmol) was slowly added at 0° C. The reaction was heated in a microwave reactor at 120° C. for 10 minutes. The mixture was concentrated in vacuo and extracted with twice with 2-methyltetrahydrofuran and water. The organic layers were combined and washed with water. The organic layer was dried with Na2SO4, filtered, concentrated, and purified by silica gel chromatography to give the title compound. MS (m/z) 252.84 [M+H]+.
    • Synthesis of (3bS,4aR)-ethyl 5-hydroxy-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carboxylate (140E)
  • A solution of (3bS,4aR)-ethyl 5-(methoxymethoxy)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carboxylate (140D) (1.2 g, 4.76 mmol) in 1:1 AcOH:H2O (5 ml) was heated in a microwave reactor at 130° C. for 10 minutes. The resulting mixture was concentrated in vacuo and extracted with three times with EtOAc and water. The combined organic layers were dried with Na2SO4, filtered, concentrated in vacuo, and partially purified by silica gel chromatography eluting with ethyl acetate and hexanes. MS (m/z) 208.98 [M+H]+.
    • Synthesis of (3bS,4aR)-ethyl 2-(2-(tert-butoxy)-2-oxoethyl)-5-hydroxy-3b,4,4a,5-tetrahydro-2H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carboxylate (140F)
  • To a solution of (3bS,4aR)-ethyl 5-hydroxy-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carboxylate (140E) (990 mg) in DMF (10 ml) was added cesium carbonate (2.32 g, 7.14 mmol) followed by tert-butyl bromoacetate (0.70 ml, 4.76 mmol). After heating the reaction at 45° C. for 1 h, the resulting mixture was extracted with EtOAc and water. The organic layer was dried with Na2SO4, filtered, concentrated in vacuo, and purified by silica gel chromatography to give the title compound. MS (m/z) 322.83 [M+H]+.
    • Synthesis of (3bS,4aR)-ethyl 2-(2-(tert-butoxy)-2-oxoethyl)-5-oxo-3b,4,4a,5-tetrahydro-2H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carboxylate (140G)
  • To a solution of (3bS,4aR)-ethyl 2-(2-(tert-butoxy)-2-oxoethyl)-5-hydroxy-3b,4,4a,5-tetrahydro-2H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carboxylate (140F) (0.27 g, 0.83 mmol) in DCM (10 ml) was added Dess Martin periodinane (0.34 g, 0.91 mmol). After stirring at room temperature for 3 h, mixture was solid loaded onto silica gel and purified by silica gel chromatography to give the title compound. MS (m/z) 320.74 [M+H]+.
    • Synthesis of sodium (3bS,4aR)-2-(2-(tert-butoxy)-2-oxoethyl)-5-oxo-3b,4,4a,5-tetrahydro-2H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carboxylate (140H)
  • To a solution of (3bS,4aR)-ethyl 2-(2-(tert-butoxy)-2-oxoethyl)-5-oxo-3b,4,4a,5-tetrahydro-2H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carboxylate (140G) (0.22 g, 0.69 mmol) in THF (2 ml) was added 0.25M aqueous NaOH (1.87 ml). The reaction was heated at 60° C. for 1.5 h. Upon completion, the reaction was concentrated in vacuo, and dried under vacuum. The crude product was taken to next step without further purification. MS (m/z) 291.04 [M−H]−.
    • Synthesis of tert-butyl 2-((3bS,4aR)-3-amino-5-oxo-3b,4,4a,5-tetrahydro-2H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-2-yl)acetate (140I)
  • The title compound (140I) was prepared according to the method presented for the synthesis of compound (148B) of Example 148 utilizing sodium (3bS,4aR)-2-(2-(tert-butoxy)-2-oxoethyl)-5-oxo-3b,4,4a,5-tetrahydro-2H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carboxylate (140H). MS (m/z) 263.86 [M+H]+.
    • Synthesis of tert-butyl 2-((3bS,4aR)-3-chloro-5-oxo-3b,4,4a,5-tetrahydro-2H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-2-yl)acetate (140J)
  • The title compound (140J) was prepared according to the method presented for the synthesis of compound (149) of Example 149 utilizing tert-butyl 2-((3bS,4aR)-3-amino-5-oxo-3b,4,4a,5-tetrahydro-2H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-2-yl)acetate (140I). MS (m/z) 282.73 [M+H]+.
    • Synthesis of 2-((3bS,4aR)-3-chloro-4,4a-dihydrospiro[cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-5,2′-[1,3]dithiolane]-2(3bH)-yl)acetic acid (140K)
  • To a solution of tert-butyl 2-((3bS,4aR)-3-chloro-5-oxo-3b,4,4a,5-tetrahydro-2H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-2-yl)acetate (140J) (19 mg, 0.07 mmol), 1,2-ethanedithiol (11.3 μl, 0.13 mmol), and acetic acid (19.2 μl, 0.34 mmol) in dichloromethane (400 μl) was added boron trifluoride diethyl etherate (20.7 μl, 0.17 mmol). After stirring at room temperature for 2 h, the mixture was dry loaded onto silica and purified by silica gel chromatography to give the title compound as a partially purified product. MS (m/z) 302.93 [M+H]+.
    • Synthesis of 2-((3bS,4aR)-3-chloro-5,5-difluoro-3b,4,4a,5-tetrahydro-2H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-2-yl)acetic acid (140L)
  • To a solution of N-iodosuccinimide (27.9 mg, 0.12 mmol) in dichloromethane (0.10 ml) was added dropwise 70% HF in pyridine (0.10 ml) at −78° C. After stirring for 15 minutes, a suspension of 140K (15 mg, 0.05 mmol) in dichloromethane (0.10 ml) was added and the reaction was gradually warmed to 0° C. over 1 h. The mixture was extracted with 2-methyltetrahydrofuran and water. The organic layer was washed with brine, dried with Na2SO4, filtered, and concentrated in vacuo. The product was purified by preparative TLC eluting to give the title compound. MS (m/z) 249.05 [M+H]+.
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-chloro-5,5-difluoro-3b,4,4a,5-tetrahydro-2H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-2-yl)acetamide (140M)
  • The title compound (140M) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound (33F) of Example 33 utilizing 19F and 2-((3bS,4aR)-3-chloro-5,5-difluoro-3b,4,4a,5-tetrahydro-2H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-2-yl)acetic acid (140L). 1H NMR (400 MHz, Methanol-d4) δ 8.75 (t), 7.71 (dd), 7.54 (dd), 7.27-7.15 (m), 7.10 (d), 6.81-6.72 (m), 6.69-6.59 (m), 6.50 (d), 6.46-6.36 (m), 5.30-5.21 (m), 5.05-4.95 (m), 4.81 (s), 4.77 (s), 3.35 (s), 3.26 (s), 3.28-3.21 (m), 3.23 (s), 3.19-3.12 (m), 3.03 (s), 3.04-2.97 (m), 2.45-2.32 (m), 1.94 (s), 1.64 (s), 1.64 (s), 1.42-1.25 (m), 1.01-0.96 (m), 0.96-0.92 (m). MS (m/z) 804.14[M+H]+.
    • Example 141
  • Figure US20210009555A1-20210114-C00382
    • Synthesis of N-(7-bromo-4-methoxy-1-methyl-1H-indazol-3-yl)methanesulfonamide (141A)
  • The title compound (141A) was prepared according to the method presented for the synthesis of compound 19D of Example 19 utilizing 114C. MS (m/z) 334.1 [M+H]+.
    • Synthesis of (S)-tert-butyl (2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(4-methoxy-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)ethyl)carbamate (141B)
  • In a microwave vial, (117B, 30 mg, 0.07 mmol) was combined with (141A, 65 mg, 0.2 mmol), PdCl2(PPh3)2 (5 mg, 0.007 mmol), and K2CO3 (0.2 ml of 2 M aqueous solution) in dioxane (1.5 ml) and DMF (0.1 ml). Nitrogen was bubbled into the reaction solution for 5 min. The reaction was heated in a microwave reactor at 120° C. for 15 min. After cooling to ambient temperature, the reaction was partitioned between EtOAc and brine. The organics were separated, dried, and removed in vacuo and the residue was purified by column chromatography on silica to provide the title compound as a mixture of atropisomers. MS (m/z) 670.3 [M+H]+.
    • Synthesis of (S)—N-(7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-4-methoxy-1-methyl-1H-indazol-3-yl)methanesulfonamide (141C)
  • The title compound (141C) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 19F of Example 19 utilizing 141B. MS (m/z) 570.1 [M+H]+.
    • Synthesis of 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-2-(3,5-difluorophenyl)-1-(6-(3-hydroxy-3-methylbut-1-yn-1-yl)-3-(4-methoxy-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)ethyl)acetamide (141D)
  • The title compound (141D) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 10A of Example 10 utilizing 141C and 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. 1H NMR (Chloroform-d) δ: 7.91-7.84 (m), 7.64 (dd), 7.54-7.42 (m), 7.34-7.28 (m), 6.70 (t), 6.68-6.61 (m), 6.55-6.53 (m), 6.52-6.44 (m), 6.30-6.24 (m), 6.24-6.15 (m), 5.74-5.66 (m), 5.12-5.01 (m), 4.78 (d), 4.71 (d), 4.03 (s), 3.99 (s), 3.39 (d), 3.25 (s), 3.07 (s), 3.06-2.91 (m), 2.81-2.54 (m), 2.54-2.36 (m), 1.71 (s), 1.41 (dd), 1.30-1.22 (m), 1.22-1.10 (m). MS (m/z) 816.5 [M+H]+.
    • Example 142
  • Figure US20210009555A1-20210114-C00383
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-((S)-3-hydroxybut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (142)
  • To the reaction vial containing 168A (20 mg, 0.027 mmol) in DMF (1 mL) was added (S)-but-3-yn-2-ol (0.012 mL, 0.13 mmol), PdCl2[P(Ph)3]2 (1.9 mg, 0.003 mmol), and diethylamine (0.02 mL, 0.27 mmol). The reaction mixture was flushed with argon gas for 5 min then sealed and heated in a microwave reactor to 125° C. for 20 min. Upon cooling, the reaction mixture was filtered and purified by reverse phase HPLC, to provide the title compound 142 as a mixture of atropisomers. 1H NMR (400 MHz, cd3od) 1H NMR (400 MHz, cd3od) δ 8.62 (dd), 7.70 (dd), 7.54 (dd), 7.16 (s), 7.07 (d), 6.88-6.52 (m), 6.44-6.33 (m),5.31-5.23 (m), 5.02-4.92 (m), 4.82-4.64 (m), 3.33 (s), 3.24 (d), 3.18-3.08 (m), 3.04-2.91 (m), 2.53-2.39 (m), 1.57 (dd), 1.42-1.32 (m), 1.11-1.08 (m), 1.07-0.99 (m). MS (m/z) 806.1 [M+H]+.
    • Example 143
  • Figure US20210009555A1-20210114-C00384
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-((R)-3-hydroxybut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (143)
  • The title compound (143) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 142 of Example 142 utilizing (R)-but-3-yn-2-ol. 1H NMR (400 MHz, cd3od) δ 8.63 (dd), 7.70 (dd), 7.54 (dd), 7.16 (s), 7.06 (d), 6.88-6.52 (m), 6.44-6.33 (m),5.30-5.25 (m), 5.02-4.92 (m), 4.83-4.64 (m), 3.33 (s), 3.24 (d), 3.18-3.08 (m), 3.04-2.91 (m), 2.50-2.39 (m), 1.57 (dd), 1.38 (m), 1.05 (s), 1.03 (s). MS (m/z) 806.1 [M+H]+.
    • Example 144
  • Figure US20210009555A1-20210114-C00385
    • Synthesis of N-((1S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(4-fluoro-3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (144)
  • The title compound (144) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 142 of Example 142 utilizing 1-fluoro-2-methylbut-3-yn-2-ol. 1H NMR (400 MHz, cd3od) δ 8.69 (t), 7.71 (dd), 7.56 (dd), 7.17 (s), 7.07 (d), 6.87-6.52 (m), 6.44-6.34 (m), 5.33-5.23 (m), 5.03-4.94 (m), 4.78-4.63 (m), 4.50 (d), 4.38 (d), 3.24 (d), 3.19-3.08 (m), 3.05-2.92 (m), 2.44 (ddd), 1.63 (dd), 1.39 (dd), 1.08 (s), 1.02 (s). MS (m/z) 839.1 [M+H]+.
    • Example 145
  • Figure US20210009555A1-20210114-C00386
    • Synthesis of N-((1S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxypent-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (145)
  • To the reaction vial containing 157F (20 mg, 0.025 mmol) in DMF (1 mL) was added pent-1-yn-3-ol (0.011 g, 0.13 mmol), Pd(PPh3)2Cl2 (1.7 mg, 0.003 mmol), and diethylamine (0.02 mL, 0.25 mmol). The reaction mixture was flushed with argon gas for 5 min then sealed and heated in a microwave reactor to 125° C. for 20 min. Upon cooling, the reaction mixture was filtered and purified by reverse phase HPLC the title compound 145 as a mixture of atropisomers. 1H NMR (400 MHz, cd3od) δ 8.72 (dd), 7.70 (dd), 7.54 (dd), 7.16 (d), 7.06 (d), 6.81-6.71 (m), 6.66-6.59 (m), 6.46-6.34 (m), 5.35-5.20 (m), 5.03-4.93 (m), 4.81-4.70 (m), 4.61-4.52 (m), 3.34 (s), 3.24 (d), 3.20-3.11 (m), 3.05-2.93 (m), 2.52-2.43 (m), 1.96-1.79 (m), 1.41 (dt), 1.13 (td). MS (m/z) 840.0 [M+H]+.
    • Example 146
  • Figure US20210009555A1-20210114-C00387
    • Synthesis of 3,5-dichloro-N-methoxy-N-methylpyrazine-2-carboxamide (146B)
  • To a solution of 146A (10 g, 51.82 mmol) and HATU (21.67 g, 57 mmol) in DMF (50 mL), DIEA (19.86 mL, 114 mmol) was added to the solution. After 30 minutes, N,O-dimethylhydroxyamine hydrochloride (6.09 g, 62.18 mmol) was added to the solution. The mixture was stirred for overnight. 300 mL of water was added and extracted with EtOAc three times (100 mL). The crude product was purified by flash column to provide the desired product. MS (m/z) 236 [M+H]+.
    • Synthesis of 3-chloro-N-methoxy-N-methyl-5-(methylthio)pyrazine-2-carboxamide (146C)
  • To a solution of 146B (2 g, 8.47 mmol) in DMF (10 mL), 1 eq. of sodium methanethiolate was added to the solution. After 5 hours, 0.5 eq. of sodium methanethiolate was added to the suspension. The reaction was stirred overnight then diluted with EtOAc and washed with NaHCO3(aq) and brine. The organic layer was concentrated and purified by flash column to provide the title compound. MS (m/z) 248 [M+H]+.
    • Synthesis of 3-chloro-5-(methylthio)pyrazine-2-carbaldehyde (146D)
  • To a solution of 146C (750 mg, 3.03 mmol) in THF at −78° C., DIBAL-H (3.33 mL, 3.33 mmol) in toluene was added to the solution slowly. Then, it was stirred for 2 hours at −78° C. 4 mL of 1 N HCl(aq) was added to the solution and warmed to 0° C. The mixture was stirred for 20 minutes at 0° C. then extracted with EtOAc twice. The organic layer was dried and concentrated and used without further purification. MS (m/z) 189 [M+H]+.
    • Synthesis of (S,Z)—N-((3-chloro-5-(methylthio)pyrazin-2-yl)methylene)-2-methylpropane-2-sulfinamide (146E)
  • The title compound (146E) was prepared according to the method presented for the synthesis of compound 21C of Example 21 utilizing 146D. MS (m/z) 292 [M+H]+.
    • Synthesis of (S)—N—((S)-1-(3-chloro-5-(methylthio)pyrazin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-methylpropane-2-sulfinamide (146F)
  • The title compound (146F) was prepared according to the method presented for the synthesis of compound 182D of Example 182 utilizing 146E. MS (m/z) 420 [M+H]+.
    • Synthesis of (S)-1-(3-chloro-5-(methylthio)pyrazin-2-yl)-2-(3,5-difluorophenyl)ethanamine hydrochloride (146G)
  • The title compound (146G) was prepared according to the method presented for the synthesis of compound 21E of Example 21 utilizing 146F. MS (m/z) 316 [M+H]+.
    • Synthesis of N—((S)-1-(3-chloro-5-(methylthio)pyrazin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (146H)
  • The title compound (146H) was prepared according to the method presented for the synthesis of compound 10A of Example 10 utilizing 146G and 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. MS (m/z) 562 [M+H]+.
    • Synthesis of N—((S)-1-(3,5-bis(1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyrazin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (1461)
  • The title compound (1461) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 19E of Example 19 utilizing 33B and 146H. 1H NMR (400 MHz, Methanol-d4) δ 9.15 (d), 8.91 (s), 7.93 (t), 7.63 (d), 7.35-7.25 (m), 7.23-7.1 (m), 6.85-6.75 (m), 6.74-6.6 (m), 6.6-6.50 (m), 6.4-6.32 (m), 5.75-5.6 (m), 5.10-5.25 (m), 4.71 (s), 3.65 (s), 3.56 (s), 3.10-3.25 (m), 2.92 (s), 2.60-2.40 (m), 1.45-1.30 (m), 1.1-0.80 (m). MS (m/z) 928 [M+H]+.
    • Example 147
  • Figure US20210009555A1-20210114-C00388
    • Synthesis of (3bS,4aR)-1-(2-(((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)amino)-2-oxoethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carboxylic acid (147)
  • A solution of 158G (0.41 g, 0.49 mmol) in THF (0.5 ml) was treated with 1M NaOH (2 ml). The reaction was stirred at room temperature for 1.5 h. The solution was acidified to pH=4 with AcOH and extracted with 2-MeTHF (2×5 mL) and water (5 mL). The organics were dried with Na2SO4, filtered, and concentrated. The crude material was purified by reverse phase HPLC to provide the product 147 as a mixture of atropisomers. 1H NMR (400 MHz, cd3od) δ, 8.69 (d), 7.69 (d), 7.53 (dd), 7.19 (d), 7.06 (d), 6.81-6.71 (m), 6.63 (t), 6.46-6.35 (m), 5.32-5.23 (m), 5.03-4.93 (m), 4.85-4.80 (m), 4.72 (s), 3.36 (s), 3.26 (s), 3.23 (s), 3.22-3.09 (m), 3.05-2.92 (m), 2.63-2.51 (m), 2.50-2.39 (m), 1.65 (s), 1.64 (s), 1.49-1.35 (m), 1.15-1.07 (m), 1.08-0.97 (m). MS (m/z) 814.1 [M+H]+.
    • Example 148
  • Figure US20210009555A1-20210114-C00389
    • Synthesis of sodium (3bS,4aR)-1-(2-(((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)amino)-2-oxoethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carboxylate (148A)
  • To a solution of 158G (0.22 g, 0.26 mmol) in THF (0.65 ml) was added 1M NaOH (0.65 ml). The reaction was stirred at room temperature for 1.5 h. The solution was acidified to ˜pH=4 with AcOH and extracted with 2-MeTHF (2×5 mL) and brine (5 mL). The organic layer was washed with NaHCO3 (10 mL). The organics were dried with Na2SO4, filtered, and concentrated. The product was taken to the next step without further purification. MS (m/z) 814.1 [M+H]+.
    • Synthesis of 2-((3bS,4aR)-3-amino-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)acetamide (148B)
  • To a solution of 148A (110 mg, 0.13 mmol) in DMF (1.0 ml) was added diphenyl phosphoryl azide (28.35 μl, 0.13 mmol). The reaction was stirred at room temperature for 45 min. The solution was cooled to 0° C. and water (0.75 mL) was added dropwise. The resulting solution was sealed and heated in microwave reactor at 130° C. for 15 min. The crude material treated with TFA (20 μl) and purified by prep HPLC to provide the product 148B as a mixture of atropisomers. 1H NMR (400 MHz, cd3od) δ 8.72-8.59 (m), 7.75-7.65 (m), 7.53 (dd), 7.22-7.15 (m), 7.09 (d), 6.83-6.72 (m), 6.67-6.60 (m), 6.46-6.33 (m), 5.28 (dd), 4.96 (t), 4.90-4.70 (m), 4.69-4.52 (m), 3.35 (s), 3.26 (s), 3.25-3.22 (m), 3.20 (s), 3.17-3.10 (m), 3.04-2.91 (m), 2.51-2.33 (m), 1.65 (s), 1.47-1.31 (m), 1.15-1.06 (m), 1.03 (m). MS (m/z) 785.2 [M+H]+.
    • Example 149
  • Figure US20210009555A1-20210114-C00390
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-chloro-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (149)
  • A solution of 148B (19.1 mg, 0.02 mmol), ground lithium chloride (5.16 mg, 0.12 mmol), and cupric chloride (6.54 mg, 0.05 mmol) in ACN (1 ml) was sonicated for 5 min. Isoamyl nitrite (6.51 μl, 0.05 mmol) was added and the reaction was sonicated for an additional 5 min then stirred for 45 min. The crude material was purified by prep HPLC to provide the desired product 149 as a mixture of atropisomers. 1H NMR (400 MHz, cd3od) δ 8.67 (d), 8.62 (d), 7.69 (dd), 7.53 (dd), 7.19 (s), 7.07 (d), 6.82-6.72 (m), 6.68-6.58 (m), 6.47-6.32 (m), 5.27 (m), 5.03-4.92 (m), 4.69-4.67 (m), 4.64 (d), 3.34 (s), 3.26 (s), 3.24 (s), 3.18-3.08 (m), 3.05-2.92 (m), 2.53-2.30 (m), 1.64 (s), 1.45-1.27 (m), 1.13-1.07 (m), 1.08-1.01 (m). MS (m/z) 804.1 [M+H]+.
    • Example 150
  • Figure US20210009555A1-20210114-C00391
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (150)
  • To a solution of 148B (10 mg, 0.01 mmol) in ACN (0.2 ml) and 50% hypophosphorus acid in water (50 μl) was added isoamyl nitrite (3.41 μl, 0.03 mmol). The reaction mixture was stirred at room temperature for 30 min. The crude material was purified by prep HPLC to provide the title product 150 as a mixture of atropisomers. 1H NMR (400 MHz, cd3od) δ 8.48 (d), 8.41 (d), 7.74-7.63 (m), 7.54 (d), 7.51 (d), 7.34 (s), 7.31 (s), 7.17 (s), 7.07 (d), 6.81-6.72 (m), 6.66-6.58 (m), 6.45-6.33 (m), 5.34-5.26 (m), 5.02-4.93 (m), 4.74 (d), 4.69 (d), 3.33 (s), 3.26 (s), 3.24 (s), 3.14-3.06 (m), 3.03-2.91 (m), 2.46-2.33 (m), 1.65 (s), 1.39-1.28 (m), 1.03 (s), 1.00-0.93 (m). MS (m/z) 770.1 [M+H]+.
    • Example 151
  • Figure US20210009555A1-20210114-C00392
    • Synthesis of N-((1S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3,4-dihydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (151)
  • The title compound (151) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 145 of Example 145 utilizing 2-methylbut-3-yne-1,2-diol. H NMR (400 MHz, cd3od) δ 8.78 (d), 7.70 (dd), 7.62-7.52 (m), 7.16 (s), 7.05 (d), 6.81-6.72 (m), 6.65-6.60 (m), 6.44-6.30 (m), 5.28 (d), 4.97 (d), 4.84-4.70 (m), 3.66 (d), 3.33 (s), 3.24 (d), 3.14 (dd), 3.07-2.92 (m), 2.86 (s), 2.53-2.42 (m), 1.59 (d), 1.47-1.36 (m), 1.29 (t), 1.19-1.10 (m), 1.09-1.04 (m). MS (m/z) 854.1 [M+H]+.
    • Example 152
  • Figure US20210009555A1-20210114-C00393
    • Synthesis of N-((1S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(4-fluoro-3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (152)
  • The title compound (152) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 145 of Example 145 utilizing 1-fluoro-2-methylbut-3-yn-2-ol. 1H NMR (400 MHz, cd3od) δ 7.71 (dd), 7.64-7.51 (m), 7.22-7.12 (m), 7.06 (d), 6.81-6.71 (m),6.68-6.58 (m), 6.44-6.33 (m), 5.30-5.21 (m), 4.98 (t), 4.85-4.70 (m), 4.50 (d), 4.38 (d), 3.24 (d), 3.20-3.11 (m), 3.06-2.93 (m), 2.56-2.43 (m), 1.62 (s), 1.47-1.27 (m),1.16-1.10 (m), 1.09-1.04 (s). MS (m/z) 858.0 [M+H]+.
    • Example 153
  • Figure US20210009555A1-20210114-C00394
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-(2-hydroxyethoxy)prop-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (153)
  • The title compound (153) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 145 of Example 145 utilizing 2-(prop-2-yn-1-yloxy)ethanol. 1H NMR (400 MHz, cd3od) δ 8.67 (d), 7.71 (dd), 7.62-7.52 (m), 7.17 (d), 7.07 (d), 6.81-6.71 (m), 6.68-6.60 (m), 6.45-6.34 (m), 5.29-5.24 (m), 4.98 (q), 4.84-4.70 (m), 4.54 (d), 3.86-3.80 (m), 3.80-3.66 (m), 3.36-3.31 (m), 3.28-3.09 (m), 2.98 (d), 2.52-2.44 (m), 1.40 (q), 1.16-1.11 (m), 1.10-1.05 (m). MS (m/z) 854.2 [M+H]+.
    • Example 154
  • Figure US20210009555A1-20210114-C00395
    • Synthesis of N-((1S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-4-methoxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (154)
  • The title compound (154) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 145 of Example 145 utilizing 1-methoxy-2-methylbut-3-yn-2-ol. 1H NMR (400 MHz, cd3od) δ 8.67 (d), 7.71 (dd), 7.62-7.52 (m), 7.17 (d), 7.07 (d), 6.81-6.71 (m), 6.64 (d), 6.45-6.34 (m), 5.26 (s), 4.98 (q), 4.84-4.70 (m), 4.62 (s), 4.54 (d), 3.86-3.80 (m), 3.80-3.66 (m), 3.34 (s), 3.28-3.09 (m), 2.98 (d), 2.48 (dd), 1.40 (q), 1.14 (m), 1.07 (m). MS (m/z) 869.1 [M+H]+.
    • Example 155
  • Figure US20210009555A1-20210114-C00396
    Figure US20210009555A1-20210114-C00397
    • Synthesis of (E)-7-bromo-1-methyl-4-(prop-1-en-1-yl)-1H-indazol-3-amine (155A)
  • To 58B (7.4 g, 21.0 mmol) in dioxane (40 mL) and DMF (40 ml) was added potassium trifluoro(prop-1-en-1-yl)borate (3.7 g, 25.2 mmol), 2M K2CO3 in water (21.0 ml), and Pd(PPh3)2Cl2 (740.0 mg, 1.1 mmol). The reaction mixture was stirred for 2 hours at 100° C. The reaction was cooled, diluted with EtOAc and brine. The mixture was extracted 2× with EtOAc, the organic layer was dried over sodium sulfate, was concentrated and purified by flash column chromatography to provide the title compound. MS (m/z) 266.3 [M+H]+.
    • Synthesis of (E)-N-(7-bromo-1-methyl-4-(prop-1-en-1-yl)-1H-indazol-3-yl)-N-(methylsulfonyl)methanesulfonamide (155B)
  • To 155A (3.7 g, 13.9 mmol) in DCM (100 mL) was added N,N-diisopropylethylamine (9.7 ml, 55.6 mmol) then the reaction was cooled in an ice bath and methanesulfonyl chloride (3.2 ml, 41.7 mmol) was added. The reaction mixture was stirred for 30 minutes at 0° C. The reaction was diluted with water and extracted 2× with DCM. The organic layer was dried over sodium sulfate and concentrated. The mixture was purified by flash column chromatography to provide the title compound. MS (m/z) 421.9 [M+H]+.
    • Synthesis of N-(7-bromo-4-formyl-1-methyl-1H-indazol-3-yl)-N-(methylsulfonyl)methanesulfonamide (155C)
  • Around bottom is charged with 155B (2.7 g, 6.4 mmol) and DCM (100 mL). The mixture was cooled to −78° C. and ozone was bubbled into the reaction. Once the conversion was complete, DMS was added to quench the reaction under stirring for 30 minutes. To the stirring mixture a saturated sodium thiosulfate solution was added and the mixture was allowed to warm to room temperature and stirred another 30 minutes. The layers were separated and the water layer was extracted again with DCM. The combined organic layers were dried over sodium sulfate and concentrated. The residue was dissolved in DCM and followed by the addition of hexane. The mixture was filtered to provide the title compound. MS (m/z) 410.0 [M+H]*.
    • Synthesis of N-(7-bromo-4-(difluoromethyl)-1-methyl-1H-indazol-3-yl)-N-(methylsulfonyl)methanesulfonamide (155D)
  • A teflon flask was charged with 155C (650 mg, 1.6 mmol) and DCM (100 mL). The mixture was cooled to 0° C. and Deoxo-Fluor (0.4 ml, 2.4 mmol) was added into the reaction and then the mixture was allowed to warm to room temperature. The mixture is stirred for 8 hours and checked. Another equivalent of Deoxo-Fluor was added and the mixture was stirred overnight. The mixture is diluted with water and extracted 2× with DCM. The organic layers are dried over sodium sulfate and concentrated. The residue was dissolved in DCM followed by the addition of hexane. The mixture was filtered to provide the title compound. MS (m/z) 431.9 [M+H]+.
    • Synthesis of N-(7-bromo-4-(difluoromethyl)-1-methyl-H-indazol-3-yl)methanesulfonamide (155E)
  • To 155D (5.9 g, 13.7 mmol), THF (50 ml) and MeOH (20 ml) was added a saturated solution of LiOH (10 ml) and water (10 ml). The mixture was stirred for 10 minutes, then diluted with water and extracted 2× EtOAc. The organic layers were dried over sodium sulfate and concentrated. The residue was dissolved in DCM followed by the addition of hexane. The mixture was filtered to provide the title compound. MS (m/z) 354.6 [M+H]+.
    • Synthesis of N-(4-(difluoromethyl)-1-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-yl)methanesulfonamide (155F)
  • The title compound (155F) was prepared according to the method presented for the synthesis of compound 19C of Example 19 utilizing 155E. MS (m/z) 402.3 [M+H]+.
    • Synthesis of (S)-tert-butyl (1-(3-(4-(difluoromethyl)-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (155G)
  • To 14B (100 mg, 0.2 mmol) in dioxane (8 mL) and DMF (2 ml) was added 2N K2CO3 (0.2 ml), and Pd(PPh3)2C2 (7.1 mg, 0.01 mmol). The reaction mixture was stirred at 110° C., then 155F (170 mg, 0.4 mml) dissolved in dioxane (4 ml) and DMF (2 ml) was slower added into the reaction by syringe. The reaction was cooled after 8 hours, diluted with EtOAc and brine. The mixture was extracted 2× with EtOAc, the organic layer was dried over sodium sulfate, was concentrated and purified by flash column chromatography to provide the title compound as a mixture of atropisomers. MS (m/z) 689.8 [M+H]+.
    • Synthesis of (S)—N-(7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-4-(difluoromethyl)-1-methyl-1H-indazol-3-yl)methanesulfonamide (155H)
  • The title compound (155H) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 19F of Example 19 utilizing 155G. MS (m/z) 590.1 [M+H]+.
    • Synthesis of N—((S)-1-(3-(4-(difluoromethyl)-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (155I)
  • The title compound (155I) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 10A of Example 10 utilizing 155H and 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. 1H NMR (Chloroform-d) δ: 7.60 (dd), 7.53 (dd), 7.49-7.38 (m), 7.30-7.19 (m), 7.14 (s), 6.83-6.78 (m), 6.70 (t), 6.69-6.62 (m), 6.34 (d), 6.25-6.14 (m), 4.95 (q), 4.75-4.69 (m), 3.59-3.42 (m), 3.35 (s), 3.01-2.88 (m), 2.56-2.36 (m), 1.72 (s), 1.46-1.37 (m), 1.19-1.09 (m). MS (m/z) 836.2 [M+H]+.
    • Example 156
  • Figure US20210009555A1-20210114-C00398
    • Synthesis of ethyl 1-(2-(tert-butoxy)-2-oxoethyl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate (156B)
  • To 156A (2 g, 10.3 mmol) in MeTHF (100 mL) and DMF (5 ml) was added Cs2CO3 (4.0 g, 12.3 mmol) and tert-butyl 2-bromoacetate (2.3 ml, 15.5 mmol). The reaction mixture was stirred for 4 hours. Solids were filtered, the eluent was concentrated and purified by flash column chromatography to provide the title compound. MS (m/z) 309.6 [M+H]+.
    • Synthesis of tert-butyl 2-(3-(1-hydroxycyclopropyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetate (156C)
  • To 156B (300 mg, 1.0 mmol) in MeTHF (20 mL) was added titanium (iv) isopropoxide (2.9 ml, 9.73 mmol). To the stirring mixture 3M EtMgBr (3.2 ml) was slowly added. The reaction mixture was stirred for 1 hour. The reaction was diluted with EtOAc and brine. The mixture was extracted 2× with EtOAc, the organic layer was dried over sodium sulfate, was concentrated and purified by flash column chromatography to provide the title compound. MS (m/z) 293.0 [M+H]+.
    • Synthesis of 2-(3-(1-hydroxycyclopropyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetic acid (156D)
  • To 156C (20 mg, 0.07 mmol) in DCM (2 mL) was added TFA (0.5 ml). The reaction mixture was stirred for 0.5 hours at RT. The reaction was concentrated and then diluted with 1 N HCl and extracted 2× with DCM. The water layer was lyophilized to provide the title compound. MS (m/z) 237.1 [M+H]+.
    • Synthesis of (S)—N-(1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(1-hydroxycyclopropyl)-4,5,6,7-tetrahydro-1-H-indazol-1-yl)acetamide (156E)
  • The title compound (156E) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 10A of Example 10 utilizing 156D and 19F. 1H NMR (Methanol-d4) δ: 7.76-7.68 (m), 7.53 (dd), 7.25-7.14 (m), 6.64 (tt), 6.39 (dd), 5.27 (dd), 4.64 (d), 3.28-3.21 (m), 3.21-3.10 (m), 3.04 (s), 2.98 (dd), 2.67-2.55 (m), 2.47-2.37 (m), 1.86-1.69 (m), 1.64 (s), 1.10-0.97 (m). MS (m/z) 792.3 [M+H]+.
    • Example 157
  • Figure US20210009555A1-20210114-C00399
    Figure US20210009555A1-20210114-C00400
    • Synthesis of (S)-tert-butyl (1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (157A)
  • (S)-tert-butyl (1-(3-bromopyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (1.0 g, 2.42 mmol), N-(4-chloro-1-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-yl)methanesulfonamide (19D, 1.12 g, 2.90 mmol), and PdCl12[P(cy)3]2 (89.0 mg, 0.121 mmol) were suspended in 1,4-dioxane (12 mL) and 1.0 M aqueous NaHCO3 (4 mL). The reaction mixture was degassed by bubbling argon for 5 minutes then sealed and heated at 150° C. for 15 minutes in a microwave reactor. Upon cooling, the reaction mixture was diluted with water and extracted with three portions of EtOAc. The combined organic layers were dried over Na2SO4, filtered, concentrated in vacuo, and purified by silica gel column chromatography to give the title compound 157A. MS (m/z) 591.72 [M+H]+.
    • Synthesis of (S)—N-(1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2,2,2-trifluoroacetamide (157B)
  • To (S)-tert-butyl (1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (157A, 3.39 g, 5.73 mmol) in DCM (5 mL) was added trifluoroacetic acid (5 mL). The reaction mixture was stirred at room temperature for 2.5 hours. Upon complete removal of the Boc protecting group, trifluoroacetic anhydride (2.02 mL, 14.31 mmol) was added. The reaction mixture was stirred at room temperature for 30 minutes. Upon completion, the reaction mixture was filtered through celite, concentrated in vacuo, taken in EtOAc, and carefully neutralized with 1M aqueous NaHCO3 until the aqueous layer was at pH 10. The organic layer was collected and the aqueous layer extracted once more with EtOAc. The combined organic layers were dried over Na2SO4, filtered, concentrated in vacuo, and purified by silica gel column chromatography to give the title compound 157B. MS (m/z) 588.14 [M+H]+.
    • Synthesis of (S)-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-2-(2-(3,5-difluorophenyl)-1-(2,2,2-trifluoroacetamido)ethyl)pyridine 1-oxide (157C)
  • To a solution of (S)—N-(1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2,2,2-trifluoroacetamide (157B, 8.0 g, 13.61 mmol) in DCM (70 mL) was added MCPBA (3.659 g, 16.33 mmol) in 4 portions over a 15 minute period. The reaction mixture was stirred at room temperature for 16 hours. Upon completion, the reaction was quenched with 1M aqueous NaHSO3 and saturated aqueous NaHCO3. The organic layer was collected and the aqueous layer was extracted an additional time with DCM. The combined organic layers were dried over Na2SO4, filtered, concentrated in vacuo, and purified by silica gel column chromatography to give the title compound 157C. MS (m/z) 604.10 [M+H]+.
    • Synthesis of (S)—N-(1-(6-chloro-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2,2,2-trifluoroacetamide (157D)
  • (S)-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-2-(2-(3,5-difluorophenyl)-1-(2,2,2-trifluoroacetamido)ethyl)pyridine 1-oxide (157C, 1.0 g, 1.66 mmol) was taken in POCl3 (2.32 mL, 24.84 mmol). The reaction mixture was heated at 115° C. for 2 hours. Upon cooling, the reaction was concentrated in vacuo, taken in DCM, and vigorously stirred with saturated aqueous NaHCO3 for 1 hour. The organic layer was collected, and the aqueous layer was extracted an additional time with DCM. The combined organic layers were dried over Na2SO4, filtered, concentrated in vacuo, and purified by silica gel column chromatography to give the title compound 157D. MS (m/z) 622.13 [M+H]+.
    • Synthesis of (S)—N-(7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-6-chloropyridin-3-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide (157E)
  • To a solution of (S)—N-(1-(6-chloro-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2,2,2-trifluoroacetamide (157D, 870 mg, 1.40 mmol) in EtOH (16 mL) was added 2M aqueous LiOH (7.0 mL, 13.98 mmol). The reaction was heated at 130° C. for 10 minutes. Upon cooling, the reaction mixture was acidified with 2N aqueous HCl until at pH 5. The reaction mixture was then concentrated in vacuo and taken in EtOAc. To the solution was added saturated aqueous NaHCO3 until the aqueous layer was at pH 10. The organic layer was collected, and the aqueous layer was extracted an additional time with EtOAc. The combined organic layers were dried over Na2SO4, filtered, concentrated in vacuo, and used without further purification. MS (m/z) 526.06 [M+H]+.
    • Synthesis of N—((S)-1-(6-chloro-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (157F)
  • To a solution of crude (S)—N-(7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-6-chloropyridin-3-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide (157E, 400 mg, 0.76 mmol) in DMA (6 mL) was added NEt3 (0.32 mL, 2.28 mmol), 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid (160.6 mg, 0.61 mmol), then HATU (173.4 mg, 0.46 mmol). The reaction mixture was stirred at room temperature for 15 minutes, then additional HATU (86.7 mg, 0.23 mmol) was added. The reaction mixture was stirred at room temperature for an additional 15 minutes. Upon completion, the reaction mixture was concentrated in vacuo and purified by silica gel column chromatography to give the title compound 157F. MS (m/z) 790.12 [M+H]+.
    • Synthesis of N-((1S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(4,4-difluoro-3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (157G)
  • N—((S)-1-(6-chloro-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (157F, 20 mg, 0.025 mmol), 1,1-difluoro-2-methylbut-3-yn-2-ol (15.2 mg, 0.126 mmol), PdCl2(PPh3)2 (1.8 mg, 0.003 mmol), and CuI (0.5 mg, 0.003 mmol) were taken in DMF (0.25 mL). To the reaction mixture was added diethylamine (26 μL, 0.253 mmol), and the reaction mixture was degassed by bubbling argon for 5 minutes then sealed and heated at 125° C. for 30 minutes in a microwave reactor. Upon cooling, the reaction mixture was filtered and purified by reverse phase HPLC to give the title compound 157G as a mixture of atropisomers. 1H NMR (400 MHz, Methanol-d4) δ 8.88-8.78 (m), 7.74 (dd), 7.60 (dd), 7.24-7.13 (m), 7.10-7.05 (m), 6.77 (t), 6.64 (t), 6.46-6.33 (m), 5.82 (t), 5.35-5.23 (m), 5.00 (q), 4.82 (s), 4.79 (s), 4.76 (s), 3.34 (s), 3.26 (s), 3.23 (s), 3.20-3.10 (m), 3.07-2.93 (m), 2.58-2.37 (m), 1.63 (s), 1.50-1.34 (m), 1.18-1.11 (m), 1.10-1.01 (m). MS (m/z) 874.07 [M+H]+.
    • Example 158
  • Figure US20210009555A1-20210114-C00401
    Figure US20210009555A1-20210114-C00402
    • Synthesis of (3bS,4aR)-ethyl 1-(2-methoxy-2-oxoethyl)-5-(methoxymethoxy)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carboxylate (158A)
  • To a solution of (3bS,4aR)-ethyl 5-(methoxymethoxy)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carboxylate (140D) (3.3 g, 13.1 mmol) in DMF (12 ml) was added portionwise potassium t-butoxide (1.61 g, 14.39 mmol) at 0° C. To the reaction was added 2-methyltetrahydrofuran (12 ml) followed by a dropwise addition of methyl bromoacetate (1.36 ml, 14.4 mmol). After gradually warming to room temperature and stirring for 1 h, the reaction was extracted with EtOAc and water. The organic layer was washed with water. The organics layer was dried with Na2SO4, filtered, and concentrated in vacuo. The crude product was taken to next step without further purification. MS (m/z) 324.96 [M+H]+.
    • Synthesis of (3bS,4aR)-ethyl 5-hydroxy-1-(2-methoxy-2-oxoethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carboxylate (158B)
  • To a solution of (3bS,4aR)-ethyl 1-(2-methoxy-2-oxoethyl)-5-(methoxymethoxy)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carboxylate (158A) (4.2 g) in acetic acid (15 ml) was added water (30 ml). After stirring at reflux for 2h, the reaction was concentrated in vacuo. The resulting mixture was diluted with dioxane (40 ml) and concentrated in vacuo. The crude product was dissolved in dichloromethane (20 ml), dried with Na2SO4, filtered, and concentrated in vacuo. The crude product was taken to next step without further purification. MS (m/z) 281.02 [M+H]+.
    • Synthesis of (3bS,4aR)-ethyl 1-(2-methoxy-2-oxoethyl)-5-oxo-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carboxylate (158C)
  • To a solution of 156B (3.63 g, 12.95 mmol) in DCM (30 mL) was added Dess-Martin periodinane (4.87 g, 12.95 mmol). The reaction was stirred at room temperature overnight. The reaction mixture was filtered through celite, solid loaded onto silica and purified by silica gel chromatography to give the title compound. MS (m/z) 278.9 [M+H]+.
    • Synthesis of (3bS,4aR)-ethyl 1-(2-methoxy-2-oxoethyl)-1,3b,4,4a-tetrahydrospiro[cyclopropa[3,4]cyclopenta 1,2-c]pyrazole-5,2′-[1,3]dithiolane-3-carboxylate (158D)
  • To a solution of 158C (0.69 g, 2.61 mmol), 1,2-ethanedithiol (0.44 ml, 5.22 mmol), acetic acid (0.75 ml, 13.06 mmol) in DCM (10 ml) was added boron trifluoride diethyl etherate (0.81 ml, 6.53 mmol). The reaction was stirred at room temperature for 2 days. The reaction mixture was concentrated, solid loaded onto silica and purified by silica chromatography to give the title compound 158D. MS (m/z) 354.9 [M+H]+.
    • Synthesis of (3bS,4aR)-ethyl 5,5-difluoro-1-(2-methoxy-2-oxoethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carboxylate (158E)
  • To suspension of N-iodosuccinimide, 98% (1.35 g, 6.0 mmol) in DCM (5 ml) was added dropwise 70% HF in pyridine (5 ml) at −78° C. After stirring for 15 min 158D (0.85 g, 2.39 mmol) in DCM (5 ml) was added and the reaction was slowly warmed to ˜30° C. and stirred at that temperature for 1h. The resulting solution was carefully poured onto ice containing 1.0 N NaHCO3. The product was extracted with ethyl acetate, washed with NaHSO3, brine and water. The combined organic layers were dried with Na2SO4, filtered, and concentrated. The crude material was purified by silica chromatography to give the title compound 158E. MS (m/z) 300.9 [M+H]+.
    • Synthesis of sodium 2-((3bS,4aR)-3-(ethoxycarbonyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetate (158F)
  • To a solution of 158E (0.16 g, 532.87 μmol) in dioxane (3 ml) was added dropwise 1M NaOH (0.55 ml). The reaction was stirred at room temperature for 0.5 h. An additional 0.500 mL of 1M NaOH was added and stirred for an additional 0.5 h. The reaction was concentrated, diluted with DMA (3 mL) and concentrated until dryness. The crude product was taken to next step without further purification. MS (m/z) 286.9 [M+H]+.
    • Synthesis of (3bS,4aR)-ethyl 1-(2-(((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)amino)-2-oxoethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carboxylate (158G)
  • To a solution of 19F (305.45 mg, 532.1 μmol) and 158F (164 mg, 532.1 μmol) in DMA (2 mL) was added HATU (212.31 mg, 558.7 μmol). The reaction was stirred at room temperature for 0.5 h. The reaction was diluted with 0.1 M NaCl (10 mL) and extracted with ethyl acetate (2×10 mL). The combined organic layers was washed with water (20 mL), dried with Na2SO4, filtered, and concentrated. The crude material was purified by silica chromatography to give the title compound 158G as a mixture of atropisomers. 1H NMR (400 MHz, cd3od) δ 8.77 (d), 8.75-8.68 (m), 8.43 (dd), 7.70 (t), 7.57-7.48 (m), 7.22-7.15 (m), 7.06 (d), 6.81-6.72 (m), 6.68-6.59 (m), 6.41 (dd), 5.30-5.19 (m), 4.99 (q), 4.82 (d), 4.73 (s), 4.42-4.31 (m), 3.36 (s), 3.34-3.27 (m), 3.25 (s), 3.22 (s), 3.17 (dd), 3.04-2.97 (m), 2.96 (s), 2.63-2.39 (m), 1.65 (s), 1.64 (s), 1.49-1.32 (m), 1.14-1.07 (m), 1.07-0.99 (m). MS (m/z) 842.2 [M+H]+.
    • Example 159
  • Figure US20210009555A1-20210114-C00403
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-cyano-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (159)
  • To a solution of 160 (11 mg, 12.2 μmol) in DMSO (0.2 ml) was added cuprous cyanide (2.7 mg, 30.7 μmol). The reaction mixture sealed and heated to 180° C. for 0.5 h. The reaction was cooled rt, diluted with ethyl acetate, and washed with water. The organic phase was then dried with Na2SO4, filtered and concentrated. The crude material was purified by prep HPLC to provide the product 159 as a mixture of atropisomers. 1H NMR (400 MHz, cd3od) δ 8.87-8.78 (m), 7.73-7.66 (m), 7.58-7.48 (m), 7.18 (s), 7.07 (d), 6.81-6.71 (m), 6.68-6.58 (m), 6.48-6.32 (m), 5.32-5.20 (m), 5.03-4.91 (m), 4.80 (d), 3.34 (s), 3.25 (s), 3.24 (s), 3.15 (dd), 3.06-2.93 (m), 2.63-2.47 (m), 1.64 (s), 1.45 (dd), 1.19-1.14 (m), 1.11-1.06 (m). MS (m/z) 795.1 [M+H]+.
    • Example 160
  • Figure US20210009555A1-20210114-C00404
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-iodo-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (160)
  • To a solution of 148B (75 mg, 95.5 μmol) in trifluoroacetic acid (0.5 ml) and water (0.2 mL was added sodium nitrite (1M in water, 0.3 mL) followed by stirring for 15 min at room temperature. The reaction mixture was then treated with potassium iodide (238 mg, 1.4 mmol), acetonitrile (0.8 mL) and stirred for an additional 1.5 h. The reaction was basified with 1M NaHCO3, quenched with 1M NaHSO3, and extracted with ethyl acetate (20 mL). The organic phase was then dried with Na2SO4, filtered and concentrated. The crude material was purified by prep HPLC to provide the product 160 as a mixture of atropisomers. 1H NMR (400 MHz, cd3od) 67.75-7.63 (m), 7.58-7.48 (m), 7.18 (s), 7.12-7.02 (m), 6.82-6.72 (m), 6.68-6.58 (m), 6.46-6.32 (m), 5.32-5.22 (m), 4.96 (t), 4.76-4.56 (m), 3.34 (s), 3.30-3.22 (m), 3.26 (s), 3.25 (s), 3.20-3.06 (m), 3.04-2.91 (m), 2.51-2.35 (m), 2.30-2.16 (m), 2.03 (O), 1.65 (s), 1.42-1.27 (m), 1.10-1.04 (m), 1.04-0.99 (m). MS (m/z) 896.0 [M+H]+.
    • Example 161
  • Figure US20210009555A1-20210114-C00405
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(dimethylamino)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (161)
  • To a solution of 148B (10 mg, 12.7 μmol) in acetic acid (0.1 ml) and formaldehyde (35% in water, 6.71, 63.6 μmol) was added sodium cyanoborohydride (1.7 mg, 26.7 μmol) followed by stirring for 16 h at rt. The reaction mixture was diluted with ACN and purified by prep HPLC to provide the product 161 as a mixture of atropisomers. 1H NMR (400 MHz, cd3od) δ 7.74-7.64 (m), 7.58-7.48 (m), 7.16 (q), 7.07 (d), 6.82-6.72 (m), 6.68-6.56 (m), 6.45-6.30 (m), 5.28 (dd), 4.95 (t), 4.51 (d), 4.47 (d), 3.33 (s), 3.26 (s), 3.25 (s), 3.27-3.18 (m), 3.09 (dd), 2.98 (s), 2.92 (s), 2.92 (s), 2.49-2.40 (m), 2.40-2.28 (m), 1.65 (s), 1.41-1.29 (m), 1.09-0.98 (m). MS (m/z) 813.2 [M+H]+.
    • Example 162
  • Figure US20210009555A1-20210114-C00406
    • Synthesis of methyl ((3bS,4aR)-1-(2-(((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)amino)-2-oxoethyl-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-3-yl)carbamate (162)
  • To a solution of 148B (6 mg, 7.64 μmol) in DCM (0.1 ml) was added pyridine (3.08 μl, 38.21 μmol) followed by methylchloroformate (0.7 mg, 7.18 μmol) then stirred for 30 min at rt. The reaction was concentrated and the product was purified by prep HPLC to provide the product 162 as a mixture of atropisomers. 1H NMR (400 MHz, cd3od) δ 7.72-7.65 (m), 7.54 (d), 7.51 (d), 7.17 (s), 7.06 (d), 6.81-6.73 (m), 6.67-6.59 (m), 6.44-6.33 (m), 5.27 (dd), 4.96 (t), 4.59 (d), 4.54 (d), 3.76 (s), 3.75 (s), 3.34 (s), 3.26 (s), 3.23 (s), 3.15-3.07 (m), 3.04-2.91 (m), 2.61 (s), 2.37-2.22 (m), 1.64 (s), 1.37-1.25 (m), 1.06-0.99 (m), 0.99-0.93 (m). MS (m/z) 843.2 [M+H]+.
    • Example 163
  • Figure US20210009555A1-20210114-C00407
    • Synthesis of 2-((3bS,4aR)-3-acetamido-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)acetamide (163)
  • The title compound (163) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 162 of Example 162 utilizing acetyl chloride. H NMR (400 MHz, cd3od) δ 7.69 (t), 7.54 (d), 7.51 (d), 6.80-6.74 (m), 6.67-6.60 (m), 6.44-6.33 (m), 5.27 (dd), 4.96 (t), 4.61 (s), 4.56 (d), 3.34 (s), 3.26 (s), 3.23 (s), 3.16-3.07 (m), 3.02-2.92 (m), 2.68-2.56 (m), 2.34-2.23 (m), 2.12 (s), 2.11 (s), 1.64 (s), 1.36-1.25 (m), 1.03-0.98 (m), 0.98-0.92 (m). MS (m/z) 827.1 [M+H]+.
    • Example 164
  • Figure US20210009555A1-20210114-C00408
    • Synthesis of (3bS,4aR)-1-(2-(((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)amino)-2-oxoethyl)-5,5-difluoro-N,N-dimethyl-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carboxamide (164)
  • To a solution of 148A (6 mg, 7.18 μmol) in DMA (100 μl) was added a solution of HATU (2.73 mg, 7.18 μmol) in DMA (50 μl) followed by dimethylamine (2M in THF, 50 μl, 0.1 mmol), then stirred for 16 h at rt. The reaction mixture was concentrated, filtered, and purified by reverse phase HPLC to provide the product 164 as a mixture of atropisomers. 1H NMR (400 MHz, cd3od) δ 8.64 (d), 8.59 (d), 7.76-7.65 (m), 7.54 (d), 7.51 (d), 7.16 (s), 7.08 (d), 6.80-6.72 (m), 6.66-6.60 (m), 6.44 (d), 6.42-6.34 (m), 5.28 (dd), 4.98 (t), 4.78 (s), 4.73 (d), 3.34 (s), 3.33 (s), 3.28 (s), 3.25 (s), 3.23 (s), 3.15-3.07 (m), 3.09 (s), 3.07 (s), 3.03-2.92 (m), 2.57-2.38 (m), 1.66-1.61 (m), 1.43-1.26 (m), 1.13-1.07 (m), 1.03 (dt). MS (m/z) 841.1 [M+H]+.
    • Example 165
  • Figure US20210009555A1-20210114-C00409
    • Synthesis of (3bS,4aR)-1-(2-(((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)amino)-2-oxoethyl)-5,5-difluoro-N-methyl-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-3-carboxamide (165)
  • The title compound (165) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 164 of Example 164 utilizing methylamine. 1H NMR (400 MHz, cd3od) δ 8.65-8.60 (m), 7.18-7.07 (m), 6.79-6.61 (m), 7.73-7.65 (m), 7.54 (d), 7.51 (d), 7.17 (s), 7.08 (d), 6.81-6.71 (m), 6.65-6.57 (m), 6.45 (d), 6.42-6.34 (m), 5.29 (dd), 4.97 (t), 4.78 (s), 4.72 (d), 3.34 (s), 3.25 (s), 3.21 (s), 3.24-3.11 (m), 3.02-2.93 (m), 2.88 (s), 2.87 (s), 2.69-2.52 (m), 2.51-2.36 (m), 1.64 (s), 1.45-1.24 (m), 1.10-1.02 (m), 1.02-0.95 (m). MS (m/z) 827.2 [M+H]+.
    • Example 166
  • Figure US20210009555A1-20210114-C00410
    • Synthesis of N-((1S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3,4-dihydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (166)
  • The title compound (166) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 142 of Example 142 utilizing 2-methylbut-3-yne-1,2-diol. 1H NMR (400 MHz, cd3od) 1H NMR (400 MHz, Methanol-d4) δ 8.68 (d), 7.70 (dd), 7.62-7.52 (m), 7.17 (s), 7.06 (d), 6.88-6.66 (m), 6.65-6.52 (m), 6.44-6.32 (m), 5.00-4.93 (m), 4.78-4.64 (m), 3.67 (s), 3.24 (d), 3.02-2.92 (m), 2.49-2.42 (m), 1.59 (s), 1.40-1.34 (m), 1.12-1.07 (m), 1.05-0.98 (s). MS (m/z) 837.9 [M+H]+.
    • Example 167
  • Figure US20210009555A1-20210114-C00411
    • Synthesis of (S)—N-(1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-cyclopropyl-4-(2-hydroxyethyl)-5-methyl-1H-pyrazol-1-yl)acetamide (167)
  • The title compound (167) was prepared as a mixture of atropisomers according to the method presented in the synthesis of 10A in Example 10 utilizing 19F and 2-(3-cyclopropyl-4-(2-hydroxyethyl)-5-methyl-1H-pyrazol-1-yl)acetic acid (prepared as described in US2012045761). 1H NMR (400 MHz, Methanol-d4) δ 7.71 (dd), 7.53 (dd), 7.27-7.15 (m), 7.12 (d), 6.80-6.70 (m), 6.69-6.58 (m), 6.55 (d), 6.44-6.29 (m), 5.33-5.22 (m), 5.03-4.93 (m), 4.73-4.52 (m), 3.69-3.53 (m), 3.32 (s), 3.27-3.21 (m), 3.17-3.08 (m), 3.05 (s), 2.99-2.85 (m), 2.76-2.60 (m), 2.11 (s), 2.01 (s), 1.88-1.78 (m), 1.64 (s), 0.93-0.86 (m), 0.79-0.70 (m). MS (m/z) 780.8 [M+H]+.
    • Example 168
  • Figure US20210009555A1-20210114-C00412
    • Synthesis of N—((S)-1-(6-chloro-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (168A)
  • The title compound (168A) was prepared according to the method presented for the synthesis of compound 157F of Example 157 utilizing 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. MS (m/z) 772.03 [M+H]+.
    • Synthesis of N—((S)-1-(6-(1-(tert-butyl)-1H-pyrazol-4-yl)-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (168B)
  • N—((S)-1-(6-chloro-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (168A, 20 mg, 0.026 mmol), 1-t-Butylpyrazole-4-boronic acid, pinacol ester (7.77 mg, 0.031 mmol), Pd(PPh3)4 (1.50 mg, 0.001 mmol), and K2CO3 (10.7 mg, 0.078 mmol) were suspended in 1,4-dioxane (0.2 mL). To the suspension was added water (0.05 mL). The resulting reaction mixture was degassed by bubbling argon for 60 seconds then sealed and heated thermally at 110° C. for 3.5 hours. Upon completion, the reaction mixture was filtered, concentrated in vacuo, taken in DMF, and purified by reverse phase HPLC to give the title compound 168B as a mixture of atropisomers. 1H NMR (400 MHz, Methanol-d4) δ 8.51 (s), 8.50 (s), 8.25 (s), 8.22 (d), 7.70 (t), 7.68-7.60 (m), 7.17 (s), 7.08 (s), 7.06 (s), 6.87-6.51 (m), 6.46-6.33 (m), 5.34-5.24 (m), 4.98 (dd), 4.81 (s), 4.79 (s), 4.77 (s), 3.38 (s), 3.26 (s), 3.24 (s), 3.22-3.17 (m), 3.04 (s), 2.98 (dd), 2.53-2.36 (m), 1.70 (s), 1.46-1.27 (m), 1.08 (m), 1.00 (m). MS (m/z) 860.21 [M+H]+.
    • Example 169
  • Figure US20210009555A1-20210114-C00413
    • Synthesis of N-((1S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(4,4-difluoro-3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (169)
  • The title compound (169) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 142 of Example 142 utilizing 1,1-difluoro-2-methylbut-3-yn-2-ol. 1H NMR (400 MHz, cd3od) δ 8.73 (t), 7.77-7.68 (d), 7.64-7.59 (m), 7.22-7.13 (m), 7.07 (dd), 6.87-6.51 (m), 6.46-6.34 (m), 5.82 (t), 5.37-5.21 (m), 5.04-4.93 (m), 4.78-4.63 (m), 3.24 (d), 3.05-2.93 (m), 2.45 (m), 1.63 (s), 1.47-1.32 (m), 1.08 (s), 1.01 (s). MS (m/z) 857.1 [M+H]+.
    • Example 170
  • Figure US20210009555A1-20210114-C00414
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(4-fluoro-3-(fluoromethyl)-3-hydroxybut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (170)
  • N—((S)-1-(6-chloro-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (168A, 20 mg, 0.025 mmol), 1-fluoro-2-(fluoromethyl)but-3-yn-2-ol (15.5 mg, 0.129 mmol), PdCl2(PPh3)2 (1.8 mg, 0.003 mmol), and CuI (0.5 mg, 0.003 mmol) were suspended in DMF (0.25 mL). To the reaction mixture was added diethylamine (27 μL, 0.259 mmol), and the reaction mixture was degassed by bubbling argon for 5 minutes then sealed and heated at 125° C. for 30 minutes in a microwave reactor. Upon cooling, the reaction mixture was filtered and purified by reverse phase HPLC. Fractions containing the product were pooled and lyophilized to give the title compound 170 as a mixture of atropisomers. 1H NMR (400 MHz, Methanol-d4) δ 8.72 (t), 7.74 (dd), 7.61 (dd), 7.22-7.14 (m), 7.09 (s), 7.07 (s), 6.87-6.53 (m), 6.46-6.35 (m), 5.35-5.26 (m), 4.99 (q), 4.76 (s), 4.72 (s), 4.70 (s), 4.66 (d), 4.54 (d), 3.33 (s), 3.26 (s), 3.23 (s), 3.18-3.09 (m), 3.05-2.91 (m), 2.54-2.37 (m), 1.45-1.33 (m), 1.09 (s), 1.02 (s). MS (m/z) 856.09 [M+H]+.
    • Example 171
  • Figure US20210009555A1-20210114-C00415
    • Synthesis of (4-chloro-1-methyl-3-(trifluoromethylsulfonamido)-1H-indazol-7-yl)boronic acid (171A)
  • 4-chloro-1-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (19C) (0.20 g, 0.65 mmol) was dissolved in dichloromethane (10 mL) and triethylamine (0.36 mL, 2.6 mmol). The mixture was cooled to 0° C. and triflic anhydride (0.55 g, 1.95 mmol) was added dropwise. After stirring for 30 minutes the reaction was quenched with water (10 mL) and extracted with dichloromethane (3×20 mL). The combined extracts were washed with brine and evaporated under vacuum. The residue was dissolved in ethanol (10 mL) and cooled to 0° C. 50% aqueous KOH solution (0.2 mL) was added dropwise and stirring was continued for 30 minutes. The mixture was acidified with 1N aqueous HCl. The formed precipitate was filtered and dried to give the title compound. MS (m/z) 358.0 [M+H]+.
    • Synthesis of (S)-tert-butyl (1-(3-(4-chloro-1-methyl-3-(trifluoromethylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (171B)
  • (4-chloro-1-methyl-3-(trifluoromethylsulfonamido)-1H-indazol-7-yl)boronic acid (171A, 26 mg, 0.073 mmol), (S)-tert-butyl (1-(3-bromo-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (14B, 36 mg, 0.073 mmol), and PdCl2(PPh3)2 (5.1 mg, 0.007 mmol) were suspended in 1,4-dioxane (1 mL) and 1.0 M aqueous NaHCO3 (1 mL). The reaction mixture was heated at 150° C. for 15 minutes in a microwave reactor. After cooling, the reaction mixture was diluted with EtOAc (50 mL), washed with water and brine, concentrated in vacuo, and purified by silica gel column chromatography, eluting with 20-100% EtOAc in hexanes to give the title compound. MS (m/z) 728.3 [M+H]+.
    • Synthesis of (S)—N-(7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-4-chloro-1-methyl-1H-indazol-3-yl)-1,1,1-trifluoromethanesulfonamide (171C)
  • To a solution of (S)-tert-butyl (1-(3-(4-chloro-1-methyl-3-(trifluoromethylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (171B, 43 mg, 0.059 mmol) in DCM (1 mL) was added trifluoroacetic acid (1 mL). The reaction mixture was stirred at room temperature for 3 hours and then concentrated in vacuo and azeotroped once with toluene (20 mL) to give the title compound. MS (m/z) 628.2 [M+H]+.
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(trifluoromethylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (171D)
  • To a solution of crude (S)—N-(7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-6-((2-hydroxyethyl)(methyl)amino)pyridin-3-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide (171C, 44 mg, 0.059 mmol) in DMF (1 mL) was added 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid (15.6 mg, 0.059 mmol), and HATU (27 mg, 0.071 mmol) followed by diisopropylethylamine (31 μL, 0.177 mmol). After stirring for two hours at ambient temperature, the reaction mixture was filtered and purified by reverse phase HPLC to provide the title compound as a mixture of atropisomers. 1H NMR (400 MHz, DMSO-d6) δ 9.11 (d), 8.95 (d), 7.87 (d), 7.83 (d), 7.51 (d), 7.26 (d), 7.19 (s), 7.12-6.74 (m), 6.62-6.56 (m), 6.49-6.35 (m), 4.95 (q), 4.79-4.54 (m), 3.26 (s), 3.06 (s), 3.31-2.92 (m), 2.58-2.38 (m), 1.52 (s), 1.42-1.30 (m), 0.95-0.78 (m). MS (m/z) 874.2 [M+H]+.
    • Example 172
  • Figure US20210009555A1-20210114-C00416
    • Synthesis of N—((S)-1-(5-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-[2,2′-bipyridin]-6-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (172)
  • To the reaction vial containing 157F (20 mg, 0.025 mmol) in dioxane (0.25 mL) was added 2-(tributylstannyl)pyridine (0.01 mL, 0.027 mmol), Pd(dppf)Cl2.DCM (1.2 mg, 0.001 mmol), and KF (4 mg, 0.75 mmol). The reaction mixture was flushed with argon gas for 5 min then sealed and heated in a microwave reactor to 135° C. for 30 min. Upon cooling, the reaction mixture was filtered and purified by reverse phase HPLC to provide the title compound 172 as a mixture of atropisomers. 1H NMR (400 MHz, cd3od) δ 9.90-9.8 (m), 8.80-8.76 (m), 8.74-8.70 (m), 8.52-8.45 (m), 7.98-7.88 (m, 1H), 7.30-7.04 (m), 6.82-6.71 (m), 6.51-6.34 (m), 5.45-5.35 (m), 5.14-5.05 (m), 4.98-4.86 (m), 3.35 (s), 3.21-3.00 (m), 2.60-2.38 (m), 1.42-1.22 (m), 1.19-1.09 (m), 1.06-1.00 (m). MS (m/z) 833.2 [M+H]*.
    • Example 173
  • Figure US20210009555A1-20210114-C00417
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (173)
  • N—((S)-1-(6-chloro-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (157F, 20 mg, 0.025 mmol), 1-methylpyrazole-4-boronic acid (3.8 mg, 0.030 mmol), Pd(PPh3)4 (1.5 mg, 0.001 mmol), and K2CO3 (10.5 mg, 0.076 mmol) were suspended in 1,4-dioxane (0.2 mL). To the suspension was added water (0.05 mL). The resulting reaction mixture was degassed by bubbling argon for 60 seconds then sealed and heated thermally at 110° C. for 2 hours. Upon completion, the reaction mixture was filtered, concentrated in vacuo, taken in DMF, and purified by reverse phase HPLC to give the title compound 173 as a mixture of atropisomers. 1H NMR (400 MHz, Methanol-d4) δ 8.39 (s), 8.35 (s), 8.23 (s), 8.20 (s), 7.71-7.60 (m), 7.15 (s), 7.06 (d), 6.76 (tt), 6.63 (tt), 6.49-6.41 (m), 6.41-6.34 (m), 5.24 (dd), 4.99 (dd), 4.03 (s), 4.02 (s), 3.46-3.41 (m), 3.39 (s), 3.26 (s), 3.24 (s), 3.23-3.17 (m), 3.07-2.95 (m), 2.59-2.38 (m), 1.49-1.34 (m), 1.17-1.11 (m), 1.09-1.03 (m). MS (m/z) 836.16 [M+H]+.
    • Example 174
  • Figure US20210009555A1-20210114-C00418
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(1-isopropyl-1H-pyrazol-4-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (174)
  • The title compound (174) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 173 of Example 173 utilizing 1-isopropylpyrazole-4-boronic acid, pinacol ester. 1H NMR (400 MHz, Methanol-d4) δ 8.46 (s), 8.44 (s), 8.24 (s), 8.22 (s), 7.72-7.60 (m), 7.16 (s), 7.06 (d), 6.76 (tt), 6.68-6.57 (m), 6.49-6.42 (m), 6.41-6.33 (m), 5.26 (dd), 4.99 (dd), 4.86 (s), 4.70-4.58 (m), 3.47-3.40 (m), 3.39 (s), 3.37-3.34 (m), 3.26 (s), 3.24 (s), 3.23-3.16 (m), 3.09-2.93 (m), 2.59-2.37 (m), 1.61 (d), 1.49-1.34 (m), 1.17-1.11 (m), 1.09-1.02 (m). MS (m/z) 864.20 [M+H]+.
    • Example 175
  • Figure US20210009555A1-20210114-C00419
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(1-methyl-1H-pyrazol-5-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (175)
  • The title compound (175) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 173 of Example 173 utilizing 1-methyl-1H-pyrazole-5-boronic acid pinacol ester. H NMR (400 MHz, Methanol-d4) δ 7.87-7.78 (m), 7.59 (d), 7.31 (d), 7.20 (d), 7.11 (d), 6.90 (d), 6.88 (d), 6.79 (tt), 6.63 (tt), 6.55-6.51 (m), 6.47-6.37 (m), 5.40 (dd), 5.07 (dd), 4.78 (s), 4.77 (s), 4.43 (s), 4.34 (s), 3.39 (s), 3.25 (s), 3.24-3.21 (m), 3.15-3.12 (m), 3.11-3.02 (m), 2.59-2.35 (m), 1.47-1.33 (m), 1.15-1.08 (m), 1.06-0.98 (m). MS (m/z) 836.15 [M+H]+.
    • Example 176
  • Figure US20210009555A1-20210114-C00420
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(pyrimidin-2-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (176)
  • The title compound (176) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 172 of Example 172 utilizing 2-(tributylstannyl)pyrimidine. 1H NMR (400 MHz, cd3od) δ 9.90 9.86 (m), 9.84-9.80 (m), 8.80-8.75 (m, 1H), 8.74 (d), 8.47 (d),7.92 (t), 7.25-7.12 (m), 6.80-6.50 (m), 6.45-6.40 (m), 5.45-5.38 (m), 5.15-5.05 (m), 4.90-4.81 (m), 3.37 (s), 3.18-3.04 (m), 2.50-2.39 (m), 1.44-1.25 (m), 1.15-1.09 (m), 1.08-0.97 (m). MS (m/z) 835.1 [M+H]+.
    • Example 177
  • Figure US20210009555A1-20210114-C00421
    Figure US20210009555A1-20210114-C00422
    • Synthesis of (S)-tert-butyl (1-(5-bromo-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (177A)
  • Compound 183A (0.500 g, 0.82 mmol) was added to a stirred suspension of t-BuONO (0.15 mL, 1.24 mmol) and CuBr2 (0.276 g, 1.24 mmol) in acetonitrile with ice bath, the suspension was allowed to warm up to room temperature and stirred overnight. Aqueous ammonium chloride was added. The mixture was extracted with EtOAc. The organic layer was dried with MgSO4, concentrated and purified by silica gel column to afford the title compound as mixture of atropisomers (177A). MS (m/z) 670 [M+H]+.
    • Synthesis of (S)-tert-butyl (1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-5-phenylpyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (177B)
  • Compound 177A (31.3 mg, 0.047 mmol), phenylboronic acid (6.3 mg, 0.051 mmol), K2CO3 (39 mg, 0.28 mmol) and Pd(dppf)Cl2 (14 mg, 0.019 mmol) were mixed together. Toluene (1 mL), iPrOH (0.5 mL) and water (1 mL) were added. The vial was capped tight, stirred at 60° C. for 30 minutes. The reaction mixture was diluted with EtOAc, washed with brine, dried with MgSO4 and concentrated. The crude was purified by silica gel column to afford the title compound as mixture of atropisomers (177B). MS (m/z) 668 [M+H]+.
    • Synthesis of (S)—N-(7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-5-phenylpyridin-3-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide (177C)
  • Compound 177B (21.7 mg, 0.032 mmol) was dissolved in DCM (1 mL). TFA (0.5 mL) was added. The resultant solution was stirred at ambient temperature for 2 hours. The reaction was concentrated to afford title compound as mixture of atropisomers (177C). MS (m/z) 568 [M+H]+.
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-5-phenylpyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (177D)
  • Compound 177C (18.4 mg, 0.032 mmol) and 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid (8.6 mg, 0.032 mmol) were dissolved in DMF (1 mL). TEA (23 uL, 0.162 mmol) and HATU (18.5 mg, 0.049 mmol) were added. Upon completion, a few drops of 1M HCl were added. The reaction was purified by HPLC to afford the title compound as mixture of atropisomers (177D). H NMR (400 MHz, Acetonitrile-d3) 9.04 (dd), 7.99 (dd), 7.82-7.73 (m), 7.69 (d), 7.59-7.43 (m), 7.34 (d), 7.29-7.18 (m), 7.15 (d), 6.90 (d), 6.85-6.73 (m), 6.69-6.58 (m), 6.49-6.36 (m), 5.30 (q), 4.96 (q), 4.69 (d), 3.33 (s), 3.28 (s), 3.27 (s), 3.20-2.91 (m), 2.58-2.40 (m), 1.40 (q), 1.09-0.97 (m). MS (m/z) 814 [M+H]+.
    • Example 178
  • Figure US20210009555A1-20210114-C00423
    • Synthesis of N—((S)-1-(6-(2-(tert-butyl)thiazol-5-yl)-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (178)
  • N—((S)-1-(6-chloro-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (157F, 20 mg, 0.025 mmol), 2-(tert-butyl)-5-(tributylstannyl)thiazole (12.03 mg, 0.028 mmol), Pd(dppf)Cl2 (1.1 mg, 0.001 mmol), and KF (4.4 mg, 0.076 mmol) were suspended in 1,4-dioxane (0.25 mL). The resulting reaction mixture was degassed by bubbling argon for 60 seconds then sealed and heated at 130° C. for 30 minutes in a microwave reactor. Upon cooling, the reaction mixture was filtered, concentrated in vacuo, taken in DMF, and purified by reverse phase HPLC to give the title compound 178 as a mixture of atropisomers. 1H NMR (400 MHz, Methanol-d4) δ 8.40 (s), 7.91 (dd), 7.76 (d), 7.74 (d), 7.20-7.13 (m), 7.08 (d), 6.77 (tt), 6.65 (tt), 6.55-6.47 (m), 6.45-6.38 (m), 5.20 (dd), 5.02 (dd), 4.80 (s), 3.41 (s), 3.26 (s), 3.25 (s), 3.09-2.98 (m), 2.95 (s), 2.60-2.39 (m), 1.71 (s), 1.70 (s), 1.69 (s), 1.48-1.34 (m), 1.17-1.11 (m), 1.09-1.03 (m). MS (m/z) 897.04 [M+H]+.
    • Example 179
  • Figure US20210009555A1-20210114-C00424
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(1-methyl-1H-imidazol-4-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (179)
  • The title compound (179) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 178 of Example 178 utilizing 1-methyl-4-(tributylstannyl)-1H-imidazole. H NMR (400 MHz, Methanol-d4) δ 8.89 (s), 8.84 (s), 8.29 (s), 8.25 (s), 7.94-7.82 (m), 7.19 (s), 7.07 (d), 6.78 (tt), 6.64 (tt), 6.48-6.41 (m), 6.37 (dd), 5.35 (dd), 5.05 (dd), 4.81 (s), 4.77 (s), 4.05 (s), 4.04 (s), 3.36 (s), 3.27 (s), 3.25 (s), 3.23-3.18 (m), 3.12-2.98 (m), 2.59-2.41 (m), 1.48-1.37 (m), 1.33-1.26 (m), 1.16-1.10 (m), 1.09-1.03 (m). MS (m/z) 836.15 [M+H]+.
    • Example 180
  • Figure US20210009555A1-20210114-C00425
    • Synthesis of tert-butyl ((1S)-1-(3-(4-chloro-1-methyl-3-(methylsulfinamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (180A)
  • (S)-tert-butyl(1-(3-(3-amino-4-chloro-1-methyl-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (55A,61 mg, 0.102 mmol) was dissolved in dichloromethane (2 mL) and diisopropylethylamine (0.071 mL, 0.409 mmol). The mixture was cooled to 0° C. and methanesulfinyl chloride (30.3 mg, 0.307 mmol) was added dropwise. After stirring at ambient temperature overnight the reaction mixture was diluted with ethyl acetate (50 mL), washed with water and brine and evaporated under vacuum. Purification on silica gel gave the title compound. MS (m/z) 658.3 [M+H]+.
    • Synthesis of N-(7-(2-((S)-1-amino-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfinamide (180B)
  • To a solution of tert-butyl ((1S)-1-(3-(4-chloro-1-methyl-3-(methylsulfinamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (180A, 50 mg, 0.076 mmol) in DCM (1 mL) was added trifluoroacetic acid (1 mL). The reaction mixture was stirred at room temperature for 3 hours and then concentrated in vacuo and azeotroped once with toluene (20 mL) to give the title compound. MS (m/z) 558.2 [M+H]+.
    • Synthesis of N-((1S)-1-(3-(4-chloro-1-methyl-3-(methylsulfinamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (180C)
  • To a solution of crude N-(7-(2-((S)-1-amino-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfinamide (180B, 52 mg, 0.076 mmol) in DMF (1 mL) was added 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid (20 mg, 0.076 mmol), and HATU (34.7 mg, 0.091 mmol) followed by diisopropylethylamine (66 μL, 0.38 mmol). After stirring for two hours at ambient temperature, the reaction mixture was filtered and purified by reverse phase HPLC to provide the title compound as a mixture of diastereomers and atropisomers. 1H NMR (400 MHz, DMSO-d6) δ 8.99-8.60 (m), 7.85-7.70 (m), 7.55 (d), 7.05-6.70 (m), 6.56-6.28 (m), 4.93-4.49 (m), 3.30-2.59 (m), 2.96 (s), 2.65 (s), 2.48-2.30 (m), 1.72-1.66 (m), 1.42-1.30 (m), 0.95-0.78 (m). MS (m/z) 804.2 [M+H]+.
    • Example 181
  • Figure US20210009555A1-20210114-C00426
    • Synthesis of (S)-tert-butyl (1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-5-(2-chlorophenyl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (181A)
  • The title compound as mixture of atropisomers (181A) was prepared according to the method presented for the synthesis of compound 177B of Example 177 utilizing compound 177A and 2-chlorophenylbronic acid. MS (m/z) 702 [M+H]+.
    • Synthesis of (S)—N-(7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-5-(2-chlorophenyl)pyridin-3-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide (181A)
  • The title compound as mixture of atropisomers (181B) was prepared according to the method presented for the synthesis of compound 177C of Example 177 utilizing compound 181A. MS (m/z) 602 [M+H]+.
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-5-(2-chlorophenyl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (181C)
  • The title compound as mixture of atropisomers (181C) was prepared according to the method presented for the synthesis of compound 177D of Example 177 utilizing compound 181B and 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. 1H NMR (400 MHz, DMSO-d6) δ 9.82 (s), 9.75 (s), 9.07 (d), 8.94 (d), 8.87 (dd), 7.97 (d), 7.90 (d), 7.69-7.39 (m), 7.23-6.74 (m), 6.54 (d), 6.44 (d), 5.03 (q), 4.90-4.53 (m), 3.32 (s), 3.23-2.89 (m), 2.60-2.37 (m), 1.47-1.30 (m), 0.83 (s). MS (m/z) 848 [M+H]+.
    • Example 182
  • Figure US20210009555A1-20210114-C00427
    Figure US20210009555A1-20210114-C00428
    Figure US20210009555A1-20210114-C00429
    • Synthesis of 2-(5-bromo-6-methylpyridin-3-yl)isoindoline-1,3-dione (182A)
  • A mixture of phthalic anhydride (3.7 g, 25 mmol), 5-bromo-6-methylpyridin-3-amine (3.9 g, 20.85 mmol) and sodium acetate (1.5 g, 25 mmol) in glacial acetic acid (44 ml) was refluxed for overnight. After cooling down to room temperature, the precipitate was collected by vacuum filtration and washed with water. Then it was dried under high vacuum to afford the title compound 182A. MS (m/z) 318.91 [M+H]+.
    • Synthesis of 3-bromo-5-(1,3-dioxoisoindolin-2-yl)picolinaldehyde (182B)
  • To a microwave tube was charged with compound 182A (1.5 g, 4.73 mmol) and selenium dioxide (682 mg, 6.15 mmol). To it was added 14 mL of 1,2-dimethoxyethane and the microwave tube was sealed. The reaction mixture was heated in a 130° C. heating bath for 20 hours. The reaction mixture was cooled down and the solids filtered off. The filtrate was concentrated to afford the title compound 182B. 1H NMR (400 MHz, DMSO) δ 10.04 (s, 1H), 8.95 (d, J=1.9 Hz, 1H), 8.41 (d, J=1.7 Hz, 1H), 8.07-7.84 (m, 4H).
    • Synthesis of (S,Z)—N-((3-bromo-5-(1,3-dioxoisoindolin-2-yl)pyridin-2-yl)methylene)-2-methylpropane-2-sulfinamide (182C)
  • Copper(II) sulfate (anhydrous, 5.8 g, 36.2 mmol) was added to a solution of 3-bromo-5-(1,3-dioxoisoindolin-2-yl)picolinaldehyde (182B, 6 g, 18 mmol) and (S)-2-methylpropane-2-sulfinamide (2.2 g, 18 mmol) in CH2Cl2 (60 mL). The reaction mixture was stirred at ambient temperature for 2 hours and then filtered and washed with CH2Cl2. The filtrate was concentrated and the residue was purified by silica gel chromatography eluting with EtOAc and methylene chloride to yield the title compound 182C. MS (m/z) 433.87 [M+H]+.
    • Synthesis of (S)—N—((S)-1-(3-bromo-5-(1,3-dioxoisoindolin-2-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-methylpropane-2-sulfinamide (182D)
  • To a solution of compound (182C, 3.7 g, 8.5 mmol) and Cu(OTf)2 (154 mg, 0.4 mmol) in methylene chloride (30 ml) at 0° C. was added (3,5-difluorobenzyl)zinc bromide (0.5 M in THF, 25.5 ml, 12.8 mmol) dropwise. The reaction stirred at room temperature for one hour. Ammonium chloride (aq, 100 ml) was added to the reaction and the mixture was extracted with methylene chloride (2×100 ml). The organic layer was dried over Na2SO4, filtered and concentrated. The reaction mixture was purified by silica gel chromatography then by reverse phase HPLC to afford the title compound 182D. MS (m/z) 563.83 [M+H]+.
    • Synthesis of (S)-tert-butyl 1-(3-bromo-5-(1,3-dioxoisoindolin-2-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethylcarbamate (182E)
  • Compound 182D (2.6 g, 4.6 mmol) was dissolved in 40 mL of methanol and cooled to 0° C. To it was added 4N HC/1,4-dioxane (4.6 ml). The reaction mixture was allowed to stir at room temperature for 10 minutes and concentrated to afford product (S)-2-(6-(1-amino-2-(3,5-difluorophenyl)ethyl)-5-bromopyridin-3-yl)isoindoline-1,3-dione hydrochloride. To the mixture of the above HCl salt (˜4.6 mmol) and Di-tert-Butyl dicarbonate (1 g, 4.6 mmol) in 50 mL of CH2C2 was added triethylamine (1.28 mL, 9.2 mmol) at 0° C. The reaction mixture was stirred for overnight and concentrated in vacuo. The residue was partitioned between EtOAc and water. The organic layer was washed with brine, dried over MgSO4, filtered and concentrated. Then it was purified on silica gel chromatography to yield the title compound 182E. MS (m/z) 559.71 [M+H]+.
    • Synthesis of (S)-tert-butyl (1-(5-amino-3-bromopyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (182F)
  • To a mixture of compound 182E (1.5 g, 2.7 mmol) in 27 ml of ethanol, 0.9 ml of hydrazine monohydrate was added and stirred at room temperature for 2 hours. More ethanol was added to the reaction mixture. The precipitate was filtered off and the filtrate was concentrated. The residue was diluted with ethyl acetate, and washed with water and then with a saturated sodium chloride solution. The organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography to give the title compound 182F. MS (m/z) 427.83 [M+H]+.
    • Synthesis of (S)-tert-butyl (1-(5-amino-3,6-dibromopyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (182G)
  • A solution of compound 182F (960 mg, 2.24 mmol) in 20 mL of acetonitrile was cooled to 0° C. and treated with N-Bromosuccinimide (399 mg, 2.24 mmol) as a solution in 20 mL of acetonitrile. The reaction mixture was partitioned with EtOAc and saturated aqueous NaHCO3. The organic layer was separated and washed with brine, then dried over MgSO4 and concentrated in vacuo. The residue was purified by silica gel chromatography to afford the title compound 182G. MS (m/z): 507.52 [M+H]+.
    • Synthesis of (S)-tert-butyl (1-(5-amino-3-bromo-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (182H)
  • The title compound (182H) was prepared according to the method presented for the synthesis of compound 4F of Example 4 utilizing compound 182G. MS (m/z) 511.87 [M+H]+.
    • Synthesis of (S)-tert-butyl (1-(3-bromo-6-(3-hydroxy-3-methylbut-1-yn-1-yl)-5-(methylamino)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (182I)
  • Compound 182H (200 mg, 0.39 mmol) was dissolved in 2 mL of acetonitrile, to it was added formaldehyde (0.1 mL, 37% in H2O) and acetic acid (0.2 mL, 4 mmol) followed by slow addition of sodium cyanoborohydride solution (1.2 mL, 1M in THF). The reaction mixture was allowed to stir at room temperature for 3 hours and quenched by adding aqueous sodium bicarbonate. It was extracted with ethyl acetate. The organic layer was washed with water, dried over Na2SO4 and concentrated under reduced pressure. The crude product was purified by RP-HPLC to afford the title compound 182I. MS (m/z): 525.99 [M+H]+.
    • Synthesis of (S)-tert-butyl (1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)-5-(methylamino)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (182J)
  • The title compound (182J) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 19E of Example 19 utilizing compound 182I and compound 19D. MS (m/z) 703.35 [M+H]+.
    • Synthesis of (S)—N-(7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)-5-(methylamino)pyridin-3-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide (182K)
  • The title compound (182K) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 105C of Example 105 utilizing compound 182J. MS (m/z) 603.17 [M+H]+.
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)-5-(methylamino)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (182L)
  • The title compound (182L) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 37E of Example 37 utilizing 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid and compound 182K. 1H NMR (400 MHz, Methanol-d4) δ 7.00 (d), 6.82 (d), 6.76 (tt), 6.70 (t), 6.43-6.30 (m), 6.24 (d), 4.78-4.56 (m), 3.39 (s), 3.22 (s), 3.16-2.99 (m), 2.98-2.88 (m), 2.84 (s), 2.52-2.31 (m), 1.66 (d), 1.49-1.21 (m), 1.12-0.86 (m). MS (m/z) 849.90 [M+H]+.
    • Example 183
  • Figure US20210009555A1-20210114-C00430
    Figure US20210009555A1-20210114-C00431
    • Synthesis of (S)-tert-butyl (1-(5-amino-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (183A)
  • The title compound (183A) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 19E of Example 19 utilizing compound 182F and compound 19D. MS (m/z) 606.88 [M+H]+.
    • Synthesis of (S)-tert-butyl (1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-5-(dimethylamino)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (183B)
  • The title compound (183B) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 182I of Example 182 utilizing compound 183A. MS (m/z) 635.48 [M+H]+.
    • Synthesis of (S)-tert-butyl (1-(6-bromo-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-5-(dimethylamino)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (183C)
  • The title compound (183C) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 182G of Example 182 utilizing compound 183B. MS (m/z) 714.81 [M+H]+.
    • Synthesis of (S)-tert-butyl (1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-5-(dimethylamino)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (183D)
  • The title compound (183D) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 4F of Example 4 utilizing compound 183C. MS (m/z) 717.62 [M+H]+.
    • Synthesis of (S)—N-(7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-5-(dimethylamino)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide (183E)
  • The title compound (183E) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 105C of Example 105 utilizing compound 183D. MS (m/z) 617.09 [M+H]+.
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-5-(dimethylamino)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (183F)
  • The title compound (183F) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 37E of Example 37 utilizing 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid and compound 183E. 1H NMR (400 MHz, Methanol-d4) δ 7.26-7.10 (m), 7.03 (d), 6.76 (t), 6.69 (t), 6.60 (t), 6.52-6.33 (m), 6.32 (d), 4.85-4.78 (m), 4.78-4.60 (m), 3.37 (s), 3.23 (d), 3.10 (dd), 2.99 (d), 2.98-2.74 (m), 2.45 (ddd), 1.66 (s), 1.48-1.30 (m), 1.17-0.92 (m).). MS (m/z): 863.19 [M+H]+.
    • Example 184
  • Figure US20210009555A1-20210114-C00432
    • Synthesis of tert-butyl (4-(5-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-((S)-1-(2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)pyridin-2-yl)-2-hydroxy-2-methylbut-3-yn-1-yl)carbamate (184)
  • The title compound (184) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 145 of Example 145 utilizing tert-butyl (2-hydroxy-2-methylbut-3-yn-1-yl)carbamate. MS (m/z) 953.9 [M+H]+. HPLC retention time 7.54 min and 7.69 min (2-98% acetonitrile: water with 0.1% trifluoroacetic acid, 8.5 min gradient on a Phenomonex Kinetex C18 column).
    • Example 185
  • Figure US20210009555A1-20210114-C00433
    • Synthesis of (S)-tert-butyl (1-(5-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-[3,3′-bipyridin]-6-yl-2-(3,5-difluorophenyl)ethyl)carbamate (185A)
  • The title compound as mixture of atropisomers (185A) was prepared according to the method presented for the synthesis of compound 177B of Example 177 utilizing compound 177A and 3-pyridinebronic acid. MS (m/z) 669 [M+H]+.
    • Synthesis of (S)—N-(7-(6-(1-amino-2-(3,5-difluorophenyl)ethyl)-[3,3′-bipyridin]-5-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide (185B)
  • The title compound as mixture of atropisomers (185B) was prepared according to the method presented for the synthesis of compound 177C of Example 177 utilizing compound 185A. MS (m/z) 569 [M+H]+.
    • Synthesis of N—((S)-1-(5-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-[3,3′-bipyridin]-6-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (185C)
  • The title compound as mixture of atropisomers (185C) was prepared according to the method presented for the synthesis of compound 177D of Example 177 utilizing compound 185B. 1H NMR (400 MHz, Acetonitrile-d3) δ 9.07 (t), 8.96 (dd), 8.66 (dd), 8.15-8.06 (m), 8.03 (dd), 7.56-7.44 (m), 7.35 (d), 7.28 (d), 7.22 (d), 7.16 (dd), 6.93-6.87 (m), 6.86-6.72 (m), 6.69-6.57 (m), 6.48-6.34 (m), 5.37-5.29 (q), 4.98 (q), 4.78-4.59 (m), 3.36-2.91 (m), 2.49 (dtd), 1.41 (p), 1.05 (t). MS (m/z) 815 [M+H]+.
    • Example 186
  • Figure US20210009555A1-20210114-C00434
    Figure US20210009555A1-20210114-C00435
    • Synthesis of (S)-tert-butyl (1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-5-cyanopyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (186A)
  • To a suspension of 177A (140 mg, 0.21 mmol) in anhydrous/degassed DMF (1.5 ml) was treated with Zn(CN)2 (14.7 mg, 0.125 mmol), and tetrakis(triphenylphosphine)palladium(0) (24.1 mg, 0.021 mmol). The mixture was heated at 90° C. for 16 hours under a nitrogen atmosphere. The reaction mixture was allowed to cool to ambient temperature and poured into EtOAc (50 ml). The organic layer was washed with brine, dried (MgSO4), and concentrated under reduced pressure. The residue was purified on flash column to provide the title compound as a mixture of atropisomers. MS (m/z) 617 [M+H]+.
    • Synthesis of (S)—N-(7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-5-cyanopyridin-3-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide hydrochloride (186B)
  • The title compound (186B) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 21E of Example 21 utilizing 186A. MS (m/z) 517 [M+H]+.
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-5-cyanopyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (186C)
  • The title compound (186C) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 10A of Example 10 utilizing 186B and 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. MS (m/z) 763 [M+H]+.
    • Synthesis of 5-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-((S)-1-(2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)nicotinamide (186D)
  • To a suspension of 186C (21 mg, 0.028 mmol) and K2CO3(38 mg, 0.28 mmol) in DMSO, H2O2 (30 wt. % in H2O, 0.028 mL, 0.28 mmol) was added to the suspension slowly. After 10 minutes, the mixture was filtered and purified by reverse phase HPLC to provide the title compound as a mixture of atropisomers. 1H NMR (400 MHz, Methanol-d4) 1H NMR (400 MHz, Methanol-d4) δ 9.26 (t), 8.73 (t), 8.14 (dd), 7.31-7.14 (m), 7.09 (d), 6.77 (tt),6.72 (t), 6.68-6.59 (m), 6.49-6.30 (m), 5.35-5.25 (m), 5.08-5.00 (m), 4.78-4.68 (m), 3.25 (d), 3.18-3.09 (m), 3.05-2.93 (m), 2.65 (s), 2.44 (ddd), 1.39 (dq), 1.01 (h). MS (m/z) 781 [M+H]+.
    • Example 187
  • Figure US20210009555A1-20210114-C00436
    Figure US20210009555A1-20210114-C00437
    • Synthesis of (S)—N—((S)-1-(3,6-dibromopyridin-2-yl)-2-(3-fluorophenyl)ethyl)-2-methylpropane-2-sulfinamide (187A)
  • To a solution of (S,Z)—N-((3,6-dibromopyridin-2-yl)methylene)-2-methylpropane-2-sulfinamide (1.0 g, 2.717 mmol) and Cu(OTf)2 (49.1 mg, 0.136 mmol) in DCM (10 mL) was added 3-fluorobenzyl zinc chloride (0.5M in THF, 7.6 mL, 3.803 mmol) dropwise over 7 minutes at 0° C. The reaction mixture was stirred at 0° C. for 1 hour, then quenched with saturated aqueous NH4Cl and diluted with EtOAc. The organic layer was collected, and the aqueous layer was extracted an additional time with EtOAc. The combined organic layers were dried over Na2SO4, filtered, concentrated, and purified by silica gel column chromatography to provide the title compound 187A. MS (m/z) 476.93, 478.84, 480.79 [M+H]+.
    • Synthesis of (S)-1-(3,6-dibromopyridin-2-yl)-2-(3-fluorophenyl)ethanamine (187B)
  • To a solution of (S)—N—((S)-1-(3,6-dibromopyridin-2-yl)-2-(3-fluorophenyl)ethyl)-2-methylpropane-2-sulfinamide (187A, 714.2 mg, 1.493 mmol) in MeOH (3.7 mL) was added HCl (4M in 1,4-dioxane, 3.7 mL, 14.93 mmol). The reaction mixture was stirred at room temperature for 30 minutes. Upon completion, the reaction mixture was concentrated in vacuo to provide the title compound 187B, which was used without purification. MS (m/z) 373.08, 374.92, 376.86 [M+H]+.
    • Synthesis of (S)-tert-butyl (1-(3,6-dibromopyridin-2-yl)-2-(3-fluorophenylethyl)carbamate (187C)
  • To a solution of (S)-1-(3,6-dibromopyridin-2-yl)-2-(3-fluorophenyl)ethanamine (187B, 558.62 mg, 1.493 mmol) in DCM was added DIPEA (0.52 mL, 2.987 mmol). The reaction mixture was cooled to 0° C., then Boc2O (358.6 mg, 1.643 mmol) was added. The reaction mixture was warmed to room temperature and stirred at room temperature for 2.5 hours. Upon completion, the reaction mixture was concentrated in vacuo and purified by silica gel column chromatography to provide the title compound 187C. MS (m/z) 472.71, 474.68, 476.68 [M+H]+.
    • Synthesis of (S)-tert-butyl (1-(3-bromo-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3-fluorophenyl)ethyl)carbamate (187D)
  • A solution of (S)-tert-butyl (1-(3,6-dibromopyridin-2-yl)-2-(3-fluorophenyl)ethyl)carbamate (187C, 200.0 mg, 0.422 mmol) in 2-MeTHF was degassed by bubbling argon for 60 seconds. To the degassed solution were added NEt3 (0.18 mL, 1.268 mmol) and 2-methyl-3-butyn-2-ol (62 μL, 0.633 mmol) followed by CuI (2.4 mg, 0.013 mmol) and PdCl2(PPh3)2 (8.9 mg, 0.013 mmol). The reaction mixture was stirred at room temperature for 30 minutes. Upon completion, the reaction mixture was diluted with water and extracted three times with EtOAc. The combined organic layers were dried over Na2SO4, filtered, concentrated in vacuo, and purified by silica gel column chromatography to provide the title compound 187D. MS (m/z) 476.91, 478.83 [M+H]+.
    • Synthesis (S)-tert-butyl (1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3-fluorophenyl)ethyl)carbamate (187E)
  • (S)-tert-butyl (1-(3-bromo-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3-fluorophenyl)ethyl)carbamate (187D, 189.7 mg, 0.397 mmol), N-(4-chloro-1-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-yl)methanesulfonamide (19D, 214.6 mg, 0.556 mmol), and PdCl2(PPh3)2 (27.9 mg, 0.04 mmol) were taken in 1,4-dioxane (10 mL) and NaHCO3 (1 M in water, 1.19 mL, 1.19 mmol). The resulting solution was degassed by bubbling argon for 5 minutes, then the reaction flask was sealed and the reaction heated at 150° C. for 20 minutes in a microwave reactor. Upon cooling, the reaction mixture was filtered, concentrated in vacuo, and purified by silica gel column chromatography to provide the title compound 187E as a mixture of atropisomers. MS (m/z) 655.92 [M+H]+.
    • Synthesis of (S)—N-(7-(2-(1-amino-2-(3-fluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide (187F)
  • To a solution of (S)-tert-butyl (1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3-fluorophenyl)ethyl)carbamate (187E, 257.3 mg, 0.392 mmol) in DCM (4 mL) was added TFA (4 mL). The reaction mixture was stirred at room temperature for 1 hour 15 minutes. Upon completion, the reaction mixture was concentrated in vacuo to provide the title compound 187F as a mixture of atropisomers which was used without further purification. MS (m/z) 556.15 [M+H]+.
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3-fluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (187G)
  • To a solution of (S)—N-(7-(2-(1-amino-2-(3-fluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-3-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide (187F, 218.0 mg, 0.392 mmol) in DMA (3 mL) was added NEt3 (0.16 mL, 1.176 mmol), 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid (77.5 mg, 0.274 mmol), then HATU (104.4 mg, 0.274 mmol) at room temperature. The reaction mixture was stirred at room temperature for 15 minutes. Upon completion, the reaction mixture was filtered and purified by reverse phase HPLC. Fractions containing the product were pooled and lyophilized to give the title compound 187G as a mixture of atropisomers. 1H NMR (400 MHz, Methanol-d4) δ 8.80-8.70 (m), 7.65 (dd), 7.51 (dd), 7.22-7.11 (m), 6.99 (d), 6.96-6.89 (m), 6.77 (t), 6.60-6.46 (m), 6.15-6.07 (m), 5.37-5.25 (m), 5.02-4.93 (m), 4.84 (s), 4.80 (s), 4.78 (s), 4.74 (s), 3.26 (s), 3.23 (s), 3.21-3.11 (m), 3.04-2.94 (m), 2.82 (s), 2.61-2.39 (m), 1.65 (s), 1.50-1.35 (m), 1.19-1.12 (m), 1.11-1.02 (m). MS (m/z) 820.12 [M+H]+.
    • Example 188
  • Figure US20210009555A1-20210114-C00438
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3-fluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (188)
  • The title compound (188) was prepared as a mixture of atropisomers according to the method presented for the synthesis of compound 187G of Example 187 utilizing 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid. 1H NMR (400 MHz, Methanol-d4) δ 8.72-8.62 (m), 7.65 (dd), 7.57-7.44 (m), 7.33 (dd), 7.22-7.11 (m), 6.99 (d), 6.98-6.65 (m), 6.61-6.46 (m), 6.14 (d), 6.13 (d), 5.31 (dd), 4.96 (dd), 4.79 (s), 4.74 (s), 4.72 (s), 4.68 (s), 3.26 (s), 3.22 (s), 3.20-3.11 (m), 3.04-2.92 (m), 2.83 (s), 2.55-2.39 (m), 1.65 (s), 1.45-1.32 (m), 1.15-1.07 (m), 1.07-0.98 (m). MS (m/z) 802.15 [M+H]+.
    • Example 189
  • Figure US20210009555A1-20210114-C00439
    • Synthesis of (S)-2-(3,5-bis(difluoromethyl)-1H-pyrazol-1-yl)-N-(1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)acetamide (189)
  • The title compound (189) was prepared as a mixture of atropisomers according to the method presented in the synthesis of 10A in Example 10 utilizing 19F and 2-(3,5-bis(difluoromethyl)-1H-pyrazol-1-yl)acetic acid. 1H NMR (400 MHz, Methanol-d4) δ 7.70 (dd), 7.53 (dd), 7.18 (q), 7.07 (d), 7.01-6.56 (m), 6.42 (d), 6.40-6.31 (m), 5.26 (dd), 5.04-4.86 (m), 3.25 (s), 3.21 (s), 3.15 (dd), 3.04-2.93 (m), 1.64 (s). MS (m/z) 783.1 [M+H]+.
    • Example 190
  • Figure US20210009555A1-20210114-C00440
    • Synthesis of (S)—N-(1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(trifluoromethyl)-4,5-dihydropyrano[3,4-c]pyrazol-1(7H)-yl)acetamide (190)
  • The title compound (190) was prepared as a mixture of atropisomers according to the method presented in the synthesis of 10A in Example 10 utilizing 19F and 2-(3-(trifluoromethyl)-4,5-dihydropyrano[3,4-c]pyrazol-1(7H)-yl)acetic acid. 1H NMR (400 MHz, Methanol-d4) δ 7.71 (dd), 7.53 (dd), 7.17 (q), 7.09 (d), 6.82-6.69 (m), 6.68-6.59 (m), 6.42 (dd), 5.28-5.19 (m), 5.01-4.92 (m), 4.69 (t), 4.52 (s), 3.92-3.78 (m), 3.25 (d), 3.20-3.09 (m), 3.01 (s), 2.96 (dd), 2.73-2.59 (m), 1.64 (s). MS (m/z) 807.0 [M+H]+.
    • Example 191
  • Figure US20210009555A1-20210114-C00441
    • Synthesis of (S)—N-(1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetamide (191)
  • The title compound (191) was prepared as a mixture of atropisomers according to the method presented in the synthesis of 10A in Example 10 utilizing 19F and 2-(5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetic acid. 1H NMR (400 MHz, Methanol-d4) δ 7.71 (dd), 7.53 (dd), 7.27 (d), 7.17 (d), 7.10 (d), 6.80-6.72 (m), 6.67-6.58 (m), 6.52 (d), 6.45-6.33 (m), 6.24 (s), 6.19 (s), 5.37-5.22 (m), 5.05-4.95 (m), 4.90 (d), 3.23 (d), 3.21-3.08 (m), 3.05 (s), 3.03-2.93 (m), 1.64 (s), 1.59-1.47 (m), 1.04-0.90 (m), 0.69-0.55 (m). MS (m/z) 791.0 [M+H]+.
    • Example 192
  • Figure US20210009555A1-20210114-C00442
    • Synthesis of (S)—N-(1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(5-hydroxy-2-methyl-1H-indol-3-yl)acetamide (192)
  • The title compound (192) was prepared as a mixture of atropisomers according to the method presented in the synthesis of 10A in Example 10 utilizing 19F and 2-(5-hydroxy-2-methyl-1H-indol-3-yl)acetic acid. 1H NMR (400 MHz, Methanol-d4) δ 7.63 (dd), 7.46 (dd), 7.13-7.03 (m), 7.03-6.92 (m), 6.74-6.54 (m), 6.46 (d), 6.35 (d), 6.26 (d), 5.29-5.18 (m), 5.04-4.89 (m), 3.47 (d), 3.43 (s), 3.22 (d), 3.18-3.08 (m), 2.97 (s), 2.95-2.75 (m), 2.31 (s), 2.28 (s), 1.65 (s). MS (m/z) 761.5 [M+H]+.
    • Example 193
  • Figure US20210009555A1-20210114-C00443
    • Synthesis of (S)—N-(1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(5-fluoro-1H-indol-3-yl)acetamide (193)
  • The title compound (193) was prepared as a mixture of atropisomers according to the method presented in the synthesis of 10A in Example 10 utilizing 19F and 2-(5-fluoro-1H-indol-3-yl)acetic acid. 1H NMR (400 MHz, Methanol-d4) δ 7.63 (d), 7.53-7.43 (m), 7.34-7.24 (m), 7.18-7.06 (m), 7.02 (dd), 6.91-6.77 (m), 6.74-6.64 (m), 6.64-6.56 (m), 6.49 (d), 6.43-6.30 (m), 5.26-5.16 (m), 5.05-4.95 (m), 3.64-3.39 (m), 3.24 (s), 3.23 (s), 3.14-2.80 (m), 1.64 (s). MS (m/z) 749.5 [M+H]+.
    • Example 194
  • Figure US20210009555A1-20210114-C00444
    • Synthesis of (S)—N-(1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(5-methoxy-1H-pyrrolo[3,2-b]pyridin-3-yl)acetamide (194)
  • The title compound (194) was prepared as a mixture of atropisomers according to the method presented in the synthesis of 10A in Example 10 utilizing 19F and 2-(5-methoxy-1H-pyrrolo[3,2-b]pyridin-3-yl)acetic acid. 1H NMR (400 MHz, Methanol-d4) δ 8.32-8.20 (m), 7.77-7.59 (m), 7.56-7.49 (m), 7.17 (dd), 7.09-6.97 (m), 6.94 (d), 6.72 (d), 6.57-6.48 (m), 6.38 (d), 6.29 (d), 5.29-5.17 (m), 5.12-5.00 (m), 4.18-4.14 (m), 4.03 (d), 3.69-3.45 (m), 3.29-3.18 (m), 3.20-3.03 (m), 3.03-2.90 (m), 1.65 (s). MS (m/z) 762.3 [M+H]+.
    • Example 195
  • Figure US20210009555A1-20210114-C00445
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-phenylpropanamide (195)
  • The title compound (195) was prepared as a mixture of atropisomers according to the method presented in the synthesis of 10A in Example 10 utilizing 19F and 2-phenylpropanoic acid. 1H NMR (400 MHz, Methanol-d4) δ 7.71 (dd), 7.63-7.42 (m), 7.37-7.05 (m), 6.81-6.72 (m), 6.69 (d), 6.67-6.52 (m), 6.49 (d), 6.47-6.39 (m), 6.35-6.24 (m), 5.28-5.22 (m), 5.08-5.00 (m), 5.00-4.95 (m), 3.72-3.49 (m), 3.39 (s), 3.29-3.22 (m), 3.18-2.95 (m), 2.91 (s), 2.88-2.84 (m), 2.81 (s), 1.64 (s), 1.35 (dd), 1.32-1.19 (m). MS (m/z) 706.8 [M+H]+.
    • Example 196
  • Figure US20210009555A1-20210114-C00446
    • Synthesis of N—((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(4,7-dimethyl-2-oxoindolin-3-yl)acetamide (196)
  • The title compound (196) was prepared as a mixture of atropisomers according to the method presented in the synthesis of 10A in Example 10 utilizing 19F and 2-(4,7-dimethyl-2-oxoindolin-3-yl)acetic acid. 1H NMR (400 MHz, Methanol-d4) δ 7.69-7.61 (m), 7.61-7.41 (m), 7.16 (d), 7.12-7.06 (m), 7.03 (d), 6.89-6.76 (m), 6.76-6.68 (m), 6.67 (d), 6.64-6.54 (m), 6.49 (d), 6.43-6.36 (m), 6.34 (d), 5.18 (s), 5.14-5.06 (m), 4.83-4.75 (m), 3.67-3.57 (m), 3.57-3.43 (m), 3.36 (s), 3.25 (dd), 3.21-3.11 (m), 3.10-2.97 (m), 2.97-2.68 (m), 2.35-2.06 (m), 1.71-1.59 (m). MS (m/z) 776.1 [M+H]+.
    • Example 197
  • Figure US20210009555A1-20210114-C00447
    • Synthesis of (S)—N-(1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(4-ethylpiperazin-1-yl)acetamide (197)
  • The title compound (197) was prepared as a mixture of atropisomers according to the method presented in the synthesis of 10A in Example 10 utilizing 19F and 2-(4-ethylpiperazin-1-yl)acetic acid. 1H NMR (400 MHz, Methanol-d4) δ 7.75 (dd), 7.54 (dd), 7.35 (d), 7.27 (d), 7.20 (d), 6.82 (d), 6.80-6.73 (m), 6.69-6.62 (m), 6.50-6.37 (m), 5.47-5.39 (m), 5.07 (dd), 3.40 (s), 3.27 (s), 3.23-2.87 (m), 1.63 (s), 1.35 (td). MS (m/z) 729.0 [M+H]+.
    • Example 198
  • Figure US20210009555A1-20210114-C00448
    • Synthesis of (S)-2-(benzo[d]isoxazol-3-yl)-N-(1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)acetamide (198)
  • The title compound (198) was prepared as a mixture of atropisomers according to the method presented in the synthesis of 10A in Example 10 utilizing 19F and 2-(benzo[d]isoxazol-3-yl)acetic acid. 1H NMR (400 MHz, Methanol-d4) δ 7.72-7.63 (m), 7.60 (d), 7.59-7.49 (m), 7.37-7.30 (m), 7.31-7.24 (m), 7.16 (d), 7.11 (d), 7.00 (d), 6.74-6.66 (m), 6.58 (d), 6.47-6.38 (m), 5.30-5.22 (m), 5.07-4.95 (m), 3.93-3.76 (m), 3.24 (s), 3.21-3.10 (m), 3.08-2.93 (m), 1.65 (s). MS (m/z) 733.2 [M+H]+.
    • Example 199
  • Figure US20210009555A1-20210114-C00449
    • Synthesis of (S)—N-(1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(5,6-dimethyl-1H-benzo[d]imidazol-1-yl)acetamide (199)
  • The title compound (199) was prepared as a mixture of atropisomers according to the method presented in the synthesis of 10A in Example 10 utilizing 19F and 2-(5,6-dimethyl-1H-benzo[d]imidazol-1-yl)acetic acid. H NMR (400 MHz, Methanol-d4) δ 9.19 (s), 9.07 (s), 7.74 (dd), 7.63-7.50 (m), 7.49-7.33 (m), 7.27 (s), 7.24-6.99 (m), 6.74-6.56 (m), 6.47-6.34 (m), 5.38-5.29 (m), 5.22-4.91 (m), 4.03 (s), 3.25 (d), 3.23-3.19 (m), 3.14 (s), 3.09-2.95 (m), 2.52-2.38 (m), 1.65 (s). MS (m/z) 761.1 [M+H]+.
    • Example 200
  • Figure US20210009555A1-20210114-C00450
    • Synthesis of (S)—N-(1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-(naphthalen-2-yl)acetamide (200)
  • The title compound (200) was prepared as a mixture of atropisomers according to the method presented in the synthesis of 10A in Example 10 utilizing 19F and 2-(naphthalen-2-yl)acetic acid. 1H NMR (400 MHz, Methanol-d4) δ 7.86-7.69 (m), 7.69-7.62 (m), 7.59 (s), 7.55-7.49 (m), 7.50-7.37 (m), 7.34 (d), 7.25-7.19 (m), 7.10 (dd), 6.99 (d), 6.84 (d), 6.71-6.62 (m), 6.60-6.57 (m), 6.55 (dd), 6.47-6.34 (m), 5.24-5.16 (m), 5.02 (t), 3.64-3.44 (m), 3.24 (s), 3.20 (s), 3.18-3.11 (m), 3.10 (d), 3.03-2.93 (m), 1.64 (s). MS (m/z) 742.8 [M+H]+.
    • Example 201
  • Large scale preparation of (S)—N-(1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-ynyl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(difluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (19G).
  • Figure US20210009555A1-20210114-C00451
    Figure US20210009555A1-20210114-C00452
    • Synthesis of bicyclo[3.1.0]hexan-3-ol (19AB)
  • Et2Zn (1M in hexane, 2.37 L, 2.37 mol) was added drop-wise to a solution of compound 19AA (100 g, 1.19 mol) in DCM (800 ml) under N2 at 0-5° C. The mixture was stirred at 0-5° C. for 30 min, then CH2I2 (636 g, 2.37 mol) in DCM (200 ml) was added drop-wise in 1 h at 0-5° C. The resulting mixture was stirred at room temperature overnight. The mixture was added slowly to ice-cold aq. NH4Cl (1.5 L). The mixture was filtered. The aqueous phase was extracted with DCM (2L×3). The combined organic layer was dried over MgSO4, concentrated in vacuo to give crude residue, which was purified by distillation (20 mmHg, 80° C.-82° C.) to give compound 19AB. 1H NMR: (400 MHz, CDCl3) δ 4.35 (t, J=6.4 Hz, 1H), 2.10-2.06 (m, 2H), 1.70 (d, J=14.0 Hz, 2H), 1.65 (s, 1H), 1.27-1.24 (m, 2H), 0.52-0.47 (m, 2H).
    • Synthesis of bicyclo[3.1.0]hexan-3-one (19AC)
  • To a solution of K2Cr2O7 (240 g, 0.82 mol) in H2O (2 L), H2SO4 (240 g, 2.45 mol) was added drop-wise at room temperature. The mixture was stirred at room temperature for 1 h. The system was cooled to 0° C., compound 19AB (100 g, 1.02 mol) in TBME (2 L) was added drop-wise. The reaction mixture was stirred at room temperature for 4 h. The organic layer was separated. The aqueous layer was extracted with TBME (1 L×3). The combined organic layer was dried over MgSO4, filtered, concentrated in vacuo to give the crude product, which was purified by distillation (20 mmHg, 60° C.-62° C.) to give compound 19AC. 1H NMR (400 MHz, CDCl3) δ 2.57-2.52 (m, 2H), 2.13-2.08 (m, 2H), 1.50-1.47 (m, 2H), 0.88-0.85 (m, 1H), 0.08-0.01 (m, 1H).
    • Synthesis of 2-(2,2-difluoroacetyl)bicyclo[3.1.0]hexan-3-one (19AD)
  • To the solution of compound 19AC (100 g, 1.04 mol) in THF (1 L), LDA (700 ml, 1.05 mol, 1.5M in THF) was added drop-wise under N2 over a period of 2 h. The resulting mixture was stirred 1 h at −78° C. Ethyl difluoroacetate (142 g, 1.14 mol) in THF (500 ml) was added drop-wise over a period of 1 h and the reaction was stirred 1 h at −78° C. The reaction was warmed to room temperature and stirred for 4 h. The reaction was quenched by aqueous 1N HCl (1.5 L) and then partitioned between EA (1.0 L) and aqueous citric acid (300 ml). The organic layer was separated and washed with brine. Solvents were removed in vacuo to give compound 19AD which was used for the next step without further purification. 1H NMR (400 MHz, CDCl3) δ 6.17 (t, J=53.6 Hz, 1H), 2.78-2.73 (m, 1H), 2.44-2.39 (m, 1H), 2.25-2.24 (m, 1H), 1.70-1.69 (m, 1H), 1.22-1.14 (m, 1H), 0.31-0.27 (m, 1H).
    • Synthesis of 3-(difluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazole (19AE)
  • N2H4H2O (104 g, 2.08 mol) was added drop-wise in 30 min to the solution of compound 19AD (380 g, 2.08 mol) in EtOH (4 L) at room temperature. The mixture was stirred at reflux overnight. The mixture was concentrated in vacuo then purified by silica gel column chromatography (PE:EA=10:1-5:1) to give compound 19AE. MS (m/z): 171.1 [M+H]t+H NMR (400 MHz, CDCl3) δ 6.74 (t, J=55.6 Hz, 1H), 2.99-2.94 (m, 1H), 2.82-2.78 (m, 1H), 2.13-2.07 (m, 2H), 1.14-1.08 (m, 1H), 0.30-0.27 (m, 1H).
    • Synthesis of ethyl 2-(3-(difluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetate (19AF)
  • To a solution of compound 19AE (201 g, 1.18 mol) in DMF (2 L), ethyl bromoacetate (207 g, 1.24 mol) and Cs2CO3 (404 g, 1.24 mol) were added in one portion at room temperature. The mixture was stirred at room temperature for 3 h. The mixture was poured into H2O (4 L) and then extracted with EA (2 L×3). The combined organic phase was washed with brine (2 L×3), dried over MgSO4, and concentrated in vacuo. The crude product was purified by silica gel column chromatography (PE:EA=20:1-8:1) to obtain a mixture of N1 and N2 alkylation isomers. An additional purification from PE/EA (10/1) provided compound 19AF. MS (m/z): 257.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 6.61 (t, J=55.2 Hz, 1H), 4.70 (dd, J=17.2, 11.2 Hz, 2H), 4.23 (q, J=7.2 Hz, 2H), 2.91 (dd, J=16.0, 6.0 Hz, 1H), 2.72 (d, J=16.4 Hz, 1H), 2.17-2.09 (m, 1H), 1.28 (t, J=7.2 Hz, 3H), 1.10-1.07 (m, 1H), 0.33-0.30 (m, 1H).
    • Synthesis of ethyl 2-(3-(difluoromethyl)-5-oxo-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetate (19AG)
  • Compound 19AF (102 g, 0.39 mol) and celite 545 (390 g) were added to cyclohexane (3.5 L) and the mixture was stirred at 10° C. PDC (599 g, 1.59 mol) was added in one portion followed by TBHP (289 ml, 1.59 mol) drop-wise in 30 min at 10° C. The reaction was slowly warmed to room temperature and stirred for 4 days. The reaction was filtered through celite and filter cake was washed with EtOAc (600 ml). The combined organic layer was stirred with saturated aqueous Na2S2O3 (1000 ml) for 1 h. The organic layer was separated and treated with half saturated FeSO4 (300 ml), washed with brine and dried over Na2SO4. Solvents were removed in vacuo to give crude product, which was additionally purified from PE (300 ml) to give compound 19AG. MS (n/z): 271.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 6.67 (t, J=54.8 Hz, 1H), 4.94 (s, 2H), 4.23 (q, J=7.2 Hz, 2H), 2.79-2.78 (m, 1H), 2.59-2.56 (m, 1H), 1.70-1.65 (m, 2H), 1.28 (t, J=6.8 Hz, 3H).
    • Synthesis of ethyl 2-(3-(difluoromethyl)-4,4a-dihydrospiro[cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-5,2′-[1,3]dithiolane]-1(3bH)-yl)acetate (19AH)
  • To compound 19AG (148.5 g, 0.55 mol) in DCM (2.0 L) was added ethane-1,2-dithiol (88.0 g, 0.94 mol) in one portion and the solution was stirred at room temperature. BF3.2AcOH (175.8 g, 0.94 mol) was added to above solution. The reaction was stirred at room temperature for 12 h. The system was cooled to 0° C. and quenched with saturated aqueous NaHCO3 (1000 ml). The organic layer was separated, washed with brine (500 ml) and dried over Na2SO4. Solvents were removed in vacuo and the residue was purified by silica gel column chromatography (PE:EtOAc=30:1-10:1) to provide compound 19AH. MS (m/z): 347.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 6.61 (t, J=55.0 Hz, 1H), 4.90 (dd, J=17.2, 10.8 Hz, 2H), 4.21 (q, J=4.8 Hz, 2H), 3.51-3.45 (m, 4H), 2.60-2.58 (m, 1H), 2.43-2.42 (m, 1H), 1.29-1.23 (m, 4H), 0.63-0.61 (m, 1H).
    • Synthesis of ethyl 2-(3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetate (19AI)
  • A solution of DBDMH (99 g, 0.35 mol) in dry DCM (120 mL) was cooled to −78° C. in a teflon bottle. HF/Py (120 mL) was added drop-wise over a period of 30 min. The reaction was stirred at −78° C. for 30 min. Then a solution of compound 19AH (40 g, 0.12 mol) in dry DCM (80 mL) was added drop-wise over a period of 15 min at −78° C. The resulting mixture was stirred for 30 min at this temperature, then slowly warm to −30° C. and stirred for 1.5 h. The reaction mixture was slowly poured into aq. NaHCO3 (500 mL) and extracted with EA (500 mL×3). The combined organic layer was washed with 10% aq. Na2S2O3 (500 mL), brine (500 mL) and dried over Na2SO4. Solvents were removed in vacuo to afford the crude product, which was further purified by column chromatography (PE:EA=80:1 to 50:1) to give compound 19AI. MS (m/z): 293.2 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 6.63 (t, J=54.8 Hz, 1H), 4.83 (s, 2H), 4.24 (q, J=7.2 Hz, 2H), 2.48-2.45 (m, 2H), 1.38-1.36 (m, 1H), 1.28 (t, J=7.2 Hz, 3H), 1.13-1.12 (m, 1H).
    • Synthesis of 2-(3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid (19AJ)
  • To a solution of compound 19AI (50 g, 171 mmol) in THF (87.5 mL) and MeOH (350 mL) was added the solution of LiOH (6.2 g, 257 mmol) in H2O (350 mL). The mixture was stirred at 20° C. for 3 h. The mixture was concentrated to remove most of THF and MeOH, the aqueous was acidified by 1N HCl to adjust pH to 2-3, then extracted with EA (600 mL×2). The organic phase was separated and combined, dried over Na2SO4, filtered and concentrated in vacuum to give compound 19AJ.
    • 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid (19AK) and 2-((3bR,4aS)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid (19AL)
  • Compound 19AJ was separated by SFC (ChiralPak IC-10 u, 300×50 mm I.D., mobile phase: CO2/isopropanol (0.1% NH3.H2O), 35% gradient, 200 mL/min flow rate, 38° C. column temperature, detection at 220 nm) to give compound 19AK (79.3 g) and 19AL (80.8 g). 19AK: MS (m/z): 265.0 [M+H]+; 1H NMR: (400 MHz, DMSO-d6) δ 13.43 (br, 1H), 7.04 (t, J=54.0 Hz, 1H), 4.99-4.87 (m, 2H), 2.62-2.57 (m, 2H), 1.46-1.41 (m, 1H), 0.96 (s, 1H). 19AL: MS (m/z): 265.0 [M+H]+; H NMR: (400 MHz, DMSO-d6) δ 13.42 (br, 1H), 7.04 (t, J=54.0 Hz, 1H), 4.99-4.88 (m, 2H), 2.63-2.51 (m, 2H), 1.46-1.41 (m, 1H), 0.97 (s, 1H).
  • Figure US20210009555A1-20210114-C00453
    Figure US20210009555A1-20210114-C00454
    • Synthesis of 3,6-dibromo-2-(dibromomethyl)pyridine (5A)
  • To a stirred solution of 3,6-dibromo-2-methylpyridine (200.0 g, 797.06 mmol) in CCl4 (4000 mL), benzoyl peroxide (192.89 g, 797.06 mmol) followed by NBS (565.0 g, 3188.0 mmol) was added at room temperature. After addition was completed, the resulting reaction mixture was stirred in presence of white light 400 watt bulb at room temperature for 20 h. The reaction mixture was stirred at room temperature for 20 h. The reaction mixture was filtered and washed with CCl4 (2×800 mL). The filtrate was evaporated under reduced pressure which was further purified by column chromatography on silica gel using 0-5% EA in hexane as an eluent to afford compound 5A. MS (m/z): 409.66 [M+H]+.
    • Synthesis of 3,6-dibromopicolinaldehyde (5B)
  • To a solution of compound 5A (100.0 g, 244.67 mmol) in EtOH (1000 mL) at 80° C., aqueous silver nitrate (103.9 g, 611.6 mmol, in 300 mL water) was added drop-wise, in 1 h at same temperature. After addition was completed, the resulting reaction mixture was stirred to reflux for another 5 h. The reaction mixture was cooled to room temperature and filtered. The filtrate was evaporated under reduced pressure and the resultant crude was diluted with water (1000 mL). The aqueous layer was extracted with ethyl acetate (3×400 mL). The combined organic layers were washed with water (2×400 mL), dried over sodium sulfate and distilled off under reduced pressure gave compound 5B. MS (m/z): 265.96. [M+H]+
    • Synthesis of (S,Z)—N-((3,6-dibromopyridin-2-yl)methylene)-2-methylpropane-2-sulfinamide (5C)
  • To a stirred solution of compound 5B (68.0 g, 256.7 mmol) in DCM (1400 mL), copper (11) sulfate anhydrous (102.3 g, 641.75 mmol) was added followed by (S)-2-methylpropane-2-sulfinamide (37.3 g, 308.0 mmol) at room temperature. The resulting suspension was stirred at room temperature for 16 h. The reaction mixture was filtered and washed with DCM (100 mL). The eluent was evaporated under reduced pressure. The resultant crude compound was recrystallized from diethyl ether (300 mL) to provide compound 5C. MS (m/z) 368.86 [M+H]+
    • Synthesis of (S)—N—((S)-1-(3,6-dibromopyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-methylpropane-2-sulfinamide (5D)
  • To a stirred solution of compound 5C (20.0 g, 54.33 mmol) in dry THF (300 mL), at −78° C. a solution of 3,5-difluorobenzylmagnesium bromide (260.8 mL, 0.2M in ether, 65.20 mmol) was added drop-wise in 1 h at −78° C. After addition was completed, the resulting reaction mixture was stirred at −78° C. for 1h. The reaction mixture was quenched with aqueous NH4Cl (200 mL) at same temperature. Organic layer was separated and aqueous layer was extracted with EtOAc (3×150 mL). The combined organic layers were washed with water (2×200 mL) and brine, dried over Na2SO4. The solvent was distilled off under reduced pressure and the resultant crude compound was purified by column chromatography on silica-gel using 0-18% EA in hexane as an eluent to provide compound 5D. MS (m/z) 496.99 [M+H]+
    • Synthesis of (S)-1-(3,6-dibromopyridin-2-yl)-2-(3,5-difluorophenyl)ethanamine hydrochloride(5E)
  • To a solution of compound 5D (53 g, 107 mmol) in methanol (100 mL) was slowly added 4 N HCl in dioxane (30 mL) at room temperature. Upon completion of the reaction, the volatiles were removed in vacuo. The resulting solid was suspended in ether (200 mL) and collected by filtration to provide compound 5E. MS (m/z) 393.17 [M+H]+
    • Synthesis of (S)-tert-butyl 1-(3,6-dibromopyridin-2-yl)-2-(3,5-difluorophenyl)ethylcarbamate (14A)
  • To a suspension of compound 5E (5 g, 11.7 mmol) in DCM (50 mL) was added di-tert-butyl dicarbonate (3.1 g, 14 mmol) and triethylamine (2.4 g, 23 mmol) at room temperature. Upon completion of the reaction, the volatiles were removed in vacuo. The resulting residue was dissolved in EtOAc and washed with saturated aqueous ammonium chloride and brine. The organic layer was dried over sodium sulfate. The solvent was distilled off under reduced pressure and the resultant crude compound was purified by column chromatography on silica-gel using ethyl acetate in hexane as an eluent to provide compound 14A. MS (m/z) 492.96 [M+H]+
    • Synthesis of (S)-tert-butyl (1-(3-bromo-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (14B)
  • A solution of compound 14A (570 mg, 1.16 mmol), 3-methyl butynol (179 μL, 1.74 mmol), CuI (6 mg, 0.03 mmol), Pd(PPh3)2Cl2 (20 mg, 0.03 mmol) and triethylamine (0.5 mL) in THF (2 mL) was degassed with argon for 15 min. The resulting solution was then heated at 35° C. for 2 h. Upon completion of the reaction, the mixture was filtered through a pad of celite and washed with ethyl acetate. The combined organic layers were washed with aqueous NH4Cl, water and brine, dried over Na2SO4. The solvent was distilled off under reduced pressure and the resultant crude compound was purified by column chromatography on silica-gel using ethyl acetate in hexane as an eluent to provide compound 14B. MS (m/z) 496.90 [M+H]G
  • Figure US20210009555A1-20210114-C00455
    • Synthesis of (S)-tert-butyl 1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-ynyl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethylcarbamate (19E)
  • To a flask of 14B (4000 mg, 8.075 mmol) in dioxane (150 mL) and DMF (75 ml) was added N-(4-chloro-1-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-yl)methanesulfonamide (3114 mg, 8.075 mmol), 1N sodium bicarbonate (20.2 ml, 20.2 mmol), and dichlorobis(tricyclohexylphosphine)palladium(II) (715.3 mg, 0.97 mmol). The reaction mixture was degassed by N2 for 30 minutes and then moved to oil bath at 150° C. for 45 minutes. The reaction was cooled to room temperature and filtered. The filtrate was concentrated and dissolved in EtOAc (300 mL) and washed with brine twice. The organic layer was dried over sodium sulfate, concentrated and purified by column chromatography on silica-gel using 50-90% EtOAc in hexane as an eluent to provide 19E. MS (m/z) 674.7 [M+H]+.
    • Synthesis of (S)—N-(7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-6-(3-hydroxy-3-methylbut-1-ynyl)pyridin-3-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide TFA salt (19FF)
  • To a flask of 19E (g, 1.48 mmol), 10 mL of 40% of TFA in dichloromethane was added to the flask. The mixture was neutralized by NaHCO3 (aq) and extracted with EtOAc (200 mL twice). The organic layer was concentrated and dried to provide 0.85 g of the desired product 19FF that was used without further purification. MS (m/z) 574.4 [M+H]+.
    • Synthesis of (S)—N-(1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-ynyl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(difluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (19G)
  • To a flask of 19FF (850 mg, 1.48 mmol) and DIEA (0.5 mL, 2.96 mmol) in 20 mL DMF, 19AK (350 mg, 1.33 mmol) and HATU (507 mg, 1.33 mmol) in 10 mL of DMF was added to the mixture slowly at 0° C. The mixture was diluted with EtOAc (300 mL) and washed with NaHCO3. The organic layer was concentrated and purify by column chromatography on silica-gel using 50-80% EtOAc in hexane as an eluent to provide 19G. MS (m/z) 820.8 [M+H]+.
    • Example 202
  • The following illustrate representative pharmaceutical dosage forms, containing a compound of formula I (‘Compound X’), for therapeutic or prophylactic use in humans.
  • (i) Tablet 1 mg/tablet
    Compound X = 100.0
    Lactose 77.5
    Povidone 15.0
    Croscarmellose sodium 12.0
    Microcrystalline cellulose 92.5
    Magnesium stearate 3.0
    300.0
  • (ii) Tablet 2 mg/tablet
    Compound X = 20.0
    Microcrystalline cellulose 410.0
    Starch 50.0
    Sodium starch glycolate 15.0
    Magnesium stearate 5.0
    500.0
  • (iii) Capsule mg/capsule
    Compound X = 10.0
    Colloidal silicon dioxide 1.5
    Lactose 465.5
    Pregelatinized starch 120.0
    Magnesium stearate 3.0
    600.0
  • (iv) Injection 1 (1 mg/ml) mg/ml
    Compound X = (free acid form)  1.0
    Dibasic sodium phosphate 12.0
    Monobasic sodium phosphate  0.7
    Sodium chloride  4.5
    1.0N Sodium hydroxide solution q.s.
    (pH adjustment to 7.0-7.5)
    Water for injection q.s. ad 1 mL
  • (v) Injection 2 (10 mg/ml) mg/ml
    Compound X = (free acid form)  10.0
    Monobasic sodium phosphate  0.3
    Dibasic sodium phosphate  1.1
    Polyethylene glycol 400 200.0
    1.0N Sodium hydroxide solution q.s.
    (pH adjustment to 7.0-7.5)
    Water for injection q.s. ad 1 mL
  • (vi) Aerosol mg/can
    Compound X = 20.0
    Oleic acid 10.0
    Trichloromonofluoromethane 5,000.0
    Dichlorodifluoromethane 10,000.0
    Dichlorotetrafluoroethane 5,000.0
  • The above formulations may be obtained by conventional procedures well known in the pharmaceutical art.
  • All references, including publications, patents, and patent documents are incorporated by reference herein, as though individually incorporated by reference. The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.
  • The use of the terms “a” and “an” and “the” and similar references in the context of this disclosure (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., such as, preferred, preferably) provided herein, is intended merely to further illustrate the content of the disclosure and does not pose a limitation on the scope of the claims. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the present disclosure.
  • Alternative embodiments of the claimed disclosure are described herein, including the best mode known to the inventors for practicing the claimed invention. Of these, variations of the disclosed embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing disclosure. The inventors expect skilled artisans to employ such variations as appropriate (e.g., altering or combining features or embodiments), and the inventors intend for the invention to be practiced otherwise than as specifically described herein.
  • Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
  • The use of individual numerical values is stated as approximations as though the values were preceded by the word “about” or “approximately.” Similarly, the numerical values in the various ranges specified in this application, unless expressly indicated otherwise, are stated as approximations as though the minimum and maximum values within the stated ranges were both preceded by the word “about” or “approximately.” In this manner, variations above and below the stated ranges can be used to achieve substantially the same results as values within the ranges. As used herein, the terms “about” and “approximately” when referring to a numerical value shall have their plain and ordinary meanings to a person of ordinary skill in the art to which the disclosed subject matter is most closely related or the art relevant to the range or element at issue. The amount of broadening from the strict numerical boundary depends upon many factors. For example, some of the factors which may be considered include the criticality of the element and/or the effect a given amount of variation will have on the performance of the claimed subject matter, as well as other considerations known to those of skill in the art. As used herein, the use of differing amounts of significant digits for different numerical values is not meant to limit how the use of the words “about” or “approximately” will serve to broaden a particular numerical value or range. Also, the disclosure of ranges is intended as a continuous range including every value between the minimum and maximum values plus the broadening of the range afforded by the use of the term “about” or “approximately.” Thus, recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. In one aspect, about a value includes and intends that value per se. For example, about x includes and intends x per se.
  • It is to be understood that any ranges, ratios and ranges of ratios that can be formed by, or derived from, any of the data disclosed herein represent further embodiments of the present disclosure and are included as part of the disclosure as though they were explicitly set forth. This includes ranges that can be formed that do or do not include a finite upper and/or lower boundary. Accordingly, a person of ordinary skill in the art most closely related to a particular range, ratio or range of ratios will appreciate that such values are unambiguously derivable from the data presented herein.
    • Embodiments
  • Provided below are certain embodiments.
  • Embodiment I-1. A compound of formula I:
  • Figure US20210009555A1-20210114-C00456
  • wherein:
  • A is a 6-membered monocyclic-heteroaryl with one or two nitrogen atoms, wherein the 6-membered monocyclic-heteroaryl is substituted with one Z1 group at the position shown, one Z2 group, and optionally substituted with one or more (e.g., 1 or 2) Z3 groups;
  • R1 is 6-12 membered aryl, 5-12 membered heteroaryl or 3-12 membered heterocycle, wherein any 6-12 membered aryl, 5-12 membered heteroaryl or 3-12 membered heterocycle of R1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z4 groups;
  • R2 is phenyl, 5-membered monocyclic-heteroaryl, 6-membered monocyclic-heteroaryl or (C3-C7)carbocycle, wherein any phenyl, 5-membered monocyclic-heteroaryl, 6-membered monocyclic-heteroaryl or (C3-C7)carbocycle of R2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z5 groups;
  • each R3a and R3b is independently selected from H, halogen, (C1-C3)alkyl and (C1-C3)haloalkyl, or R3a is selected from H, (C1-C3)alkyl and (C1-C3)haloalkyl and R3b is selected from —OH and —CN;
  • Z1 is selected from 6-12 membered aryl, 5-14 membered heteroaryl and 3-14 membered heterocycle, wherein any 6-12 membered aryl, 5-14 membered heteroaryl and 3-14 membered heterocycle of Z1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1a or Z1b;
  • each Z1a is independently selected from (C3-C7)carbocycle, 6-12 membered aryl, 5-12 membered heteroaryl, 3-12 membered heterocycle, halogen, —CN, —ORn1, —OC(O)Rp1, —OC(O)NRq1Rr1, —SRn1, —S(O)Rp1, —S(O)2OH, —S(O)2Rp1, —S(O)2NRq1Rr1, —NRq1Rr1, —NRn1CORp1, —NRn1CO2Rp1, —NRn1CONRq1Rr1, —NRn1S(O)2Rp1, —NRn1S(O)2ORp1, —NRn1S(O)2NRq1Rr1, NO2, —C(O)Rn1, —C(O)ORn1, —C(O)NRq1Rr1 and —S(O)2NRn1CORp1, wherein any (C3-C7)carbocycle, 6-12 membered aryl, 5-12 membered heteroaryl and 3-12 membered heterocycle of Z1a is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c or Z1d groups;
  • each Z1b is independently selected from (C1-C8)alkyl, (C2-C8)alkenyl and (C2-C8)alkynyl, wherein any (C1-C8)alkyl, (C2-C8)alkenyl and (C2-C8)alkynyl of Z1b is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c groups;
  • each Z1b is independently selected from (C3-C7)carbocycle, phenyl, 5-6 membered monocyclic-heteroaryl, 3-7 membered heterocycle, halogen, —CN, —ORn2, —OC(O)Rp2, —OC(O)NRq2Rr2, —SRn2, —S(O)Rp2, —S(O)2OH, —S(O)2Rp2, —S(O)2NRq2Rr2, —NRq2Rr2, —NRn2CORp2, —NRn2CO2Rp2, —NRn2CONRq2Rr2, —NRn2S(O)2Rp2, —NRn2S(O)2ORp2, —NRn2S(O2NRq2Rr2, NO2, —C(O)Rn2, —C(O)ORn2, —C(O)NRq2Rr2, halophenyl, 5-6 membered haloheteroaryl, 3-7 membered haloheterocycle and (C1-C8)heteroalkyl;
  • each Z1d is independently selected from (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl and (C1-C8)haloalkyl;
  • each Rn1 is independently selected from H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl and phenyl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl and phenyl of Rn1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c or Z1d groups, and wherein any (C1-C8)alkyl, (C2-C8)alkenyl and (C2-C8)alkynyl of R1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c groups;
  • each Rp1 is independently selected from (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl and phenyl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl and phenyl of Rp1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c or Z1d groups, and wherein any (C1-C8)alkyl, (C2-C8)alkenyl and (C2-C8)alkynyl of Rp1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c groups;
  • Rq1 and Rr1 are each independently selected from H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl and phenyl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl and phenyl of Rq1 or Rr1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c or Z1d groups, and wherein any (C1-C8)alkyl, (C2-C8)alkenyl and (C2-C8)alkynyl of Rq1 or Rr1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c groups, or Rq1 and Rr1 together with the nitrogen to which they are attached form a 5, 6 or 7-membered heterocycle, wherein the 5, 6 or 7-membered heterocycle is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c or Z1d groups;
  • each Rn2 is independently selected from H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl, phenyl, halophenyl, 5-6 membered monocyclic-haloheteroaryl, 3-7 membered haloheterocycle, (C1-C8)haloalkyl and (C1-C8)heteroalkyl;
  • each Rp2 is independently selected from (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl, phenyl, halophenyl, 5-6 membered monocyclic-haloheteroaryl, 3-7 membered haloheterocycle, (C1-C8)haloalkyl and (C1-C8)heteroalkyl;
  • Rq2 and Rr2 are each independently selected from H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl, phenyl, halophenyl, 5-6 membered monocyclic-haloheteroaryl, 3-7 membered haloheterocycle, (C1-C8)haloalkyl and (C1-C8)heteroalkyl, or Rq2 and Rr2 together with the nitrogen to which they are attached form a 5, 6 or 7-membered heterocycle;
  • Z2 is selected from (C2-C8)alkenyl, (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, —C(O)Rn3 and —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl and 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2b or Z2c groups, and wherein any (C2-C8)alkenyl and (C2-C8)alkynyl of Z2 is optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) Z2c groups;
  • each Z2a is independently selected from (C3-C7)carbocycle, 6-12 membered aryl, 5-12 membered heteroaryl, 3-12 membered heterocycle, halogen, —CN, —ORn4, —OC(O)Rp4, —OC(O)NRq4Rr4, —SRn4, —S(O)Rp4, —S(O)2OH, —S(O)2Rp4, —S(O)2NRq4Rr4, —NRq4Rr4, —NRn4CORp4, —NRn4CO2Rp4, —NRn4CONRq4Rr4, —NRn4S(O)2Rp4, —NRn4S(O)2ORp4, —NRn4S(O)2NRq4Rf4 NO2, —C(O)Rn4, —C(O)ORn4 and —C(O)NRq4Rr4, wherein any (C3-C7)carbocycle, 6-12 membered aryl, 5-12 membered heteroaryl and 3-12 membered heterocycle of Z2a is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2b or Z2c groups;
  • each Z2b is independently selected from (C1-C4)alkyl, (C1-C4)heteroalkyl and (C1-C4)haloalkyl;
  • each Z2c is independently selected from halogen, —CN, —ORn4, —OC(O)Rp4, —OC(O)NRq4Rr4, —SRn4, —S(O)Rp4, —S(O)2OH, —S(O)2Rp4, —S(O)2NRq4Rr4, —NRq4Rr4, —NRn4CORp4, —NRn4 CO2Rp4, —NRn4CONRq4Rr4, —NRn4S(O)2Rp4, —NRn4S(O)2ORp4, —NRn4S(O)2NRq4Rr4 NO2, —C(O)Rn4, —C(O)ORn4 and —C(O)NRq4Rr4;
  • each Rn3 is independently selected from H, (C1-C4)alkyl, (C2-C4)alkenyl, (C3-C7)carbocycle, 3-12 membered heterocycle, 5-12 membered heteroaryl and 6-12 membered aryl, wherein any (C3-C7)carbocycle, 3-12 membered heterocycle, 5-12 membered heteroaryl and 6-12 membered aryl of Rn3 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2b or Z2c groups, and wherein any (C1-C4)alkyl, (C2-C4)alkenyl and (C2-C4)alkynyl of Rn3 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2a groups;
  • Rq3 and Rr3 are each independently selected from H, (C1-C4)alkyl, (C2-C4)alkenyl, (C3-C7)carbocycle, 3-12 membered heterocycle, 5-12 membered heteroaryl and 6-12 membered aryl, wherein any (C3-C7)carbocycle, 3-12 membered heterocycle, 5-12 membered heteroaryl and 6-12 membered aryl of Rq3 or Rr3 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2b or Z2c groups, and wherein any (C1-C4)alkyl and (C2-C4)alkenyl of Rq3 or Rr3 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2a groups, or Rq3 and Rr3 together with the nitrogen to which they are attached form a heterocycle or heteroaryl, wherein the heterocycle or heteroaryl is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2b or Z2c groups;
  • each Rn4 is independently selected from H, (C1-C4)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C1-C4)haloalkyl and (C1-C4)heteroalkyl;
  • each Rp4 is independently selected from (C1-C8)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)haloalkyl and (C1-C4)heteroalkyl;
  • Rq4 and Rr4 are each independently selected from H, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)haloalkyl and (C1-C4)heteroalkyl;
  • each Z3 is independently selected from halogen, (C1-C4)alkyl, —OH, —CN, (C1-C4)heteroalkyl and (C1-C4)haloalkyl;
  • each Z4 is independently selected from (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, halogen, —CN, —ORn5, —OC(O)Rp5, —OC(O)NRq5Rr5, —SRn5, —S(O)Rp5, —S(O)2OH, —S(O)2Rp5, —S(O)2NRq5Rr5, —NRq5Rr5, —NRn5CORp5, —NRn5CO2Rp5, —NRn5CONRq5Rr5, —NRn5S(O)2Rp5, —NRn5S(O)2ORp5, —NRn5S(O)2NRq5Rr5, NO2, —C(O)Rn5, —C(O)ORn5 and —C(O)NRq5Rr5, wherein any (C3-C7)carbocycle, of Z4 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z4a or Z4b groups, and wherein any (C1-C8)alkyl, (C2-C8)alkenyl and (C2-C8)alkynyl of Z4 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z4a groups;
  • each Z4a is independently selected from halogen, —CN, —ORn6, —OC(O)Rp6, —OC(O)NRq6Rr6, —SRn6, —S(O)Rp6, —S(O)2OH, —S(O)2Rp6, —S(O)2NRq6Rr6, —NRq6Rr6, —NRn6CORp6, —NRn6CO2Rp6, —NRn6CONRq6Rr6, —NRn6S(O)2Rp6, —NRn6S(O)2ORp6, —NRn6S(O)2NRq6Rr6, NO2, —C(O)Rn6, —C(O)ORn6 and —C(O)NRq6Rr6;
  • each Z4b is independently selected from (C1-C4)alkyl, (C2-C4)alkenyl (C2-C4)alkynyl and (C1-C4)haloalkyl;
  • each Rn5 is independently selected from H, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)heteroalkyl, (C2-C4)alkenyl and (C2-C4)alkynyl;
  • each Rp5 is independently selected from (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)heteroalkyl, (C2-C4)alkenyl and (C2-C4)alkynyl;
  • Rq5 and Rr5 are each independently selected from H, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)heteroalkyl, (C2-C4)alkenyl and (C2-C4)alkynyl;
  • each Rn6 is independently selected from H, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)heteroalkyl, (C2-C4)alkenyl and (C2-C4)alkynyl;
  • each Rp6 is independently selected from (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)heteroalkyl, (C2-C4)alkenyl and (C2-C4)alkynyl;
  • Rq6 and Rr6 are each independently selected from H, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)heteroalkyl, (C2-C4)alkenyl and (C2-C4)alkynyl;
  • each Z5 is independently selected from (C1-C6)alkyl, halogen, —CN and —ORn7,
  • wherein any (C1-C6)alkyl of Z5 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) halogen; and
  • each Rn7 is independently selected from H, (C1-C3)alkyl, (C1-C3)haloalkyl and (C3-C7)carbocycle;
  • or a pharmaceutically acceptable salt thereof.
  • Embodiment I-2. The compound of Embodiment I-1 which is a compound of formula Ia:
  • Figure US20210009555A1-20210114-C00457
  • or a pharmaceutically acceptable salt thereof.
    Embodiment I-3. The compound of Embodiment I-1 or Embodiment I-I-2 wherein R3a and R3b are each H.
    Embodiment I-4. The compound of any one of Embodiments I-1 to I-3 wherein R2 is phenyl or a 5-membered monocyclic-heteroaryl, wherein any phenyl or 5-membered monocyclic-heteroaryl of R2 is optionally substituted with one or more Z5 groups.
    Embodiment I-5. The compound of any one of Embodiments I-1 to I-3 wherein R2 is phenyl optionally substituted with one or more Z5 groups.
    Embodiment I-6. The compound of any one of Embodiments I-1 to I-5 wherein each Z5 is halogen.
    Embodiment I-7. The compound of any one of Embodiments I-1 to I-5 wherein each Z5 is fluoro.
    Embodiment I-8. The compound of Embodiment I-1 or Embodiment I-2 wherein R2 is 3,5-difluorophenyl.
    Embodiment I-9. The compound of Embodiment I-1 which is a compound of formula Ig:
  • Figure US20210009555A1-20210114-C00458
  • or a pharmaceutically acceptable salt thereof.
    Embodiment I-10. The compound of Embodiment I-1 which is a compound of formula Ie:
  • Figure US20210009555A1-20210114-C00459
  • or a pharmaceutically acceptable salt thereof.
    Embodiment I-11. The compound of any one of Embodiments I-1 to I-10 wherein A is pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein any pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl of A is substituted with one Z1 group at the position shown, one Z2 group, and optionally substituted with one or more Z3 groups.
    Embodiment I-12. The compound of any one of Embodiments I-1 to I-10 wherein A is pyridinyl, wherein any pyridinyl of A is substituted with one Z1 group at the position shown, one Z2 group, and optionally substituted with one or more Z3 groups.
    Embodiment I-13. The compound of any one of Embodiments I-1 to I-12 wherein A is substituted with one Z1 group at the position shown and one Z2 group.
    Embodiment I-14. The compound of any one of Embodiments I-1 to I-10 wherein A-Z is selected from:
  • Figure US20210009555A1-20210114-C00460
  • wherein each Z3a is independently selected from H and Z3.
    Embodiment I-15. The compound of any one of Embodiments I-1 to I-10 wherein A-Z is selected from:
  • Figure US20210009555A1-20210114-C00461
  • wherein each Z3a is independently selected from H and Z3.
    Embodiment I-16. The compound of any one of Embodiments I-1 to I-10 wherein A-Z is:
  • Figure US20210009555A1-20210114-C00462
  • wherein each Z3a is independently selected from H and Z3.
    Embodiment I-17. The compound of any one of Embodiments I-1 to I-10 wherein A-Z is:
  • Figure US20210009555A1-20210114-C00463
  • wherein Z3a is selected from H and Z3.
    Embodiment I-18. The compound of any one of Embodiments I-1 to I-10 wherein A-Z1 is:
  • Figure US20210009555A1-20210114-C00464
  • wherein Z3a is selected from H and Z3.
    Embodiment I-19. The compound of any one of Embodiments I-14 to I-18 wherein each Z3a is H.
    Embodiment I-20. The compound of any one of Embodiments I-1 to I-19 wherein Z1 is selected from phenyl, 5-14 membered heteroaryl and 3-14 membered heterocycle, wherein any phenyl, 5-14 membered heteroaryl and 3-14 membered heterocycle of Z1 is optionally substituted with one or more Z1a or Z1b groups.
    Embodiment I-21. The compound of any one of Embodiments I-1 to I-19 wherein Z1 is selected from phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle and 9-12 membered tricyclic-heterocycle wherein any phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle and 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with one or more Z1a or Z1b groups.
    Embodiment I-22. The compound of any one of Embodiments I-1 to I-19 wherein Z1 is selected from phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle and 9-12 membered tricyclic-heterocycle, wherein the 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle and 9-12 membered tricyclic-heterocycle have 1-11 carbon atoms and 1-5 heteroatoms in the ring system, and wherein any phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle and 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with one or more Z1a or Z1b groups.
    Embodiment I-23. The compound of any one of Embodiments I-1 to I-19 wherein Z1 is selected from 8-10 membered bicyclic-heteroaryl and 8-10 membered bicyclic-heterocycle, wherein any from 8-10 membered bicyclic-heteroaryl and 8-10 membered bicyclic-heterocycle of Z1 is optionally substituted with one or more Z1a or Z1b groups.
    Embodiment I-24. The compound of any one of Embodiments I-1 to I-19 wherein Z1 is selected from 8-10 membered bicyclic-heteroaryl and 8-10 membered bicyclic-heterocycle, wherein the 8-10 membered bicyclic-heteroaryl and 8-10 membered bicyclic-heterocycle have 3-9 carbon atoms and 1-5 heteroatoms in the ring system, and wherein any 8-10 membered bicyclic-heteroaryl and 8-10 membered bicyclic-heterocycle of Z1 is optionally substituted with one or more Z1a or Z1b groups.
    Embodiment I-25. The compound of any one of Embodiments I-1 to I-19 wherein Z1 is selected from phenyl, 1H-pyrrolo[2,3-b]pyridinyl, 1-oxoisoindolinyl, 4-oxo-3,4-dihydroquinazolinyl, 3-oxospiro[cyclopropane-1,1′-isoindolin]-yl, 1H-2-oxo-pyridinyl and 2,4-dioxo-1,2,3,4-tetrahydorquinazolinyl, wherein any phenyl, 1H-pyrrolo[2,3-b]pyridinyl, 1-oxoisoindolinyl, 4-oxo-3,4-dihydroquinazolinyl, 3-oxospiro[cyclopropane-1,1′-isoindolin]-yl, 1H-2-oxo-pyridinyl and 2,4-dioxo-1,2,3,4-tetrahydorquinazolinyl of Z1 is optionally substituted with one or more Z1a or Z1b groups.
    Embodiment I-26. The compound of any one of Embodiments I-1 to I-19 wherein Z1 is selected from phenyl, 1H-pyrrolo[2,3-b]pyridin-5-yl, 1-oxoisoindolin-5-yl, 1-oxoisoindolin-4-yl, 4-oxo-3,4-dihydroquinazolin-8-yl, 3′-oxospiro[cyclopropane-1,1′-isoindolin]-5′-yl, 1H-2-oxo-pyridin-4-yl and 2,4-dioxo-1,2,3,4-tetrahydorquinazolin-8-yl, wherein any phenyl, 1H-pyrrolo[2,3-b]pyridin-5-yl, 1-oxoisoindolin-5-yl, 1-oxoisoindolin-4-yl, 4-oxo-3,4-dihydroquinazolin-8-yl, 3′-oxospiro[cyclopropane-1,1′-isoindolin]-5′-yl, 1H-2-oxo-pyridin-4-yl and 2,4-dioxo-1,2,3,4-tetrahydorquinazolin-8-yl of Z1 is optionally substituted with one or more Z1a or Z1b groups.
    Embodiment I-27. The compound of any one of Embodiments I-1 to I-26 wherein each Z1a is independently selected from halogen, —ORn1, NRq1Rr1, and —C(O)NRq1Rr1.
    Embodiment I-28. The compound of any one of Embodiments I-1 to I-26 wherein each Z1a is independently selected from halogen and —C(O)NRq1Rr1.
    Embodiment I-29. The compound of any one of Embodiments I-1 to I-26 wherein Rn1, Rq1 and Rr1 are each H.
    Embodiment I-30. The compound of any one of Embodiments I-1 to I-19 wherein Z1 is selected from:
  • Figure US20210009555A1-20210114-C00465
  • Embodiment I-31. The compound of any one of Embodiments I-1 to I-30 wherein Z2 is selected from (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle and —C(O)NRq3Rr3 wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl and 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with one or more Z2b or Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with one or more Z2c groups.
    Embodiment I-32. The compound of any one of Embodiments I-1 to I-30 wherein Z2 is selected from (C2-C8)alkynyl, phenyl, 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heterocycle and —C(O)NRq3Rr3, wherein any phenyl, 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl and 8-10 membered C-linked-bicyclic-heterocycle of Z2 is optionally substituted with one or more Z2b or Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with one or more Z2c groups.
    Embodiment I-33. The compound of any one of Embodiments I-1 to I-30 wherein Z2 is selected from (C2-C8)alkynyl, phenyl, 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heterocycle and —C(O)NRq3Rr3, wherein the 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl and 8-10 membered C-linked-bicyclic-heterocycle have 1-9 carbon atoms and 1-4 heteroatoms in the ring system, and wherein any phenyl, 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl, 8-10 membered and C-linked-bicyclic-heterocycle of Z2 is optionally substituted with one or more Z2b or Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with one or more Z2c groups.
    Embodiment I-34. The compound of any one of Embodiments I-1 to I-30 wherein Z2 is selected from 4-methylpentynyl, phenyl, pyridinyl, 1H-2-oxo-pyridinyl, triazolyl, 1-oxoisoindolinyl, 1H-pyrrolo[2,3-b]pyridinyl and —C(O)NRq3Rr3, wherein any phenyl, pyridinyl, 2-oxopyridinyl, triazolyl, 1-oxoisoindolinyl and 1H-pyrrolo[2,3-b]pyridinyl of Z2 is optionally substituted with one or more Z2b or Z2c groups, and wherein any 4-methylpentynyl of Z2 is optionally substituted with one or more Z2c groups.
    Embodiment I-35. The compound of any one of Embodiments I-1 to I-30 wherein Z2 is selected from 4-methylpentyn-1-yl, phenyl, pyridin-4-yl, 1H-2-oxo-pyridin-2-yl, triazol-4-yl, 1-oxoisoindolin-6-yl, 1H-pyrrolo[2,3-b]pyridine-5-yl and —C(O)NRq3Rr3, wherein any phenyl, pyridin-4-yl, 2-hydroxypyridin-2-yl, triazol-4-yl, 1-oxoisoindolin-6-yl and 1H-pyrrolo[2,3-b]pyridine-5-yl of Z2 is optionally substituted with one or more Z2b or Z2c groups, and wherein any 4-methylpentyn-1-yl of Z2 is optionally substituted with one or more Z2c groups.
    Embodiment I-36. The compound of any one of Embodiments I-1 to I-35 wherein Z2 is optionally substituted with one or more Z2c groups.
    Embodiment I-37. The compound of any one of Embodiments I-1 to I-36 wherein Rq3 and Rr3 are each H.
    Embodiment I-38. The compound of any one of Embodiments I-1 to I-37 wherein each Z2c is independently selected from halogen, —ORn4 and —C(O)NRq4Rr4.
    Embodiment I-39. The compound of any one of Embodiments I-1 to I-38 wherein Rn4 is H or methyl, and Rq4 and Rr4 are each H.
    Embodiment I-40. The compound of any one of Embodiments I-1 to I-30 wherein Z2 is selected from:
  • Figure US20210009555A1-20210114-C00466
  • Embodiment I-41. The compound of any one of Embodiments I-1 to I-10 wherein A-Z1 is selected from:
  • Figure US20210009555A1-20210114-C00467
    Figure US20210009555A1-20210114-C00468
    Figure US20210009555A1-20210114-C00469
    Figure US20210009555A1-20210114-C00470
  • Embodiment I-42. The compound of any one of Embodiments I-1 to I-41 wherein R1 is a 5-12 membered heteroaryl, wherein any 5-12 membered heteroaryl of R is optionally substituted with one or more Z4 groups.
    Embodiment I-43. The compound of any one of Embodiments I-1 to I-41 wherein R1 is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl, wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R is optionally substituted with one or more Z4 groups.
    Embodiment I-44. The compound of any one of Embodiments I-1 to I-41 wherein R1 is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl, wherein the 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl have 4-10 carbon atoms and 1-5 heteroatoms in the ring system, and wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R is optionally substituted with one or more Z4 groups.
    Embodiment I-45. The compound of any one of Embodiments I-1 to I-41 wherein R1 is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl, wherein the 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl contains at least one partially unsaturated ring, and wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z4 groups.
    Embodiment I-46. The compound of any one of Embodiments I-1 to I-41 wherein R1 has the following formula IIIb:
  • Figure US20210009555A1-20210114-C00471
  • wherein:
  • C together with the two carbon atoms of ring B to which it is attached forms a 3-7 membered monocyclic-carbocycle, 5-8 membered bicyclic-carbocycle, 3-7 membered monocyclic-heterocycle or 5-8 membered bicyclic heterocycle, wherein any 3-7 membered monocyclic-carbocycle, 5-8 membered bicyclic-carbocycle, 3-7 membered monocyclic-heterocycle or 5-8 membered bicyclic heterocycle of C is optionally substituted with one or more (e.g. 1, 2, 3, 4 or 5) Z4 groups; and
  • B is a 5 or 6 membered monocyclic-heteroaryl having 1, 2 or 3 nitrogen atoms;
  • V is C or N;
  • W is CZ4c, NZ4c or N;
  • X is CZ4c NZ4c or N;
  • Y is CZ4c, N or absent;
  • the dashed bonds are selected from single bonds and double bonds, wherein the dashed bonds, V, W, X and Y are selected so that the 5 or 6 membered monocyclic-heteroaryl B is aromatic; and
  • each Z4c is independently selected from H or Z4.
  • Embodiment I-47. The compound of any one of Embodiments I-1 to I-41 wherein R1 has the following formula IId:
  • Figure US20210009555A1-20210114-C00472
  • wherein:
  • C together with the two carbon atoms to which it is attached forms a 3-7 membered monocyclic-carbocycle, 5-9 membered bicyclic-carbocycle, 3-7 membered monocyclic-heterocycle or 5-9 membered bicyclic heterocycle, wherein any 3-7 membered monocyclic-carbocycle, 5-9 membered bicyclic-carbocycle, 3-7 membered monocyclic-heterocycle or 5-9 membered bicyclic heterocycle of C is optionally substituted with one or more (e.g. 1, 2, 3, 4 or 5) Z4 groups; and
  • each Z4c is independently selected from H or Z4.
  • Embodiment I-48. The compound of any one of Embodiments I-1 to I-41 wherein R1 is selected from 3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazolyl and 4,5,6,7-tetrahydro-indazolyl, wherein any 3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazolyl and 4,5,6,7-tetrahydro-indazolyl of R1 is optionally substituted with one or more Z4 groups.
    Embodiment I-49. The compound of any one of Embodiments I-1 to I-41 wherein R1 is selected from 3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl and 4,5,6,7-tetrahydro-indazol-1-yl, wherein any 3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl and 4,5,6,7-tetrahydro-indazol-1-yl of R1 is optionally substituted with one or more Z4 groups.
    Embodiment I-50. The compound of any one of Embodiments I-1 to I-49 wherein each Z4 is independently selected from (C1-C6)alkyl and halogen, wherein any (C1-C6)alkyl of Z4 is optionally substituted with one or more halogen.
    Embodiment I-51. The compound of any one of Embodiments I-1 to I-49 wherein each Z4 is independently selected from fluoro, trifluoromethyl and difluoromethyl.
    Embodiment I-52. The compound of any one of Embodiments I-1 to I-41 wherein R1 is selected from:
  • Figure US20210009555A1-20210114-C00473
  • Embodiment I-53. The compound of any one of Embodiments I-1 to I-41 wherein R1 is selected from:
  • Figure US20210009555A1-20210114-C00474
  • Embodiment I-54. The compound of Embodiment I-1 selected from:
  • Figure US20210009555A1-20210114-C00475
    Figure US20210009555A1-20210114-C00476
    Figure US20210009555A1-20210114-C00477
    Figure US20210009555A1-20210114-C00478
    Figure US20210009555A1-20210114-C00479
  • and pharmaceutically acceptable salts thereof.
    Embodiment I-55. A pharmaceutical composition comprising a compound of formula I as described in any one of Embodiments I-1 to I-54, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
    Embodiment I-56. A method for treating a Retroviridae virus infection in a mammal comprising administering a therapeutically effective amount of a compound of any one of Embodiments I-1 to I-54, or a pharmaceutically acceptable salt thereof, to the mammal.
    Embodiment I-57. The method of claim 56 wherein the Retroviridae virus infection is an HIV virus infection.
    Embodiment I-58. A method for treating an HIV infection in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of formula I as described in any one of Embodiments I-1 to I-54, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, and other drugs for treating HIV, and combinations thereof.
    Embodiment I-59. A compound of formula I as described in any of Embodiments I-1 to I-54, or a pharmaceutically acceptable salt thereof for use in medical therapy.
    Embodiment I-60. A compound of formula I as described in any one of Embodiments I-1 to 1-54 or a pharmaceutically acceptable salt thereof, for the prophylactic or therapeutic treatment of a Retroviridae virus infection or an HIV virus infection.
    Embodiment I-61. The use of a compound as described in any one of Embodiments I-1 to I-54 or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating a Retroviridae virus infection or an HIV virus infection in a mammal.
    Embodiment I-62. A compound or method as described herein.
  • Also provided below are certain embodiments.
  • Embodiment II-1. A compound of formula I:
  • Figure US20210009555A1-20210114-C00480
  • wherein:
  • A is a 6-membered monocyclic-heteroaryl with one or two nitrogen atoms, wherein the 6-membered monocyclic-heteroaryl is substituted with one Z group at the position shown, one Z2 group, and optionally substituted with one or more (e.g., 1 or 2) Z3 groups;
  • R1 is 6-12 membered aryl, 5-12 membered heteroaryl or 3-12 membered heterocycle, wherein any 6-12 membered aryl, 5-12 membered heteroaryl or 3-12 membered heterocycle of R1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z4 groups;
  • R2 is phenyl, 5-membered monocyclic-heteroaryl, 6-membered monocyclic-heteroaryl or (C3-C7)carbocycle, wherein any phenyl, 5-membered monocyclic-heteroaryl, 6-membered monocyclic-heteroaryl or (C3-C7)carbocycle of R2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z5 groups;
  • each R3a and R3b is independently selected from H, halogen, (C1-C3)alkyl and (C1-C3)haloalkyl, or R3a is selected from H, (C1-C3)alkyl and (C1-C3)haloalkyl and R3b is selected from —OH and —CN;
  • Z1 is selected from 6-12 membered aryl, 5-14 membered heteroaryl and 3-14 membered heterocycle, wherein any 6-12 membered aryl, 5-14 membered heteroaryl and 3-14 membered heterocycle of Z is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1a or Z1b;
  • each Z1a is independently selected from (C3-C7)carbocycle, 6-12 membered aryl, 5-12 membered heteroaryl, 3-12 membered heterocycle, halogen, —CN, —ORn1, —OC(O)Rp1, —OC(O)NRq1Rr1, —SRn1, —S(O)Rp1, —S(O)2OH, —S(O)2Rp1, —S(O)2NRq1Rr1, —NRq1Rr1, —NRn1CORp1, —NRn1CO2Rp1, —NRn1CONRq1Rr1, —NRn1S(O)2Rp1, —NRn1S(O)2ORp1, —NRn1S(O)2NRq1Rr1 NO2, —C(O)Rn1, —C(O)ORn1, —C(O)NRq1Rr1 and —S(O)2NRn1CORp1, wherein any (C3-C7)carbocycle, 6-12 membered aryl, 5-12 membered heteroaryl and 3-12 membered heterocycle of Z1a is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c or Z1d groups;
  • each Z1b is independently selected from (C1-C8)alkyl, (C2-C8)alkenyl and (C2-C8)alkynyl, wherein any (C1-C8)alkyl, (C2-C8)alkenyl and (C2-C8)alkynyl of Z1b is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c groups;
  • each Z1c is independently selected from (C3-C7)carbocycle, phenyl, 5-6 membered monocyclic-heteroaryl, 3-7 membered heterocycle, halogen, —CN, —ORn2, —OC(O)Rp2, —OC(O)NRq2Rr2, —SRn2, —S(O)Rp2, —S(O)2OH, —S(O)2Rp2, —S(O)2NRq2Rr2, —NRq2Rr2, —NRn2CORp2, —NRn2CO2Rp2, —NRn2CONRq2Rr2, —NRn2S(O)2ORp2, —NRn2S(O)2ORp2, —NRn2S(O2NRq2Rr2, NO2, —C(O)Rn2, —C(O)ORn2, —C(O)NR2R2, halophenyl, 5-6 membered haloheteroaryl, 3-7 membered haloheterocycle and (C1-C8)heteroalkyl;
  • each Z1d is independently selected from (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl and (C1-C8)haloalkyl;
  • each Rn1 is independently selected from H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl and phenyl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl and phenyl of Rn1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c or Z1d groups, and wherein any (C1-C8)alkyl, (C2-C8)alkenyl and (C2-C8)alkynyl of Rn1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c groups;
  • each Rp1 is independently selected from (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl and phenyl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl and phenyl of Rp1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c or Z1d groups, and wherein any (C1-C8)alkyl, (C2-C8)alkenyl and (C2-C8)alkynyl of Rp1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c groups;
  • Rq1 and Rr1 are each independently selected from H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl and phenyl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl and phenyl of Rq1 or Rr1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c or Z1d groups, and wherein any (C1-C8)alkyl, (C2-C8)alkenyl and (C2-C8)alkynyl of Rq1 or Rr1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c groups, or Rq1 and Rr1 together with the nitrogen to which they are attached form a 5, 6 or 7-membered heterocycle, wherein the 5, 6 or 7-membered heterocycle is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c or Z1d groups;
  • each Rn2 is independently selected from H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl, phenyl, halophenyl, 5-6 membered monocyclic-haloheteroaryl, 3-7 membered haloheterocycle, (C1-C8)haloalkyl and (C1-C8)heteroalkyl;
  • each Rp2 is independently selected from (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl, phenyl, halophenyl, 5-6 membered monocyclic-haloheteroaryl, 3-7 membered haloheterocycle, (C1-C8)haloalkyl and (C1-C8)heteroalkyl;
  • Rq2 and Rr2 are each independently selected from H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl, phenyl, halophenyl, 5-6 membered monocyclic-haloheteroaryl, 3-7 membered haloheterocycle, (C1-C8)haloalkyl and (C1-C8)heteroalkyl, or Rq2 and Rr2 together with the nitrogen to which they are attached form a 5, 6 or 7-membered heterocycle;
  • Z2 is selected from (C2-C8)alkenyl, (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, —C(O)Rn3 and —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl and 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2b or Z2c groups, and wherein any (C2-C8)alkenyl and (C2-C8)alkynyl of Z2 is optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) Z2c groups;
  • each Z2a is independently selected from (C3-C7)carbocycle, 6-12 membered aryl, 5-12 membered heteroaryl, 3-12 membered heterocycle, halogen, —CN, —ORn4, —OC(O)Rp4, —OC(O)NRq4Rr4, —SRn4, —S(O)Rp4, —S(O)2OH, —S(O)2Rp4, —S(O)2NRq4Rr4, —NRq4Rr4, —NRn4CORp4, —NRn4 CO2Rp4, —NRn4CONRq4Rr4, —NRn4S(O)2Rp4, —NRn4S(O)2ORp4, —NRn4S(O)2NRq4Rr4, NO2, —C(O)Rn4, —C(O)ORn4 and —C(O)NRq4Rr4, wherein any (C3-C7)carbocycle, 6-12 membered aryl, 5-12 membered heteroaryl and 3-12 membered heterocycle of Z2a is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2b or Z2c groups;
  • each Z2b is independently selected from (C1-C4)alkyl, (C1-C4)heteroalkyl and (C1-C4)haloalkyl;
  • each Z2c is independently selected from halogen, —CN, —ORn4, —OC(O)Rp4, —OC(O)NRq4Rr4, —SRn4, —S(O)Rp4, —S(O)2OH, —S(O)2Rp4, S(O)2NRq4Rr4, —NRq4Rr4, —NRn4CORp4, —NRn4CO2Rp4, —NRn4CONRq4Rr4, —NRn4S(O)2Rp4, —NRn4S(O)2ORp4, —NRn4S(O)2NRq4Rr4 NO2, —C(O)Rn4, —C(O)ORn4 and —C(O)NRq4Rr4;
  • each Rn3 is independently selected from H, (C1-C4)alkyl, (C2-C4)alkenyl, (C3-C7)carbocycle, 3-12 membered heterocycle, 5-12 membered heteroaryl and 6-12 membered aryl, wherein any (C3-C7)carbocycle, 3-12 membered heterocycle, 5-12 membered heteroaryl and 6-12 membered aryl of Rn3 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2b or Z2c groups, and wherein any (C1-C4)alkyl, (C2-C4)alkenyl and (C2-C4)alkynyl of Rn3 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2a groups;
  • Rq3 and Rr3 are each independently selected from H, (C1-C4)alkyl, (C2-C4)alkenyl, (C3-C7)carbocycle, 3-12 membered heterocycle, 5-12 membered heteroaryl and 6-12 membered aryl, wherein any (C3-C7)carbocycle, 3-12 membered heterocycle, 5-12 membered heteroaryl and 6-12 membered aryl of Rq3 or Rr3 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2b or Z2c groups, and wherein any (C1-C4)alkyl and (C2-C4)alkenyl of Rq3 or Rr3 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2a groups, or Rq3 and Rr3 together with the nitrogen to which they are attached form a heterocycle or heteroaryl, wherein the heterocycle or heteroaryl is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2b or Z2c groups;
  • each Rn4 is independently selected from H, (C1-C4)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C1-C4)haloalkyl and (C1-C4)heteroalkyl;
  • each Rp4 is independently selected from (C1-C8)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)haloalkyl and (C1-C4)heteroalkyl;
  • Rq4 and Rr4 are each independently selected from H, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)haloalkyl and (C1-C4)heteroalkyl;
  • each Z3 is independently selected from halogen, (C1-C4)alkyl, —OH, —CN, (C1-C4)heteroalkyl and (C1-C4)haloalkyl;
  • each Z4 is independently selected from (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, halogen, —CN, —ORn5, —OC(O)Rp5, —OC(O)NRq5Rr5, —SRn5, —S(O)Rp5, —S(O)2OH, —(O) S(O)2NRq5Rr5, —NRq5Rr5, —NRn5CORp5, —NRn5CO2Rp5, —NRn5CONRq5Rr5, —NRn5S(O)2Rp5, —NRn5S(O)2ORp5, —NRn5S(O)2NRq5Rr5, NO2, —C(O)Rn5, —C(O)ORn5 and —C(O)NRq6Rr6, wherein any (C3-C7)carbocycle, of Z4 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z4a or Z4b groups, and wherein any (C1-C8)alkyl, (C2-C8)alkenyl and (C2-C8)alkynyl of Z4 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z4′ groups;
  • each Z4a is independently selected from halogen, —CN, —ORn6, —OC(O)Rp6, —OC(O)NRq6Rr6, —SRn6, —S(O)Rp6, —S(O)2OH, —S(O)2Rp6, —S(O)2NRq6Rr6, —NRq6Rr6, —NRn6CORp6, —NRn6CO2NRp6, —NRn6CONRq6Rr6, —NRn6S(O)2Rp6, —NRn6S(O)2ORp6, —NRn6S(O)2NRq6Rr6, NO2, —C(O)Rn6, —C(O)ORn6 and —C(O)NRq6Rr6;
  • each Z4b is independently selected from (C1-C4)alkyl, (C2-C4)alkenyl (C2-C4)alkynyl and (C1-C4)haloalkyl;
  • each Rn5 is independently selected from H, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)heteroalkyl, (C2-C4)alkenyl and (C2-C4)alkynyl;
  • each Rp5 is independently selected from (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)heteroalkyl, (C2-C4)alkenyl and (C2-C4)alkynyl;
  • Rq5 and Rr5 are each independently selected from H, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)heteroalkyl, (C2-C4)alkenyl and (C2-C4)alkynyl;
  • each Rn6 is independently selected from H, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)heteroalkyl, (C2-C4)alkenyl and (C2-C4)alkynyl;
  • each Rp6 is independently selected from (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)heteroalkyl, (C2-C4)alkenyl and (C2-C4)alkynyl;
  • Rq6 and Rr6 are each independently selected from H, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)heteroalkyl, (C2-C4)alkenyl and (C2-C4)alkynyl;
  • each Z5 is independently selected from (C1-C6)alkyl, halogen, —CN and —ORn7, wherein any (C1-C6)alkyl of Z5 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) halogen; and
  • each Rn7 is independently selected from H, (C1-C3)alkyl, (C1-C3)haloalkyl and (C3-C7)carbocycle;
  • or a pharmaceutically acceptable salt thereof.
  • Embodiment II-2. The compound of Embodiment II-1 which is a compound of formula Ia:
  • Figure US20210009555A1-20210114-C00481
  • or a pharmaceutically acceptable salt thereof.
    Embodiment II-3. The compound of Embodiment II-1 or Embodiment II-2 wherein R3a and R3b are each H.
    Embodiment II-4. The compound of any one of Embodiments II-1-3 wherein R2 is phenyl or a 5-membered monocyclic-heteroaryl, wherein any phenyl or 5-membered monocyclic-heteroaryl of R2 is optionally substituted with one or more Z5 groups.
    Embodiment II-5. The compound of any one of Embodiments II-1 to II-3 wherein R2 is phenyl optionally substituted with one or more Z5 groups.
    Embodiment II-6. The compound of any one of Embodiments II-1 to II-5 wherein each Z5 is halogen.
    Embodiment II-7. The compound of any one of Embodiments II-1 to II-5 wherein each Z5 is fluoro.
    Embodiment II-8. The compound of Embodiment II-1 or Embodiment II-2 wherein R2 is 3,5-difluorophenyl.
    Embodiment II-9. The compound of Embodiment II-1 which is a compound of formula Ig:
  • Figure US20210009555A1-20210114-C00482
  • or a pharmaceutically acceptable salt thereof.
    Embodiment II-10. The compound of Embodiment II-1 which is a compound of formula Ie:
  • Figure US20210009555A1-20210114-C00483
  • or a pharmaceutically acceptable salt thereof.
    Embodiment II-11. The compound of any one of Embodiments II-1 to II-10 wherein A is pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein any pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl of A is substituted with one Z1 group at the position shown, one Z2 group, and optionally substituted with one or more Z3 groups.
    Embodiment II-12. The compound of any one of Embodiments II-1 to II-10 wherein A is pyridinyl, wherein any pyridinyl of A is substituted with one Z1 group at the position shown, one Z2 group, and optionally substituted with one or more Z3 groups.
    Embodiment II-13. The compound of any one of Embodiments II-1 to II-12 wherein A is substituted with one Z group at the position shown and one Z2 group.
    Embodiment II-14. The compound of any one of Embodiments II-1 to II-10 wherein A-Z1 is selected from:
  • Figure US20210009555A1-20210114-C00484
  • wherein each Z3a is independently selected from H and Z3.
    Embodiment II-15. The compound of any one of Embodiments II-1 to II-10 wherein A-Z is selected from:
  • Figure US20210009555A1-20210114-C00485
  • wherein each Z3a is independently selected from H and Z3.
    Embodiment II-16. The compound of any one of Embodiments II-1 to II-10 wherein A-Z is:
  • Figure US20210009555A1-20210114-C00486
  • wherein each Z3a is independently selected from H and Z3.
    Embodiment II-17. The compound of any one of Embodiments II-1 to II-10 wherein A-Z is:
  • Figure US20210009555A1-20210114-C00487
  • wherein Z3a is selected from H and Z3.
    Embodiment II-18. The compound of any one of Embodiments II-1 to II-10 wherein A-Z is:
  • Figure US20210009555A1-20210114-C00488
  • wherein Z3a is selected from H and Z3.
    Embodiment II-19. The compound of any one of Embodiments II-14 to II-18 wherein each Z3a is H.
    Embodiment II-20. The compound of any one of Embodiments II-1 to II-19 wherein Z1 is selected from phenyl, 5-14 membered heteroaryl and 3-14 membered heterocycle, wherein any phenyl, 5-14 membered heteroaryl and 3-14 membered heterocycle of Z1 is optionally substituted with one or more Z1a or Z1b groups.
    Embodiment II-21. The compound of any one of Embodiments II-1 to II-19 wherein Z1 is selected from phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle and 9-12 membered tricyclic-heterocycle wherein any phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle and 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with one or more Z1a or Z1b groups.
    Embodiment II-22. The compound of any one of Embodiments II-1 to II-19 wherein Z1 is selected from phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle and 9-12 membered tricyclic-heterocycle, wherein the 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle and 9-12 membered tricyclic-heterocycle have 1-11 carbon atoms and 1-5 heteroatoms in the ring system, and wherein any phenyl, 5-6 membered monocyclic-heteroaryl, 8-10 membered bicyclic-heteroaryl, 8-10 membered bicyclic-heterocycle and 9-12 membered tricyclic-heterocycle of Z1 is optionally substituted with one or more Z1a or Z1b groups.
    Embodiment II-23. The compound of any one of Embodiments II-1 to II-19 wherein Z1 is selected from 8-10 membered bicyclic-heteroaryl and 8-10 membered bicyclic-heterocycle, wherein any from 8-10 membered bicyclic-heteroaryl and 8-10 membered bicyclic-heterocycle of Z1 is optionally substituted with one or more Z1a or Z1b groups.
    Embodiment II-24. The compound of any one of Embodiments II-1 to II-19 wherein Z1 is selected from 8-10 membered bicyclic-heteroaryl and 8-10 membered bicyclic-heterocycle, wherein the 8-10 membered bicyclic-heteroaryl and 8-10 membered bicyclic-heterocycle have 3-9 carbon atoms and 1-5 heteroatoms in the ring system, and wherein any 8-10 membered bicyclic-heteroaryl and 8-10 membered bicyclic-heterocycle of Z1 is optionally substituted with one or more Z1a or Z1b groups.
    Embodiment II-25. The compound of any one of Embodiments II-1 to II-19 wherein Z1 is selected from phenyl, 1H-pyrrolo[2,3-b]pyridinyl, 1-oxoisoindolinyl, 4-oxo-3,4-dihydroquinazolinyl, 3-oxospiro[cyclopropane-1,1′-isoindolin]-yl, 1H-2-oxo-pyridinyl and 2,4-dioxo-1,2,3,4-tetrahydorquinazolinyl, wherein any phenyl, 1H-pyrrolo[2,3-b]pyridinyl, 1-oxoisoindolinyl, 4-oxo-3,4-dihydroquinazolinyl, 3-oxospiro[cyclopropane-1,1′-isoindolin]-yl, 1H-2-oxo-pyridinyl and 2,4-dioxo-1,2,3,4-tetrahydorquinazolinyl of Z1 is optionally substituted with one or more Z1a or Z1b groups.
    Embodiment II-26. The compound of any one of Embodiments II-1 to II-19 wherein Z1 is selected from phenyl, 1H-pyrrolo[2,3-b]pyridin-5-yl, 1-oxoisoindolin-5-yl, 1-oxoisoindolin-4-yl, 4-oxo-3,4-dihydroquinazolin-8-yl, 3′-oxospiro[cyclopropane-1,1′-isoindolin]-5′-yl, 1H-2-oxo-pyridin-4-yl and 2,4-dioxo-1,2,3,4-tetrahydorquinazolin-8-yl, wherein any phenyl, 1H-pyrrolo[2,3-b]pyridin-5-yl, 1-oxoisoindolin-5-yl, 1-oxoisoindolin-4-yl, 4-oxo-3,4-dihydroquinazolin-8-yl, 3′-oxospiro[cyclopropane-1,1′-isoindolin]-5′-yl, 1H-2-oxo-pyridin-4-yl and 2,4-dioxo-1,2,3,4-tetrahydorquinazolin-8-yl of Z1 is optionally substituted with one or more Z1a or Z1b groups.
    Embodiment II-27. The compound of any one of Embodiments II-1 to II-19 wherein Z1 is 1H-indazol-7-yl, wherein Z1 is optionally substituted with one or more Z1a or Z1b groups.
    Embodiment II-28. The compound of any one of Embodiments II-1 to II-27 wherein each Z1a is independently selected from halogen, —ORn1, NRq1Rr1, and —C(O)NRq1Rr1.
    Embodiment II-29. The compound of any one of Embodiments II-1 to II-27 wherein each Z1a is independently selected from halogen and —NRn1S(O)2Rp1.
    Embodiment II-30. The compound of any one of Embodiments II-1 to II-27 wherein each Z1b is independently selected from (C1-C8)alkyl.
    Embodiment II-31. The compound of any one of Embodiments II-1 to II-27 wherein each Z1a is independently selected from halogen and —NRn1 S(O)2Rp1 and each Z1b is independently selected from (C1-C8)alkyl.
    Embodiment II-32. The compound of any one of Embodiments II-1 to II-27 wherein each Z1a is independently selected from halogen and —C(O)NRq1Rr1.
    Embodiment II-33. The compound of any one of Embodiments II-1 to II-27 wherein Rn1, Rq1 and Rr1 are each H.
    Embodiment II-34. The compound of any one of Embodiments I-1 to II-19 wherein Z1 is selected from:
  • Figure US20210009555A1-20210114-C00489
  • Embodiment II-35. The compound of any one of Embodiments II-1 to II-19 wherein Z1 is
  • Figure US20210009555A1-20210114-C00490
  • Embodiment II-36. The compound of any one of Embodiments IT-1 to II-19 wherein Z1 is selected from
  • Figure US20210009555A1-20210114-C00491
  • Embodiment II-37. The compound of any one of Embodiments II-1 to II-36 wherein Z2 is selected from (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle and —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl and 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with one or more Z2b or Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with one or more Z2c groups.
    Embodiment II-38. The compound of any one of Embodiments I-1 to II-36 wherein Z2 is selected from (C2-C8)alkynyl, phenyl, 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heterocycle and —C(O)NRq3Rr3, wherein any phenyl, 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl and 8-10 membered C-linked-bicyclic-heterocycle of Z2 is optionally substituted with one or more Z2b or Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with one or more Z2c groups.
    Embodiment II-39. The compound of any one of Embodiments II-1 to II-36 wherein Z2 is selected from (C2-C8)alkynyl, phenyl, 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heterocycle and —C(O)NRq3Rr3, wherein the 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl and 8-10 membered C-linked-bicyclic-heterocycle have 1-9 carbon atoms and 1-4 heteroatoms in the ring system, and wherein any phenyl, 5-6 membered C-linked-monocyclic-heteroaryl, 8-10 membered C-linked-bicyclic-heteroaryl, 8-10 membered and C-linked-bicyclic-heterocycle of Z2 is optionally substituted with one or more Z2b or Z2c groups, and wherein any (C2-C8)alkynyl of Z2 is optionally substituted with one or more Z2c groups.
    Embodiment II-40. The compound of any one of Embodiments II-1 to II-36 wherein Z2 is selected from 4-methylpentynyl, phenyl, pyridinyl, 1H-2-oxo-pyridinyl, triazolyl, 1-oxoisoindolinyl, 1H-pyrrolo[2,3-b]pyridinyl and —C(O)NRq1 Rr1, wherein any phenyl, pyridinyl, 2-oxopyridinyl, triazolyl, 1-oxoisoindolinyl and 1H-pyrrolo[2,3-b]pyridinyl of Z2 is optionally substituted with one or more Z2b or Z2c groups, and wherein any 4-methylpentynyl of Z2 is optionally substituted with one or more Z2c groups.
    Embodiment II-41. The compound of any one of Embodiments II-1 to II-36 wherein Z2 is selected from 4-methylpentyn-1-yl, phenyl, pyridin-4-yl, 1H-2-oxo-pyridin-2-yl, triazol-4-yl, 1-oxoisoindolin-6-yl, 1H-pyrrolo[2,3-b]pyridine-5-yl and —C(O)NRq3Rr3, wherein any phenyl, pyridin-4-yl, 2-hydroxypyridin-2-yl, triazol-4-yl, 1-oxoisoindolin-6-yl and 1H-pyrrolo[2,3-b]pyridine-5-yl of Z2 is optionally substituted with one or more Z2b or Z2c groups, and wherein any 4-methylpentyn-1-yl of Z2 is optionally substituted with one or more Z2c groups.
    Embodiment II-42. The compound of any one of Embodiments II-1 to II-41 wherein Z2 is optionally substituted with one or more Z2c groups.
    Embodiment II-43. The compound of any one of Embodiments II-1 to II-42 wherein Rq and R1 are each H.
    Embodiment II-44. The compound of any one of Embodiments II-1 to II-43 wherein each Z2c is independently selected from halogen, —ORn4 and —C(O)NRq4Rr4.
    Embodiment II-45. The compound of any one of Embodiments II-1 to II-44 wherein Rn4 is H or methyl, and Rq4 and Rr4 are each H.
    Embodiment II-46. The compound of any one of Embodiments II-1 to II-36 wherein Z2 is selected from:
  • Figure US20210009555A1-20210114-C00492
  • Embodiment II-47. The compound of any one of Embodiments II-1 to II-10 wherein A-Z is selected from:
  • Figure US20210009555A1-20210114-C00493
    Figure US20210009555A1-20210114-C00494
    Figure US20210009555A1-20210114-C00495
    Figure US20210009555A1-20210114-C00496
  • Embodiment II-48. The compound of any one of Embodiments II-1 to II-10 wherein A-Z1 is selected from:
  • Figure US20210009555A1-20210114-C00497
  • Embodiment II-49. The compound of any one of Embodiments II-1 to II-48 wherein R1 is a 5-12 membered heteroaryl, wherein any 5-12 membered heteroaryl of R1 is optionally substituted with one or more Z4 groups.
    Embodiment II-50. The compound of any one of Embodiments II-1 to II-48 wherein R1 is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl, wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R1 is optionally substituted with one or more Z4 groups.
    Embodiment II-51. The compound of any one of Embodiments II-1 to II-48 wherein R1 is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl, wherein the 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl have 4-10 carbon atoms and 1-5 heteroatoms in the ring system, and wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R1 is optionally substituted with one or more Z4 groups.
    Embodiment II-52. The compound of any one of Embodiments II-1 to II-48 wherein R1 is a 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl, wherein the 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl contains at least one partially unsaturated ring, and wherein any 8-12 membered bicyclic-heteroaryl or 8-12 membered tricyclic-heteroaryl of R1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z4 groups.
    Embodiment II-53. The compound of any one of Embodiments II-1 to II-48 wherein R1 has the following formula IIIb:
  • Figure US20210009555A1-20210114-C00498
  • wherein:
  • C together with the two carbon atoms of ring B to which it is attached forms a 3-7 membered monocyclic-carbocycle, 5-8 membered bicyclic-carbocycle, 3-7 membered monocyclic-heterocycle or 5-8 membered bicyclic heterocycle, wherein any 3-7 membered monocyclic-carbocycle, 5-8 membered bicyclic-carbocycle, 3-7 membered monocyclic-heterocycle or 5-8 membered bicyclic heterocycle of C is optionally substituted with one or more (e.g. 1, 2, 3, 4 or 5) Z4 groups; and
  • B is a 5 or 6 membered monocyclic-heteroaryl having 1, 2 or 3 nitrogen atoms;
  • V is C or N;
  • W is CZ4c, NZ4c or N;
  • X is CZ4c, NZ4c or N;
  • Y is CZ4c, N or absent;
  • the dashed bonds are selected from single bonds and double bonds, wherein the dashed bonds, V, W, X and Y are selected so that the 5 or 6 membered monocyclic-heteroaryl B is aromatic; and
  • each Z4c is independently selected from H or Z4.
  • Embodiment II-54. The compound of any one of Embodiments II-1 to II-48 wherein R1 has the following formula IId:
  • Figure US20210009555A1-20210114-C00499
  • wherein:
  • C together with the two carbon atoms to which it is attached forms a 3-7 membered monocyclic-carbocycle, 5-9 membered bicyclic-carbocycle, 3-7 membered monocyclic-heterocycle or 5-9 membered bicyclic heterocycle, wherein any 3-7 membered monocyclic-carbocycle, 5-9 membered bicyclic-carbocycle, 3-7 membered monocyclic-heterocycle or 5-9 membered bicyclic heterocycle of C is optionally substituted with one or more (e.g. 1, 2, 3, 4 or 5) Z4 groups; and
  • each Z4c is independently selected from H or Z4.
  • Embodiment II-55. The compound of any one of Embodiments II-1 to II-48 wherein R1 is selected from 3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazolyl and 4,5,6,7-tetrahydro-indazolyl, wherein any 3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazolyl and 4,5,6,7-tetrahydro-indazolyl of R1 is optionally substituted with one or more Z4 groups.
    Embodiment 56. The compound of any one of Embodiments II-1 to II-48 wherein R1 is selected from 3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl and 4,5,6,7-tetrahydro-indazol-1-yl, wherein any 3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl and 4,5,6,7-tetrahydro-indazol-1-yl of R1 is optionally substituted with one or more Z4 groups.
    Embodiment II-57. The compound of any one of Embodiments I-1 to II-56 wherein each Z4 is independently selected from (C1-C6)alkyl and halogen, wherein any (C1-C6)alkyl of Z4 is optionally substituted with one or more halogen.
    Embodiment II-58. The compound of any one of Embodiments II-1 to II-56 wherein each Z4 is independently selected from fluoro, trifluoromethyl and difluoromethyl.
    Embodiment II-59. The compound of any one of Embodiments II-1 to II-48 wherein R1 is selected from:
  • Figure US20210009555A1-20210114-C00500
  • Embodiment II-60. The compound of any one of Embodiments II-1 to II-48 wherein R1 s
  • Figure US20210009555A1-20210114-C00501
  • Embodiment II-61. The compound of any one of Embodiments II-1 to II-48 wherein R is selected from:
  • Figure US20210009555A1-20210114-C00502
  • Embodiment II-62. The compound of any one of Embodiments II-1 to II-48 wherein R1 is
  • Figure US20210009555A1-20210114-C00503
  • Embodiment II-63. The compound of Embodiment II-1 selected from:
  • Figure US20210009555A1-20210114-C00504
    Figure US20210009555A1-20210114-C00505
    Figure US20210009555A1-20210114-C00506
    Figure US20210009555A1-20210114-C00507
    Figure US20210009555A1-20210114-C00508
  • and pharmaceutically acceptable salts thereof.
    Embodiment II-64. The compound of Embodiment II-1 selected from:
  • Figure US20210009555A1-20210114-C00509
  • and pharmaceutically acceptable salts thereof.
    Embodiment II-65. A pharmaceutical composition comprising a compound of formula I as described in any one of Embodiments II-1 to II-64, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
    Embodiment II-66. A method for treating a Retroviridae virus infection in a mammal comprising administering a therapeutically effective amount of a compound of any one of Embodiments II-1 to II-64, or a pharmaceutically acceptable salt thereof, to the mammal.
    Embodiment II-67. The method of Embodiment II-66 wherein the Retroviridae virus infection is an HIV virus infection.
    Embodiment II-68. A method for treating an HIV infection in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of formula I as described in any one of Embodiments II-1 to II-64, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, and other drugs for treating HIV, and combinations thereof.
    Embodiment II-69. A compound of formula I as described in any of Embodiments II-1 to II-44, or a pharmaceutically acceptable salt thereof for use in medical therapy.
    Embodiment II-70. A compound of formula I as described in any one of Embodiments II-1 to II-44 or a pharmaceutically acceptable salt thereof, for the prophylactic or therapeutic treatment of a Retroviridae virus infection or an HIV virus infection.
    Embodiment II-71. The use of a compound as described in any one of Embodiments II-1 to II-44 or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating a Retroviridae virus infection or an HIV virus infection in a mammal.
    Embodiment II-72. A compound or method as described herein.

Claims (10)

1-54. (canceled)
55. A process for preparing a compound of formula A11:
Figure US20210009555A1-20210114-C00510
or a pharmaceutically acceptable salt thereof,
wherein,
A is a 6-membered monocyclic-heteroaryl with one or two nitrogen atoms, wherein the
6-membered monocyclic-heteroaryl is substituted with one Z1 group, one Z2 group, and optionally substituted with one or more (e.g., 1 or 2) Z3 groups;
R1 is 6-12 membered aryl, 5-12 membered heteroaryl or 3-12 membered heterocycle,
wherein any 6-12 membered aryl, 5-12 membered heteroaryl or 3-12 membered heterocycle of R1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z4 groups; R2 is phenyl, 5-membered monocyclic-heteroaryl, 6-membered monocyclic-heteroaryl or (C3-C7)carbocycle, wherein any phenyl, 5-membered monocyclic-heteroaryl, 6-membered monocyclic-heteroaryl or (C3-C7)carbocycle of R2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z5 groups;
each R3a and R3b is independently selected from H, halogen, (C1-C3)alkyl and (C1-C3)haloalkyl, or R3a is selected from H, (C1-C3)alkyl and (C1-C3)haloalkyl and R3b is selected from —OH and —CN;
Z1 is selected from 6-12 membered aryl, 5-14 membered heteroaryl and 3-14 membered heterocycle, wherein any 6-12 membered aryl, 5-14 membered heteroaryl and 3-14 membered heterocycle of Z1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1a or Z1b;
each Z1a is independently selected from (C3-C7)carbocycle, 6-12 membered aryl, 5-12 membered heteroaryl, 3-12 membered heterocycle, halogen, —CN, —ORn1, —OC(O)Rp1, —OC(O)NRq1Rr1, —SRn1, —S(O)Rp1, —S(O)2OH, —S(O)2Rp1, —S(O)2NRq1Rr1, —NRq1Rr1, —NRn1CORp1, —NRn1CO2Rp1, —NRn1CONRq1Rr1, —NRn1S(O)2Rp1, —NRn1S(O)2ORp1, —NRn1S(O)2NRq1Rr1, NO2, —C(O)Rn1, —C(O)ORn1, —C(O)NRq1Rr1 and —S(O)2NRn1CORp1, wherein any (C3-C7)carbocycle, 6-12 membered aryl, 5-12 membered heteroaryl and 3-12 membered heterocycle of Z1a is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c or Z1d groups;
each Z1b is independently selected from (C1-C8)alkyl, (C2-C8)alkenyl and (C2-C8)alkynyl, wherein any (C1-C8)alkyl, (C2-C8)alkenyl and (C2-C8)alkynyl of Z1b is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c groups;
each Z1c is independently selected from (C3-C7)carbocycle, phenyl, 5-6 membered monocyclic-heteroaryl, 3-7 membered heterocycle, halogen, —CN, —ORn2, —OC(O)Rp2, —OC(O)NRq2Rr2, —SRn2, —S(O)Rp2, —S(O)2H, —S(O)2Rp2, —S(O)2NRq2Rr2, —NRq2Rr2, —NRn2CORp2, —NRn2CO2Rp2, —NRn2CONRq2Rr2, —NRn2S(O)2Rp2, —NRn2S(O)2ORp2, —NRn2S(O2NRq2Rr2, NO2, —C(O)Rn2, —C(O)ORn2, —C(O)NRq2Rr2, halophenyl, 5-6 membered haloheteroaryl, 3-7 membered haloheterocycle and (C1-C8)heteroalkyl;
each Z1d is independently selected from (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl and (C1-C8)haloalkyl;
each Rn1 is independently selected from H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl and phenyl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl and phenyl of Rn1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c or Z1d groups, and wherein any (C1-C8)alkyl, (C2-C8)alkenyl and (C2-C8)alkynyl of Rn1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c groups;
each Rp1 is independently selected from (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl and phenyl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl and phenyl of Rp1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c or Z1d groups, and wherein any (C1-C8)alkyl, (C2-C8)alkenyl and (C2-C8)alkynyl of Rp1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c groups;
Rq1 and Rr1 are each independently selected from H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl and phenyl, wherein any (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl and phenyl of Rq1 or Rr1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c or Z1d groups, and wherein any (C1-C8)alkyl, (C2-C8)alkenyl and (C2-C8)alkynyl of Rq1 or Rr1 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c groups, or Rq1 and Rr1 together with the nitrogen to which they are attached form a 5, 6 or 7-membered heterocycle, wherein the 5, 6 or 7-membered heterocycle is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z1c or Z1d groups;
each R2 is independently selected from H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl, phenyl, halophenyl, 5-6 membered monocyclic-haloheteroaryl, 3-7 membered haloheterocycle, (C1-C8)haloalkyl and (C1-C8)heteroalkyl;
each Rp2 is independently selected from (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl, phenyl, halophenyl, 5-6 membered monocyclic-haloheteroaryl, 3-7 membered haloheterocycle, (C1-C8)haloalkyl and (C1-C8)heteroalkyl;
Rq2 and Rr2 are each independently selected from H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, 3-7 membered heterocycle, 5-6 membered monocyclic-heteroaryl, phenyl, halophenyl, 5-6 membered monocyclic-haloheteroaryl, 3-7 membered haloheterocycle, (C1-C8)haloalkyl and (C1-C8)heteroalkyl, or Rq2 and Rr2 together with the nitrogen to which they are attached form a 5, 6 or 7-membered heterocycle;
Z2 is selected from (C2-C8)alkenyl, (C2-C8)alkynyl, 6-12 membered aryl, 5-12 membered C-linked-heteroaryl, 3-12 membered C-linked-heterocycle, —C(O)Rn3 and —C(O)NRq3Rr3, wherein any 6-12 membered aryl, 5-12 membered C-linked-heteroaryl and 3-12 membered C-linked-heterocycle of Z2 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2b or Z2c groups, and wherein any (C2-C8)alkenyl and (C2-C8)alkynyl of Z2 is optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) Z2c groups;
each Z2a is independently selected from (C3-C7)carbocycle, 6-12 membered aryl, 5-12 membered heteroaryl, 3-12 membered heterocycle, halogen, —CN, —ORn4, —OC(O)Rp4, —OC(O)NRq4Rr4, —SRn4, —S(O)Rp4, —S(O)2OH, —S(O)2Rp4, —S(O)2NRq4Rr4, —NRq4Rr4, —NRn4CORp4, —NRn4CO2Rp4, —NRn4CONRq4Rr4, —NRn4S(O)2Rp4, —NRn4S(O)2ORp4, —NRn4S(O)2NRq4Rr4, NO2, —C(O)Rn4, —C(O)ORn4 and —C(O)NRq4Rr4, wherein any (C3-C7)carbocycle, 6-12 membered aryl, 5-12 membered heteroaryl and 3-12 membered heterocycle of Z2a is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2b or Z2c groups;
each Z2b is independently selected from (C1-C4)alkyl, (C1-C4)heteroalkyl and (C1-C4)haloalkyl;
each Z2c is independently selected from halogen, —CN, —ORn4, —OC(O)Rp4, —OC(O)NRq4Rr4, —SRn4, —S(O)Rp4, —S(O)2OH, —S(O)2Rp4, —S(O)2NRq4Rr4, —NRq4Rr4, —NRn4CORp4, —NRn4CO2Rp4, —NRn4CONRq4Rr4, —NRn4S(O)2Rp4, —NRn4S(O)2ORp4, —NRn4S(O)2NRq4Rr4, NO2, —C(O)Rn4, —C(O)ORn4 and —C(O)NRq4Rr4;
each Rn3 is independently selected from H, (C1-C4)alkyl, (C2-C4)alkenyl, (C3-C7)carbocycle, 3-12 membered heterocycle, 5-12 membered heteroaryl and 6-12 membered aryl, wherein any (C3-C7)carbocycle, 3-12 membered heterocycle, 5-12 membered heteroaryl and 6-12 membered aryl of Rn3 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2b or Z2c groups, and wherein any (C1-C4)alkyl, (C2-C4)alkenyl and (C2-C4)alkynyl of Rn3 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2a groups;
Rq3 and Rr3 are each independently selected from H, (C1-C4)alkyl, (C2-C4)alkenyl, (C3-C7)carbocycle, 3-12 membered heterocycle, 5-12 membered heteroaryl and 6-12 membered aryl, wherein any (C3-C7)carbocycle, 3-12 membered heterocycle, 5-12 membered heteroaryl and 6-12 membered aryl of Rq3 or Rr3 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2b or Z2c groups, and wherein any (C1-C4)alkyl and (C2-C4)alkenyl of Rq3 or Rr3 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2a groups, or Rq3 and Rr3 together with the nitrogen to which they are attached form a heterocycle or heteroaryl, wherein the heterocycle or heteroaryl is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z2b or Z2c groups;
each Rn4 is independently selected from H, (C1-C4)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C1-C4)haloalkyl and (C1-C4)heteroalkyl;
each Rp4 is independently selected from (C1-C8)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)haloalkyl and (C1-C4)heteroalkyl;
Rq4 and Rr4 are each independently selected from H, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)haloalkyl and (C1-C4)heteroalkyl;
each Z3 is independently selected from halogen, (C1-C4)alkyl, —OH, —CN, (C1-C4)heteroalkyl and (C1-C4)haloalkyl;
each Z4 is independently selected from (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C7)carbocycle, halogen, —CN, —ORn5, —OC(O)Rp5, —OC(O)NRq5Rr5, —SRn5, —S(O)Rp5, —S(O)2OH, —S(O)2Rp5, —S(O)2NRq5Rr5, —NRq5Rr5, —NRn5CORp5, —NRn5CO2Rp5, —NRn5CONRq5Rr5, —NRn5S(O)2Rp5, —NRn5S(O)2ORp5, —NRn5S(O)2NRq5Rr5, NO2, —C(O)Rn5, —C(O)ORn5 and —C(O)NRq5Rr5, wherein any (C3-C7)carbocycle, of Z4 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z4a or Z4b groups, and wherein any (C1-C8)alkyl, (C2-C8)alkenyl and (C2-C8)alkynyl of Z4 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) Z4a groups;
each Z4a is independently selected from halogen, —CN, —ORn6, —OC(O)Rp6, —OC(O)NRq6Rr6, —SRn6, —S(O)Rp6, —S(O)2OH, —S(O)2Rp6, —S(O)2NRq6Rr6, —NRq6Rr6, —NRn6CORp6, —NRn6CO2Rp6, —NRn6CONRq6Rr6, —NRn6S(O)2Rp6, —NRn6S(O)2ORp6, —NRn6S(O)2NRq6Rr6, NO2, —C(O)Rn6, —C(O)ORn6 and —C(O)NRq6Rr6;
each Z4b is independently selected from (C1-C4)alkyl, (C2-C4)alkenyl (C2-C4)alkynyl and (C1-C4)haloalkyl;
each Rn5 is independently selected from H, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)heteroalkyl, (C2-C4)alkenyl and (C2-C4)alkynyl;
each Rp5 is independently selected from (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)heteroalkyl, (C2-C4)alkenyl and (C2-C4)alkynyl;
Rq5 and Rr5 are each independently selected from H, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)heteroalkyl, (C2-C4)alkenyl and (C2-C4)alkynyl;
each Rn6 is independently selected from H, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)heteroalkyl, (C2-C4)alkenyl and (C2-C4)alkynyl;
each Rp6 is independently selected from (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)heteroalkyl, (C2-C4)alkenyl and (C2-C4)alkynyl;
Rq6 and Rr6 are each independently selected from H, (C1-C4)alkyl, (C1-C4)haloalkyl, (C1-C4)heteroalkyl, (C2-C4)alkenyl and (C2-C4)alkynyl;
each Z5 is independently selected from (C1-C6)alkyl, halogen, —CN and —ORn7, wherein any (C1-C6)alkyl of Z5 is optionally substituted with one or more (e.g., 1, 2, 3, 4 or 5) halogen; and
each R7 is independently selected from H, (C1-C3)alkyl, (C1-C3)haloalkyl and (C3-C7)carbocycle;
comprising
(a) forming a compound of formula A9 by coupling a compound of formula A7:
Figure US20210009555A1-20210114-C00511
wherein X is NH2, SH, or halogen, and the compound of formula A9 is represented by:
Figure US20210009555A1-20210114-C00512
56. The process of claim 55, wherein the forming of a compound of formula A9 in step (a) is carried out in the presence of 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU), N,N-diisopropylethylamine (DIPEA) and dimethylformamide (DMF).
57. The process of claim 55, further comprising:
(b) converting a compound of formula A5:
Figure US20210009555A1-20210114-C00513
to a compound of formula A7 in the presence of hydrochloric acid (HC).
58. The process of claim 55, further comprising:
(c) reacting a compound of formula A4:
Figure US20210009555A1-20210114-C00514
with a Grignard reagent
Figure US20210009555A1-20210114-C00515
wherein X is Br, to form a compound of formula A5.
59. The process of claim 55, further comprising:
(d) reacting a compound of formula A3:
Figure US20210009555A1-20210114-C00516
with
Figure US20210009555A1-20210114-C00517
to form a compound of formula A4.
60. The process of claim 59, wherein the reacting of a compound of formula A3 with
Figure US20210009555A1-20210114-C00518
in step (d) is carried out in the presence of copper sulfate (CuSO4) and dichloromethane (DCM).
61. The process of claim 55, further comprising:
(e) reacting a compound of formula A2:
Figure US20210009555A1-20210114-C00519
with diisobutylaluminum hydride (DIBAL-H) to form a compound of formula A3.
62. The process of claim 55, further comprising:
(f) reacting a compound of formula A1:
Figure US20210009555A1-20210114-C00520
with
Figure US20210009555A1-20210114-C00521
to form a compound of formula A2.
63. The process of claim 62, wherein the reacting of a compound of formula A1 with
Figure US20210009555A1-20210114-C00522
in step (f) is carried out in the presence of 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU), N,N-diisopropylethylamine (DIPEA) and dimethylformamide (DMF).
US16/882,804 2013-03-01 2020-05-26 Therapeutic compounds Pending US20210009555A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/882,804 US20210009555A1 (en) 2013-03-01 2020-05-26 Therapeutic compounds

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361771655P 2013-03-01 2013-03-01
US201361857636P 2013-07-23 2013-07-23
PCT/US2014/019663 WO2014134566A2 (en) 2013-03-01 2014-02-28 Therapeutic compounds
US201514771779A 2015-08-31 2015-08-31
US15/910,083 US20180273508A1 (en) 2013-03-01 2018-03-02 Therapeutic compounds
US16/882,804 US20210009555A1 (en) 2013-03-01 2020-05-26 Therapeutic compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US15/910,083 Continuation US20180273508A1 (en) 2013-03-01 2018-03-02 Therapeutic compounds

Publications (1)

Publication Number Publication Date
US20210009555A1 true US20210009555A1 (en) 2021-01-14

Family

ID=50382584

Family Applications (4)

Application Number Title Priority Date Filing Date
US14/194,623 Abandoned US20140303164A1 (en) 2013-03-01 2014-02-28 Therapeutic compounds
US14/771,779 Active US9951043B2 (en) 2013-03-01 2014-02-28 Therapeutic compounds
US15/910,083 Abandoned US20180273508A1 (en) 2013-03-01 2018-03-02 Therapeutic compounds
US16/882,804 Pending US20210009555A1 (en) 2013-03-01 2020-05-26 Therapeutic compounds

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US14/194,623 Abandoned US20140303164A1 (en) 2013-03-01 2014-02-28 Therapeutic compounds
US14/771,779 Active US9951043B2 (en) 2013-03-01 2014-02-28 Therapeutic compounds
US15/910,083 Abandoned US20180273508A1 (en) 2013-03-01 2018-03-02 Therapeutic compounds

Country Status (37)

Country Link
US (4) US20140303164A1 (en)
EP (3) EP2961742B1 (en)
JP (5) JP6519486B2 (en)
KR (1) KR102229989B1 (en)
CN (2) CN108516974A (en)
AP (1) AP2015008717A0 (en)
AU (3) AU2014223973B2 (en)
BR (1) BR112015021027B1 (en)
CA (2) CA3007006A1 (en)
CL (1) CL2015002445A1 (en)
CR (2) CR20190504A (en)
CU (1) CU24340B1 (en)
CY (1) CY1121047T1 (en)
DK (1) DK2961742T3 (en)
EA (1) EA035127B1 (en)
ES (2) ES2688571T3 (en)
HK (3) HK1222169A1 (en)
HR (1) HRP20181679T1 (en)
HU (1) HUE039521T2 (en)
IL (1) IL240519B (en)
LT (1) LT2961742T (en)
MD (1) MD20150092A2 (en)
MX (1) MX2015011478A (en)
MY (1) MY195364A (en)
NZ (3) NZ631754A (en)
PE (2) PE20151749A1 (en)
PH (1) PH12015501881A1 (en)
PL (2) PL3409667T3 (en)
PT (2) PT3409667T (en)
RS (1) RS57718B1 (en)
SG (2) SG10201710764YA (en)
SI (2) SI2961742T1 (en)
TW (2) TWI694071B (en)
UA (1) UA120346C2 (en)
UY (1) UY35362A (en)
WO (1) WO2014134566A2 (en)
ZA (1) ZA201506098B (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11117886B2 (en) 2018-02-16 2021-09-14 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds
US11267801B2 (en) 2018-02-15 2022-03-08 Gilead Sciences, Inc. Therapeutic compounds
US11267799B2 (en) 2017-08-17 2022-03-08 Gilead Sciences, Inc. Solid forms of an HIV capsid inhibitor
US11266638B2 (en) 2017-08-17 2022-03-08 Gilead Sciences, Inc. Choline salt forms of an HIV capsid inhibitor
US11680064B2 (en) 2020-06-25 2023-06-20 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
US11787825B2 (en) 2021-12-03 2023-10-17 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
US11807625B2 (en) 2019-11-26 2023-11-07 Gilead Sciences, Inc. Capsid inhibitors for the prevention of HIV
US11944611B2 (en) 2018-07-16 2024-04-02 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2729448B1 (en) 2011-07-06 2015-09-09 Gilead Sciences, Inc. Compounds for the treatment of hiv
TW201443037A (en) * 2013-01-09 2014-11-16 Gilead Sciences Inc Therapeutic compounds
EP2943487B1 (en) 2013-01-09 2016-11-16 Gilead Sciences, Inc. 5-membered heteroaryls and their use as antiviral agents
TWI694071B (en) * 2013-03-01 2020-05-21 美商基利科學股份有限公司 Therapeutic compounds for treating a retroviridae viral infection
CA2898680A1 (en) * 2013-03-15 2014-09-18 Genentech,Inc. Substituted benzoxazoles and methods of use thereof
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
NZ729150A (en) * 2014-08-29 2018-02-23 Gilead Sciences Inc Antiretroviral agents
WO2016040084A1 (en) 2014-09-09 2016-03-17 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US20160145344A1 (en) * 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
KR20230130175A (en) 2014-12-26 2023-09-11 에모리 유니버시티 N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2016123629A1 (en) * 2015-01-30 2016-08-04 Vanderbilt University Indazole and azaindazole substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
JP6738830B2 (en) * 2015-04-23 2020-08-12 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド Inhibitors of human immunodeficiency virus replication
TW201702215A (en) 2015-04-23 2017-01-16 必治妥美雅史谷比公司 Inhibitors of human immunodeficiency virus replication
US20170040479A1 (en) 2015-08-07 2017-02-09 Solaero Technologies Corp. Reliable interconnection of solar cells
US20170081324A1 (en) * 2015-09-18 2017-03-23 F. Hoffmann-La Roche Ag Triazolones derivatives and their use in the treatment, amelioration or prevention of a viral disease
ES2836402T3 (en) 2016-06-30 2021-06-25 Viiv Healthcare Uk No 5 Ltd Azadecalin derivatives as inhibitors of human immunodeficiency virus replication
EP3478661A1 (en) 2016-06-30 2019-05-08 ViiV Healthcare UK (No.5) Limited Aza-substituted inhibitors of human immunodeficiency virus replication
US20190135857A1 (en) 2016-06-30 2019-05-09 Viiv Healthcare Uk (No. 5) Limited Triterpenoid inhibitors of human immunodeficiency virus replication
KR20200131351A (en) * 2016-08-19 2020-11-23 길리애드 사이언시즈, 인코포레이티드 Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
EA036921B1 (en) * 2017-02-10 2021-01-15 Джилид Сайэнс, Инк. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
UY37710A (en) * 2017-05-02 2018-11-30 Viiv Healthcare Uk No 5 Ltd INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
CN111372592A (en) 2017-12-07 2020-07-03 埃默里大学 N4-hydroxycytidine and derivatives and antiviral uses related thereto
EP3774775B8 (en) 2018-04-11 2023-11-15 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
WO2020031112A1 (en) 2018-08-09 2020-02-13 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP3849982A1 (en) 2018-09-14 2021-07-21 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP3853228A1 (en) 2018-09-20 2021-07-28 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
MA53973A (en) 2018-10-24 2022-02-09 Viiv Healthcare Uk No 5 Ltd HUMAN IMMUNODEFICIENCY VIRUS REPLICATION INHIBITORS
WO2020084491A1 (en) 2018-10-24 2020-04-30 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
ES2942998T3 (en) 2018-10-25 2023-06-08 Viiv Healthcare Uk No 5 Ltd Human immunodeficiency virus replication inhibitors
EP3873607B1 (en) 2018-10-29 2023-11-29 VIIV Healthcare UK (No.5) Limited Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication
JP2022509919A (en) 2018-11-05 2022-01-25 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド Inhibitor of human immunodeficiency virus replication
JP2022506399A (en) 2018-11-05 2022-01-17 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド Inhibitor of human immunodeficiency virus replication
UY38559A (en) 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd HUMAN IMMUNODEFICIENCY VIRUS REPLICATION INHIBITORS
EP3962603A1 (en) 2019-04-30 2022-03-09 ViiV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
CA3143136A1 (en) 2019-06-19 2020-12-24 VIIV Healthcare UK (No.5) Limited Pyrido[2,3-d]pyrimidine derivatives as capsid inhibitors for treating human immunodeficiency virus
JP2022551254A (en) 2019-10-01 2022-12-08 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド Replication inhibitor of human immunodeficiency virus
JP2022551256A (en) 2019-10-01 2022-12-08 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド Replication inhibitor of human immunodeficiency virus
TW202128648A (en) 2019-10-04 2021-08-01 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 Inhibitors of human immunodeficiency virus replication
WO2021070054A1 (en) 2019-10-08 2021-04-15 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JPWO2021107066A1 (en) 2019-11-28 2021-06-03
AU2020390305A1 (en) * 2019-11-29 2022-07-07 Jiangsu Hengrui Medicine Co., Ltd. Fused pyridine ring derivative, preparation method therefor, and pharmaceutical use thereof
JP2023513047A (en) * 2020-01-30 2023-03-30 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト Pesticidal effective condensed bicyclic aromatic heterocyclic amino compounds
US20230106880A1 (en) 2020-03-06 2023-04-06 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
AU2021231447A1 (en) * 2020-03-06 2022-09-22 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
US20230149408A1 (en) 2020-04-15 2023-05-18 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
TWI815194B (en) 2020-10-22 2023-09-11 美商基利科學股份有限公司 INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE
KR20230107288A (en) 2020-11-11 2023-07-14 길리애드 사이언시즈, 인코포레이티드 Method for identifying HIV patients susceptible to therapy with gp120 CD4 binding site-directed antibody
TW202313584A (en) * 2021-05-28 2023-04-01 大陸商江蘇恒瑞醫藥股份有限公司 Pharmaceutically acceptable salt, crystal form of fused pyridine ring derivative, and preparation method thereof
TW202342447A (en) 2021-12-03 2023-11-01 美商基利科學股份有限公司 Therapeutic compounds for hiv virus infection
US20230203071A1 (en) * 2021-12-03 2023-06-29 Zhimin Du Therapeutic compounds for hiv virus infection
TW202400172A (en) 2022-04-06 2024-01-01 美商基利科學股份有限公司 Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20240034724A1 (en) * 2022-07-01 2024-02-01 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
WO2024044477A1 (en) 2022-08-26 2024-02-29 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007120729A2 (en) 2006-04-12 2007-10-25 Merck & Co., Inc. Pyridyl amide t-type calcium channel antagonists
EP2212293A4 (en) 2007-10-24 2010-12-01 Merck Sharp & Dohme Heterocycle amide t-type calcium channel antagonists
JP5524071B2 (en) * 2007-10-24 2014-06-18 メルク・シャープ・アンド・ドーム・コーポレーション Heterocyclic phenylamide T-type calcium channel antagonist
JP5285709B2 (en) 2007-11-16 2013-09-11 ギリアード サイエンシス インコーポレーテッド Human immunodeficiency virus replication inhibitor
KR20110118176A (en) 2009-02-25 2011-10-28 빅텍 프라이빗 리미티드 Probes and primers for detection of chikungunya
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US20110035387A1 (en) * 2009-08-10 2011-02-10 Telcordia Technologies, Inc. System and method for the controlled introduction of noise to information filtering
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
US20130165489A1 (en) 2010-05-03 2013-06-27 The Trustees Of The University Of Pennsylvania Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof
WO2011143772A1 (en) 2010-05-21 2011-11-24 Boehringer Ingelheim International Gmbh Inhibitors of hiv replication
EP2588455B1 (en) 2010-07-02 2018-04-04 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
BR112013000043A2 (en) 2010-07-02 2019-09-24 Gilead Sciences Inc naphth-2-ylacetic acid derivatives to treat AIDS
CN102464654B (en) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 Antiviral compound
PL2688403T3 (en) 2011-03-23 2017-09-29 Trevena, Inc. Opioid receptor ligands and methods of using and making same
CN103797001B (en) 2011-04-21 2016-04-20 吉利德科学公司 Benzothiazole compound and application pharmaceutically thereof
EP2729448B1 (en) 2011-07-06 2015-09-09 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (en) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 Antiviral compound
WO2013019653A1 (en) * 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
RU2014115227A (en) 2012-04-20 2015-10-27 Джилид Сайэнс, Инк. DERIVATIVES OF BENZOTIAZOL-6-IL ACETIC ACID AND THEIR APPLICATION FOR TREATMENT OF HIV INFECTION
GB201213087D0 (en) 2012-07-24 2012-09-05 Medical Res Council Inhibition of HIV-1 infection
WO2014028931A2 (en) 2012-08-17 2014-02-20 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
EP2943487B1 (en) 2013-01-09 2016-11-16 Gilead Sciences, Inc. 5-membered heteroaryls and their use as antiviral agents
TW201443037A (en) * 2013-01-09 2014-11-16 Gilead Sciences Inc Therapeutic compounds
CA2897268C (en) 2013-01-09 2018-12-04 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
US20140296266A1 (en) 2013-03-01 2014-10-02 Gilead Sciences, Inc. Therapeutic compounds
TWI694071B (en) 2013-03-01 2020-05-21 美商基利科學股份有限公司 Therapeutic compounds for treating a retroviridae viral infection
GB201312991D0 (en) 2013-07-19 2013-09-04 Isis Innovation Process
CA2928541A1 (en) 2013-10-24 2015-04-30 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
NZ729150A (en) 2014-08-29 2018-02-23 Gilead Sciences Inc Antiretroviral agents
WO2016040084A1 (en) 2014-09-09 2016-03-17 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
TW201702215A (en) 2015-04-23 2017-01-16 必治妥美雅史谷比公司 Inhibitors of human immunodeficiency virus replication
JP6738830B2 (en) 2015-04-23 2020-08-12 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド Inhibitors of human immunodeficiency virus replication
JP6620763B2 (en) * 2017-01-16 2019-12-18 マツダ株式会社 Electric vehicle

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11267799B2 (en) 2017-08-17 2022-03-08 Gilead Sciences, Inc. Solid forms of an HIV capsid inhibitor
US11266638B2 (en) 2017-08-17 2022-03-08 Gilead Sciences, Inc. Choline salt forms of an HIV capsid inhibitor
US11833143B2 (en) 2017-08-17 2023-12-05 Gilead Sciences, Inc. Choline salt forms of an HIV capsid inhibitor
US11845739B2 (en) 2017-08-17 2023-12-19 Gilead Sciences, Inc. Solid forms of an HIV capsid inhibitor
US11267801B2 (en) 2018-02-15 2022-03-08 Gilead Sciences, Inc. Therapeutic compounds
US11753399B2 (en) 2018-02-15 2023-09-12 Gilead Sciences, Inc. Therapeutic compounds
US11117886B2 (en) 2018-02-16 2021-09-14 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds
US11760746B2 (en) 2018-02-16 2023-09-19 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds
US11944611B2 (en) 2018-07-16 2024-04-02 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
US11807625B2 (en) 2019-11-26 2023-11-07 Gilead Sciences, Inc. Capsid inhibitors for the prevention of HIV
US11680064B2 (en) 2020-06-25 2023-06-20 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
US11787825B2 (en) 2021-12-03 2023-10-17 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection

Also Published As

Publication number Publication date
EP3409667A1 (en) 2018-12-05
AU2018247348A1 (en) 2018-11-08
SI2961742T1 (en) 2018-11-30
PE20151749A1 (en) 2015-12-12
EP3954679A2 (en) 2022-02-16
CA2901502C (en) 2018-07-17
CA3007006A1 (en) 2014-09-04
JP2023101723A (en) 2023-07-21
EA201591457A1 (en) 2016-03-31
HK1226078B (en) 2017-09-22
PH12015501881B1 (en) 2016-01-11
BR112015021027B1 (en) 2020-02-18
KR20150121720A (en) 2015-10-29
HK1222169A1 (en) 2017-06-23
AU2014223973B2 (en) 2016-12-22
EP2961742B1 (en) 2018-08-01
UY35362A (en) 2014-08-29
ZA201506098B (en) 2022-05-25
DK2961742T3 (en) 2018-09-24
HRP20181679T1 (en) 2018-12-14
JP2019214599A (en) 2019-12-19
UA120346C2 (en) 2019-11-25
US20180273508A1 (en) 2018-09-27
SI3409667T1 (en) 2021-11-30
TWI694071B (en) 2020-05-21
HUE039521T2 (en) 2019-01-28
EP3954679A3 (en) 2022-04-20
AU2014223973A1 (en) 2015-09-10
JP2022009742A (en) 2022-01-14
PE20191461A1 (en) 2019-10-16
TW201938551A (en) 2019-10-01
AP2015008717A0 (en) 2015-09-30
BR112015021027A8 (en) 2020-01-14
CR20150454A (en) 2015-11-20
IL240519B (en) 2020-11-30
MY195364A (en) 2023-01-16
NZ728537A (en) 2018-08-31
PL3409667T3 (en) 2021-12-13
EA035127B1 (en) 2020-04-30
MD20150092A2 (en) 2016-02-29
PL2961742T3 (en) 2018-12-31
TW201446755A (en) 2014-12-16
EP3409667B1 (en) 2021-07-21
CA2901502A1 (en) 2014-09-04
ES2688571T3 (en) 2018-11-05
CR20190504A (en) 2020-03-11
AU2016262671A1 (en) 2016-12-08
HK1260892A1 (en) 2019-12-27
PT2961742T (en) 2018-10-26
WO2014134566A3 (en) 2014-12-24
MX2015011478A (en) 2016-02-03
JP2016510038A (en) 2016-04-04
SG11201506929VA (en) 2015-10-29
JP6893899B2 (en) 2021-06-23
CL2015002445A1 (en) 2016-02-19
AU2016262671B2 (en) 2018-11-08
CN108516974A (en) 2018-09-11
EA201591457A8 (en) 2018-05-31
ES2887578T3 (en) 2021-12-23
CU20150096A7 (en) 2016-07-29
CN105705500A (en) 2016-06-22
US20140303164A1 (en) 2014-10-09
KR102229989B1 (en) 2021-03-18
LT2961742T (en) 2018-09-25
PT3409667T (en) 2021-09-16
SG10201710764YA (en) 2018-02-27
EP2961742A2 (en) 2016-01-06
CN105705500B (en) 2018-05-29
NZ631754A (en) 2017-02-24
US20160108030A1 (en) 2016-04-21
IL240519A0 (en) 2015-10-29
PH12015501881A1 (en) 2016-01-11
NZ742681A (en) 2019-05-31
TWI706945B (en) 2020-10-11
BR112015021027A2 (en) 2017-07-18
RS57718B1 (en) 2018-12-31
WO2014134566A2 (en) 2014-09-04
US9951043B2 (en) 2018-04-24
CY1121047T1 (en) 2019-12-11
JP6519486B2 (en) 2019-05-29
JP2018141018A (en) 2018-09-13
CU24340B1 (en) 2018-05-08

Similar Documents

Publication Publication Date Title
US9951043B2 (en) Therapeutic compounds
US9050344B2 (en) Therapeutic compounds
US9873680B2 (en) Therapeutic compounds
US20140296266A1 (en) Therapeutic compounds
OA17473A (en) Amide compounds for the treatment of HIV

Legal Events

Date Code Title Description
AS Assignment

Owner name: GILEAD SCIENCES, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRIZGYS, GEDIMINAS;CANALES, EDA;CHOU, CHIEN-HUNG;AND OTHERS;SIGNING DATES FROM 20140219 TO 20171114;REEL/FRAME:052890/0470

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS